<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2025-12-08 09:20:51 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine</td>
          <td>90</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, S. Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>134</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Z. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, Joan Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/48deb9a97772c3939779b0a727ea3595d2e4a10f" target='_blank'>
              PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustion
              </a>
            </td>
          <td>
            Teresa Dinter, Sebastian Mackowiak, Zachary J. Rogers, Vidit Bhandarkar, Molly Carney, Yiming J. Zhang, D. Morgan, Lorelai Pop, Fiona Chatterjee, E. Lutz, Yajit Jain, Adityanarayanan Radhakrishnan, Eric Lander, K. Dane Wittrup, J. C. Love, Alexander Meissner, Stefani Spranger
          </td>
          <td>2025-11-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="ABSTRACT The cancer-immunity cycle is regulated by a series of stimulatory and inhibitory factors. The stimulator of interferon genes (STING) pathway, a key stimulator of type I interferon production, connects innate and adaptive immunity to promote antitumor responses. Using a syngeneic pancreatic tumor model, we characterized the single-cell landscape changes induced by STING stimulation. Our findings revealed that STING agonist treatment reprograms transcription across multiple cell lineages, enhances innate immune responses and activates lymphocytes, thereby promoting antitumor effects. Single-cell transcriptome sequencing identified significant increases in monocytes, neutrophils, macrophages, and CD8 T cells, indicating augmented tumor inflammation. Differential gene expression analysis highlighted upregulated genes related to immune cell effector mechanisms and antigen presentation. Functional assays confirmed the enhanced tumor killing effects induced by STING activation. These results underscore the potential of STING agonists in reprogramming the tumor microenvironment to potentiate antitumor immunity, although clinical translation remains challenging owing to pharmacokinetic limitations and potential systemic toxicity. Further research is needed to optimize STING agonist delivery and dosage for effective cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dbc5d5398d9317cc8645ea9323e07cb973e30cab" target='_blank'>
              cGAS-STING signaling in the tumor microenvironment induces myeloid cell activation and favors T cell-mediated antitumor immunity
              </a>
            </td>
          <td>
            Meiqi Ren, Zhichao Eric Ai, Yan Zhang, Linghong Shi, Yafei Liu, Haixia Liu, Hong Shen, Xiangyu Yao, Zhipeng Yan
          </td>
          <td>2025-11-30</td>
          <td>Cancer Biology & Therapy</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Epstein-Barr virus (EBV) infects >95% of the adult population with diverse outcomes ranging from benign latency to cancers and autoimmune diseases. Immunological control of EBV infection is known to be an important determinant of EBV infection outcomes. However, species-specific viral tropism and limited infection models have impeded mechanistic insights into early host–immune control of EBV infection. Here, we use ex vivo infection of peripheral blood mononuclear cells (PBMCs), rather than routinely used B cell enriched culture systems, to study immune and viral dynamics during primary EBV infection. We combined bulk RNA sequencing, EBV transcript enrichment, and flow cytometry to characterize cellular responses across Days 1, 7–8, and 14 post-infection. Early infection triggered a monocyte-specific antiviral response marked by changes in the expression of genes associated with lipid metabolism (LIPA, lysosomal acid lipase) and chemotaxis (CCR1 and CCR2). Inhibitors of LIPA increased EBV titers during primary infection, indicating that LIPA is part of an early monocyte-driven antiviral response. At later timepoints post-infection, donor-dependent variability in lymphoblastoid cell line (LCL) outgrowth was associated with divergent immune states. Donors that failed to generate LCLs demonstrated increased frequencies of CD8+ T cells and reduced numbers of regulatory T cells (CD4⁺CD25⁺FOXP3⁺). EBV transcriptomics revealed that LCL-failed donors exhibited elevated early lytic gene expression but did not establish a type III latency program. Our findings suggest that individual variations in immune cell composition and gene expression may account for differences in the immune response to EBV. These findings define temporal immune and viral signatures that predict transformation outcome and highlight intact PBMCs as a tractable model to study EBV pathogenesis in a genetically diverse, human-specific context. AUTHOR SUMMARY Individual variation in response to Epstein-Barr virus (EBV) infection can lead to diverse pathogenic outcomes, ranging from cancers to autoimmune disease. To study this variation, we analyzed immune cell response and viral dynamics during the ex vivo primary EBV infection of peripheral blood mononuclear cells (PBMCs) from donors that either fail or succeed to generate lymphoblastoid cell lines (LCLs). Flow cytometry and RNA-seq revealed a rapid monocyte-specific antiviral response among all donors marked by genes associated with lipid metabolism (LIPA) and chemotaxis (CCR1 and CCR2). LIPA inhibition increased EBV titers during primary infection, demonstrating a functional antiviral role. At later timepoints, donor-specific differences in CD8+ T cells and Treg subsets, along with EBV gene expression, were correlated with successful LCL outgrowth. Treatment with the Treg-depleting antibody RG6292 suppressed viral transformation in donors that otherwise supported LCL outgrowth, confirming a functional role for Tregs in shaping early EBV infection outcomes. Viral transcript enrichment-seq revealed an upregulation of early lytic and failure to sustain latent gene expression correlating with failure to generate LCL. These findings highlight intact PBMCs as a tractable model to study EBV viral-host interaction in a genetically diverse, human-specific context, and that Tregs play a key determining role in viral transformation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8803f87b9598f62e1119244e26857dfd233ed68" target='_blank'>
              EBV INFECTION OUTCOMES DETERMINED BY MONOCYTE AND T REG -DRIVEN IMMUNE DYNAMICS IN AN EX VIVO PBMC MODEL
              </a>
            </td>
          <td>
            Leena Yoon, Lauren N. MacMullen, Leonardo Josué Castro Muñoz, Alina Gu, Jamie Bregman, Mary Campion, Avi Srivastava, Rena R. Xian, Richard F Ambinder, A. Kossenkov, Samantha S. Soldan, Paul M. Lieberman
          </td>
          <td>2025-11-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/49cdf4d2b06dc0c77173ce97caf0d6a3fa0e9a28" target='_blank'>
              Single-Cell Immune Profiling Reveals Non-classical Monocyte-Driven Immunodepression in Tuberculosis Treatment Non-Responders
              </a>
            </td>
          <td>
            Yang Che, Yiqun Xiong, Dongliang Zhang, Yahong Qu, Hao Shen, Weixin Wang, Junshun Gao, ZhenBo Wang, Yi Chen, Zhihong Shen
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/755725f1743ee5ddbe628ca1f1641cb9240f2088" target='_blank'>
              T-Cell Synaptosomes Orchestrate Long-Term Anti-Tumor Immunity via Proliferative and Metabolic Reprogramming
              </a>
            </td>
          <td>
            Sun-Kyoung Kang, Na-Young Kim, Sunghee Lee, Hyeonhee Lee, Won-Chang Soh, J. Park, Hee-Tae Kang, Jihwan Park, Sunjae Lee, Yujeong Shim, Joonha Kwon, Hye-Ran Kim, Chang-Duk Jun
          </td>
          <td>2025-11-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Chemokines and their receptors play a pivotal role in shaping the tumor microenvironment (TME) and modulating immune responses by orchestrating immune cell recruitment, spatial positioning, and facilitating cell-cell interactions. However, the exact mechanisms underlying chemokine signaling across different cell populations within the TME remain poorly understood. In this study, we utilized multiple-omics approaches to explore the relationship between CCR1+ macrophages, CD8+ exhausted T (Tex) cells, and immune checkpoint blockade (ICB) therapy response, as well as the role of chemokine signaling in the formation of CCR1+ macrophage and CD8+ Tex cell niches. We found that CCR1+ macrophages were closely associated with ICB outcomes in melanoma. Additionally, combination therapy with a CCR1 antagonist and anti-PD-1 monoclonal antibody significantly reduced tumor burden in melanoma mouse models, which was attributed to the substantial depletion of CD8+ Tex cells. Further, CCR1+ macrophages were found to co-localize with CD8+ Tex cells in human melanoma tissue, and the CCR1+ macrophage-CD8+ Tex cell niche was correlated with ICB treatment response in mice. Importantly, the CCR1-CCL3 axis was identified as a critical mediator in the formation of this niche. Overall, our study underscores the spatial relationship between CCR1+ macrophages and CD8+ Tex cells in ICB therapy, providing a promising strategy to overcome ICB resistance in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a30817fcd20d9c5c0a1a97d6e2d28c75431189be" target='_blank'>
              Blocking CCR1+ macrophages overcomes resistance to immune checkpoint inhibitors in melanoma
              </a>
            </td>
          <td>
            Xinyu Su, Rong Huang, Donglin Kang, Jiayu Wang, Lin Li, Zhengyun Zou
          </td>
          <td>2025-11-03</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Myelodysplastic syndrome (MDS) is characterized by bone marrow failure, clonal evolution and leukemic progression, but the pathophysiologic processes driving these events remain incompletely understood. Here, by establishing a comprehensive single-cell transcriptional taxonomy of human MDS, we reveal that inflammatory remodeling of bone marrow stromal niches is a common early feature, irrespective of the genetic driver landscape. We identify an activated CD8-T-cell subset as a source of stromal inflammation via TNF-receptor signaling, which prompts the inflammatory rewiring and loss of repopulating ability of residual normal hematopoietic stem/progenitor cells (HSPC). Mutant HSPCs display relative resistance to this inflammatory stress and reside predominantly in a transcriptional ‘high output’ state, providing a biological framework to their competitive advantage in an inflammatory microenvironment. Consistent with this, stromal inflammation associates with leukemic progression and reduced survival. Our data thus support a model of immune-stromal inflammatory signaling driving tissue failure and clonal evolution in the hematopoietic system. Mechanisms of clonal evolution in myeloid neoplasms remain incompletely understood. Darwinian theory predicts that the (micro)environment of clone-propagating stem cells may contribute to clonal selection. Here, we provide data fitting this model, establishing a relationship between stromal niche inflammation, inflammatory stress in HSPCs, clonal resistance and leukemic evolution in human MDS. Mechanisms of clonal evolution in myeloid neoplasms remain incompletely understood. Darwinian theory predicts that the (micro)environment of clone-propagating stem cells may contribute to clonal selection. Here, authors provide data fitting this model, establishing a relationship between stromal niche inflammation, inflammatory stress in HSPCs, clonal resistance and leukemic evolution in human myelodysplastic syndrome.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7d21dc014f548d4524dba3eed50e502490dcae8e" target='_blank'>
              An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome
              </a>
            </td>
          <td>
            Lanpeng Chen, Yujie Bian, Eline Pronk, Claire van Dijk, Tim V.D. van Tienhoven, R. Hoogenboezem, E. Bindels, Dennis Bosch, Sadaf Fazeli, A. D. de Graaf, Theresia M. Westers, M. Kholmatov, Judith B. Zaugg, Pedro L. Moura, Eva Hellström-Lindberg, A. A. van de Loosdrecht, J. Jansen, M. Sanders, M. H. Raaijmakers
          </td>
          <td>2025-11-18</td>
          <td>Nature Communications</td>
          <td>1</td>
          <td>48</td>
        </tr>

        <tr id="Abstract Objectives Immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, represent a pivotal approach in the treatment of multiple myeloma (MM). However, the complex immunosuppressive tumor microenvironment (TME) poses significant challenges to their efficacy. Among the immunosuppressive cells in the MM TME, granulocytic myeloid-derived suppressor cells (G-MDSCs) are predominant, yet their functions remain incompletely understood. This study aimed to comprehensively analyze the role of G-MDSCs in MM patients undergoing CAR-T therapy. Methods Single-cell transcriptomic data from seven MM patients before and after CAR-T therapy were analyzed to characterize G-MDSCs. Functional enrichment and gene set enrichment analysis (GSEA) were performed to identify signaling pathways. A risk prediction model was constructed using RNA-seq and survival data from 713 MM patients, and validated by Kaplan–Meier analysis. In vitro experiments were conducted to assess the immunosuppressive functions of G-MDSCs. Results The findings, though exploratory due to limited sample size and inter-patient heterogeneity, suggested pathological activation and immunosuppressive roles of G-MDSCs potentially linked to patient prognosis. G-MDSCs were identified as key modulators of immune responses within the TME, with GSEA indicating regulation via IFN-α/γ signaling. They may facilitate immune evasion of MM cells by promoting proliferation through the IGF1–IGF1R axis and inhibiting T cells and other immune cells via the SIRPA–CD47 pathway. The risk prediction model based on G-MDSC gene signatures demonstrated high prognostic accuracy (AUC = 0.94). PTGS1 was identified as a key marker associated with high-risk groups, and functional assays confirmed its role in mediating G-MDSC immunosuppressive activity. Conclusions This study provides preliminary insights into the functional role of G-MDSCs in the MM TME and highlights their impact on CAR-T therapy outcomes. The findings suggest potential therapeutic strategies, including targeting PTGS1, to enhance CAR-T efficacy. Larger and more diverse cohorts are required to substantiate these observations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e8ff33894cad405d661ae879b8aae448cec342e" target='_blank'>
              Functional role of granulocytic myeloid-derived suppressor cells in CAR-T therapy: insights from single-cell RNA sequencing in multiple myeloma
              </a>
            </td>
          <td>
            Chaoyu Zhang, Fang An
          </td>
          <td>2025-11-02</td>
          <td>Immunopharmacology and Immunotoxicology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Penile squamous cell carcinoma (PSCC) is a malignancy characterized by a poor prognosis and lack of reliable biomarkers, presenting considerable therapeutic challenges. Tertiary lymphoid structures (TLSs) are critical modulators of antitumor immunity; however, the immunological dynamics, particularly the roles of B cells and their interactions with naive T cells in PSCC tissues, remain inadequately understood. This study integrates transcriptomic approaches, including spatial transcriptomics, single‐cell sequencing (scRNA‐seq), and bulk RNA sequencing (bulk RNA‐seq), and immunohistochemistry to elucidate the immune architecture of and functional mechanisms within TLSs. The results reveal a positive correlation between TLS density and patient survival, with CD74⁺ B cells tending to be enriched during early TLS formation. These cells exhibit strong immune activation and a propensity to differentiate into plasma cells. By engaging with naive T cells through HLA‐DRA via ligand–receptor interactions, CD74⁺ B cells activate transcription factors, including NFKB1, NFKB2, NFATC1, NFATC2, FOS, and RUNX1, in naive T cells, thereby enhancing the immune response. Consequently, CD74⁺ B cells represent a compelling biomarker for and therapeutic target of PSCC, offering profound insights into the immunological mechanisms that drive PSCC progression and response to immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f775dcc4d8e646b4cd53d88e405d27443da1f7f" target='_blank'>
              Spatial Transcriptional Dynamics of CD74⁺ B Cells in Tertiary Lymphoid Structures Drive Immune Evolution in Penile Squamous Cell Carcinoma
              </a>
            </td>
          <td>
            Ting Xue, Chuangzhong Deng, Jingya Liu, Ru Yan, Jing Li, Xiheng Hu, Xueying Li, Xiao Xiao, Jietian Jin, Hongzhen Tang, Desi Chen, Zihan Zuo, Yujie Liang, Dongbin Wang, Bonan Chen, Hui Han, Zaishang Li
          </td>
          <td>2025-10-20</td>
          <td>Advanced Science</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive tumor microenvironment, which features a dense desmoplastic stroma enriched with cancer-associated fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising potential in eliciting antitumor immunity, the mechanisms by which stromal components modulate OV efficacy remain poorly understood. Methods To investigate the interplay between immune and stromal components in PDAC following OV treatment, we employed murine and patient-derived tumor models. We characterized immune cell populations using single-cell RNA sequencing and flow cytometry. Functional studies included the engineering of a next-generation oncolytic herpes simplex virus expressing FLT3 ligand, OX40 ligand, and interleukin-12 (IL-12), combined with CD40 agonist antibodies to restore dendritic cell (DC) function and enhance T-cell responses. Results We identified a novel immunosuppressive circuit wherein monocytes, sensing damage-associated molecular patterns and pathogen-associated molecular patterns from OV-infected tumor cells, secrete interleukin-1β. This, in turn, triggers IL-6 production by CAFs, creating an IL-6-rich milieu that impairs DC maturation and co-stimulatory signaling, thereby attenuating T cell-mediated antitumor immunity and restricting OV therapeutic efficacy. Importantly, combination therapy with the engineered OV and CD40 agonist antibodies restored DC functionality and elicited robust tumor-specific T-cell responses in both murine and patient-derived models. Conclusion Our findings reveal a previously unrecognized monocyte-CAF-DC axis that mediates resistance to OV therapy through IL-1β and IL-6-driven suppression of DC function in PDAC. This study provides a mechanistically informed and translationally promising approach to overcome stromal immune suppression, restore effective antitumor immunity, and improve therapeutic outcomes for patients with PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b3ad6676052a006d7f44e56422f87b86b5aaedd5" target='_blank'>
              Oncolytic virus-induced IL-1β+ monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer
              </a>
            </td>
          <td>
            Fan Li, Jingru Chen, Yuanke Li, Wei Wang, Yi Yang, Jie Wang, Minghui Han, Han Wang, Feilong Zhou, Wenxuan Ma, Yi Wang, Zhaoyuan Zhang, Jufeng Yu, Zhen Zhao, Li Deng, Shiyu Liu, Yajuan Wan, Zhigang Zhao, Song‐Tao Xu, Jiangmei Li, Youjia Cao, Hongkai Zhang
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Background COVID-19, including its post-acute sequelae (Long COVID), is increasingly recognized as involving persistent immune dysregulation and chronic inflammation. Severe and prolonged disease states are often accompanied by sustained cytokine release, immune cell exhaustion, and ongoing cell-cell communication that shapes the inflammatory milieu. Among immune subsets, CD8+ T cells play a central role in antiviral defense, yet the molecular mechanisms linking their dysfunction to prolonged inflammation remain incompletely understood. Methods We analyzed 73,110 peripheral blood mononuclear cells (PBMCs) from individuals across four disease states (Healthy, Exposed, Infected, and Hospitalized) using single-cell RNA sequencing. Immune cell subsets were annotated, and T cell heterogeneity was profiled. Cytokine and inflammatory scores were calculated to assess immune activation. Differentially expressed genes (DEGs) underwent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Cell-cell communication was evaluated to map ligand-receptor networks. Additionally, nine machine learning models were trained on a bulk RNA-seq cohort, and the SHapley Additive exPlanations (SHAP) framework was applied to interpret key predictive genes. Results Progressive disease severity was associated with a decline in T cell proportions, enrichment of pro-inflammatory myeloid cells, and elevated cytokine expression, particularly IL-32. Memory CD8+ T cells showed increased exhaustion and inflammatory scores while maintaining a central position in MHC-I-mediated communication networks. Persistent activation of immune and metabolic pathways, including antigen presentation and oxidative phosphorylation, was observed in prolonged disease states. Seven genes (RPS26, RPS29, RPL36, RPL39, RPS28, RPS21, and CD3E) were identified as strong predictors of chronic immune dysregulation, with the XGBoost model achieving the highest AUC. SHAP analysis confirmed their contributions to disease classification. Conclusion This study maps the immune landscape of COVID-19 and Long COVID at single-cell resolution, revealing that persistent immune cell communication, particularly involving memory CD8+ T cells, may sustain chronic inflammation beyond the acute phase. The identified molecular signatures offer potential biomarkers and therapeutic targets for mitigating post-viral inflammatory syndromes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/536000d345ef1e6f7663efc28145b0e979e70e7b" target='_blank'>
              Immune cell communication networks and memory CD8+ T cell signatures sustaining chronic inflammation in COVID-19 and Long COVID
              </a>
            </td>
          <td>
            Hengrui Liu, Zewen Xu, Ilayda Karsidag, Panpan Wang, Jieling Weng
          </td>
          <td>2025-10-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) and poor prognosis. While major histocompatibility complex class II (MHC-II) expression is traditionally associated with professional antigen-presenting cells, its role in PDAC malignant cells remains underexplored. Herein, we utilized single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, bulk RNA sequencing, multiplex immunohistochemistry (mIHC) and ex vivo studies in culture with both human and murine models to investigate the prognostic relevance of MHC-II expression in malignant PDAC cells. Elevated MHC-II expression in malignant cells was strongly associated with increased infiltration of CD4+ T and CD8+ T cells in human PDAC, and pronounced co-localization with plasma cells, indicative of an antigen-activated immune microenvironment. In the KPC mouse model of PDAC, pharmacologic induction of MHC-II expression by cobimetinib treatment in malignant epithelial cells significantly enhanced the therapeutic response to immune checkpoint blockade (ICB). These findings highlight the role of malignant cell- intrinsic MHC-II expression in promoting antigen presentation and fostering an anti-tumor immune microenvironment. Our results position MHC-II as a promising prognostic biomarker and therapeutic target in PDAC, paving the way for novel immunomodulatory strategies. Summary of highlights Single-cell and spatial transcriptomic analyses reveal that elevated MHC-II expression in malignant PDAC cells correlates with increased infiltration of CD4⁺ and CD8⁺ T cells. Stimulating MHC-II expression in tumors effectively enhances immunotherapeutic responses to ICB in the PDAC KPC mouse model, including PDAC tumors previously resistant to therapeutic interventions. MHC-II serves as a prognostic biomarker and a promising target for immunotherapy in PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2ff8a35ccf490f14b05887357dfa21e7336b426" target='_blank'>
              Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy
              </a>
            </td>
          <td>
            Canping Chen, Kyle P Gribbin, Xi Li, T. Ozmen, F. Ozmen, Shamilene Sivagnanam, James Kim, Katie E. Blise, Xinxing Yang, Yi Zhang, Roselyn S. Dai, D. Keith, Mara H Sherman, Mu-Shui Dai, L. Coussens, Charles D. Lopez, Rosalie C. Sears, Gordon B. Mills, Katelyn T. Byrne, Zheng Xia
          </td>
          <td>2025-10-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>96</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8bf2e04bf6e2797aba3ea1f4f0aeb768b1def37b" target='_blank'>
              Memory Regulatory T Cells Reprogram into Protective Tfh-like Effectors in Recurrent Malaria
              </a>
            </td>
          <td>
            Nana Appiah Essel Charles-Chess, A. Ruberto, Carson Bowers, N. Obeng-Adjei, M. R. Hansen, Disha Bangalore Renuka Prasad, B. Traore, K. Klonowski, Peter D. Crompton, S. P. Kurup
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>47</td>
        </tr>

        <tr id="Stem-like T cells (TSL) represent a distinct subset of CD4+ and CD8+ T cells characterized by self-renewal, multipotent differentiation, and long-term persistence, and have emerged as pivotal regulators of immune responses in chronic disease contexts. Despite growing interest, the developmental programs, molecular signatures, and clinical relevance of TSL remain incompletely understood, limiting their translational potential. Recent evidence highlights the central role of key transcription factors such as TCF-1 and BCL6, metabolic circuits including the Wnt-β-catenin and STAT3 pathways, and microenvironmental signals in sustaining the identity and function of TSL subsets. In various pathologies—including chronic infections, cancer, autoimmunity, and transplant rejection—TSL cells contribute to both immune persistence and pathogenic activation through their capacity to replenish exhausted effectors or differentiate into inflammatory subtypes. These cells not only shape immune trajectory but also hold promise as dynamic biomarkers and therapeutic targets. Targeted modulation of TSL via cytokine supplementation, immune checkpoint blockade, adoptive transfer, or niche interference is under investigation, with encouraging results in preclinical and early translational studies. This review outlines the molecular regulation and functional diversity of stem-like CD4+ and CD8+ T cells, evaluates their disease-specific roles, and discusses strategies to harness or inhibit these populations for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/957ce990207260aaa43e17d3f30590a154a82c00" target='_blank'>
              Stem-like T cells: molecular regulation, functional diversity, and therapeutic implications across diseases
              </a>
            </td>
          <td>
            Wang Zhan, Longyong Lai, Shuan Ran, Yuan Li, Jiulu Zhao, Jie Wu, Chao Guo, Jikai Cui, Jiahong Xia
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Abstract Introduction Synovial natural killer (NK) cells contribute to inflammation in arthritis by secreting cytokines and modulating synovial fibroblast activation. The aim of this study was to describe systemic versus local inflammatory changes of NK cell subsets as well as their physical cell-cell interactions in arthritis patients. Methods Spectral flow cytometry was used to compare paired peripheral blood (PB) and synovial fluid (SF) immune cells from patients with active inflammatory arthritis and healthy controls. Physical cell-cell interactions within tissues were studied by applying a recently developed cellular interaction mapping framework. Results Our paired approach revealed significant local enrichment of immature and activated NK cells in SF, characterized by elevated markers of early differentiation, immune-checkpoint regulation, and tissue-residency, highlighting tightly controlled immune activation at inflamed sites. Single-cell analysis confirmed heterogeneity within SF-NK cells, suggesting multiple co-existing activation states and developmental stages. PB-NK cells from patients differed profoundly compared to healthy controls, showing less immature NK cell subsets and an enrichment of mature, pro-inflammatory subsets indicative of systemic immune activation. Cellular interaction mapping revealed mainly NK/neutrophil interactions of patients’ NK cells, while interactions with B-cells, T-cells, or monocytes were negligible. T-cells also displayed profound local and systemic alterations. Cellular interaction mapping revealed that next to NK/neutrophil interactions, interactions between B-cells with monocytes and T-cells with neutrophils characterize joint inflammation. Conclusion This paired high-dimensional analysis revealed systemic and local alterations in NK cell subsets shaped by co-existing developmental stages and immune regulatory mechanisms. Cellular interaction mapping indicated that neutrophils are a main interaction-partner of NK cells in inflamed joints.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/33e0fc210c968311a194a2ca7566f89ed217a080" target='_blank'>
              Compartment-Specific NK Cell Phenotypes Reveal Distinct Maturation and Activation States in Inflammatory Arthritis
              </a>
            </td>
          <td>
            F. Deicher, T. Exner, Maren Claus, S. Yousefian, Lea Rodon, Sophie Elisabeth Leonhardt, J. H. Distler, Carsten Watzl, Hanns-Martin Lorenz, Simon Haas, Daniel Hübschmann, Wolfgang Merkt
          </td>
          <td>2025-10-31</td>
          <td>Journal of Innate Immunity</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Tumor-infiltrating lymphocytes (TILs) are a promising autologous cell therapy to treat solid tumors. TILs are manufactured by expanding and reinfusing tumor-reactive T cells from tumor biopsies. Efficacy of TIL therapies has been limited by the heterogeneity of expanded TIL products and the high prevalence of dysfunctional exhausted CD8+ T cells (TEX). While a subset of CD8+ TILs co-expressing CD103 and CD39 are enriched for tumor-reactive TILs across multiple cancer types, these cells are often in the TEX state with low proliferative potential. To identify regulators of human TIL proliferation, we screened an open reading frame library encoding for all human transcription factors (TFs). RELB emerged as the dominant driver of human TIL expansion with a skew towards CD8+ cells. TCR diversity was maintained after multiple days of in vitro expansion driven by RELB. Transcriptome profiling of multiple RELB-expressing TIL subtypes revealed a shift towards a memory/costimulatory-like phenotype. Using a HER2-targeting CAR and tumor co-culture model, RELB conferred improved persistence after multiple tumor challenges in vitro and improved solid tumor control in mouse xenografts in vivo. Finally, co-culture of RELB-overexpressing TILs with patient-matched tumor organoids showed an increase in TIL product polyfunctionality, tumor reactivity, and tumor killing. Collectively these results support promoting RELB expression as a strategy for broadly enabling TIL therapy for treating solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e0439a6de8243c20d60a46c125842a0d34a0ceda" target='_blank'>
              RELB Reprograms Exhausted Tumor-Infiltrating Lymphocytes for Improved Adoptive Cell Therapy
              </a>
            </td>
          <td>
            Christian D. McRoberts Amador, Rachel E. Conover, Michael C. Brown, Liliana S. Lyniv, P. Noldner, Ying Zhou, Aretha R. Gao, Sean R. McCutcheon, S. Antonia, Charles A. Gersbach
          </td>
          <td>2025-10-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="ABSTRACT Chronic antigen exposure drives CD4⁺ T cell senescence, yet how autoimmunity and persistent viral infections differentially shape T cell differentiation and function remains unclear. Using cytomegalovirus (CMV) and rheumatoid arthritis (RA) as models of chronic immune activation, we performed high‐dimensional mass cytometry and functional assays to define their impact on CD4⁺ T cells. In CMV‐seropositive individuals, CD27−CD28− CD4⁺ T cells were abundant and exhibited a predominantly cytotoxic, nonproliferative phenotype. Only a minor fraction was CMV‐reactive, suggesting that bystander‐driven differentiation contributes to this subset. In the absence of CMV, senescent CD4⁺ T cells were infrequent and phenotypically distinct, though they still exhibited low proliferative capacity. EBV and HSV did not independently increase CD27−CD28− CD4⁺ T cell frequency. Similarly, RA had little effect on their abundance but instead tuned the functional quality of senescent cells. In CMV‐seropositive RA patients, senescent CD4⁺ T cells produced less pro‐inflammatory cytokines and showed impaired cytotoxic degranulation. Central memory CD4⁺ and CD27−CD28− CD8⁺ T cell functions were preserved, with no evidence for CMV reactivation, suggesting maintained viral control by unaffected T cell responses. These findings highlight distinct, nonredundant effects of CMV and RA on CD4⁺ T cell senescence and reveal RA‐specific functional defects in senescent CD4⁺ T cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3441dc9dbc45e96d9b0a98bad7c5d0ce97797b4d" target='_blank'>
              Divergent Effects of Cytomegalovirus and Rheumatoid Arthritis on Senescent CD4+ T Cells
              </a>
            </td>
          <td>
            Lea Williams, Ali O Saber, Silina Awad, Xi Su, Asgar Ansari, Ruozhang Xu, Hannah Jung, Anupama Shahane, Joshua F. Baker, Laura F. Su
          </td>
          <td>2025-11-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Tumor-associated macrophages (TAMs) can switch between immune-activating and cancer-promoting states; yet, the stress pathways that lock them into procancerous states remain obscure. Here we defined the role of transcription factor NRF2 as a mediator of procancerous macrophages. Methods We combined spatial transcriptomics, single-cell RNA sequencing, three-dimensional (3D) cell culture and in vivo tumor models to explore how NRF2 activation status in tumor-associated macrophages modifies responses to immunotherapy. Results In MC38 colon tumors, repeated anti-CD40 or radiotherapy created necrosis that split TAMs into peripheral Cxcl9+ and peri-necrotic Spp1+ subsets. Spatial transcriptomics, single-cell RNA sequencing, and Keap1-deficient mice showed that the latter are NRF2-imprinted “stress-TAMs”, with immunosuppressive and tumor-promoting activity. The same NRF2 activation gradient separates pro-inflammatory CXCL9+ and anti-inflammatory SPP1+TAMs across diverse human cancers. NRF2-imprinted TAMs silence IFN-STAT1 programs, lose major histocompatibility complex-II and chemokine expression, fail to expand T cells, drive tumor cell invasion in 3D co-cultures, and foster metastasis. Constitutive hematopoietic NRF2 activation accelerated the growth of therapy-naïve MMTV-PyMT breast tumors and markedly impaired the efficacy of agonistic anti-CD40 antibody therapy in MC38 subcutaneous and lung-metastasis models. Conversely, macrophage-specific Nrf2 deletion restored immunogenic TAMs and potentiated anti-CD40 and anti-programmed cell death protein-1 treatments. Conclusions Our data pinpoint a previously underappreciated cytoprotective mechanism, which inadvertently sustains immunosuppressive macrophages and confers therapy resistance. These results define stress-induced TAMs as an untapped driver of macrophage-based immune evasion. Inhibiting NRF2 activity alongside standard immunotherapies could restore a pro-inflammatory macrophage–T-cell amplification loop, potentially improving patient responses to T-cell—and macrophage-directed immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3b564268f908e2668ba03acbe4a747ca42980a5" target='_blank'>
              Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy
              </a>
            </td>
          <td>
            Dominik J. Schaer, Nadja Schulthess-Lutz, Livio Baselgia, Kahrisan Kunasingam, R. Humar, K. Hansen, Melanie Eschment, Elena Duerst, F. Vallelian
          </td>
          <td>2025-10-31</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Massive immune cell infiltration and persistent inflammation in the central nervous system (CNS) are key hallmarks of multiple sclerosis. Here, we report a myeloid-derived suppressor cell (MDSC)–based therapeutic strategy, named CNS Immune Targeting Enabled by MDSCs (CITED), which uses surface-decorated MDSCs carrying rapamycin nanoparticles (NPs) for targeted multimodal immune reprogramming in CNS. We show that NP decoration enhances MDSC immunomodulatory function, facilitates their trafficking to inflamed CNS regions, and increases NP accumulation within CNS. In an experimental autoimmune encephalomyelitis model, CITED exhibited robust therapeutic efficacy, resulting in reduced disease progression, improved motor function, and diminished myelin damage. Mechanistic studies reveal that CITED exerts its therapeutic effects by targeted reprogramming of both innate and adaptive immune responses in CNS. Specifically, CITED inhibits immune cell infiltration, rebalances CD4 T cell phenotypes, and promotes the polarization of myeloid cells toward anti-inflammatory phenotypes. Collectively, CITED could provide a broadly effective approach for targeted immune restoration in multiple sclerosis and potentially other autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8f24c23e0ed496fd13e4cd70e0bb4daac42d668" target='_blank'>
              Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis
              </a>
            </td>
          <td>
            Endong Zhang, H. Algarni, Luyu Zhang, Chih-Jia Chao, Shan He, Aditi Upadhye, Qing Bao, Dahee Jung, Shubhi Srivastava, Edidiong Michael Udofa, Philana Phan, Dejan S. Nikolic, Steve Seung-Young Lee, Jalees Rehman, Zongmin Zhao
          </td>
          <td>2025-10-15</td>
          <td>Science Advances</td>
          <td>1</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/739a87fd565af12d2e067e28eb04d43a769bbc0a" target='_blank'>
              Skin-derived G-CSF activates pathological granulopoiesis upon psoriasis
              </a>
            </td>
          <td>
            Tomson Kosasih, Tatsuya Morishima, Sohyeon Lee, Jungyeon Yoon, Kanako Wakahashi, Pilhan Kim, Aiko Sada, Hitoshi Takizawa
          </td>
          <td>2025-10-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="B lymphocytes exhibit a multifaceted and context-dependent role in tumor biology, acting as both promoters and suppressors of malignancy through dynamic interactions within the tumor microenvironment (TME). This review synthesizes current evidence on the dual functions of B cells in tumor immunity, highlighting their capacity to orchestrate antitumor responses via antigen presentation, antibody-dependent cytotoxicity, and tertiary lymphoid structure (TLS)-mediated T cell activation, while paradoxically driving immunosuppression through regulatory B cells (Bregs), pro-angiogenic signaling, and immune checkpoint modulation. Key mechanisms include TLS formation, which enhances cytotoxic T cell priming and correlates with improved immunotherapy outcomes, and Breg-mediated secretion of IL-10/TGF-β, which fosters T cell exhaustion and myeloid-derived suppressor cell recruitment. Tumor-type specificity is evident: TLS-rich malignancies like melanoma and Non-Small Cell Lung Cancer (NSCLC) show B cell-driven immune activation, whereas pancreatic and hepatocellular carcinomas demonstrate B cell functional plasticity influenced by metabolic and epigenetic reprogramming. Therapeutically, B cell-targeted strategies—including CD20 antibodies, CAR-T cells, and B cell epitope vaccines—demonstrate efficacy in hematologic and solid tumors, yet face challenges due to subset heterogeneity and sex-specific response disparities. Emerging approaches combine immune checkpoint inhibitors (ICBs) with TLS-inducing agents or exploit B cell-derived biomarkers for personalized therapy. Future directions emphasize deciphering B cell metabolic-niche crosstalk, optimizing combinatorial regimens, and leveraging spatial multiomics to resolve functional heterogeneity. By bridging mechanistic insights with clinical translation, this work underscores B cells as pivotal regulators of tumor immunity and advocates for precision strategies to harness their antitumor potential while mitigating pro-tumor plasticity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ebd579b54f9dae49f949806c09388f29afa2ecc8" target='_blank'>
              The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications
              </a>
            </td>
          <td>
            Zhuangwei Lv, Ruohao Yang, Kai Zhang, Ruihan Wang, Xiaoyu Shi, Jinhua Wu, Lulu Liu, J. Jiao
          </td>
          <td>2025-10-30</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b26845defb7abdc1bf1c1d65b82acb78bc096a5c" target='_blank'>
              Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer
              </a>
            </td>
          <td>
            Chaitanya N. Parikh, Kelly D. DeMarco, Griffin I. Kane, Nikita Bhalerao, Ronnie W. Dinnell, Boyang Ma, Hadiya K. Giwa, Zhen Zhao, Lin Zhou, Katherine C. Murphy, Loretah Chibaya, Haruka Mori, Youwei Qiao, Brian Lewis, Wen Xue, Jason R. Pitarresi, Prabhani U. Atukorale, M. Ruscetti
          </td>
          <td>2025-10-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Effective anti-tumor immunity critically depends on functional CD8+ T cells, yet in almost all solid tumors, these cells become dysfunctional, exhausted, or spatially excluded. This breakdown of immune surveillance arises not only from cell-intrinsic T cell exhaustion but also from multimodal communication among tumor, stromal, and immune cells within the tumor microenvironment (TME). This communication is mediated not only through direct receptor-ligand interactions but also through a suite of indirect mechanisms, such as metabolic competition, secretion of immunosuppressive metabolites and cytokines, extracellular vesicle exchange, and even mitochondrial transfer via tunneling nanotubes or membrane transfer through T cell trogocytosis. Together, these suppressive interactions impair CD8+ T cell metabolism, effector function, and persistence, thereby enabling tumor immune evasion. In this review, we summarize current understanding of how multimodal cell-cell communication, including immune checkpoints, metabolic reprogramming, and stromal crosstalk, cooperatively drive CD8+ T cell dysfunction. We also highlight emerging therapeutic strategies aimed at rewiring these suppressive networks, with emphasis on translational potential. A deeper understanding of the spatial, molecular, and metabolic context of CD8+ T cell suppression offers new avenues to enhance the efficacy of cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5ae6993d7bfa10b0ab3f27994a45882bb6514da" target='_blank'>
              Multimodal cell-cell communication driving CD8+ T cell dysfunction and immune evasion
              </a>
            </td>
          <td>
            Liping Chen, Qianping Huang, Peipei Zhou
          </td>
          <td>2025-11-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/394995c0fcb10ae0448160919d2f62f9453d3170" target='_blank'>
              Comprehensive single-cell analysis reveals mast cells’ roles in cancer immunity
              </a>
            </td>
          <td>
            Hao Qian, Wenbo Wang, Jiaomeng Pan, Ming Zhao, Li Gao, Jia Zeng, Hang Gong, Guangyan Zhangyuan, Zi Li, Mao Zhang, Xia Shen, Yuanchi Weng, Xiaxing Deng, Yingying Huang
          </td>
          <td>2025-10-10</td>
          <td>Oncogene</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Autoimmune diseases (AID) comprise a diverse group of disorders driven by aberrant B-cell and T-cell reactivity against self-tissues. In recent years, cell-based therapies utilizing engineered T cells have emerged as a promising therapeutic strategy for AIDs. Notably, chimeric antigen receptor (CAR)-T cells have demonstrated the ability to selectively target and eliminate autoreactive immune populations, including pathogenic B cells and antibody-producing plasma cells. Beyond T-cell modulation, macrophages (MΦs) exhibit remarkable plasticity, differentiating into pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes in response to microenvironmental cues. Advances in genetic engineering have enabled the development of CAR-MΦs (CAR-M), which hold potential for adoptive immunotherapy in certain diseases. However, CAR-M therapy remains experimental and requires further clinical validation. This review systematically evaluates the therapeutic potential of CAR-T and CAR-M in AIDs, comparing their respective advantages and limitations to provide a comprehensive foundation for future translational applications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c46f22e6da6fa9574631f492a654bb7d068badb4" target='_blank'>
              Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects
              </a>
            </td>
          <td>
            Mingxuan Zheng, Jiale Chen, Hong Yang
          </td>
          <td>2025-11-20</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Abstract SLAMF8 is predominantly expressed in macrophages and plays an important role in autoimmune diseases and inflammation. Our previous studies have focused on SLAMF8, however, the potential of SLAMF8 as an immunotherapeutic target and its role in regulating the tumor immune microenvironment remain to be elucidated. This study demonstrated that macrophage-specific SLAMF8 is significantly associated with a poor prognosis for colorectal cancer (CRC). Additionally, M2 macrophage and tumor-associated macrophages (TAMs) models were used to verify that SLAMF8 induces an immunosuppressive phenotype in macrophages and regulates antitumor immunity by inhibiting the activation and function of CD8+ T cells. In vivo, we confirmed that SLAMF8 inhibition promoted remodeling of the immunosuppressive microenvironment and augmented immunotherapy sensitivity in CRC. Mechanistically, we demonstrated that SLAMF8 promotes the polarization of macrophages toward the M2 phenotype via the PI3K/AKT and JAK/STAT3 signaling pathways. In summary, this study confirmed that inhibiting SLAMF8 exerts an antitumor effect by reversing the immunosuppressive tumor microenvironment in CRC, providing new therapeutic targets and strategies for combined immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0eb7d8ffd5d61d0e44a547a2d1181cb708517e0e" target='_blank'>
              Inhibiting SLAMF8 modulates tumor-associated macrophages and restores CD8+ T cell-mediated antitumor immunity in colorectal cancer
              </a>
            </td>
          <td>
            Xingzhi Han, Xueying Bai, Ning Wang, Yuexin Sun, Jing Hu, Li Li, Zhihao Liu, Yaping Zhang, Zixin Liang, Liuqi Sang, Lu Han, Qun Zhang, Xiaoping Qian
          </td>
          <td>2025-11-10</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Background Oncolytic virus M1 (OVM), a naturally occurring alphavirus, has demonstrated potent antitumor activity in various solid tumor models by inducing immunogenic cell death and activating CD8+ T cells. However, its in vivo efficacy varies widely, and resistance mechanisms remain poorly understood. Tumor-associated macrophages (TAMs), key immunosuppressive cells within the tumor microenvironment, may limit OVM therapeutic potential. Methods We investigated the role of TAMs in OVM resistance using multiple syngeneic mouse tumor models (MC38 colorectal cancer, KPC1199 pancreatic cancer, RM1 prostate cancer, and B16F10 melanoma). TAMs were depleted using clodronate liposomes or CSF1R (Colony Stimulating Factor 1 Receptor) antibodies. Flow cytometry, mass cytometry, quantitative reverse transcription-PCR, and transcriptomic sequencing were employed to assess TAMs infiltration, viral load, and immune responses. CD8+ T cells were selectively depleted to determine their functional relevance. Results TAMs infiltration was positively correlated with resistance to OVM across tumor models. Depletion of TAMs increased intratumoral viral load and promoted accumulation of GZMB+ CD8+ T cells. RNA sequencing analysis revealed upregulation of antiviral and T-cell immune pathways in TAMs-depleted tumors. Importantly, the therapeutic benefit of TAMs depletion was abrogated on CD8+ T-cell depletion, confirming their essential role in mediating OVM efficacy. In both OVM non-responsive and responsive tumors, TAMs depletion enhanced OVM-mediated tumor suppression and survival. Conclusions TAMs, particularly M1-like subsets, play a critical role in mediating resistance to OVM therapy by reducing viral persistence and suppressing CD8+ T-cell responses. Targeting TAMs significantly improves the antitumor efficacy of OVM in solid tumors. These findings support the development of TAMs-targeted combination strategies to optimize oncolytic virotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/753ddef784ec7db8d4ec432d89df4bf7bbfc40f0" target='_blank'>
              TAMs-mediated resistance to oncolytic virus M1 in solid tumors
              </a>
            </td>
          <td>
            Xuanming Liang, Jingjie Li, Jie-Si Chen, Chaoxin Chen, Honghui Li, Caixin Yan, Cui Guo, Yu Han, Wenfeng Liu, Ke Sai, Yuan Lin, Guangmei Yan, Wenbo Zhu, Ying Liu
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Background Immune checkpoint inhibitors (ICIs) have been proven to be one of the most promising and effective immunotherapies; however, their efficacy in colorectal cancer (CRC) remains significantly limited. Therefore, understanding the mechanism of resistance to ICIs therapy in CRC patients is of great significance for the development of new anti-tumor immunotherapy targets. Methods Ccl7 myeloid cell-specific knockout mice and MC38 tumor-bearing mouse models were established to investigate the role of Ccl7 during CRC progression. Proteomic analysis, RNA-seq, and flow cytometry analysis were used to determine the role of Ccl7 in the tumor immune microenvironment. Results Herein, we found that elevated CCL7+ tumor-associated macrophages (TAMs) in tumors correlated with tolerance to ICIs blockage therapy in patients with CRC. Deletion of CCL7 in myeloid cells resulted in reduced accumulation of immunosuppressive TAMs and increased infiltration of activated CD8+ T cells within the tumor. Mechanistically, CCL7 modulates peroxisome biogenesis and fatty acid oxidation, thereby promoting the immunosuppressive functions of TAMs via the PI3K-AKT-PEX3 signaling pathway. Furthermore, CCL7 inhibits the expression of chemokine CXCL10 by suppressing the AKT2-STAT1 signaling pathway, which reduces the infiltration of activated CD8+ T cells in the tumor. Blocking CCL7 delays CRC progression and enhances the therapeutic efficacy of PD-L1. Conclusion Our study highlights the novel role and regulatory mechanisms of CCL7+ TAMs in ICIs immunotherapy resistance, suggesting that CCL7 may serve as a potential combined therapeutic target for ICIs immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/53a194d2240d9d29b67527ded8020c64d8c9fb2a" target='_blank'>
              Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells
              </a>
            </td>
          <td>
            Yijiao Chen, Xudong Liu, Jiongming Chen, Liwen Kuang, Nan Zhang, Danyang Li, Dan Zhao, Dongmei Xue, Juan Lei, Jiangang Zhang, Yongsheng Li, Lei Wu
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Plasmacytoid dendritic cells (pDCs) mount powerful antiviral type I interferon (IFN-I) responses, yet only a fraction of pDCs produces high levels of IFN-I. Here we report that peripheral pDCs in naive mice comprise three subsets (termed A, B and C) that represent progressive differentiation stages. This heterogeneity was generated by tonic IFN-I signaling elicited in part by the cGAS/STING and TLR9 DNA-sensing pathways. A small ‘IFN-I-naive’ subset (pDC-A) could give rise to other subsets; it was expanded in STING deficiency or after the IFN-I receptor blockade, but was abolished by exogenous IFN-I. In response to RNA viruses, pDC-A showed increased Bcl2-dependent survival and superior IFN-I responses, but was susceptible to virus infection. Conversely, the majority of pDCs comprised the ‘IFN-I-primed’ subsets (pDC-B/C) that showed lower IFN-I responses and poor survival, but did not support virus replication. Thus, tonic IFN-I signaling decreases the cytokine-producing capacity and survival of pDCs but increases their virus resistance, facilitating optimal antiviral responses. Pucella, Maqueda-Alfaro and colleagues distinguish three developmentally related subsets of mouse plasmacytoid dendritic cells that differ in their ability to produce type I interferon and their susceptibility to virus.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d74835f8e845ea18beb20340e5bd3f281ac019ce" target='_blank'>
              Tonic type I interferon signaling optimizes the antiviral function of plasmacytoid dendritic cells
              </a>
            </td>
          <td>
            Joseph N. Pucella, Raul A Maqueda-Alfaro, Hai Ni, Fernando Bandeira Sulczewski, Anna Eichinger, E. Esteva, Ai C Ra, Annesa Das, Oriana A. Perez, Jue Feng, Marlon Stoeckius, Peter Smibert, Alireza Khodadadi-Jamayran, Igor Dolgalev, E. Ivanova, Stela Sota, Ken Cadwell, S. Koralov, Judy Zhong, Chetna Soni, Daniel B. Stetson, Stuart P Weisberg, Donna L. Farber, Juliana Idoyaga, Boris Reizis
          </td>
          <td>2025-10-14</td>
          <td>Nature Immunology</td>
          <td>1</td>
          <td>46</td>
        </tr>

        <tr id="Background: HCC is a notably immunosuppressive malignancy with limited therapeutic options and poor prognosis. Macrophages, as major immune cell populations within the tumor microenvironment, significantly influence disease progression and therapy efficacy. We aim to identify pivotal macrophage subsets associated with HCC progression and resistance to immunotherapy. Methods: Immunotherapy-associated macrophage-specific marker genes were identified by single-cell RNA-sequencing analysis and transcriptome analysis. The clinical relevance of macrophages with heme oxygenase 1 (HMOX1) positive was assessed in HCC patients by immunofluorescence. The immune microenvironment of HCC and the functional phenotype of HMOX1+ macrophages were explored using cytometry by time-of-flight (CyTOF). Results: Single-cell RNA-sequencing analyses revealed that HMOX1 was predominantly expressed in intratumoral macrophages within the HCC microenvironment. Intratumoral HMOX1+ macrophages abundance was associated with worse prognosis and immunotherapy efficacy in patients with HCC. CyTOF analysis showed that the HCC microenvironment with high infiltration of HMOX1+ macrophages was characterized by high infiltration of CD4+ regulatory T cells (Tregs) and high expression of programmed death-1 (PD-1) in CD8+ T cells. Besides, HMOX1+ macrophages exhibited an immunosuppressive functional state. Pharmacological inhibition of HMOX1 by Znpp enhanced the therapeutic efficacy of anti-PD-1 antibody in the HCC mouse model. Conclusions: Macrophage-specific HMOX1 serves as a novel biomarker for predicting the efficacy of immunotherapy, and targeting HMOX1 has the potential to enhance the efficacy of anti-PD-1 therapy in HCC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20a58e4f02cc5693944528514521ad6b571bd6a6" target='_blank'>
              HMOX1+ macrophages determine immunosuppressive microenvironment and immunotherapy efficacy in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Yabing Du, Wenxin Xu, Zhenkun Liu, Peihao Wen, Ruifeng Song, Weiwei Hao, Yating Liu, Xinlei Zhao, Meiying Gu, Jialei Weng, Wei He
          </td>
          <td>2025-10-14</td>
          <td>Hepatology Communications</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ee5dbb33a6a382fa70961ac781d31dc13ae0aa3f" target='_blank'>
              Tumor cell dissemination is facilitated through regulatory T cell-driven extracellular matrix remodeling
              </a>
            </td>
          <td>
            Ailen D. Garcia-Santillan, Jessanne Y. Lichtenberg, He Shen, Jasmine M. Rodriguez, Sandra Makar, Jonathan Barra, Nicholas M. Clark, Wei Du, Leandro M. Martinez, Ashley D. Hadjis, Taylor Calicchia, Mikhail G. Dozmorov, J. Bravo-Cordero, Amy L. Olex, Priscilla Y. Hwang, Paula D. Bos
          </td>
          <td>2025-10-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Despite effective viral suppression with antiretroviral therapy (ART), people living with HIV (PLWH) experience persistent inflammation, immune dysfunction, and premature onset of cardiovascular and aging-related comorbidities. To define the underlying mechanisms, we performed longitudinal transcriptomic profiling in peripheral blood mononuclear cells (PBMCs) from a cohort of simian immunodeficiency virus (SIV)-infected rhesus macaques spanning four key stages: pre-infection, acute infection, short-term ART, and long-term ART. Bulk RNA sequencing revealed dynamic immune remodeling across infection and treatment. Acute SIV infection induced robust antiviral and inflammatory programs, with upregulation of interferon-stimulated genes (ISGs), IL-27, JAK/STAT, and NF-κB signaling, coupled with suppression of T- and B-cell activation pathways. Short-term ART effectively reversed these transcriptional perturbations, restoring adaptive immune gene expression and reducing innate antiviral responses to near-baseline levels. In contrast, chronic SIV infection on long-term ART maintained viral suppression but was characterized by reactivation of innate immune pathways, including TLR2/TLR4/MYD88, NF-κB, and inflammasome (NLRP3/or NLRP12, caspase-1) signaling, along with sustained macrophage activation, platelet/coagulation signaling, and senescence-associated secretory phenotype. Protein analyses confirmed persistent CASPASE-1 and NF-κB activation in spleen tissue. Pathologic evaluation of a carotid artery from an SIV-infected, long-term ART– treated macaque revealed macrophage-rich plaques with p21⁺ senescent cells with intraluminal thrombus formation, recapitulating key features of HIV-associated atherogenesis. Together, these findings demonstrate that while ART normalizes acute infection–induced immune dysregulation, chronic SIV infection sustains a chronic, macrophage- and TLR-driven inflammatory state linked to vascular injury and aging process regardless of long-term suppression of viremia. Targeting inflammasome, NF-κB, and senescence pathways may mitigate non-AIDS comorbidities in PLWH.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7a8f96a2324d1327914a92bba9009e04dbf070e" target='_blank'>
              Persistent Activation of Monocytes/Macrophages and Cell Senescence in SIV-Infected Macaques on ART
              </a>
            </td>
          <td>
            Yilin Chen, Xiaofeng Ding, Sonalika Ray, Siva Thirugnanam, Robert V. Blair, Ahmad Saied, S. Sukhanov, J. Kolls, Woong-Ki Kim, P. Delafontaine, Jay Rappaport, Xuebin Qin, Namita Rout
          </td>
          <td>2025-11-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>46</td>
        </tr>

        <tr id="


 Introduction: Immune effector cell-associated hemophagocytic-like syndrome (IEC-HS) is an increasingly recognized, life-threatening, hyperinflammatory complication of chimeric antigen receptor (CAR) T-cell therapy across multiple CAR constructs. The pathogenesis and optimal management of IEC-HS remains poorly understood. We previously reported the potential pathogenic role of persistent, expanded CAR and non-CAR activated T-cells in IEC-HS. To further delineate the mechanisms of IEC-HS, we conducted a comprehensive proteomic and transcriptional evaluation of patients receiving CD22 CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (NCT02315612).
 Methods: We performed an in-depth plasma proteomic evaluation using the SomaScan® platform in 10-patients that developed IEC-HS with samples collected during their initial cytokine release syndrome (CRS) and at IEC-HS onset compared to 10 control-patients that developed CRS only with samples collected at a matched timepoint corresponding to IEC-HS (median day +13). Additionally, to explore cellular transcriptional changes and tissue-level immune dysregulation, we performed single cell RNA (scRNA) sequencing on peripheral blood samples at IEC-HS onset and spatial transcriptomics using the 10x Genomics Visium platform on bone marrow biopsy samples pre- and post-CAR T-cell therapy (Day +28) from 5-patients: 3 that developed IEC-HS and 2 who experienced CRS only. Unsupervised clustering, differential abundance, and pathway analyses were performed to compare the groups.
 Results: Twenty-five patients that received CD22 CAR T-cells with a median age of 19-years (interquartile range: 15-23) were analyzed. Fifteen (60%) were male and 12 (48%) were non-White. All patients developed CRS (median CRS max grade: 2, range: 1-4) and 96% had a complete remission after treatment. Hierarchical clustering of the 1000-most variable proteins demonstrated the IEC-HS group at IEC-HS onset clustered together and independently of samples collected at CRS onset from the same patients. These samples from CRS onset in IEC-HS patients more closely resembled the CRS only control population. Pathway analyses comparing IEC-HS onset to the matched timepoint of CRS only patients identified a significant increase in cell proliferation pathways (Myc and E2F Targets, normalized enrichment score [NES]=1.6, p<0.05), type II interferon responses (NES=1.7, p<0.05), and glycolysis (NES=1.3) (p<0.05). A similar analysis comparing the paired samples from the IEC-HS group at CRS vs IEC-HS onset identified upregulation of the same pathways during IEC-HS (p<0.05). Due to the potential role of inflammasome activation in IEC-HS, associated proteins were specifically interrogated; significant increases in IL18, the IL18 receptor, and the IL1 receptor in IEC-HS compared to the other groups (Kruskal-Wallis, p<0.001) were seen. scRNA sequencing identified a unique cluster of rapidly proliferating, hyperactivated T-cells producing interferon-γ (IFNγ) in IEC-HS patients supporting that activated T-cells are driving the proliferation and Type-II interferon signaling proteomic signatures. Spatial transcriptomics of the bone marrow revealed a pronounced myeloid expansion at Day +28 post-infusion compared to the pre-infusion sample in IEC-HS patients. This corresponded to marked increases in Visium spots consisting of granulocyte-macrophage progenitors (GMPs), CD14+ macrophages, and progenitor red blood cells. Gene ontology analysis of clusters corresponding to these monocyte/myeloid progenitors populations demonstrated increased G-protein receptor activation/signaling pathways (adjusted p-value <0.001) and exhibited increased transcripts associated with innate immune activation including S100A12, ferritin light chain, and IL18, consistent with the hyperinflammatory milieu typical of HLH.
 Conclusions: IEC-HS represents a novel hyperinflammatory toxicity distinct from CRS and characterized by a strong proliferative and glycolytic proteomic signature with increased IFNγ signaling driven by pathologic T-cell activation and expansion similar to findings observed in HLH. However, prominent innate immune activation is also observed potentially due to local myeloid cell development and activation within the bone marrow. Targeting the IFNγ-IL18 axis in these patients may provide a therapeutic benefit while preserving CAR-T efficacy.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8383534d2afc3a248d2736ca48866cd4f99fd6c8" target='_blank'>
              A novel immune signature characterized by activation of the IFNγ-IL18 axis identifies immune effector cell-associated HLH-like syndrome after CD22 chimeric antigen receptor T-cell therapy
              </a>
            </td>
          <td>
            Joseph Rocco, Brett Schroeder, Logan Cook, B. Yates, Brian Sellers, Thomas Langowski, Colton McNinch, Irina Maric, Michelly Sampaio De Melo, I. Sereti, Nirali N. Shah
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>61</td>
        </tr>

        <tr id="Lung mononuclear phagocyte (MNP) subsets differ in their ability to restrict Mycobacterium tuberculosis (Mtb) during chronic infection, yet the mechanisms underlying this difference are not well defined. Here, we show that CD11clo monocyte-derived cells (MNC1), the subset of lung cells that is most permissive for Mtb viability during chronic infection, express lower levels of interferon-gamma (IFNγ) signaling proteins, resulting in reduced responses to IFNγ compared to alveolar macrophages (AM) and CD11chi MNC2. Moreover, type I IFN signaling suppresses IFNγ-mediated MHC-II expression, impairing CD4 T cell activation by MNC1 cells. Importantly, prior immunity conferred by contained Mtb infection enhances IFNγ responsiveness of monocyte-derived cells, reducing bacterial burdens in lungs and within MNC subsets. Our findings indicate that heterogeneous IFNγ responsiveness is exploited by Mtb for persistence in vivo. Overcoming or bypassing impaired IFNγ responsiveness may guide the development of more effective TB vaccines and host-directed therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1185bf27cd38b33e534c27d9aa87381e2cd898fa" target='_blank'>
              Impaired IFNγ responsiveness of monocyte-derived lung cells limits immunity to Mycobacterium tuberculosis
              </a>
            </td>
          <td>
            Weihao Zheng, J. Limberis, Zachary P. Howard, Alexander Mohapatra, Enzo Takagi, J. Ernst
          </td>
          <td>2025-11-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Administration of IL-2 may promote the suppressive function and proliferation of Treg cells that cause immune tolerance in patients with cancer, which causes low-dose IL-2 to fail in achieving an optimal anti-tumor effect. Here, we designed an immunocytokine by fusing IL-2 and an anti-TIGIT monoclonal antibody, named αTIGIT-IL2, that targets Treg cells and promotes their fragility in the tumor milieu. These fragile-like Treg cells show impaired suppressive function and high IFN-γ production, triggering an immune-reactive tumor microenvironment. Such inflammation leads to the recruitment and functional reprogramming of intratumoral neutrophils, improving cross-talk between neutrophils and CD8+ T cells and enhancing the antitumor ability of CD8+ T cells. Combination therapy with αTIGIT-IL2 and PD-1 blocker could eliminate triple-negative breast cancer (TNBC) tumors resistant to immune checkpoint blockade (ICB) therapy. These findings provide the basis for developing a new generation of immunocytokines that target Treg cells and promote their fragility in the tumor milieu, resulting in robust antitumor immunity. Interleukin-2 (IL-2) and checkpoint inhibitors such as anti-TIGIT have been used individually as tumour therapies. Here the authors fuse IL-2 and anti-TIGIT in a combined therapeutic and show that this promotes Treg cell fragility in the tumour environment which in turn promotes neutrophil function to enhance CD8 T cell anti-tumour function in mouse models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a8f381b44371297ad7f4ba1f04d5155ffd6052c5" target='_blank'>
              αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models
              </a>
            </td>
          <td>
            Tianci Wang, Yupu Xu, Zhengfeng Zhang, Yaqi Wu, Long Chen, Xiaodong Zheng, Hui-Min Peng, Qiang Zou, Rui Sun, Hongdi Ma, Haoyu Sun, Zhigang Tian, Xiaohu Zheng
          </td>
          <td>2025-10-17</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/929f5e64525cee92d0f3fab0ebf61c85bfdd0623" target='_blank'>
              The spatial landscape of infectious mononucleosis tonsils
              </a>
            </td>
          <td>
            Ciara I Leahy, Matthew Pugh, Aoife Hennessy, Nadezhda Nikulina, Stefan Dojcinov, Gerald Niedobitek, Graham S. Taylor, Paul G Murray, É. Fennell
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4e312c1a3a9dbed5ee9046577d5060ddafb93654" target='_blank'>
              Identifying the therapeutic potential of Niclosamide in overcoming IFN-gamma dependent cancer immune evasion in the Tumor Microenvironment
              </a>
            </td>
          <td>
            Yue Zhang, Sophia Peng, Hamid Akhbariyoon, Suzi Kim, Ellie Lai, En Cai
          </td>
          <td>2025-10-28</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="CD39 is an ectoenzyme in immune cells that regulates purinergic signaling by converting extracellular ATP into adenosine (ADO). Although first described on EBV-transformed B cells, CD39’s role in humoral immunity remains unclear. Using murine infection models and human samples, we confirm and extend previous findings showing that high CD39 expression identifies antibody-secreting cells (ASC) across differentiation stages, including ASC derived from memory B cells, and in various tissues, regardless of the infection phase. CD39 was resistant to enzymatic digestion, facilitating ASC identification in processed tissues. We found that while CD39 was not essential for B-cell differentiation into ASC, it remained functionally active as an ectoenzyme. ASC as well as germinal center (GC) B cells expressed ADO receptors, making them responsive to ADO signaling. Consistently, systemic ADO administration impaired GC reactions without altering the ASC number in infected mice. However, in vitro, ADO reduces antibody production both in ASC and in B cells undergoing differentiation and also impairs the differentiation of activated B cells. Finally, B cell–specific CD39 deficiency increased GC B-cell frequencies in infected mice, likely due to reduced ADO levels. These findings highlight the relevance of the purinergic pathway in B-cell biology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/29ab4395fef7413edaeb4a4f893d031d065d8aea" target='_blank'>
              CD39 is an antibody-secreting B-cell marker that modulates germinal center and antibody responses during infection
              </a>
            </td>
          <td>
            L. Almada, Yamila Gazzoni, C. Beccaria, Facundo Fiocca Vernengo, Santiago Boccardo, Melisa Gorosito Serrán, Apurwa Trivedi, C. Vinuesa, Simon C. Robson, E. A. Acosta Rodríguez, Mauro Gaya, C. Montes, A. Gruppi
          </td>
          <td>2025-10-20</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>59</td>
        </tr>

        <tr id="Non-small cell lung cancer (NSCLC) exhibits profound immune dysregulation, driven in part by the opposing roles of regulatory T cells (Tregs) and T helper 17 (Th17) cells. Tregs facilitate tumor progression through immune suppression, angiogenesis, and checkpoint engagement, while Th17 cells display dual effects depending on the tumor microenvironment, either promoting anti-tumor responses or enhancing malignancy. Importantly, plasticity between these subsets, orchestrated by cytokines such as TGF-β, IL-6, and IL-1β, allows dynamic interconversion that shapes immune outcomes. This review comprehensively summarizes the differentiation, molecular mechanisms, and functions of Tregs and Th17 cells in NSCLC. We highlight recent advances in targeting the Th17/Treg axis via immune checkpoint inhibitors, Treg depletion, and metabolic reprogramming. Understanding this immunological balance offers promising avenues for restoring anti-tumor immunity and improving therapeutic efficacy in NSCLC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc2fe215418a201aa8b5de519c7cfb5b11dfb23a" target='_blank'>
              Rewiring immune suppression in NSCLC: Roles and plasticity of Tregs and Th17 cells
              </a>
            </td>
          <td>
            Shasha Zhu, Ning Zhou, Qingling Li, Xiaoxing Liu
          </td>
          <td>2025-10-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="T cell responses are generally curtailed by suppressive mechanisms within the tumor microenvironment (TME) that prevent T cell infiltration and function. Consequently, T cell-based therapies for solid tumors have yielded limited and often non-durable clinical responses. Tumors develop a hostile TME, where tumor-associated macrophages (TAMs) that initially support T cells are converted into immune suppressive TAMs that facilitate tumor evasion from T cell control. In fact, immune suppressive TAMs represent a dominant fraction of immune cells within the TME and their presence is associated with poor prognosis and resistance to immunotherapy. Often in close contact with effector T cells, TAMs directly suppress CD8+ T cells through mechanisms involving metabolic mediators, co-signaling receptors, their ligands and/or cytokines. Here, we revisit molecular interactions behind TAM-mediated suppression of T cell responses and address the potential targeting of such molecules and pathways to re-boost anti-tumor T cell immunity. This perspective, focusing on molecular interactions between TAM and T cells, may aid the improvement of T cell-based therapies for solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c01dfbcf193a83248342e1e2c8db14cdc37f598" target='_blank'>
              Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy
              </a>
            </td>
          <td>
            R. M. Coelho, R. Debets, Dora Hammerl
          </td>
          <td>2025-10-16</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/842af96f572eb3d970548668b36cfda84da5efb2" target='_blank'>
              Glucocorticoid Receptor Signaling in Myeloid Cells Orchestrates Inflammation Resolution and Muscle Repair
              </a>
            </td>
          <td>
            Sirine Souali-Crespo, Joe G. Rizk, Emilia Calvano, Rajesh Sahu, Emina Colovic, Imane Chabba, Valentine Gilbart, Erwan Grandgirard, Bastien Morlet, Qingshuang Cai, Daniel Metzger, D. Duteil
          </td>
          <td>2025-10-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, characterized by an immunosuppressive microenvironment. To address the immune desert in GBM, immunocytokine, an innovative recombinant fusion protein that combines antibodies and cytokines, has been proposed. This molecule, targeting tumor cells while stimulating immune cells, effectively enhances the anti-tumor response. Developing a novel immunocytokine presents a promising strategy for GBM. In this study, we developed a novel immunocytokine, αBC-IL15, composed of a bispecific T cell engager (BsTCE) fused to the interleukin-15 receptor alpha-sushi domain/interleukin-15 complex (IL-15/IL-15Rα). To analyze its affection on immune cells, we co-cultured it with peripheral blood mononuclear cells in vitro. To investigate whether it enhances the cytotoxicity of T cells compared to B7-H3 BsTCE, we performed cytotoxicity assays on cell lines and spheroids in vitro. Moreover, we assessed its efficacy in vivo and analyzed the tumor microenvironment using flow cytometry and bulk sequencing. Our study assessed the bioactivity and efficiency of αBC-IL15. In vitro, αBC-IL15 effectively bound to tumor cells and T cells, inducing immune cell activation, cytokine release, and cytotoxicity toward tumor cells. In vivo, αBC-IL15 connects cytotoxic immune cells with tumor cells, leading to effective immune cell infiltration and potent redirected lysis. Overall, we developed a novel bispecific immunocytokine, αBC-IL15, which targets tumor cells while enriching and activating effector immune cells. This agent significantly enhanced anti-tumor effects both in vitro and in vivo, highlighting its potential to overcome the immunosuppressive microenvironment in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/04303ca0c55b928916530495ef259008c917a0c2" target='_blank'>
              A novel immunocytokine promotes T cell– and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma
              </a>
            </td>
          <td>
            Xiaoke Zhang, Nian Yang, Xin Tang, Nanxi Liu, Qizhong Lu, Zongliang Zhang, Long Xu, Lu Jiang, Honglin Ge, Huaqing Lu, Yongdong Chen, Mingbin Bao, Aiping Tong, Liangxue Zhou
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="T-cell exhaustion is a terminal state of immune dysfunction characterized by impaired proliferation and effector functions, diminished cytokine secretion, and sustained expression of inhibitory receptors. In coronavirus disease 2019 (COVID-19), increasing evidence links exhausted T-cell phenotypes with poor clinical outcomes, including severe disease, delayed viral clearance, and persistent symptoms associated with Long COVID. Exhaustion results from prolonged antigenic stimulation and inflammatory signals and is marked by transcriptional reprogramming, metabolic and epigenetic dysregulation, and co-expression of inhibitory receptors such as programmed cell death protein-1 (PD-1), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Notably, exhausted phenotypes in COVID-19 frequently coexist with hyperactivation, raising the unresolved question of whether inhibitory receptor expression reflects transient activation or irreversible dysfunction. Emerging therapeutic strategies to reverse these dysfunctional states include immune checkpoint inhibitors, cytokine modulation, metabolic interventions, and epigenetic therapies, although their clinical translation remains at an early stage. Critical research gaps include the scarcity of longitudinal data, incomplete profiling of T-cell subsets across disease stages during COVID-19 and Long COVID-19, and contradictory evidence of vaccine-induced exhaustion with limited understanding of its consequences. This non-systematic literature review synthesizes current advances in COVID-19 immunopathology and therapeutic strategies, underscoring that understanding T-cell exhaustion is crucial to improving outcomes and shaping next-generation immunotherapies and vaccines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fcda848fedb31d45bcaf7a6be07292887c93eed0" target='_blank'>
              T-cell exhaustion in COVID-19: what do we know?
              </a>
            </td>
          <td>
            Roderick Chen-Camaño, Rodrigo DeAntonio, S. López-Vergès
          </td>
          <td>2025-10-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Autoimmune kidney diseases (AIKDs) are a consequence of the dysregulation of immune response and the loss of tolerance to self-antigens, which led to glomerulonephritis and tissue damage. Autoantibody-producing B cells, as well as T cells, neutrophils and macrophages play a pivotal role in the pathogenesis and progression of various AIKDs. In recent years, B cell-depleting/modulating therapies and molecules that modulate T cell differentiation pathways and cytokine production have become a new hope for patients with immune-mediated kidney diseases. However, these biologicals often do not bring satisfactory therapeutic benefits, which is most likely related to incomplete B cell depletion of tissue-resident B cells. A new hope is immunotherapy with chimeric antigen receptor (CAR) effector cells. In CAR therapy, immune cells (mostly T cells) are genetically modified to express a CAR, which enables the recognition of the specific antigen on a target cell. This interaction leads to the formation of immune synapse and cytotoxicity. CAR-based strategies are a potent form of cell therapy that offers a better chance for deep and durable response than other recently approved immune therapies. Moreover, CAR-T cells can be programmed for higher precision and safety. This review explores the current landscape of CAR-T cell therapy in AIKDs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f214144b87a7be044bf71857fed9fe114ce14c2a" target='_blank'>
              CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?
              </a>
            </td>
          <td>
            Beata Kaleta
          </td>
          <td>2025-10-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/18d334efdd4d167f301eb6b862ccafe18092402f" target='_blank'>
              Localized immunomodulation with cytokine-producing cells to mitigate host immune rejection responses in rodents and a non-human primate
              </a>
            </td>
          <td>
            Boram Kim, Dilrasbonu Vohidova, A. Nash, Yuen San Chan, Samantha Fleury, Shravani Deo, Danna Murungi, Peter D Rios, Ira Joshi, Hafsa Nasir, Daisy Lopez, Mor Sela Golan, Cassidy Hart, Jose Oberholzer, H. C. Hodges, O. Veiseh
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Background The triple-negative breast cancer (TNBC) microenvironment (TME) undergoes progressive reprogramming, transitioning from an early immune-active state to a late immune-suppressed state. While tumor cell plasticity has been extensively studied, the molecular plasticity of T cells in vivo remains poorly defined. Objectives To characterize transcriptional changes in T cells during TNBC progression and identify stage-specific shifts in T cell function, polarization, and antigen-presenting cell (APC)-T cell interactions. Results Transcriptional analysis of T cells from BALB/c mice bearing 4T1 tumors at 1, 3, and 6 weeks revealed a decline in T cell-associated genes from 194 at 1 week to 156 at 6 weeks, with a significant late-stage loss of TCR diversity and contraction of natural killer T (NKT)- and γδ T cell-related transcripts. Cytokine and transcription factor dynamics reflected temporal T cell polarization: early (1 week) IL-12α/β-STAT4 signaling supports CD4+ type 1 T helper cell (Th1) and type 1 CD8+ cytotoxic T cell (Tc1) responses; intermediate (3 weeks) IL-21 and BCL6 expression suggest transient CD8+ cytotoxic follicular T cell (Tfc) skewing; and late (6 weeks) AhR and IL-1β induction reflect interleukin 17/22 producing CD8+ T cell (Tc17/Tc22) transition. Pro-inflammatory cytokines and chemokines increased over time, while immunosuppressive mediators (e.g., IL-10) declined significantly. Antigen-presenting cell (APC)-T cell crosstalk deteriorated at 6 weeks, characterized by a reduction in the expression of co-stimulatory and APC genes. Despite an early dominance of M1-like macrophage signals (e.g., IL-12α/β), persistent expression of arginase 1 (ARG1) and other M2-associated genes indicated a stable tolerogenic niche. Conclusions TNBC progression is characterized by progressive T cell functional decline, narrowing of TCR diversity, impaired APC-T cell interactions, and sustained macrophage-driven immunosuppression. These temporally coordinated immune shifts suggest tumor-driven adaptation toward immune evasion and identify potential windows for stage-specific immunotherapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb0d181b971ab9d5141b1475ee18608b8080d802" target='_blank'>
              Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors
              </a>
            </td>
          <td>
            Md. Iftehimul, Robert H. Newman, Scott H Harrison, Roshonda B. Jones, P. Muganda, Bryan L. Holloman, M. T. Hossain, C. J. Rorie, Misty D. Thomas, Joseph L. Graves, H. Kaufman, Dipongkor Saha
          </td>
          <td>2025-10-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3443903af73c8ea2603fc42506194395d5951dde" target='_blank'>
              Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
              </a>
            </td>
          <td>
            Chien-Huan Weng, Anais Assouvie, Lauren Dong, JC Beltra, S. Budhu, L. Mangarin, Yacine Marouf, Lucia Morgado-Palacin, Cailian Liu, Sébastien Monette, Jonathan F. Khan, Isabell Schulze, Dmitry Zamarin, Linda Hamadene, Fadi Samaan, Daniel Hirschhorn, S. Pourpe, David Schröder, R. Zappasodi, Pamela M. Holland, N. Anandasabapathy, E. Wherry, J. Wolchok, T. Merghoub
          </td>
          <td>2025-11-17</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>170</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/73a6affa626cddbc311a72d5431b139dc8c83520" target='_blank'>
              IgD-Expressing Mature B Cells Exhibit Enhanced Sensitivity to Glucocorticoid-Induced Cell Death
              </a>
            </td>
          <td>
            Kais Almohammad, Marc Young, S. Vettorazzi, Franziska Greulich, Mahmoud Alkhatib, J. Tuckermann, H. Jumaa, Corinna S. Setz
          </td>
          <td>2025-10-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="


 Introduction:
 Chronic Lymphocytic Leukemia (CLL) results in the expansion of immunosuppressive B-cells leading to risk for secondary malignancies, infection, and suboptimal T-cell based immunotherapeutic responses. Treatments that restore immune function (e.g. ibrutinib) may improve the efficacy of CD19 CAR T-cell (CART) therapies. We previously demonstrated that venetoclax (Ven) causes complex immunologic changes which broadly improve circulating immune cell (including T-cell) function. While we found that Ven appears to improve CD19 CART cytotoxicity in most patients, some CD19 CAR T-cells manufactured after Ven treatment did not perform as well in ex vivo cytotoxicity assays. We performed a multiomic correlation analysis to elucidate germane molecular features that may help predict and optimize Ven-enhanced CD19 CART cytotoxicity.
 Methods:
 We collected peripheral blood mononuclear cells (PBMCs) and serum from 13 consented CLL patients initiating standard of care Ven-based therapy (Ven-monotherapy N = 9, Ven+ɑCD20 N = 4; BDR-164122). Specimens were collected before treatment (D0) and after 30 days (D30) of therapy. CD19 CART were manufactured for 6 patients at both timepoints using an ɑCD19 construct (scFv/CD28/TCRζ via retroviral transduction). Cytotoxicity was measured against Raji-Luciferase cells. D0 and D30 specimens were analyzed by flow cytometry (including T-cell subsets and exhaustion markers) and RNA-seq (with xCell for cell-type deconvolution, rMATS for splicing, LISA for master regulator analysis). Enrichment analysis identified biological processes linked to cytotoxicity with statistical significance calculated as False Discovery Rate (FDR) adjusted P value. Metabolomics were performed with the Biocrates MxP Quant 500 XL assay. For each multiomic feature, magnitude change from D0 to D30 was calculated. These changes were correlated with changes in CD19 CART ytotoxicity across 7 effector-to-target ratios (1:8 through 8:1) using Spearman's correlation.
 Results:
 Enhanced CD19 CART cytotoxicity correlated with increased NK-cell frequency (CD56+/CD57+, CD56-/CD57+) determined by flow cytometry and cell-type deconvolution. In addition, RNA sequencing studies demonstrated that CD19 CART activity correlated with gene expression changes in interferon-ɑ (IFNA1, FDR<0.001) and interferon-ɣ (IFNG, FDR<0.002) response pathways. Specifically, an increase in key interferon signaling genes (GZMA, STAT1, CASP1) were associated with improved CD19 CART cytotoxicity. Moreover, a decrease in some interferon signaling genes (JAK2, STAT2, IFNAR2) was associated with a decrease in CD19 CART activity. LISA analysis identified POU2F2 and HDAC1 as key transcriptional regulators of genes associated with enhanced post-Ven CD19 CART killing. Elevated anti-inflammatory metabolites (cortisol, cortisone), as well as cysteine and phosphatidyl lipids correlated with improved CD19 CART cytotoxicity. Diminished CD19 CART cytotoxicity correlated with increased CD4+ LAG3+ T-cells coexpressing TIM3/TIGIT, and total CD3+ T-cells. Cell-type deconvolution demonstrated an inverse correlation between regulatory T-cells (T-regs) and CD19 CART cytotoxicity. Increase in NFκB signaling and splicing factor genes (e.g. RELA, RELB, NFKB1, NFKB2, TNF, U2AF1, U2AF2) were associated with a decrease in CD19 CART cytotoxicity (FDR<0.001). Alternative splicing by rMATS analysis identified a MAP3K7 (TAK1) event resulting in a TAK1 variant lacking its negative regulatory domain. This alternative splice form of TAK1 enhances NFκB signaling and impacts CD19 CART activity. Elevated serum triacylglycerols, GABA, spermine, and taurine detected by metabolic studies correlated with diminished CD19 CART cytotoxicity. Conclusion: Using a comprehensive multiomic approach we uncovered signaling pathways associated with improved CD19 CART activity following Ven-based therapy in CLL patients. The activation of the interferon-ɑ, interferon-ɣ and glucocorticoid signaling pathways enhance CART activity. In contrast, NFκB signaling and spliceosome-related pathways contribute to sustained immune activation and negative impacts on CAR T-cell function. Venetoclax treatment appears to alter T-cell (especially T-reg) and NK-cell subtypes, which influence the anti-tumor activity of CD19 CAR T-cells. Our work provides a foundation for further mechanistic inquiry into Ven-related immunologic impacts, which can improve synergistic combination treatments using CART for CLL patients.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be9262399f1e435c641b61481400c69897fe78fa" target='_blank'>
              Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL)
              </a>
            </td>
          <td>
            Jacob Wright, F. Hernandez-Ilizaliturri, C. Mavis, Joseph Tario, Alex Niu, Taylor K Mandeville, Dorothy C. Pan, Grant Schofield, , Joseph Barbi, Hua-Hsin Hsiao, Spencer Rosario, M. Cortese
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 IntroductionChronic lymphocytic leukemia (CLL) is marked by profound immune dysregulation, which compromises both the numerical and functional integrity of the T cell compartment, posing significant challenges for chimeric antigen receptor (CAR) T-cell therapy. CLL patients often exhibit an elevated expression of inhibitory receptors such as PD-1 and CTLA-4 on their T cells. Additionally, the immunosuppressive microenvironment in these patients is marked by the predominance of effector and effector memory T cells, which are less capable of sustaining long-term immune responses. Prior studies, including work from our group (Fraietta JA et al., 2018), have highlighted the importance of early memory T cell subsets in promoting CAR T cell expansion, persistence, and anti-tumor efficacy. However, these subsets are intrinsically rare in CLL, limiting the success of manufacturing strategies that rely on their enrichment or ex-vivo expansion. Studies by Ludwig LM et al. (2021) and van Bruggen JAC et al. (2022) demonstrated that short-term Venetoclax treatment selectively depletes naive T cells, but prolonged therapy led to their numerical recovery along with upregulation of OXPHOS and glycolysis pathways. However, the effects of Venetoclax on T-cell functionality and its implications for CAR T-cell manufacturing remain uncertain. We aimed to study if treatment with Venetoclax could improve the qualitative and quantitative defects in the T cells in CLL patients ensuring better CAR T-cells and identify the ideal timepoint following treatment to collect T cells for CAR T manufacturing.
 MethodsWe analyzed peripheral blood samples from discovery (n=14) and validation (n=23) cohorts of CLL patients, with one or more prior lines of therapy, treated with Venetoclax monotherapy or in combination with the anti-CD20 antibody Obinutuzumab. Deep phenotyping of T cells and their response to activation with PMA and Ionomycin was performed using a spectral flow cytometry panel. CD19-directed CAR T cells (incorporating the 4-1BB costimulatory domain) were manufactured, and their proliferation and anti-tumor efficacy were assessed by flow cytometry and restimulation assays in vitro. Statistical analyses were performed using the Friedman test, 2-way ANOVA or Kruskal Wallis test, as appropriate.
 ResultsTreatment with Venetoclax improved the qualitative and quantitative T cell defects with a significant increase in the proportion of naïve (CD45RA+CD27+CCR7+) T cells (both CD4+ and CD8+) and decrease in the effector memory (CD45RA-CD27-CCR7-) compartment. Both manual gating and unsupervised clustering analysis showed a significant decrease in the frequency of regulatory T cells (Tregs) and T cells expressing markers of effector differentiation (KLRG1, CD244, EOMES) and inhibition/exhaustion markers (PD1, CD39, CTLA4, TIGIT). The differences were more pronounced after 1 year of treatment and the findings were confirmed in an independent validation cohort. Upon activation, the treatment-naive samples showed a significant increase (percentage or absolute) in the expression of activation-exhaustion markers (ICOS, PD1, TIM3, TIGIT, CTLA4) while the increase was more restrained after Venetoclax treatment. CAR T-cells were manufactured and functionally assessed through co-culture and repeated stimulation with the aggressive, MHC-deficient CD19+ leukemia cell line NALM6. CAR T-cells manufactured with samples one year post treatment with Venetoclax exhibited greater fold expansion and population doublings on repeat stimulation with NALM6 cells compared to their paired treatment-naive samples. Cytokine analysis and cytotoxicity assays are currently being performed to strengthen our findings.
 ConclusionOur findings strongly suggest that the BCL2 inhibitor Venetoclax exerts beneficial immunomodulatory effects beyond their primary anti-tumor activity. By reducing tumor burden and potentially directly influencing T cell biology, Venetoclax facilitates not only quantitative T cell recovery but also qualitative improvements. Such improvements include phenotypic shifts away from exhaustion and towards less differentiated states (potentially enriching for early memory precursors) and the restoration of key T cell functions like proliferation and cytokine production - factors that may significantly improve CAR T cell manufacturing and therapeutic efficacy.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b0f58a6bf6fe69cb96d274bc1c6f4165ac0c965" target='_blank'>
              Venetoclax enhances T cell fitness and CAR T-cell manufacturing potential in chronic lymphocytic leukemia (CLL)
              </a>
            </td>
          <td>
            Arun Arunachalam, Beatriz Coutinho de Oliveira, Céline Grégoire, Ziran Zhao, Lily Simpson-Heavey, John C. Molina, A. Kater, F. Peters, A. Wiestner, J. Woyach, J. Melenhorst
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2dfa1103b42fb7aad2cf0d81519ef11fa1c555b5" target='_blank'>
              Proteomic profiling of the neuroblastoma secretome identifies extracellular vesicles as drivers of T cell suppression
              </a>
            </td>
          <td>
            Josephine G. M. Strijker, Ronja E. van Berkum, Elisavet Kalaitsidou, Arjan Boltjes, Naima Hiddink Verberne, Mirjam A. Damen, F. van den Ham, Liselotte E. Baaij, John Anderson, Jan J. Molenaar, Wei Wu, J. Wienke
          </td>
          <td>2025-12-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/53c31a8b62c99e8b1b20919ae0dd83a4ebc80b99" target='_blank'>
              Targeting Endothelial PERK Accelerates Lymphoid Regeneration by Enhancing DLL4-NOTCH3 Signaling at the Pre-B Niche
              </a>
            </td>
          <td>
            Bingqing Zou, Qiuyun Chen, Junjun Zheng, Yimin Ma, Jay Myers, Yinghui Shang, Mofei Huang, Paul Christensen, Stanley Adoro, Chih-Hang Anthony Tang, Chih-Chi Andrew Hu, S. Pingali, Wei Xin, Keith Syson Chan, Stephen Wong, Y. Zu, H. Jafar-Nejad, Lan Zhou
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>47</td>
        </tr>

        <tr id="Aberrant and sustained activation of microglia is implicated in the progression and severity of multiple sclerosis (MS). However, whether intrinsic alterations in microglial function impact the pathogenesis of this disease remains unclear. We conducted transcriptomic and functional analyses of microglia-like cells (iMGLs) differentiated from induced pluripotent stem cells (iPSCs) from patients with MS (pwMS) to answer this question. We generated iPSCs from six pwMS showing increased microglial activity via translocator protein (TSPO)-PET imaging. We demonstrated that the differentiated iMGL transcriptional profile resembled the microglial signature found in MS lesions. Importantly, compared with healthy controls, MS iMGLs presented cell-autonomous differences in their regulation of inflammation, both in the basal state and following inflammatory lipopolysaccharide challenge. Through transcriptomic profiling, we showed that MS iMGLs display increased expression of genes known to be upregulated in MS microglia. Furthermore, upregulated genes in MS iMGLs were associated with immune receptor activation, antigen presentation, and the complement system, with known MS implications. Finally, functional analyses indicated that the transcriptional changes in MS iMGLs corresponded with alterations in the secretion of inflammatory cytokines and chemokines and increased phagocytosis. Together, our results provide evidence of putative cell-autonomous microglial activation in pwMS and identify transcriptomic and functional changes that recapitulate the phenotypes observed in vivo in microglia from pwMS. These findings indicate that MS disease-specific iPSCs are valuable tools for studying disease-specific microglial activation in vitro and highlight microglia as potential therapeutic targets in MS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ce483627b1620ca8e2ea90bf499e8cad452ba523" target='_blank'>
              Microglia from patients with multiple sclerosis display a cell-autonomous immune activation state
              </a>
            </td>
          <td>
            Tanja Hyvärinen, J. Lotila, Luca Giudice, Iisa Tujula, M. Nylund, S. Ohtonen, Flavia Scoyni, Henna Jäntti, Sara Pihlava, H. Skottman, Susanna Narkilahti, L. Airas, T. Malm, S. Hagman
          </td>
          <td>2024-12-11</td>
          <td>Journal of Neuroinflammation</td>
          <td>2</td>
          <td>47</td>
        </tr>

        <tr id="Glioblastoma (GBM) is an aggressive malignant brain tumor, characterized by a poor prognosis and a limited response to chemoradiotherapy and immunotherapy. Increasing evidence indicates that the extracellular matrix (ECM), particularly collagen proteins, contributes to tumor progression and immune evasion. In this study, we identified COL1A2, COL6A2, COL8A1, and COL8A2 as survival‐related genes that were overexpressed in GBM and significantly upregulated in short‐term survivors. Subsequently, COL6A2 was verified to be associated with chemotherapy and immunosuppression. Functional assays demonstrated that COL6A2 promotes GBM cell proliferation, invasion, and chemoresistance. Cytometry by time‐of‐flight (CyTOF) and Tumor Immune Estimation Resource (TIMER) analysis revealed that high COL6A2 expression correlates with immunosuppressive features in the tumor microenvironment, particularly the accumulation of immature dendritic cells (DCs) and impaired cytotoxic T‐cell activity. Mechanistically, COL6A2 silencing restored DCs' activation and enhanced the infiltration and function of effector immune cells. Our findings highlight COL6A2 as a key oncogenic and immunomodulatory ECM component in GBM and suggest that targeting collagen‐mediated immune suppression may improve therapeutic outcomes in GBM patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d03956fd27bf7fdf9ad85cbf61b6fa3fe001ebf" target='_blank'>
              COL6A2: A Key Survival‐Related Gene and Restricting Antitumor Immunity in Glioblastoma
              </a>
            </td>
          <td>
            Zhenkun Yang, Jiao Meng, Daxing Xu, Jie Li, Fan Kong, Ying Yin, Bo Zhang, Yunhui Pan, Jiantong Jiao, Xinyi Jiang, Zhening Pu
          </td>
          <td>2025-10-11</td>
          <td>Cancer Science</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Radiation-induced skin injury (RISI) is a common and debilitating complication of radiotherapy, characterized by persistent inflammation and delayed wound healing. Macrophages play a central role in this process; however, the molecular mechanisms governing their dysfunction under radiation stress remain poorly understood. To elucidate the role of triggering receptor expressed on myeloid cells 2 (TREM2) in macrophage regulation after irradiation, we combined single-cell RNA sequencing, in vivo mouse models, and in vitro macrophage assays. Conditional knockout mice (LysMCreTrem2flox/flox) were used to selectively delete Trem2 in macrophages. Radiation induced a distinct TREM2+ macrophage subset; however, despite elevated Trem2 mRNA, protein levels declined due to ADAM17-mediated shedding driven by radiation-induced reactive oxygen species (ROS) accumulation and NRF2 activation. Inhibition or small interfering RNA (siRNA)-mediated knockdown of ADAM17 restored TREM2 protein expression, reduced soluble TREM2 release, improved macrophage survival, and promoted anti-inflammatory M2 polarization. Conversely, Trem2 deficiency enhanced apoptosis, sustained inflammation, and delayed wound healing, whereas Trem2 overexpression or local adoptive transfer of TREM2+ macrophages accelerated tissue repair. Mechanistically, TREM2 conferred radioprotection through extracellular signal-regulated kinase (ERK) pathway activation, linking the ROS–NRF2–ADAM17 axis to TREM2–ERK signaling in macrophage survival and polarization. Collectively, these findings identify a novel regulatory cascade, ROS–NRF2–ADAM17–TREM2–ERK, that governs macrophage fate under irradiation. Targeting this pathway or supplementing TREM2+ macrophages may offer promising therapeutic strategies for mitigating RISI.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5e8bb0105bfc306e09e4c0af1d74cb3671e412a" target='_blank'>
              TREM2 Deficiency Regulates Macrophage Apoptosis and Repair in Radiation-Induced Skin Injury
              </a>
            </td>
          <td>
            Zijian Chen, siyuan cai, Pengfei Li, ziyi zhou, zhenxing huang, juntao deng, Linbo Jin, Zucheng Luo, Dongli Fan, Junli Zhou, Fazhi Qi, Yiming Zhang
          </td>
          <td>2025-11-13</td>
          <td>Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Autoimmune diseases represent a broad group of chronic conditions characterized by loss of immune tolerance, autoreactive lymphocyte activation, and pathogenic autoantibody production. CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for hematologic malignancies, has emerged as a promising strategy to directly eliminate autoreactive B cells and reprogram immune function. CD19-CAR T infusion can induce rapid remission, reduce autoantibody levels, and sustain drug-free disease control. Despite these encouraging results, current evidence is limited to small patient cohorts with short follow-up, leaving uncertainties regarding long-term safety, durability of remission, and the stability of immune reconstitution. Most studies implicitly assume that quantitative B-cell recovery equates to restored immune health, yet the functional resilience of the post-CAR-T immune system—its ability to protect against infection, respond to vaccines, and maintain durable tolerance—remains unexplored. To address this gap, we propose an integrated framework for evaluating the functional competence of immune reconstitution following CAR T-cell therapy and for designing next-generation targeting strategies. Functional recovery should be assessed not only by quantitative B-cell repopulation but also by vaccine responsiveness, infection surveillance, and immune repertoire diversity. Vaccine challenge studies and infection monitoring can reveal whether protective immunity is restored, while sequencing-based profiling of B- and T-cell repertoires can clarify whether regulatory balance and clonal diversity are re-established. In parallel, translational innovations such as dual-target CAR constructs (e.g., CD19 + BAFF-R) and chimeric autoantibody receptor (CAAR) T cells offer complementary solutions to broaden target coverage and improve selectivity. Moreover, Epstein–Barr virus (EBV)–mediated immortalization of patient-derived autoreactive B cells provides a feasible ex vivo platform for generating physiologically relevant antigenic stimuli during CAR engineering. This approach could yield T cells that are functionally “educated” to eliminate pathogenic clones while preserving protective immunity, thereby addressing the central challenge of rebuilding a resilient and tolerant immune system.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/803ca15907028d5ecd42afcef39a38a8ff458830" target='_blank'>
              Application of CD19-CAR T cell therapy in autoimmune diseases
              </a>
            </td>
          <td>
            Lynn Choi
          </td>
          <td>2025-10-24</td>
          <td>Journal of High School Science</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 T cell-based immunotherapies have shown limited efficacy in acute myeloid leukemia (AML), likely due to an incomplete understanding of how leukemia reshapes the T cell compartment. To address this, we performed a multi-platform study integrating high-dimensional proteomics, single-cell multiomics, and in vivo modeling to dissect CD8 T cell dynamics in AML.
 Using high-dimensional mass cytometry, we profiled diagnostic (untreated) bone marrow samples from 46 AML patients and 5 healthy donors with two panels: one assessing the broader hematopoietic landscape and another focused on T cell phenotypes. AML samples exhibited a marked depletion of naïve CD8 T cells and enrichment of terminal effector (TEMRA) cells characterized by CD57, granzyme B, and perforin. While reduced naïve T cells correlated with expansion of HSPC-like progenitor cells, no specific myeloid or progenitor phenotype was associated with the presence of TEMRA cells.
 To examine transcriptional states and clonal architecture, we performed single-cell RNA and TCR sequencing on marrow-derived CD45+CD3+ T cells from 16 AML patients. Differential gene expression revealed that CD8 T cells from patients who achieved remission after induction chemotherapy were enriched for activation and cytokine-response pathways, suggesting that a pre-existing activated T cell program may support leukemic clearance in response to chemotherapy.
 TCR sequencing uncovered highly expanded CD8 T cell clones in several patients. Two individuals with TP53-mutant AML exhibited extreme clonal dominance, with single clones comprising ~50% of their marrow CD8 T cells. Overall, highly expanded clones (>10% of the patient's CD8s) showed enrichment in granzyme-mediated cell death and myeloid leukocyte activation pathways, yet lacked classical markers of exhaustion such as PDCD1 or LAG3. These findings suggest a non-canonical effector state that is potentially functional, diverging from the exhausted T cell phenotypes described in solid tumors or chronic viral infection.
 We mapped TCR sequences against public databases and identified CMV-specific clones in three AML patients. Two of these comprised >10% of the marrow CD8 T cell population, while the third represented ~1% of its respective sample. Given that the bone marrow is both the primary site of disease and a reservoir for resident memory T cells, these findings suggest that the leukemic niche may remodel both tumor-specific and bystander viral-specific T cells. CMV-specific clones expressed higher levels of SLAMF6 and GZMB. In contrast, non-viral expanded clones (potentially leukemia reactive) expressed higher levels of GNLY and NFKB1, suggesting distinct effector programs shaped by viral vs tumor-associated antigen exposure in AML.
 To interrogate CD8 dynamics in vivo, we employed three unconditioned (non-irradiated) immunocompetent mouse models of AML representing diverse genetic drivers. Transformed progenitor cells expressing Mll-Af9 or overexpressing Meis1 and Hoxa9 robustly engrafted in CD45.1+ hosts, as did bone marrow cells from an inducible Flt3ITD-Npm1c double-mutant model (Bowman 2024). Across all models, leukemia reduced CD8 T cell frequency in blood, spleen, and lymph nodes, but CD8 T cells were relatively preserved, and even enriched, within the bone marrow as a proportion of CD45.1+ host cells. This marrow-specific retention suggests selective expansion or maintenance of CD8 T cells in the leukemic niche.
 Ex vivo stimulation of AML-exposed marrow CD8 T cells with PMA and ionomycin demonstrated preserved, and in some cases enhanced, IFNγ production. Transcriptomic profiling of effector CD8 T cells from Mll-Af9 leukemic mice showed upregulation of proliferation and inflammation pathways, including E2F targets and G2M checkpoints, mirroring the activation patterns observed in patient samples.
 These findings identify a conserved terminal effector CD8 T cell phenotype in AML across diverse human and mouse systems. This population is clonally expanded, transcriptionally active, and functionally competent. Highly clonal CD8 T cell populations expressed cytotoxic gene programs without classical features of exhaustion. The presence of expanded CMV-specific clones further suggests that the AML marrow niche also shapes bystander T cells. These insights highlight preserved cytotoxic potential within the AML-associated CD8 T cell pool and suggest opportunities to refine immunotherapy strategies that leverage this effector compartment.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ca3b8fbb09173ac2b4c57e90b450510fa26803f4" target='_blank'>
              The Acute Myeloid Leukemia microenvironment is defined by ineffective immune surveillance despite the presence of activated, clonally-expanded CD8 T cells with preserved effector function
              </a>
            </td>
          <td>
            , Matthew Cottam, Chad R. Potts, Matthew T. Jenkins, Justin Cartailler, Rui Lu, Stanley Lee, Robert Bowman, R. Welner, Brent Ferrell
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="


 Despite major advances in immunotherapy, respective treatments often show only limited benefit in patients with chronic lymphocytic leukemia (CLL). Immune checkpoint blockade, which has shown durable responses in multiple malignancies, has yielded inferior efficacy in CLL. Similarly, adoptive CAR-T cell therapy, which has achieved remarkable success in other B cell malignancies, resulted in lower response rates in CLL. The lack of success of these immunotherapies is likely due to the profound T cell dysfunction and immune suppressive microenvironment, typical characteristics of this disease. The so-called “exhaustion” of T cells is marked by impaired effector capacity, sustained inhibitory receptor expression, and loss of progenitor exhausted (TPEX) populations, cell subsets which are critical for responses to PD-1 blockade. This suggests that reversing T cell exhaustion could be key to improving outcomes.
 Emerging evidence implicates the immunoregulatory cytokine interleukin-10 (IL-10) as a context-dependent modulator of T cell exhaustion. While traditionally viewed as an immunosuppressive mediator that limits tissue damage during chronic inflammation and suppresses antiviral immunity, IL-10 may, in cancer, enhance tumor-infiltrating CD8⁺ T cell function, prolong their survival, and delay T cell exhaustion.
 Using the Eµ-TCL1 adoptive transfer (TCL1-AT) mouse model of CLL, we previously identified a role for IL-10 receptor (IL-10R)–STAT3 signaling in sustaining CD8⁺ TPEX cells, preventing terminal exhaustion, with loss of signaling accelerating CLL progression (Hanna et al., Immunity 2021). As IL-10 expression is linked to better outcome in CLL patients and IL-10R loss is associated with DLBCL development early in life, we hypothesize that IL-10 improves the fitness of cytotoxic T cells thereby preventing immune escape in CLL and likely other B cell malignancies.
 To test the potential of IL-10 in modulating T cell responses against CLL, we generated a stabilized IL-10 fusion protein (IL-10-Fc) and demonstrated that treatment of TCL1-AT mice with IL-10-Fc slowed CLL progression, reduced exhausted effector T cells, and preserved TPEX populations.
 To dissect T cell-intrinsic effects, we employed an in vitro exhaustion assay by repetitive antigen-specific stimulation of T cell receptor (TCR)-transgenic murine CD8⁺ T cells with peptide-loaded target cells. IL-10 treatment maintained effector T cells in these cocultures, reduced terminal exhaustion markers TIM-3 and CD39, and promoted a polyfunctional phenotype with robust cytokine production and CD107a expression, demonstrating a direct effect of IL-10 on T cell fitness.
 To gain a broader view of IL-10-mediated immune modulation in the TCL1-AT model, we performed spectral flow cytometry and single-cell RNA-sequencing following short-term IL-10-Fc treatment. Both T cell and myeloid compartments displayed therapy-induced alterations, including shifts in regulatory T cells, CD8⁺ T cells, neutrophils, and monocytes. Notably, IL-10-Fc reduced PD-L1⁺ patrolling monocytes, which were linked to immune suppression in CLL, and increased inflammatory monocytes, which suggests a reversal of pro-tumoral myeloid activity.
 Finally, a pilot combination treatment study revealed that IL-10-Fc synergized with the BTK inhibitor ibrutinib, achieving profound disease control in the TCL1-AT mouse model beyond either agent alone. These findings position IL-10 as a promising immunomodulatory therapy in CLL, capable of restoring T cell function and remodeling the suppressive tumor microenvironment.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/189bf152f9c8c3a59e8922ef6b9ef1ab630e8fe4" target='_blank'>
              IL‑10 limits CLL progression by reprogramming T cell exhaustion and myeloid suppression
              </a>
            </td>
          <td>
            A. Floerchinger, Min Gao, Jan Philipp Schadendorf, Yuliia Borysovych, Nicolas Aubert, Hannah Briesch, L-M Pilger, Mei-Wen Peng, P. Lichter, Stella E. Autenrieth, M. Zapatka, L. Tang, M. Seiffert
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>55</td>
        </tr>

        <tr id="Glioblastoma (GBM) is characterized by fast progression, infiltrative growth pattern, and a high relapse rate. A defining feature of GBM is the existence of spatially and functionally distinct cellular niches, where malignant cells engage in paracrine crosstalk with cell types comprising the tumor microenvironment. Here, we identify pericytes as the most active paracrine signaling hub within the tumor parenchyma. Their depletion through genetic engineering results in accelerated tumor progression and shortened survival. Mechanistic studies reveal that pericyte deficiency remodels the endothelium and impacts the immune cell landscape, exacerbating tumor cell invasion and immune suppression. Specifically, the pericyte-deprived endothelium recruits perivascular, tumor-associated macrophages polarized towards an immune-suppressive phenotype. The recruited macrophages express Hepatocyte Growth Factor, which reinforces activation of its receptor tyrosine kinase MET on GBM cells harboring a pronounced mesenchymal subtype driven by the key phenotypic regulator Fosl1. Indeed, orthotopic implantation of MET-expressing GBM cells corroborates their superior tumor-initiating and invasive capabilities. Thus, pericytes represent critical modulators of GBM development by orchestrating a tumor-suppressive microenvironment, highlighting the importance of their preservation in therapy. Improved understanding of the tumor ecosystem in glioblastoma is critical for developing new treatment strategies for the disease. Here, the authors identify pericytes as an active paracrine signaling hub within the tumor parenchyma that orchestrates a tumor-suppressive microenvironment, suggesting pericyte preservation as a key feature of future therapeutic regimens for glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c09a05790107e087a632df06714ceec3176e20b4" target='_blank'>
              Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma
              </a>
            </td>
          <td>
            S. Braun, P. Bolivar, C. Oudenaarden, J. Sjölund, M. Bocci, K. Harbst, Mehrnaz Safaee Talkhoncheh, B. Phung, E. Cordero, R. Rosberg, E. Johansson, G. Jönsson, A. Pietras, Kristian Pietras
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that accumulate under pathological conditions such as cancer, where they contribute to immune evasion, tumor progression, and resistance to therapy. These cells exert potent immunosuppressive effects by inhibiting T cell activation, inducing regulatory T cells, modulating antigen-presenting cells, and shaping an immunosuppressive tumor microenvironment (TME). Their suppressive functions involve multiple mechanisms, including amino acid depletion, production of reactive oxygen and nitrogen species, expression of immune checkpoint ligands, and secretion of immunoregulatory cytokines such as IL-10 and TGF-β. Besides these immune-related roles, MDSCs also promote tumor growth through non-immunological mechanisms, including the stimulation of angiogenesis and undergoing metabolic reprogramming. These adaptations support their survival and function in the hostile TME. Given their multifaceted role in cancer, MDSCs represent a promising target for therapeutic intervention. Furthermore, their abundance and dynamic modulation during treatment confer them tremendous potential as biomarkers to monitor therapy efficacy and stratify patients. This review provides a comprehensive overview of MDSC biology, their mechanisms of action, and their emerging clinical relevance as biomarkers and therapeutic targets. We also explore current strategies aimed at targeting MDSCs, including their depletion, inhibition of recruitment, functional blockade, and promotion of their differentiation into mature myeloid cells. Integrating these approaches with existing cancer therapies holds great promise for enhancing antitumor immunity and overcoming resistance in both solid tumors and hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d195f524c3054c9a1106fbc8581ac237b69c234e" target='_blank'>
              Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
              </a>
            </td>
          <td>
            S. Silva-Romeiro, Rocio del, Carmen Flores-Campos, M. L. Sánchez-León, V. Sánchez-Margalet, L. Cruz-Merino, María, Luisa Sánchez-León
          </td>
          <td>2025-11-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Hematopoietic stem cells (HSC) sustain lifelong blood and immune system homeostasis. This study identifies P-selectin as a pivotal regulator of HSC function under aging and inflammatory stress. We observed pronounced Selp upregulation in aged HSC and inflammatory contexts, which drives excessive proliferation and differentiation while depleting their long-term self-renewal capacity. Using tissue-specific Selp overexpression models, we demonstrate that chronic Selp elevation disrupts HSC polarity, promotes oxidative stress accumulation, and induces genomic instability. Over time, sustained Selp expression leading to LT-HSC exhaustion and impaired hematopoietic reconstitution. Single-cell transcriptomics revealed that Selp enforces a pro-inflammatory transcriptional program in HSC, hyperactivating IFN-γ and PI3K-AKT-MOTR signaling pathways. Mechanistically, P-selectin directly interacted with IFNγR1 on the HSC surface, which driving activation of JAK1-STAT1 and PI3K-AKT-mTOR signaling axes. Notably, Selp overexpression suppresses the pathogenic capacity of leukemia stem cells (LSC), highlighting potential therapeutic implications. Our findings established P-selectin as a molecular nexus linking chronic inflammation and aging to hematopoietic decline, with dual therapeutic implications: targeting P-selectin may mitigate age-related hematopoietic dysfunction while offering a strategy to selectively impair LSC activity in malignancies. Selp is significantly elevated in aged HSC and under inflammatory conditions, driving HSC into active proliferation and differentiation while diminishing their ability to maintain quiescence. Selp upregulation disrupts HSC polarity, increases oxidative stress, and promotes genomic instability, long-term Selp overexpression leads to HSC exhaustion and reduced hematopoietic reconstitution capacity. Selp overexpression exacerbates inflammatory signaling in HSC, particularly through IFN-γ-PI3K-AKT-MOTR pathways. Selp overexpression reduces the pathogenic capacity of leukemia stem cells. Selp is significantly elevated in aged HSC and under inflammatory conditions, driving HSC into active proliferation and differentiation while diminishing their ability to maintain quiescence. Selp upregulation disrupts HSC polarity, increases oxidative stress, and promotes genomic instability, long-term Selp overexpression leads to HSC exhaustion and reduced hematopoietic reconstitution capacity. Selp overexpression exacerbates inflammatory signaling in HSC, particularly through IFN-γ-PI3K-AKT-MOTR pathways. Selp overexpression reduces the pathogenic capacity of leukemia stem cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c21f4b81053b964ca22b1df90c8ef3097f1bd773" target='_blank'>
              P-selectin overexpression impairs hematopoietic stem cell homeostasis via inflammatory receptor-mediated proliferation and differentiation
              </a>
            </td>
          <td>
            Wei He, Huandi Qiu, Yun-lu Feng, Q. Qiu, Li Zheng, Congbin Pan, Xue Cui, Yuanyuan Sun, Bochuan Wang, Yiguo Hu
          </td>
          <td>2025-10-21</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Monocyte-derived cells, including osteoclasts, dendritic cells, and macrophages, are key components of the immunosuppressive tumor microenvironment in multiple myeloma (MM). However, the mechanisms linking monocyte dysfunction to immune evasion remain incompletely understood. In this study, single-cell RNA sequencing (scRNA-seq) of peripheral blood (PB) and bone marrow (BM) monocytes was performed from healthy donors (HDs) and MM patients to generate a comprehensive single-cell transcriptional map. Although PB and BM monocytes displayed comparable cellular compositions, MM monocytes exhibited marked transcriptional alterations, most prominently within the type I interferon (IFN) signaling pathway. Trajectory analyses revealed IFN-driven disruptions in monocyte differentiation and developmental trajectories in both PB and BM compartments. Functional co-culture assays demonstrated that activation of the type I IFN pathway enhanced MM cell proliferation, suggesting that IFN-mediated monocyte reprogramming facilitates tumor progression. In an independent validation cohort, longitudinal sampling before and after induction therapy confirmed that anti-myeloma treatment alleviated the excessive IFN response of BM monocytes. Collectively, these findings uncover a mechanistic link between aberrant IFN activation and monocyte dysregulation in MM, providing new insights into immune dysfunction and highlighting the IFN pathway as a potential therapeutic target to restore anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c95b600545a3e90a13c96978be5b8e9b2126411" target='_blank'>
              Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
              </a>
            </td>
          <td>
            Jian Cui, Jingwei Wang, Xiaoyun Li, Lina Wang, X. Mao, Rui Lyv, Wenqiang Yan, Jingyu Xu, Jieqiong Zhou, Chenxing Du, Shuhui Deng, Mu Hao, Yan Xu, Shuhua Yi, D. Zou, Tao Cheng, Xin Gao, Lugui Qiu, Gang An
          </td>
          <td>2025-11-30</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Mucosal‐associated invariant T (MAIT) cells are a highly conserved population of immune cells that can be activated via the major histocompatibility complex class I‐related protein pathway or cytokine pathways, playing a central role in immune surveillance. This review provides comprehensive information on their thymic developmental origin, tissue‐specific distribution, and microbial regulatory networks, with a focus on analyzing the bidirectional regulatory mechanisms in diseases. In infectious diseases, MAIT cells eliminate pathogens through the rapid release of cytokines; however, sustained antigen exposure leads to functional exhaustion. In autoimmune diseases, their migration disorders and proinflammatory cytokine secretion of MAIT cells exacerbate tissue damage. In the tumor microenvironment, they play a paradoxical role, being capable of mediating antitumor effects while also being reprogrammed into a protumor phenotype. Based on their tissue targeting ability and functional plasticity, we discuss novel strategies for targeted therapy, including engineering chimeric antigen receptor–MAIT cells to enhance tumor killing, blocking exhaustion pathways to reverse functional impairment, and regulating the microbiota–metabolic axis to reprogram cell activity. This review integrates cutting‐edge evidence, reveals the translational potential of MAIT cells as a cross‐disease regulatory hub, and provides a theoretical framework for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b35d66b0d36f247e296da89c6cdd92c5b6962ca6" target='_blank'>
              Mucosal‐Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets
              </a>
            </td>
          <td>
            Cheng Zhu, Qian Huai, Yishan Du, Xingyu Li, Fumin Zhang, Yongkang Zhang, Mengwei Wu, Ying Dai, Xiaolei Li, Hanren Dai, Hua Wang
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7e104f926b9fda3602b303271493c55d2937a852" target='_blank'>
              Neuro-Immune Crypt-Associated Cells Drive Colorectal Carcinogenesis via REST-Mediated Phenotypic Reprogramming: Implications for Tumorigenesis and Viral Susceptibility
              </a>
            </td>
          <td>
            D. Díaz-Carballo, Adrien Noa-Bolaño, Udo Rahner, A. Acikelli, Sahitya Saka, Jacqueline Klein, Flevy D’Souza, S. Malak, Anne Höppner, Annabelle Kamitz, Carla Casula, Lalitha Kamada, Andrea Tannapfel, Jens Christmann, Sarah Albus, Enrico Fruth, Daniela Gerovska, Marcos J. Araúzo-Bravo, M. Senkal, Crista Ochsenfarth, D. Strumberg
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Immune checkpoint blockade therapies, particularly targeting PD-1/PD-L1 axis, have shown limited efficacy in glioblastoma (GBM), primarily due to the profoundly immunosuppressive tumor microenvironment dominated by glioma-associated microglia and macrophages (GAMs). While CMTM6 is known to stabilize PD-L1 in tumor cells by preventing its ubiquitin-mediated degradation, its role in microglia remains undefined. We employed a multi-omics approach to evaluate CMTM6 expression and function. By analyzing the bulk RNA-seq data sets from TCGA and CGGA, as well as single-cell data sets (TISCH2 and UCSC), the expression of CMTM6 across different glioma grades and immune cell populations was examined. Immunohistochemistry and immunofluorescence were used to validate CMTM6 expression and co-localization with microglial/macrophage markers in GBM tissues. In vitro, CMTM6 knockdown was performed in HMC3 microglial cells to assess changes in cytokine and immune checkpoint expression. In vivo, a tamoxifen-induced, microglia/macrophage-specific Cmtm6 conditional knockout mouse model was used to investigate tumor growth and survival outcomes. CMTM6 was significantly upregulated in high-grade gliomas and enriched in M2-like microglia/macrophages. Immunostaining confirmed elevated CMTM6 and CD68 expression in GBM samples, with CMTM6 co-localizing with microglial markers (CD68, IBA1, and TMEM119). By knocking down CMTM6 in HMC3 cells, the levels of CD274 (PD-L1) and TGFβ isoforms decreased, while the expression of pro-inflammatory cytokines IL6 and CCL3 increased, suggesting a shift toward an M1-like phenotype. In vivo, microglia/macrophage-specific deletion of Cmtm6 suppressed tumor growth, delayed body weight loss, and extended survival duration. This study identifies CMTM6 as a critical regulator of the immunosuppressive phenotype of microglia/macrophages in GBM. Targeting CMTM6 in microglia/macrophages may represent a novel strategy to reprogram the tumor immune microenvironment and improve the efficacy of immunotherapy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2983570a9c22d4513306860ad1a429e127cd5f00" target='_blank'>
              CMTM6 drives glioblastoma progression by promoting M2 polarization and suppressing antigen presentation in microglia/macrophages
              </a>
            </td>
          <td>
            Xiang Li, Wenbo Han, Wenpei Cai, Ruoxin Yang, Gaojie Bai, Changxiu Sun, Shiyuan Ge, Cheng Zhang, Xinyi Han, Han Yang, Yi Chen, Qiao Shan, Xiaohui Li, Xueli Tian, Yuan Lyu, Junqi Li, Xinjun Wang
          </td>
          <td>2025-10-27</td>
          <td>European Journal of Medical Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6fe00ac255b835c6c00b785eaad310b786023e" target='_blank'>
              Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer
              </a>
            </td>
          <td>
            Soham Bindu, Oishi Mukherjee, Roshni Bibi, Melvin George, Koustav Sarkar
          </td>
          <td>2025-12-06</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Multiple Myeloma (MM) is the second most frequent hematologic malignancy in adults in the Western world. The bone marrow microenvironment plays a critical role in MM progression by supporting malignant plasma cell (PC) survival, immune evasion, and proliferation. Among immune checkpoints, TIGIT has recently emerged as a relevant immunoregulatory molecule, capable of dampening cytotoxic responses and enhancing immune suppression. We investigated the expression of TIGIT in the bone marrow of newly diagnosed MM patients and its correlation with disease characteristics and microenvironmental features. We enrolled 25 consecutive patients with newly diagnosed MM. Bone marrow samples were collected for cytomorphology, cytogenetics (FISH), and immunohistochemistry using the Cytomatrix system. TIGIT expression was analyzed in bone marrow-infiltrating immune cells. Histological evaluation and confocal microscopy assessed immune cell localization, neutrophil extracellular trap (NET) formation, and proinflammatory cytokine expression. Clinical parameters, staging (ISS, R-ISS, R2-ISS), cytogenetic risk, and laboratory values were correlated with TIGIT status. TIGIT was expressed in 86% (19/22) of evaluable samples. TIGIT-positive patients had a significantly higher frequency of advanced R-ISS stages (p = 0.01), high-risk cytogenetics (100%), and elevated LDH (> 220 mU/ml, 100% TIGIT+). Among patients with PC% >60% or FLC ratio > 100, 92% were TIGIT+. Morphological differences were evident between groups: TIGIT-negative PCs were larger and altered, while TIGIT-positive PCs showed polarized nuclei and proximity to neutrophils. TIGIT-positive samples displayed increased neutrophils undergoing NETosis, as confirmed by neutrophil elastase and Ly6b co-expression (p = 0.0067). Elevated IL-6 (p = 0.0003) and IL-8 (p = 0.004) in TIGIT-positive samples suggest a proinflammatory microenvironment promoting neutrophil recruitment and NETosis. TIGIT expression in the bone marrow of MM patients is associated with more aggressive disease features and an inflammatory microenvironment enriched with NET-forming neutrophils. These findings support TIGIT as a potential biomarker of disease severity and a therapeutic target in MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2db043b94ebed36b09b59ae106115395215e9302" target='_blank'>
              Proinflammatory bone marrow niches and neutrophil activation are associated with TIGIT expression in multiple myeloma
              </a>
            </td>
          <td>
            V. Tomarchio, Francesca Arciprete, Monica Di Cecca, G. Maricchiolo, Viola Velardi, M. Tafuri, A. Bianchi, V. Morano, Barbara Mecorio, L. Rigacci, A. Crescenzi, M. Zingariello, O. Annibali
          </td>
          <td>2025-11-01</td>
          <td>Annals of Hematology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/02d1f577ff573db5c6fa1e5a829b978c4c5a4e28" target='_blank'>
              Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application
              </a>
            </td>
          <td>
            Yao Zhang, Yuting Lei, Yanzhao Huang, Yan Gao, Rong Liu, Kaiyun Guo, Chunlian Zhao, Ming Lei
          </td>
          <td>2025-12-03</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Rationale The impact of Th17 lymphocytes on epithelial responses to rhinovirus infection in asthma is poorly characterized. Methods Bronchial epithelial cells (BECs) from children with asthma were differentiated to an organotypic epithelium and primed via co-culture with healthy donor Th17 lymphocytes for 4 days prior to apical infection with human rhinovirus-16 (RV-16). RNA sequencing with WGCNA analysis was performed to identify modules of gene expression altered by Th17 priming or RV-16 infection in BECs or Th17 cells. Gene expression was correlated with viral copy number and with secreted protein levels. Results Analysis identified 4,030 genes grouped into 9 named modules with differential gene expression in BECs due to Th17 priming and viral infection. Modules with increased expression with Th17 priming and RV-16 infection included Interferon, MAP-kinase and TNF Signaling modules, while expression of Cilia structure/function and Metabolism modules were decreased. Th17 cells co-cultured with RV-16 infected BECs exhibited increased expression of an Interferon and Viral Response Module without detectable direct viral infection of Th17 cells.Increased expression of the Interferon Signaling in BECs and Interferon Response in Th17 cells was correlated with increased viral copy number in BECs. Th17 priming of BECs led to increased secretion of IFN-α, IFN-γ, and IL-1β following RV-16 as compared to BECs alone. Conclusions Th17 lymphocytes enhance epithelial interferon responses to RV-16 infection in bronchial epithelium from asthmatic children.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9bc60307b76a4b412a3e65454da49927d8bd70ac" target='_blank'>
              Viral replication and interferon responses in bronchial epithelia is enhanced by Th17 cells
              </a>
            </td>
          <td>
            Weston T. Powell, T. Janczyk, P.C. Dela Cruz, Basilin Benson, Elizabeth R. Vanderwall, C. Gates, Lucille M. Rich, M. White, N. Samanas, Kourtnie Whitfield, Gail H. Deutsch, T. Hallstrand, Matthew C. Altman, J. Debley
          </td>
          <td>2025-10-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="Macrophage activation markers, specifically CD163 and CD169, play pivotal roles in the modulation of immune responses within the tumor microenvironment (TME), influencing the outcome of various cancers. These markers delineate the activation states of macrophages, with CD163 associated with the protumoral phenotype and CD169 with activation of tumor immunity. This review comprehensively explores the dualistic roles of these markers in cancer progression and immune suppression, and discusses the mechanisms through which these markers influence macrophage behavior, the impact of their expression on cancer progression, and the therapeutic potential of targeting these pathways to reprogram the TME toward enhancing antitumor immunity. This review aims to underscore the therapeutic potential of macrophage activation markers as targets for cancer treatment, highlighting emerging strategies and future directions in cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/53fc1215ec60391859572318c1aaf77d4a3cec5e" target='_blank'>
              Therapeutic Strategies Targeting CD163 and CD169 in Macrophages for Cancer
              </a>
            </td>
          <td>
            Yukio Fujiwara, Yoshihiro Komohara
          </td>
          <td>2025-11-01</td>
          <td>Pathology International</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7fdd50ef3604bb5496e43d50c930df247607fa0" target='_blank'>
              Adenosine-specific transcriptional programs in murine connective tissue type mast cells
              </a>
            </td>
          <td>
            Qihua Liang, Volodymyr Tsvilovskyy, Anouar Belkacemi, Merima Bukva, Christin Richter, Nicole Ludwig, Andreas Keller, M. Freichel
          </td>
          <td>2025-11-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Atherosclerosis is a chronic inflammatory disease characterized by lipid accumulation and immune dysregulation, including expansion of pro-inflammatory monocytes and effector T cells, alongside reduced regulatory T cells (Tregs). Bacillus subtilis natto, a spore-forming probiotic, has shown anti-atherosclerotic effects, though its systemic immunomodulatory mechanisms remain unclear. In this study, we employed an AAV-mPCSK9-induced murine atherosclerotic model to investigate the effects of daily B. subtilis natto NTU-18 administration over 16 weeks. High-dimensional flow cytometry using two 13-marker panels enabled longitudinal profiling of 18 peripheral immune cell subsets across lymphoid and myeloid compartments. While no significant changes in serum cholesterol and mild decrease of body weight were observed, B. subtilis natto NTU-18-treated mice presented a significant reduction in aortic lesion area compared to PBS-treated controls. Immune profiling revealed a transient expansion of peripheral myeloid cells and CD44⁺ trained CD8⁺ T cells, followed by increased frequencies of naïve CD8⁺ T cells and reduced central/effector memory subsets at longer time point treatment. In the CD4⁺ T cell compartment, a transient increase in trained cells was accompanied by a sustained enrichment of CD25⁺CD4⁺ Tregs throughout the daily B. subtilis natto NTU-18 treatment. In contrast, no significant differences were observed in Ly6C⁻ or Ly6C⁺ monocytes, neutrophils, or eosinophils. These findings suggest that B. subtilis natto NTU-18 attenuates atherosclerosis progression not through lipid lowering or broad myeloid modulation, but via targeted reprogramming of peripheral T cell responses. This work provides mechanistic insight into the immunotherapeutic potential of B. subtilis natto NTU-18 in atherosclerosis prevention and treatment. • B. subtilis natto NTU-18 significantly reduces aortic plaque burden in atherosclerotic mice without affecting serum cholesterol levels. • B. subtilis natto NTU-18 induces transient immune remodeling, marked by early expansion of trained CD8⁺ and CD4⁺ T cells, followed by increased naïve and regulatory T cells. • The atheroprotective effect is primarily mediated through adaptive immunity as myeloid subsets remain unchanged throughout B. subtilis natto NTU-18 treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/45dd339de260cb5a70cef21d3c450ab6682f7820" target='_blank'>
              Bacillus subtilis natto NTU-18 attenuates atherosclerosis progression by modulating peripheral immune cell alterations
              </a>
            </td>
          <td>
            Jian-Da Lin, Yu-Zhen Ye, Sin-Ren Wang, Wen-Yi Kao, Kung-Ta Lee
          </td>
          <td>2025-10-17</td>
          <td>Applied Microbiology and Biotechnology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Glioblastoma (GBM) harbors a highly inflammatory microenvironment driven predominantly by activated innate immune cells, despite being classified as an immunologically cold tumor due to limited T cell infiltration. Tumor-associated macrophages (TAMs) are key contributors to disease progression, in part through their production of interleukin-1β (IL-1β), a pro-inflammatory cytokine with tumor-promoting functions. However, the precise role of IL-1β⁺ TAMs in GBM remains incompletely understood. This study aimed to elucidate the functional contributions of IL-1β⁺ TAMs to GBM malignancy and to explore their therapeutic relevance. Single-cell RNA sequencing (scRNA-seq) analysis revealed that IL-1β⁺ TAMs were enriched in GBM tissues compared to normal brain tissue, with their elevated infiltration correlating with aggressive tumor phenotypes and poor prognosis. Functionally, IL-1β stimulated GBM cells to secrete inflammatory mediators such as PGE2 and TNFα. These mediators, in turn, upregulated C/EBPβ expression in macrophages, thereby enhancing IL-1β transcription. Mechanistically, tumor-derived PGE2 and TNFα synergistically activated C/EBPβ via EP4 receptor signaling, initiating a self-sustaining IL-1β-PGE2/TNFα-EP4-C/EBPβ-IL-1β feedback loop that amplified pro-inflammatory crosstalk between GBM cells and TAMs. Disruption of PGE2/EP4 signaling effectively suppressed IL-1β+ TAM generation and attenuated tumor growth in preclinical models. Our finding highlights how GBM cells induce macrophages to secrete IL-1β through the synergistic action of PGE2 and TNFα via the EP4 receptor and C/EBPβ activation. This feedback loop between tumor cells and macrophages fosters a pro-inflammatory TME that drives GBM progression. Targeting the PGE2/EP4-C/EBPβ signaling axis may therefore present a promising immunotherapeutic strategy to disrupt tumor-TAM crosstalk and suppress GBM progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/79403f7ff1eae47b3c3514d50ed4afe7c020a741" target='_blank'>
              IL-1β+ tumor-associated macrophages accelerate glioblastoma progression by amplifying the PGE2-EP4 signaling
              </a>
            </td>
          <td>
            Hao Liang, Qunying Yang, Biling Zhong, Dan Li, Feima Wu, Jian Zhang, Chongqi Guo, Zhengquan Zhu, Min Feng, Yong Zhang, Hui Peng
          </td>
          <td>2025-10-14</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Dendritic cells (DCs) are professional antigen‐presenting cells (APCs) that play a central role in regulating immune responses by linking innate and adaptive immunity. In recent decades, substantial progress has been made in understanding the development, classification, and diverse functions of DCs. However, a comprehensive overview integrating recent advances in the biology and therapeutic targeting of DCs remains lacking. This review systematically summarizes the origin, developmental pathways, and subset heterogeneity of DCs, including classical type 1 and 2 DCs, plasmacytoid DCs, monocyte‐derived DCs, and Langerhans cells. Moreover, it further details the core biological functions of DCs, including antigen capture, migration, and maturation; antigen presentation; activation of adaptive immunity; induction of immune tolerance; and modulation of innate immune responses. The pathological roles of DCs in diseases such as cancer, diabetes, and infectious diseases are discussed, highlighting emerging DC‐based therapeutic strategies. Importantly, this review provides a summary of both preclinical studies and clinical trials involving DC‐targeted therapies, offering a translational perspective. This work aims to deepen the understanding of DC immunobiology and to provide a valuable foundation for the development of novel DC‐based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f0e677608689fc4d137f5dd944e3591ee29e3ed6" target='_blank'>
              Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential
              </a>
            </td>
          <td>
            Fangfang Jin, Lingxiang Xie, Hongqi Zhang, Xiang Fan, Jiaxing Tian, Wei Liu, Yang Xiao, Xinrong Fan
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Regulatory T cells (Treg cells or Tregs), a subset of CD4⁺ T cells with immunosuppressive properties, are essential for immune homeostasis and self-tolerance. Characterized by their immunosuppressive capabilities and reliance on the transcription factor Foxp3 (Forkhead box protein P3), Tregs employ multiple mechanisms, including cytokine secretion, metabolic control, and cell contact inhibition, to restrain excessive immune activation to prevent autoimmunity while maintaining tissue repair processes. However, dysregulation in their frequency or function—whether deficiency or hyperactivity—is implicated in diverse pathologies, spanning autoimmune disorders, cancer progression, transplant rejection, and emerging associations with neurological and cardiovascular diseases. Thus, Treg-targeted strategies represent a promising approach for restoring immune balance under various conditions. This review synthesizes current knowledge on Treg biology, from their discovery and definition of markers to their new regulatory mechanisms. We further explore the roles of Tregs across diseases, emphasizing their context-dependent therapeutic potential. Strategies to deplete or inhibit Tregs in cancer immunotherapy contrast with approaches to expand or stabilize their function in autoimmunity and transplantation. However, challenges persist, including achieving tissue-specific targeting, ensuring the functional stability of engineered Tregs, and minimizing off-target effects. By integrating mechanistic insights with translational innovations, this review provides a roadmap for advancing Treg-based therapies, ultimately aiming to restore immune equilibrium in a disease-specific manner.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4664303d5c8731e32a24c5f6aff938bbbbb96dc7" target='_blank'>
              Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential
              </a>
            </td>
          <td>
            Lingling Wang, Ying Liang, Chunxia Zhao, Peijun Ma, Shulin Zeng, Dongen Ju, Minggao Zhao, Min Yu, Yun Shi
          </td>
          <td>2025-10-14</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>6</td>
          <td>7</td>
        </tr>

        <tr id="Memory T cells endow the mammalian host with an essential form of adaptive immunity that generates durable and rapid protection following re-exposure to an infectious pathogen or a cancerous transformation1–4. How naive CD8⁺ T cells develop into memory T cells that bifurcate into long-lived central (TCM) versus effector (TEM) subsets after such an antigen encounter remains ill-defined at the molecular level. To address this gap, here we dissect the functional T-cell receptor (TCR) repertoire of 242 murine CD8⁺ TCRαβ clonotypes specific for the peptide-major histocompatibility complex molecule (pMHC) comprising an immunodominant influenza A virus (IAV) oligopeptide epitope NP366–374 presented by H-2Db 5,6. Using single-cell transcriptomics with TCR sequencing, biophysical measurements of force-dependent TCR-pMHC interactions, in vivo memory development, and structural analyses, we integrate these data to define relationships between signaling polarity and memory fate. We find that TCM and TEM polarities are reflected in distinct subunit-related mechanotransduction biases: TCM-associated TCRs favor TCRβ-driven pMHC engagement, whereas TEM-associated TCRs preferentially favor TCRα-driven pMHC engagement. Moreover, “bipolar” clonotypes (TBP) capable of generating both memory subsets exhibit more balanced signaling, the largest average clonal expansions, and broadest heterosubtypic crossreactivities. By contrast, variegated TCM TCR sequences foster mostly clonal singlets with the greatest IAV mutant recognition potential within the overall memory repertoire, thus revealing two complementary memory niche crossreactivity strategies. Weak, force-sensitive TCR bonds are pervasive for this entire repertoire, being most conspicuous amongst TCM clonotypes. At the atomic level, highly nuanced variation in TCRαβ bonding to either peptide and/or MHC modulates mechanical load transmission across the holoreceptor’s ectodomains, transmembrane segments, and CD3 cytoplasmic tails to differentially influence downstream tyrosine phosphorylation and memory development. Collectively, TCR diversity anticipates epitope-specific pathogen evolution, whereas divergent TCR signaling regulates memory fate with implications for adoptive T-cell immunotherapies seeking to maximize persistence and minimize functional exhaustion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47c5e8a658084ff1675ec010b34b843ae8e69de3" target='_blank'>
              Atomistic TCR-ligand interactions instruct memory T-cell differentiation
              </a>
            </td>
          <td>
            A. Akitsu, Kemin Tan, R. J. Mallis, Matthew A. Booker, J. Duke-Cohan, K. Brazin, Evan H. Kirkpatrick, Andrew N. Parkins, Sarita Aryal, V. Cinella, Jonathan J Lee, Kaveri I. Uberoy, Jenna K. Koenig, Matthew Biddle, Cameron M. Messier, P. Lizotte, M. Tolstorukov, Wonmuk Hwang, Matthew J Lang, Ellis L. Reinherz
          </td>
          <td>2025-11-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Type I interferon (IFN) has long been known as a critical component of the molecular machinery that first responds to viral infection in multicellular eukaryotes. More recently, type I IFN signaling has also emerged as a common process in the microenvironment of naturally developing neoplasms, as well as tumors responding to (immuno)therapy. In this setting, robust, acute but ultimately resolving type I IFN responses appear to support natural and therapy-driven cancer immunosurveillance by a number of mechanisms, including an accrued propensity of malignant cells to arrest their proliferation and undergo apoptotic cell death, as well as broad immunostimulatory effects on CD8+ cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, dendritic cells (DCs) and tumor-associated macrophages (TAMs). Conversely, weak, indolent and ultimately non-resolving type I IFN responses de facto facilitate tumor progression, not only by promoting stemness in malignant cells (which is associated with increased metastatic dissemination and resistance to therapy), but also by favoring the establishment of a highly immunosuppressive lymphoid and myeloid tumor microenvironment. Here, we provide a critical discussion of the context-dependent impact of type I IFN signaling on cancer progression and response to treatment, focusing on the tumor-intrinsic and extrinsic factors that may account for such a heterogeneity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2e617f9f9711708567426eb2cf65f4ef606f0b6" target='_blank'>
              Context-dependent impact of type I interferon signaling in cancer
              </a>
            </td>
          <td>
            Ainhoa Ruiz-Iglesias, Emma Guilbaud, Lorenzo Galluzzi, Santos Mañes
          </td>
          <td>2025-10-30</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="The tumor microenvironment (TME) constitutes a highly complex and dynamic ecosystem wherein diverse leukocyte subsets engage in intricate cross-talk that ultimately dictates the balance between tumor progression and suppression. This review provides a comprehensive analysis of the dualistic functions of key immune cell populations-including natural killer (NK) cells, effector T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs)-within this milieu. Particular emphasis is placed on the Nigerian context, where unique genetic backgrounds, such as the high prevalence of sickle cell trait, and environmental factors, including endemic infections, significantly shape immune phenotypes and cancer pathogenesis. We explore how cutting-edge single-cell technologies are revolutionizing our understanding of the spatial architecture, functional plasticity, and cellular heterogeneity of these leukocytes in patient cohorts, revealing mechanisms of both immune surveillance and tumor-promoting immunosuppression. The paradoxical roles of these cells elucidate the variable clinical outcomes observed with immunotherapies and underscore the critical need for precision medicine strategies that are tailored to individual immune landscapes. Finally, we discuss emerging therapeutic modalities aimed at selectively depleting pro-tumor subsets like Tregs or MDSCs while activating anti-tumor effectors such as NK cells, which hold substantial promise for reshaping the TME and improving oncology outcomes both in Nigeria and across the globe.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/85d4138591bf3dda987df758be78f378fdcee1f4" target='_blank'>
              Leukocyte Subset Dynamics in the Tumor Microenvironment: Dual Roles, Single-Cell Insights, and Implications for Cancer Immunotherapy in Nigeria
              </a>
            </td>
          <td>
            Okluchi Hartumu
          </td>
          <td>2025-11-25</td>
          <td>Hematological Disorders in the Single-Cell Era</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 Smoldering Multiple Myeloma (SMM) is an asymptomatic plasma cell disorder with high risk of progression, characterized by clonal plasma cell expansion with no evidence of end-organ damage. In addition to tumor cells, evolving immune dysfunction and bone marrow (BM) microenvironmental changes are believed to contribute to progression to overt malignancy. Considering the changing treatment landscape for SMM patients, it is imperative to analyze tumor microenvironment (TME) imprinting in order to improve risk stratification and therapeutic strategies. However, the early immunological alterations and stromal remodeling events that distinguish stable from progressive disease remain poorly understood.Methods:We employed single-cell RNA sequencing (scRNA-seq) to comprehensively profile the immune and stromal compartments in over 125 samples, including 42 paired BM and peripheral blood (PB) specimens from 14 SMM patients collected longitudinally at diagnosis and follow-up, 32 BM samples from age-matched healthy donors, and 51 BM samples from newly diagnosed MM patients. Our analysis focused on immune cell composition, transcriptional states, and ligand–receptor interactions. We paid special attention to immune aging signatures and macrophage inhibitory factor (MIF)-mediated stromal reprogramming.Results:We observed evidence of increased immune aging in SMM, with T cells, B cells, and NK cells exhibiting a significant increase in exhaustion and senescence markers compared to healthy donors (p < 0.001). This phenotype was characterized by loss of naïve markers, activation of inhibitory receptors such as PD-1 and LAG-3, and a shift toward effector memory differentiation. These features are consistent with hallmarks of chronic antigen exposure and immune dysfunction. Interestingly, only CD4+ (R = 0.46, p = 0.1), CD8+ (R = 0.49, p = 0.1), and rare T cell (R = 0.64, p = 0.02) populations showed correlation between BM and PB. Our finding highlights the potential use of PB as an accessible biomarker of immune dysregulation.Our ligand–receptor interaction analyses revealed that clonal plasma cells in SMM actively engage the microenvironment through enhanced MIF signaling. This pathway engages both stromal and immune cells via CD74 and CXCR4 (p < 0.01). MIF-induced stromal reprogramming was associated with increased IL-6 production from stromal cells and macrophage polarization towards a tumor-supportive phenotype. Notably, these interactions were either absent or significantly attenuated in healthy BM. In parallel, communication between monocytes and plasma cells via the TACI–BCMA pathway was increased in both SMM and MM, suggesting that innate immune remodeling begins early in disease evolution.Conclusion:Our results demonstrate that immune aging and MIF-mediated stromal rewiring synergistically remodel the bone marrow niche and promote disease in SMM. The parallel changes as observed in PB T cells underscore their potential as accessible biomarkers for tracking immune dysregulation. Furthermore, our finding highlights MIF signaling as a candidate for further studies to evaluate its impact on disease progression. Immune aging also requires more attention as it reflects the tumor cell division and the ability of the microenvironment to handle SMM cells. Integrating these immune and microenvironmental insights with clinical and genomic data may enhance disease assessment and enable understanding of the disease.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/646821916b47c212ffdfe0c508c1fe79ba89e945" target='_blank'>
              Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma
              </a>
            </td>
          <td>
            Rajib Shome, S. Talluri, Diana D Cirstea, Rie Matsubara, Farah Rexha, Advait Joshi, Andrew J. Yee, Nikhil C Munshi, Mehmet K Samur, N. Raje
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Trained immunity is reshaping our understanding of host defense by demonstrating that innate immune cells once thought to lack memory can be reprogrammed to mount heightened responses to subsequent challenges. Unlike tolerance, differentiation, or priming, trained immunity relies on epigenetic and metabolic rewiring of resident myeloid cells, particularly in mucosal barriers such as the skin, gut, and lungs, where these cells provide continuous protection against toxins and pathogens. Here, we review recent advances showing how an initial stimulus endows monocytes and macrophages with long-lasting functional changes that can be either protective or maladaptive upon re-exposure. We highlight therapeutic opportunities that harness trained immunity to boost vaccine efficacy and discuss strategies to modulate this program in cancer and hyper-inflammatory disorders. Finally, we propose new directions for enhancing or dampening trained immunity to promote human health.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57f6e83421893f19b268537080a2332361f2582c" target='_blank'>
              Innate immune memory: The evolving role of macrophages in therapy
              </a>
            </td>
          <td>
            Payal Damani-Yokota, Kamal M. Khanna
          </td>
          <td>2025-11-14</td>
          <td>eLife</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Fungal communities in the gut influence host immunity, yet most studies have focused on cell wall components rather than genetic materials. Here, we explore how fungal genomic DNA (gDNA) from Candida albicans, Saccharomyces cerevisiae, and Cryptococcus neoformans modulate immune responses in human CD4+ T cells, murine splenocytes, and THP-1-derived macrophages. We find that C. albicans gDNA promotes the development of regulatory T cells and increases IL-10, fostering immune tolerance and preserving CD4+ T cell viability in an inflammatory setting. S. cerevisiae gDNA induces moderate Treg responses with restrained effector T cell expansion and higher checkpoint gene expression, entirely consistent with its commensal nature. In contrast, C. neoformans gDNA elicits a strongly inflammatory profile, promoting Th1/Th17 cells and driving high cytokine production. Mechanistically, C. albicans and S. cerevisiae gDNA dampen DNA-sensing pathways and enhance immune checkpoint molecules that act as brakes against overactivation, while C. neoformans gDNA robustly activates innate sensing pathways with limited checkpoint induction. These species-specific signaling profiles reveal that fungal gDNA itself can influence whether the immune system adopts a tolerant or inflammatory response toward fungi. This discovery highlights fungal genomic DNA as a previously underappreciated regulator of host–fungus interactions, offering new insight into commensal persistence, pathogenic invasion, and the potential for DNA-based antifungal interventions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc70eaeb8599dabbca9b1f79f2645699f524d2e1" target='_blank'>
              Divergent Immunomodulatory Roles of Fungal DNA in Shaping Treg and Inflammatory Responses
              </a>
            </td>
          <td>
            Dongmei Li, Idalia Cruz, Yahui Feng, Maha Moussa, Jie Cheng, Digvijay Patil, Alexander Kroemer, Joseph A. Bellanti
          </td>
          <td>2025-10-22</td>
          <td>Journal of Fungi</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="T-cell based immunotherapies such as chimeric antigen receptor T (CAR-T) cell therapy face substantial hurdles when confronting solid tumors such as ovarian cancer, where metabolic constraints in the tumor microenvironment limit T cell infiltration and function. In particular, T cells exposed to nutrient deprivation and hypoxia upregulate autophagy, a lysosomal degradation pathway that negatively regulates effector responses. Here, we used CRISPR-Cas9 to target a folate receptor alpha (αFR) CAR expression cassette into the locus of the essential autophagy gene ATG5, thereby generating autophagy-deficient CAR-T cells in a single editing step. Targeted metabolite profiling revealed that deletion of ATG5 induced widespread metabolic reprogramming characterized by increased glucose and amino acid uptake. Functionally, ATG5-knockout CAR-T cells maintained high cytolytic activity when assayed in patient-derived ascites in vitro, and exhibited superior and long-lasting tumor control against ovarian tumors in vivo. Taken together, our results suggest that deletion of ATG5 metabolically primes CAR-T cells for enhanced cytotoxicity in immune-suppressive conditions, thereby improving the therapeutic potential of αFR CAR-T cells for ovarian cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8e4d37620ca392d7a89bb01813d9698710108a7a" target='_blank'>
              Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumors
              </a>
            </td>
          <td>
            G. Carleton, Sébastien Levesque, Lauren G. Zacharias, João S. Patrício, Tracey Sutcliffe, Peter H Watson, R. DeBerardinis, Yannick Doyon, Julian J. Lum
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Megakaryocytes (MKs) have traditionally been viewed as terminal hematopoietic cells responsible solely for platelet production. However, recent advances in imaging and single-cell transcriptomics have revealed substantial heterogeneity among MK populations and diverse functions beyond thrombopoiesis. MKs actively participate in innate and adaptive immunity, modulate the hematopoietic stem cell (HSC) niche, and adapt to physiological and pathological stimuli. Located in distinct anatomical sites such as bone marrow and lung, MKs exhibit compartment-specific specializations that enable them to serve as critical integrators of hemostatic, immune, and regenerative processes. Experimental models using human pluripotent stem cells and inducible MKs have enhanced mechanistic insights, while innovative bioreactor platforms and xenotransplantation strategies advance translational applications in platelet production and therapy. Furthermore, immune MK subsets derived from pluripotent stem cells show promising therapeutic potential for modulating inflammation and autoimmune diseases. Continued exploration of MK diversity, tissue-specific roles, and intercellular communication will unlock new opportunities for leveraging MK plasticity in regenerative medicine, immunotherapy, and hematologic disorders, repositioning these versatile cells as central players in systemic homeostasis and defense.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a42ed6c49b37f5e87fc8596501cc105433a716fc" target='_blank'>
              Emerging Roles of Megakaryocytes in Immune Regulation and Potential Therapeutic Prospects
              </a>
            </td>
          <td>
            Seungjun Kim, Kiwon Lee
          </td>
          <td>2025-10-27</td>
          <td>Cells</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="The tumor immune microenvironment plays a critical role in tumor progression and responses to immunotherapy. Nevertheless, its cellular complexity and heterogeneity remain incompletely understood. In this study, we employed high-resolution single-cell RNA sequencing on CD45+ immune cells isolated from ten syngeneic murine tumor models, representing seven distinct cancer types under treatment-naïve conditions, thereby enabling a comprehensive profiling of tumor-infiltrating immune cells. We identified seven principal immune cell populations and provided an in-depth characterization of T cells, NK/innate lymphoid cells, dendritic cells, monocytes/macrophages, and neutrophils. Cross-species analyses further delineated conserved immune cell states and transcriptomic features within the T cell and monocyte/macrophage compartments that are shared across syngeneic models and human tumors. To investigate the functional relevance of the predominant monocyte/macrophage compartment and the notable presence of neutrophils in syngeneic tumors, we evaluated responses to anti-PD-1 therapy across various models and analyzed the enrichment of monocyte/macrophage subsets in tumors that responded to treatment. Furthermore, we conducted neutrophil depletion experiments using anti-Ly6G antibodies, administered both as monotherapy and in combination with PD-1 blockade. Remarkably, an interferon-stimulated gene-high (ISGhigh) monocyte subset was significantly enriched in models responsive to anti-PD-1 therapy. Neutrophil depletion resulted in variable antitumor effects across models but failed to enhance the efficacy of PD-1 blockade. In summary, our single-cell profiling offered a detailed atlas of the immune microenvironment across multiple syngeneic mouse tumor models, thereby enabling rational model selection for immuno-oncology studies. We uncovered an ISGhigh monocyte subset enriched in anti-PD-1 responsive models, and showed the context-dependent effects of neutrophil depletion on tumor immunity and immunotherapy, underscoring the heterogeneity and functional divergence of immune cell sublineages.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f925e5b4fe351a72672a38a0505d78e0be84e52" target='_blank'>
              Single-cell atlas of the tumor immune microenvironment across syngeneic murine models
              </a>
            </td>
          <td>
            Jia Wang, Bin Jiang, Minjuan Deng, Han Yan, Peilin Zhang, Wei Jin, Zhirong Shen
          </td>
          <td>2025-11-14</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20f65e1524ffb4190a28bef066a656c7fa921b4e" target='_blank'>
              B-cell Follicles in the Secondary Lymphatic Tissues Act as a Critical Microanatomical Niche for Sustained Viral Replication, Virus-host Interaction and Damage During Chronic SIV Infection of Rhesus Macaques
              </a>
            </td>
          <td>
            Yilun Cheng, Miaoyun Zhao, Jackson Chen, Subhra Mandal, Mark G. Lewis, Qingsheng Li
          </td>
          <td>2025-11-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 CAR-T cells have emerged as a therapeutic strategy for autoimmune diseases, including systemic lupus erythematosus (SLE). One open question is the impact of preconditioning on therapeutic responses. In preliminary experiments using pre-irradiated lupus-prone New Zealand Black/New Zealand White (NZB/W) mice, second-generation anti-mCD19 CAR-T cells positively impacted many disease features. Significant bone marrow (BM) B-cell depletion and lower proteinuria were observed across irradiated groups, suggesting an immunosuppressive effect. Based on these findings, we aimed to demonstrate the impact of CAR-T cells over irradiation on various immunologic and clinical features by modifying the conditioning regimen in these mice. Twenty two-week-old pre-irradiated mice were treated with PBS or CAR-T cells+IL-2. Lymphocytes were assessed in blood, BM, and spleen 4-weeks post treatment. The engraftment of CAR-T cells was documented in all samples. CAR-T cell-treated mice showed persistent B cell decrease in various subsets (marginal zone/naïve B cells and plasma cells). Furthermore, increases in CD4+ and CD8+ T cells, with a lower percentage of effector/central memory T cells and higher naïve T cells were observed as an outcome of CAR-T treatment. CAR-T treated mice also displayed lower anti-dsDNA antibodies and proteinuria. Thus, CAR-T cells showed a differential impact on lupus beyond irradiation. Other disease features to ascertain CAR-T cell efficacy for SLE are being explored.



 Supported by Kyverna Therapeutics, Inc., Emeryville, CA.



 Therapeutic Approaches to Autoimmunity (THER)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e48e017f60a3235e38047b172faeb8b5872f707d" target='_blank'>
              Efficacy and engraftment of anti-CD19 CAR-T cells in murine lupus 4343
              </a>
            </td>
          <td>
            J. Romo-Tena, Shouvonik Sengupta, William Ambler, S. Nakabo, C. Carmona-Rivera, Eduardo Patino Martinez, L. P. Blanco, Shairaz Shah, Jennifer Zeng, Ashley E. Mahne, Joseph K Cheng, T. Van Blarcom, Mariana J. Kaplan
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/32e4ebc6d8827d761aced444544586c3de7b9082" target='_blank'>
              High-throughput heterospheroid-based screening identifies drugs that reprogram tumor-associated macrophages
              </a>
            </td>
          <td>
            Hiroyuki Tsuchiya, T. Hanaki, Mayu Obora, Jun Yoshida, Mikiya Kishino, Y. Fujiwara, Daisuke Nanba
          </td>
          <td>2025-11-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Background/Objectives: Extracellular vesicles (EVs) are key mediators of intercellular communication and are implicated in the neuropathogenesis of HIV-associated brain injury (HABI). However, their direct effects on glial cells, particularly in the context of antiretroviral therapy (ART), remain incompletely understood. Methods: In this study, we investigated how EVs from naïve, Simian Immunodeficiency Virus (SIV)-infected, and SIV-infected ART-treated rhesus macaques impact primary mixed glial cultures. Results: Through multiple, sequential applications mimicking chronic exposure, we found that EVs from SIV-infected animals significantly reduced glial expansion and induced a simplified, reactive astrocyte morphology indicative of neuroinflammatory stress. In contrast, EVs from naïve animals supported glial health. EVs derived from ART-treated animals provided partial protection from SIV-induced effects, yet still suppressed glial proliferation and failed to fully restore normal morphology. Furthermore, cytokine profiling revealed that both SIV and SIV + ART EVs induced a sustained proinflammatory secretory phenotype, characterized by elevated IL-6, IL-8, and IFN-γ. Conclusions: Our findings demonstrate that systemically circulating EVs in SIV infection are potential drivers of glial dysfunction. The persistence of these pathogenic EV effects despite ART suggests a vesicle-mediated mechanism that may contribute to chronic neuroinflammation and cognitive impairment in virally suppressed individuals.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67fab60169c13d075bcfdc8d7c00be88b51107c6" target='_blank'>
              Simian Immunodeficiency Virus-Derived Extracellular Vesicles Induce a Chronic Inflammatory Phenotype in Healthy Astrocytes Unresolved by Anti-Retroviral Therapy
              </a>
            </td>
          <td>
            Alison R. Van Zandt, Miranda D. Horn, Ryan P. McNamara, Tiffany A. Peterson, N. Maness, Blake Schoest, Elise M. Frost, Yijun Zhou, Matilda J. Moström, D. P. Dittmer, Andrew G. MacLean
          </td>
          <td>2025-10-24</td>
          <td>Pharmaceutics</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Natural killer T (NKT) cells play a complex role in hepatocellular carcinoma (HCC) progression. Using a diethylnitrosamine (DEN)-induced HCC mouse model, we observed a significant reduction in NKT cells within malignant liver tissue due to apoptosis, with the remaining cells exhibiting impaired cytokine production and cytotoxic potential. CD1d-deficient mice, which lack NKT cells, showed delayed tumor initiation and fewer tumors, yet the tumors that did form were larger and exhibited enhanced proliferation and immunosuppression. Notably, adoptive transfer of healthy NKT cells after tumor establishment reduced tumor burden, suggesting a protective role in later disease stages. These findings indicate that NKT cells contribute to early tumor development but may help control tumor progression in later stages. Their functional impairment in HCC underscores the need for strategies to restore their anti-tumor activity. Understanding the dual role of NKT cells in liver carcinogenesis may pave the way for novel immunotherapeutic approaches to improve HCC treatment and patient outcomes. In HCC, NKT cells promote early tumor development but restrain later growth. Adoptive transfer of healthy NKT cells after tumor establishment reduces tumor burden, highlighting their potential as immunotherapeutic targets in HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a90f2e66dfb37d54c65e9f253685e5ee9a14d1c9" target='_blank'>
              Dual regulatory role of natural killer T cells during development of hepatocellular carcinoma
              </a>
            </td>
          <td>
            Maria Papanastasatou, Marianthi Gioulbasani, Evangelia Nakou, A. Galaras, Teresa Rubio-Tomás, I. Talianidis, Aristides G. Eliopoulos, P. Hatzis, Mihalis Verykokakis
          </td>
          <td>2025-10-20</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a clonal malignancy of plasma cells that remains largely incurable despite major advances in proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Chimeric antigen receptor (CAR)-engineered immune cells have transformed the therapeutic landscape, but CAR-T cell therapy faces challenges such as severe cytokine release syndrome (CRS), neurotoxicity, limited persistence, and logistical complexity. In recent years, natural killer (NK) cells have emerged as a promising platform for next-generation cellular immunotherapy, offering innate antitumor activity, a reduced risk of graft-versus-host disease (GvHD), and the feasibility of “off-the-shelf” allogeneic production. This review summarizes current advances in CAR-NK cell therapy for MM, focusing on two major aspects: the diversity of cell sources—including NK-92, peripheral (PB) and cord blood (CB), and induced pluripotent stem cell (iPSC)-derived NK cells—and the expanding repertoire of target antigens such as BCMA (B-cell maturation antigen), NKG2D, CD38, CD70, SLAMF7, CD138, and GPRC5D. We highlight preclinical and early clinical studies demonstrating potent cytotoxicity, favorable safety profiles, and innovative multi-targeting strategies designed to overcome antigen escape and enhance persistence. Emerging clinical data suggest that CAR-NK cell therapy may combine the specificity of CAR recognition with the inherent safety and versatility of NK biology, offering a potential paradigm shift in the treatment of relapsed or refractory MM. Further clinical validation will determine whether CAR-NK cell therapy can achieve durable remission and complement or surpass current CAR-T modalities.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6c564648f2cac8ed7d5dc089469d07120d75f71b" target='_blank'>
              State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens
              </a>
            </td>
          <td>
            Asya Bastrich, Kamilla Vinogradova, D. Mokrousova, Anna Efremova, O. Makhnach, D. Goldshtein
          </td>
          <td>2025-11-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Background: Treatment resistance and relapse in myeloma and lymphoma are driven by diverse immunosuppressive mechanisms within the tumor microenvironment (TME), including expansion of myeloid-derived suppressor cells (MDSCs) and regulatory T cells, upregulation of immune checkpoints, and suppression of antigen presentation, which collectively impair cytotoxic T and natural killer (NK) cell function. Heat shock protein 70 (HSP70), highly expressed in many hematologic malignancies, including multiple myeloma and lymphoma, plays a central role in these processes by stabilizing oncoproteins, inhibiting apoptosis, and promoting immune escape. Extracellular HSP70 released from tumor cells, often bound to tumor-derived antigens, can induce pro-tumorigenic inflammation and facilitate recruitment of immunosuppressive cells, and interfere with antigen processing and stress-induced cell death. Prior attempts at HSP70–based vaccination showed limited clinical efficacy due to challenges in purifying material and efficiently targeting APCs, highlighting the need for novel strategies to leverage this pathway in myeloma and lymphoma immunotherapy.
 Methods: We developed a panel of murine monoclonal antibodies to HSP70 by immunizing BALB/c mice with murine fibroblast L-cells expressing human HSP70 fused to green fluorescent protein. This panel was then screened in immune-competent BALB/c mice injected with luciferase (luc)-expressing MOPC315.BM murine myeloma cells, selected due to the 95% homology between murine and human HSP70. Clone 77A was identified from this screen as showing the most robust in vivo anti-tumor activity and subjected to further in vitro and in vivo testing.
 Results: Clone 77A enhanced antigen-presenting cell (APC) uptake of HSP70 tumor antigen complexes, promoted cross-priming of antigen-specific T cells, and engaged FcγRIII on NK cells and antigen presenting cells and thus modulated both innate and adaptive immunity.
 In immunocompetent myeloma models (MPC11 and Vk*MYC), 77A remodeled the immunosuppressive TME by inhibiting myeloid derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs). Also, 77A promoted dendritic cell (DC) infiltration and expanded central memory CD4+ and CD8+ T- and NK-cell populations, subsequently generating a potent anti-tumor activity. Bulk RNA-seq and pathway analysis confirmed activation of antigen processing/presentation and NK cell-mediated cytotoxicity pathways.
 In the EG7.OVA (chicken ovalbumin) lymphoma model, 77A reshaped the TME to favor tumor-specific immune activation, including expansion of OVA presenting DCs and proliferation of OVA323–339-specific CD4+ T cells and OVA257-264- specific CD8+ T cells with enhanced effector function. These antigen specific T cells from 77A-treated tumor bearing mice exerted significant ex vivo cytotoxicity against EG7.OVA cells. Moreover, 77A augmented proliferation and effector function of OVA257-264- specific CD8+ T cells administered into the EG7.OVA lymphoma bearing mice, supporting its potential for a combined regimen with adoptive T cell therapy (ACT). We also found that HSP70 subcutaneous co-administration into established lymphoma tumors enhanced 77A's therapeutic efficacy in the EG7.OVA model. Additionally, 77A markedly enhanced anti-tumor activity of proteosome inhibitors (bortezomib and carfilzomib), radiation, and STING agonists (diABZI and IACS-8803) in MPC11 and Vk*MYC models. Its activity extended to solid tumors, including 4T1 breast cancer, and was further potentiated by tumor expression of immunogenic antigen hemagglutinin. or PD-1 immune checkpoint blockade.
 In the MM1.S xenograft model, 77A retained activity under NK cell depletion, likely due to myeloid polarization toward an M1 phenotype. The activity was more modest compared with that seen in more immune competent models, highlighting its long-term efficacy relied on T cell priming and effector function. Finally, 77A directly enhanced human immune function by boosting MART-1 specific CD8+ T cell expansion and enhancing NK cell cytotoxicity in healthy donor samples.
 Conclusion: 77A is a first-in-class anti-HSP70 antibody that uniquely leverages HSP70 neoantigen biology to bridge innate and adaptive immunity. It generates robust and durable anti-tumor activity in hematologic and solid tumor models, and synergizes with multiple immunomodulatory and standard therapies, supporting its clinical translation as a novel immunotherapy platform.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a887ea64b847a742d0e834756a184372d82443b" target='_blank'>
              First-in-class immunomodulatory anti-heat shock protein 70 (HSP70) antibody demonstrates broad antitumor activity across myeloma, lymphoma, and solid tumor models
              </a>
            </td>
          <td>
            Jun Wei, Richard J. Jones, I. Kuiatse, Hua Wang, R. Orlowski
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>93</td>
        </tr>

        <tr id="


 Introduction: Emerging evidence suggests that the immunosuppressive tumor microenvironment is a major limiting factor impairing CAR-T cell function. Recent studies have identified immunosuppressive erythroid precursor cells (EPCs) – a novel cell population that accumulates in pathological contexts (including neonates, cancer-bearing hosts, and infected individuals) – which potently suppress immune responses and diminish upon maturation. In this study, we aim to investigate the impact of these immunomodulatory EPCs on CAR-T cell function and explore potential strategies to overcome their suppressive effects, thereby enhancing CAR-T cell efficacy.
 Methods: We established KA539 lymphoma models in irradiated C57BL/6 mice and collected clinical peripheral blood samples from hematologic malignancy patients to quantify EPCs accumulation in extramedullary tissues. Functional profiling was performed via RNA-seq on FACS-sorted CD45⁺ versus CD45⁻ EPCs, validated by scRNA-seq. To assess EPCs-mediated CAR-T cell suppression, CD19 CAR-T cells were co-cultured with EPCs followed by multiparameter analysis including proliferation, cytokine secretion, exhaustion, and tumor-killing capacity of CAR-T cells. Mechanistically, we performed RNA-seq and Cut&Tag with erythroid precursors upon BRD4 inhibition, and genetic validation in erythroid-specific BRD4 cKO mice to demonstrate that BRD4 regulates the immunity of CD45+ EPCs.
 Results: We confirmed that both tumor-bearing mice and patients with hematologic malignancies showed significantly increased EPCs proportions in extramedullary tissues, including peripheral blood, spleen, and liver. RNA-seq analysis revealed that CD45+ EPCs exhibited elevated expression of immunosuppressive genes, including VISTA, PD-L1, LGALS3. Notably, tumor-bearing mice exhibited increased EPCs levels following CAR-T treatment, particularly in the poor-response group, suggesting a potential link between EPCs expansion and therapeutic resistance. Coculture with CD45+ EPCs significantly impaired CAR-T cell function, reducing both TNF-α secretion and proliferative capacity. Consistent with our previous findings on BRD4's role in blocking erythroid maturation, we observed that BRD4 similarly impeded EPCs' maturation in tumor-bearing mice and patient-derived samples. Furthermore, BRD4 inhibition downregulated immune-related genes and pathways in EPCs. Integrated analysis of Cut&Tag and RNA-seq data revealed that BRD4 directly transcriptionally activated immune regulatory genes in EPCs, including PD-L1 and VISTA. Besides, experiments with BRD4conditional knockout mice further confirmed that BRD4 inhibition promoted maturation of CD45+ EPCs and repressed expression of novel immune checkpoint VISTA. Importantly, flow cytometry analysis demonstrated that BRD4 inhibition significantly alleviated EPCs-induced CAR-T cell exhaustion, as evidenced by reduced expression of the exhaustion markers PD-1 and LAG-3, supporting BRD4 inhibition as a viable strategy to potentiate CAR-T cell function by modulating EPCs' immunosuppressive activity.
 Conclusion: Our study establishes that immunosuppressive EPCs directly impair CAR-T cell function. We demonstrate that BRD4 transcriptionally activates VISTA expression in EPCs, and targeting BRD4 reverses EPC-mediated CAR-T suppression. These findings unveil a novel mechanism of the immunosuppressive microenvironment in CAR-T therapy and provide a potential approach to enhance clinical efficacy against hematologic malignancies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c440cfd119e2a331ecd6f4081b0a4605fb549576" target='_blank'>
              BRD4 sustains immunosuppressive erythroid precursors to compromise CAR-T cell function
              </a>
            </td>
          <td>
            Meng Zhang, Mengmeng Huang, Yijin Chen, Haiqiong Zheng, Yanjuan Liu, Dawei Huo, Yongxian Hu, Pengxu Qian, He Huang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Background/Objectives: T cell dysfunction represents a fundamental barrier to effective cancer immunotherapy. Although immune checkpoint blockades and adoptive cell transfer have achieved clinical success, therapeutic resistance remains prevalent across cancer types. Thymopentin (TP5), a synthetic immunomodulatory pentapeptide (Arg-Lys-Asp-Val-Tyr), has demonstrated immunostimulatory properties, yet its anticancer potential remains unexplored. The aim of this study was to investigate TP5’s antitumor efficacy and underlying immunological mechanisms. Methods: We evaluated TP5’s therapeutic effects in multiple murine tumor models, including B16-F10 melanoma, MC38 colorectal carcinoma, Hepa 1-6, and LM3 hepatocellular carcinoma. Immune cell populations and functional states were characterized using flow cytometry, ELISAs, and immunofluorescence analyses. The potential of TP5 as an adjuvant for T cell-based therapies was also systematically assessed. Results: The TP5 treatment markedly suppressed tumor growth across caner models through strictly T cell-dependent mechanisms. Critically, TP5 promoted thymic rejuvenation under immunocompromised conditions, restoring the thymus–tumor immunological balance and revitalizing peripheral T cell immunity. TP5 functionally reprogrammed T cell states, preserving effector function while ameliorating exhaustion. Furthermore, TP5 demonstrated synergistic efficacy when combined with adoptive T cell therapies, enhancing both proliferation and effector functions. Conclusions: TP5 represents a promising immunomodulator that addresses fundamental limitations of current T cell therapies by simultaneously enhancing T cell function and reversing thymic involution under immunocompromised conditions. Our findings provide compelling evidence for TP5’s clinical translation in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/33660023e865ee9b3b9111ce1cf65d89f507510c" target='_blank'>
              Thymopentin Enhances Antitumor Immunity Through Thymic Rejuvenation and T Cell Functional Reprogramming
              </a>
            </td>
          <td>
            Md Amir Hossain, Ye Zhang, Li Ji, Yumei Chen, Yue Luan, Yaxuan Si, Yuqing Fang, Junlan Qiu, Zhuo Wang, Guilai Liu
          </td>
          <td>2025-10-01</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 The neuropathology observed during Venezuelan equine encephalitis virus (VEEV) infection, including blood-brain barrier (BBB) breakdown, is linked to an overwhelming immune response in the brain, but the roles of specific cell types are not fully elucidated. Here we temporally profiled the immune response to VEEV by performing single cell RNA sequencing on brains of infected mice. This data revealed activation of microglia subsets and their sequential decline in abundance concurrent with infiltration of immune cells, including cytotoxic lymphocytes NK cells and CD8+ T cells. Targeting these cells, we found depletion of NK cells and CD8+ T cells synergistically improved BBB integrity and survival. NK cell-depleted brains have fewer CD8+ T cells and both NK cell-depleted and double-depleted brains have increased microglia. NK cell-depleted infected brains had similar levels of elevated cytokines IFN-a, CCL2, CCL5, and IFN-g, chemokines CXCL1 and CXCL10, and interleukins IL-6 and IL-1b, while having higher IFN-b. Double-depleted brains had strikingly higher levels of each of these proteins, in addition to IL-10, IL-12, GM-CSF, and TNF. Through this work, we have begun profiling immune signatures associated with improved outcomes of VEEV infection, underscoring the utility in understanding complex immune responses for the development of immunomodulatory therapies aimed at limiting BBB dysfunction and improving infection outcomes.



 [1] This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Security, LLC, Lawrence Livermore National Laboratory under Contract DEAC52-07NA27344.



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3abebda82cc25e9b9ebfbc8beda7bf7d191a43b9" target='_blank'>
              Depletion of cytotoxic lymphocytes shifts brain immune response, promoting blood-brain barrier integrity and survival in Venezuelan equine encephalitis virus infection 3984
              </a>
            </td>
          <td>
            Margarita V. Rangel, A. Sebastian, N. Leon, Ashlee M. Phillips, D. Murugesh, N. Hum, D. Weilhammer
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="ABSTRACT Trained immunity is a long-term functional reprogramming of innate cells that allows for the formation of immune memory akin to adaptive responses, but with a more rapid nonspecific response. We recently identified an anti-inflammatory trained immunity response, termed trained tolerogenic immunity (TTI), induced by low virulence Candida dubliniensis, that protects against acute lethal polymicrobial sepsis via myeloid-derived suppressor cells (MDSCs). Trained immunity and MDSCs arise following hematopoietic stem and progenitor cell (HSPC) expansion in the bone marrow. Here, we show that C. dubliniensis induces inoculum-dependent protection and HSPC expansion, whereas depletion of HSPCs following C. dubliniensis immunization abrogates protection. We further show that myeloid progenitors and putative MDSCs are increased in the bone marrow following C. dubliniensis immunization, and that HSPC depletion results in reduced MDSC influx into the peritoneal cavity following lethal challenge. Bone marrow cytokine analysis revealed that mediators associated with MDSC development and trafficking, including G-CSF, CXCL2, and CCL2, are upregulated following C. dubliniensis immunization. Finally, we find that the C-type lectin receptor adaptor protein Card9 is required for C. dubliniensis-induced protection and HSPC expansion, but not fungal trafficking to the bone marrow. Taken together, these results suggest that Card9-dependent fungal recognition in the bone marrow drives myelopoiesis and the induction of immunosuppressive MDSCs that are protective against lethal inflammation and sepsis. IMPORTANCE Cells of the innate immune system can be “trained” by inducers to have enhanced memory responses, a phenomenon known as trained immunity. We recently identified an anti-inflammatory training response that is induced by low virulence fungal species (i.e., Candida dubliniensis) and is protective against acute lethal polymicrobial sepsis. Trained immunity inducers, including C. dubliniensis, can access the bone marrow and direct hematopoietic responses. Here, we demonstrate that protection is correlated with C. dubliniensis-induced bone marrow expansion, which directs a myeloid bias in the bone marrow and ultimately results in the expansion of protective myeloid-derived suppressor cells. Involvement of the C-type lectin receptor adaptor protein Card9 in the protective response suggests fungal recognition in the bone marrow drives this response. These findings offer new insights into how trained immunity inducers direct differential outcomes, which will inform the development of novel immunotherapeutics to exploit the full spectrum of trained immune responses. Cells of the innate immune system can be “trained” by inducers to have enhanced memory responses, a phenomenon known as trained immunity. We recently identified an anti-inflammatory training response that is induced by low virulence fungal species (i.e., Candida dubliniensis) and is protective against acute lethal polymicrobial sepsis. Trained immunity inducers, including C. dubliniensis, can access the bone marrow and direct hematopoietic responses. Here, we demonstrate that protection is correlated with C. dubliniensis-induced bone marrow expansion, which directs a myeloid bias in the bone marrow and ultimately results in the expansion of protective myeloid-derived suppressor cells. Involvement of the C-type lectin receptor adaptor protein Card9 in the protective response suggests fungal recognition in the bone marrow drives this response. These findings offer new insights into how trained immunity inducers direct differential outcomes, which will inform the development of novel immunotherapeutics to exploit the full spectrum of trained immune responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/28ef5d4d2e11b7eea19c57b43a1c7a076c5b6b77" target='_blank'>
              Induction of myelopoiesis by Candida dubliniensis drives protective trained immunity against sepsis in a Card9-dependent manner
              </a>
            </td>
          <td>
            S. Righi, E. Lilly, A. J. Harriett, Patrick W. Daly, MaryJane Jones, Chad Steele, Mairi C. Noverr, Paul L Fidel
          </td>
          <td>2025-10-31</td>
          <td>mBio</td>
          <td>0</td>
          <td>39</td>
        </tr>

        <tr id="


 CD19-targeted Chimeric Antigen Receptor (CAR) T cell therapy is a leading treatment for B-cell malignancies, achieving complete remission rates of ~50% in pediatric non-Hodgkin's lymphoma. However, relapse remains a major barrier, driven by immune evasion, T-cell exhaustion and/or dysfunction, and limited persistence. These challenges highlight the need for innovative CAR vector designs to improve durability and efficacy.
 One strategy is to enhance recruitment of the T cell kinase LCK to the immune synapse, thereby strengthening proximal signaling (Feucht et al., 2019; Hartl et al., 2020; James, 2018). This compensates for the absence of co-receptor–MHC interactions in native T cell receptor (TCR) signaling, which position LCK near the immunoreceptor tyrosine-based activation motifs (ITAMs) of CD3ζ. Optimizing LCK-mediated ITAM phosphorylation may yield next-generation CARs with cytotoxic potency approaching that of the native TCR.
 We engineered an optimized CAR incorporating a 37-amino-acid segment (TIP) of the Herpesvirus saimiri tyrosine-protein kinase–interacting protein that binds LCK with high specificity and modulates its activity. Incorporation of the TIP co-stimulation motif into the CAR-BB-CD3ζ domain produced several notable effects:
 The TIP motif altered early CAR T cell activation, with antigen-independent recruitment of LCK and other proximal signaling mediators to the CAR–CD3ζ complex, indicating ligand-independent priming of signaling. Despite elevated basal phosphorylation, cytokine secretion was absent and downstream transcription remained inactive, thereby preserving antigen specificity while accelerating early activation kinetics.
 Ex vivo expansion revealed a consistent enrichment of CD8⁺ T cells in TIP-CAR cultures (72% vs 35% in BBζ-CAR, p<0.0001), accompanied by higher Ki67 (46% vs 28%, p<0.05) and CD38 (85% vs 64%, p<0.01) expression in CD8+ subset across eight donors. Phenotyping also showed a skew toward a CCR7⁻CD45RA⁺ effector phenotype within the CD8⁺ compartment (59% vs 41%, p<0.01), suggesting distinct TIP-driven memory imprinting patterns across T cell lineages.
 Integrated transcriptomic profiling and flow cytometric phenotyping demonstrated that TIP co-stimulation reprograms T cell transcriptional landscape relative to BBζ-CARs, with upregulation of key TCR signaling genes (TCR variants, ZAP70, LAT) and the transcription factor TCF7, while showing no changes in exhaustion-associated transcripts, including PD1, LAG3 and TIGIT. These findings suggest that TIP co-stimulation reinforces T cell activation programs while restraining terminal differentiation and exhaustion.
 The functional performance of TIP-CAR T cells, evaluated through standard in vitro assays, demonstrated that TIP-CAR T cells showed a statistical increase in target-cell killing (p<0.0001) with robust proliferation comparable to that of BBζ-CAR T cells. To assess in vivo efficacy, we conducted a xenograft study using NSG mice engrafted with luciferase-Raji lymphoma cells. Mice (n = 6–7/group) received TIP-CAR T cells, BBζ-CAR T cells, or no treatment, using cells manufactured from two healthy donors. Bioluminescent imaging revealed a statistically significant reduction of tumor burden in TIP-CAR–treated mice compared to BBζ-CAR (p < 0.05), with rapid and sustained tumor clearance. Survival analysis showed significantly prolonged overall survival in the TIP-CAR-treated group (log-rank p < 0.001); mice treated with BBζ-CAR T cells succumbed to progressive disease, while TIP-CAR treated mice survived long-term. Notably, upon rechallenge with Raji cells several weeks after initial clearance, TIP-CAR-treated mice resisted tumor re-engraftment, indicating durable antitumor immunity and memory formation. Flow cytometric analysis of peripheral blood and bone marrow of rechallenged mice confirmed enhanced persistence and expansion of TIP-CAR T cells, enriched for CD8⁺effector-memory phenotypes.
 These findings demonstrate that the TIP co-stimulation motif enhances in vivo CAR T cell function by improving synapse formation, sustaining cytotoxic competence, and enabling long-term immune surveillance. Altogether, this study introduces a modular, virus-derived co-stimulatory motif that rewires early CAR signaling and programs durable, high-functioning T cell responses. TIP co-stimulation motif offers a broadly translatable strategy to enhance CAR T cell efficacy, persistence, and memory in hematologic malignancies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/66fd44f99beda94bebf5c7b3f684bfc12d2c3e14" target='_blank'>
              Signaling role of viral protein motif and its application in CAR T cell therapy
              </a>
            </td>
          <td>
            Wooram Jung, Kunho Chung, Jude Franklin, David N. Wald, J. Melenhorst, Jae Jung
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7bcfd3df2c5d1e60c0a8518093894d3b787fd6a7" target='_blank'>
              Azvudine remodels the local immunosuppressive microenvironment and exhibits sustained anti-tumor effects in combination with anti-PD-1 therapies.
              </a>
            </td>
          <td>
            Limin Jia, Zhaoyang Wang, Jinfa Du, Zhigang Ren, Jiandong Jiang, Pan Li
          </td>
          <td>2025-11-24</td>
          <td>Frontiers of medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="The immune system constitutes a highly coordinated network of cellular and molecular components that protect the host from infection, tissue injury, and malignant transformation. Immune cells, encompassing innate and adaptive lineages, serve as core effectors of this system. Innate immune cells, including macrophages, DCs, and NK cells, initiate rapid, nonspecific responses while shaping subsequent adaptive immunity. Adaptive immune cells, primarily T lymphocytes and B lymphocytes, mediate antigen-specific responses and long-term immunological memory. Within the tumor microenvironment (TME), these populations exhibit context-dependent functions, with cytotoxic subsets exerting tumor control and regulatory subsets facilitating immune evasion. TAMs, Tregs, and MDSCs exemplify immunosuppressive mechanisms, whereas cytotoxic CD8⁺ T cells, NK cells, and DCs drive anti-tumor immunity. Cancer immunotherapy has harnessed these mechanisms, employing immune checkpoint inhibitors targeting PD-1, PD-L1, or CTLA-4, adoptive cell therapies such as chimeric antigen receptor T cell (CAR-T) therapy and tumor-infiltrating lymphocyte (TIL) therapy, as well as therapeutic cancer vaccines. Advances in single-cell RNA sequencing and spatial transcriptomics have revealed extensive cellular heterogeneity and spatial organization within the TME, uncovering mechanisms of immune suppression and therapeutic resistance. Integrating these high-dimensional approaches with rationally designed combination therapies provides a framework for personalized immunotherapy. This review presents a comprehensive overview of immune cell roles in tumor progression, immune evasion, and therapeutic intervention, highlighting strategies to exploit the immune landscape for durable clinical benefit.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/75924b64514f97201e3f8c52cfb211dc637de3f6" target='_blank'>
              The interplay between immune cells and the tumor microenvironment: from immunosurveillance to immunotherapy
              </a>
            </td>
          <td>
            Loris Brunner, Élise Chappuis, Alessio Rosselli
          </td>
          <td>2025-10-15</td>
          <td>Clinical and translational reports</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="
 Although immunotherapy has transformed cancer treatment, glioblastoma (GBM) remains stubbornly resistant due to multiple immunosuppressive mechanisms. Our previous work identified polyamine metabolism as a key driver of this immunosuppression, with difluoromethylornithine (DFMO) improving survival in a T and B cell-dependent manner. However, DFMO alone, or in combination with PD-1/PD-L1 blockade, failed to yield durable benefits. This suggests the emergence of adaptive resistance mechanisms. To investigate this, we performed single-cell RNA sequencing (scRNA-seq) on DFMO-treated tumors, revealing increased T-cell inflammation and IFN-γ-driven gene expression. Surprisingly, the most upregulated gene was apolipoprotein D (ApoD), a lipid transport protein that sequesters arachidonic acid (AA). AA is an inflammatory lipid essential for T-cell-induced IFN-γ-STAT1-dependent ferroptosis of tumor cells during immunotherapy. Notably, this STAT1-ApoD axis was also acutely induced in response to other immunotherapies in murine GBM models. We therefore hypothesized that IFN-γ–induced ApoD expression represents a potential mechanism of tumor immune evasion. Our preliminary findings show that ApoD overexpression protects tumor cells from AA-induced lipotoxicity and ferroptotic cell death, decreasing survival in GBM mouse models, which was dependent on intact adaptive immunity. ApoD-overexpressing tumors displayed a higher myeloid-to-CD8⁺ T cell ratio and increased expression of immune checkpoints and suppressive markers, indicating a more immunosuppressive microenvironment. Collectively, our study demonstrates ApoD as a critical adaptive responder to inflammatory stress in GBM. Ongoing research will further explore ApoD-targeted interventions, including lipid nanoparticle-mediated siRNA delivery. We will investigate the intrinsic role of ApoD in controlling tumor cell susceptibility to ferroptosis, and, in parallel, examine its extrinsic effects as a secreted factor that reshapes the immune microenvironment by suppressing T cell function and promoting myeloid immunosuppression. This may lead to future therapies that enhance immunotherapy efficacy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/002ee8adc2baa74e88b71b10cd71ff6d47d4f268" target='_blank'>
              TMIC-82. Sequestration of inflammatory lipids as an immune evasion mechanism in glioblastoma
              </a>
            </td>
          <td>
            Tzu-yi Chia, Chao Wei, Leah K. Billingham, Suzi Delay, Lauren Boland, Nishanth S. Sadagopan, Jay Subbiah, Si Wang, Hanxiao Wan, Jiawei Huo, J. Duffy, Alina R Murphy, Rebecca Du, Joshua Katz, Aurora Lopez-Rosas, Yu Han, G. Vázquez-Cervantes, Hardik Shah, Peng Zhang, Irina V Balyasnikova, M. Lesniak, Catalina Lee-Chang, J. Miska
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Melanoma, the deadliest form of skin cancer, poses a significant challenge due to its genetic heterogeneity and high metastatic potential. While cytotoxic T cell (CTL)‐based immunotherapies have made remarkable progress in recent years, the therapeutic potential of natural killer‐(NK) cells is increasingly recognized. However, resistance mechanisms to both CTL‐ and NK‐cell‐mediated immunotherapies hinder effective treatment. To evaluate the exclusive role of NK‐cells in anti‐melanoma immunity, we performed 2D and 3D co‐culture‐based cytotoxicity assays under varying conditions. Our findings revealed a protective phenotype in melanoma cells following prolonged exposure to primary NK‐cells. By combining experimental data with bioinformatic analyses, we identified key genes and pathways involved in melanoma cell adaptation to NK‐cell‐mediated killing (NKmK). We found that cytokines such as IFNγ play a major role in suppressing NKmK with MHC II surface expression being a critical factor. Targeting the master regulator CIITA, which governs MHC II expression and is affected by IFNγ, significantly reduced melanoma cell resistance to NKmK. This study provides potential strategies to overcome resistance to NK‐cell‐based immunotherapies and offers novel insights into melanoma immune escape mechanisms.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5764eda312a5162e966ee86f3fed7809fb2be1df" target='_blank'>
              The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity
              </a>
            </td>
          <td>
            Lena C M Krause, Rixa-Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski
          </td>
          <td>2025-10-13</td>
          <td>Molecular Oncology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Purpose Cancer immunotherapy aims to enhance the immune system’s ability to recognize and eliminate cancer cells, providing a sustained and effective immune response. However, the tumor microenvironment (TME), characterized by an abundance of tumor-associated M2 macrophages and the presence of exhausted or naïve T cells (non-effector T cells), remains a major barrier to effective immunotherapy. Herein, inflammatory M1 macrophage-derived extracellular vesicles (M1EV) were surface-modified to display interleukin-2 (M1EV_IL2), aiming to develop a multifunctional cancer immunotherapeutic agent capable of modulating both innate and adaptive immune responses. Methods We engineered M1EV to label the surface with azide groups through metabolic glycoengineering and developed M1EV_IL2 that displayed IL-2 via bioorthogonal chemistry. M1EV_IL2 were purified by size-exclusion chromatography (SEC) and characterized through comprehensive analyses, including nanoparticle tracking analysis (NTA). In vitro macrophage repolarization and T cell activation were evaluated at the gene-expression level, followed by ex vivo assays assessing T-cell proliferation, cytokine secretion, and activation marker expression. Results M1EV_IL2 effectively retained the intrinsic physicochemical properties of EVs while displaying IL-2 stably on its surface. It upregulated M1 macrophage markers, IL-1β and CXCL10, while downregulating the M2 macrophage marker CD206, thereby inducing M2-to-M1 macrophage repolarization. In addition, M1EV_IL2 also activated CD4+ T cells and induced the activation of naïve CD8+ T cells to effector T cells, leading to enhanced cell proliferation and secretion of antitumor cytokines. Conclusion These results indicate that M1EV_IL2 has the potential to reshape the tumor immune landscape by simultaneously activating macrophages and T cells, thereby enhancing both innate and adaptive immune responses. Unlike conventional cancer therapies, which directly target tumor cells, M1EV_IL2 is expected to enhance immune responses, potentially mitigating adverse effects while improving therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b118249d7b0665de4875eb1da2d46b5bd10b41f" target='_blank'>
              Interleukin-2 Surface Displayed M1 Macrophage-Derived Extracellular Vesicles for Modulating the Tumor Microenvironment
              </a>
            </td>
          <td>
            Kyeong Tae Kim, Jeong Hyun Lee, S. Kang, W. Rhee
          </td>
          <td>2025-11-01</td>
          <td>International Journal of Nanomedicine</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Abstract Introduction Dendritic cells (DCs) are crucial in immune responses; however, the role of DCs in trauma patients remains poorly understood. Therefore, this study aimed to investigate the frequencies and functions of two major DC subsets in trauma patients: plasmacytoid DCs (pDCs) and conventional DCs (cDCs). Methods This study included 25 trauma patients and 40 healthy controls. Using flow cytometry, the frequencies, cytokine production (IFN-α, TNF-α, IL-12), and expression of co-stimulatory (CD86) and co-inhibitory (CD274) markers were analyzed in the DC subsets. The relationship between CD274+ pDCs and the Injury Severity Score (ISS) was also evaluated. Additionally, in vitro experiments were conducted using proinflammatory cytokine stimulation and blocking antibodies to assess their effects on DC activation markers. Results Trauma patients showed decreased percentages and absolute numbers of pDCs, while cDC levels remained unchanged. Cytokine production was impaired, with reduced IFN-α and TNF-α from pDCs and IL-12 from cDCs. CD86+ and CD274+ expressions were increased in pDCs but decreased in cDCs, with CD274+ pDCs positively correlating with ISS. In vitro studies revealed that proinflammatory cytokine exposure enhanced activation markers, peaking at 72 h; this observation was reversed by blocking antibodies. Conclusion This study demonstrates that trauma induces both numerical and functional deficiencies in circulating pDCs despite increased activation marker expression. The correlation between CD274+ pDCs and trauma severity, along with the temporal dynamics of cytokine-induced activation, suggests a complex role for pDCs in post-traumatic immune responses. These findings provide new insights for developing targeted therapies for trauma-related immune complications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c4f75945935db312fe6c6d357d32dd682ef1f079" target='_blank'>
              Circulating Plasmacytoid Dendritic Cells Are Numerically and Functionally Deficient in Trauma Patients
              </a>
            </td>
          <td>
            Ki-Jeong Park, H. Jin, Young-Nan Cho, Jung-Chul Kim, Seung-Jung Kee, Young-Goun Jo, Yong-Wook Park
          </td>
          <td>2025-10-23</td>
          <td>Journal of Innate Immunity</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/541160e8b435b526009e3e42eef754f3da87a632" target='_blank'>
              Hiltonol and Protamine-RNA stimulation induce an immune-activating transcriptome profile in cDC1s
              </a>
            </td>
          <td>
            Georgina Flórez-Grau, Till S. M. Mathan, Mihaela B. Mihaylova, Tom van Oorschot, G. Schreibelt, D. Sancho, I. Melero, Carl G. Figdor, I. M. D. de Vries, Johannes Textor
          </td>
          <td>2025-10-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Glioblastoma (GBM) secrete extracellular vesicles (EVs) which play a pivotal role in brain tumor progression by mediating intercellular communication within the inflamed tumor microenvironment (TME). EVs’ cargo transports biomolecules that promote tumor progression, immune evasion, and resistance to therapies. While Hippo inhibitors play a significant role in mitigating cancer inflammation, their specific impact on EVs cargo remains unknown. Human grade IV U87 GBM-derived cells were cultured and EVs isolated from the conditioned media of tumor necrosis factor (TNF)α-primed cells. Total RNA was extracted using TRIzol™, and differential gene expression assessed through gene arrays and validated by RT-qPCR. Protein cell and EVs lysates were used for immunoblotting. 3D mesenchymal stem/stromal cells (MSC) in vitro vasculogenic mimicry (VM) was assessed using Cultrex matrices. Our study shows that U87 cells are responsive to pro-inflammatory stimulation by TNFα as the phosphorylation status of ERK, IκB, and NFκB increased. Among the Hippo pathway inhibitors tested, VT107 inhibited both the TNFα-induced phosphorylation, induction of the downstream Hippo pathway CYR61, and cargo of secreted EVs as assessed upon gene array screens. Pro-inflammatory genes that were reduced by VT107 in EVs included, among others, COX2, IL6, IL1B, and several members of the CCL, CXCL, and Interleukin/Interleukin receptors family. EVs isolated from VT107-treated TNFα-primed U87 cells had decreased paracrine regulation of MSC in vitro VM. By inhibiting the Hippo pathway and TNFα-induced pro-inflammatory cargo of GBM-derived EVs, our data support VT107 as a potential candidate to inhibit tumor-promoting processes involved in therapy resistance such as paracrine induction of MSC-mediated VM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fa05d80e4910bdac3b9b63c9272d09c39377ebb6" target='_blank'>
              Hippo pathway suppression reprograms TNFα-primed glioblastoma extracellular vesicles transcripts cargo to drive mesenchymal stem/stromal cells vasculogenic mimicry
              </a>
            </td>
          <td>
            Rosalie Zilinski, Angélique Sabaoth Konan, Alain Zgheib, N. Eliopoulos, Luc H. Boudreau, B. Annabi
          </td>
          <td>2025-10-14</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Elimination of tumors is typically dependent on T cells, which require prior or ongoing activation signals. These dependencies form the basis for our understanding of “tumor‐reactive immunity” and for the successes of immunotherapies, particularly immune checkpoint blockades. Over the years, tremendous work has been done towards understanding the biology of this reactive immunity and early investigation identified dendritic cells (DC) as key contributors. Recent advances have shed more light on dendritic cell heterogeneity in tumors, revealing specialized roles for each subtype. In addition, the network of cellular interactions surrounding DCs has grown as additional cell types have been revealed to variously influence how the immune system can become most effective at eliminating malignancies. Greater understanding of intratumoral DC biology has empowered investigators to engineer dendritic cell vaccines and consider other approaches to augment this component of reactive immunity, towards the generation of anti‐tumor immune responses de novo. In this review, we will discuss the state of the field, recent advances and suggest what the near future of scientific inquiry could entail.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77f18aefa5a339d8c7ed8fce463a8ad785b49774" target='_blank'>
              Dendritic Cells at the Center of Reactive Tumor Immunity
              </a>
            </td>
          <td>
            Lomax F. Pass, Matthew F. Krummel
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid proliferation, diffuse infiltration, and resistance to conventional therapies. Despite advances in surgery, radiotherapy, and chemotherapy, the prognosis remains dismal, with median survival rarely exceeding 15 months. The immunosuppressive and heterogeneous tumor microenvironment (TME), along with profound tumor-intrinsic resistance mechanisms, contributes significantly to treatment failure. Cardiotonic steroids (CTS), such as ouabain, have recently gained attention for their pleiotropic effects beyond Na+/K+-ATPase inhibition, including modulation of intracellular signaling, induction of cell death, and immune regulation. In GBM, ouabain has been shown to reduce tumor cell viability, impair migration, disrupt angiogenesis, and alter different signaling pathways. Although direct evidence of ouabain’s effects on the GBM immune microenvironment is limited, findings from other models suggest that it can modulate both innate and adaptive immune responses, affecting T cells, regulatory T cells, dendritic cells, monocytes, and NK cells. While previous reviews have explored the anticancer and pharmacological aspects of cardiotonic steroids, the immunological dimension of ouabain’s activity remains underrepresented. This review integrates current evidence on ouabain’s dual actions in tumor biology and immune regulation, emphasizing its emerging therapeutic potential and the need for deeper investigation within high-grade glioma models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5c73049935628c7b64bd22cf222eb78736095626" target='_blank'>
              From hormonal immunomodulation to glioblastoma therapy: the emerging role of Ouabain
              </a>
            </td>
          <td>
            Arthur Gomes de Andrade, D. Carvalho, Daniel Wilson Arruda Magalhaes, A. C. de Queiroz, M. S. Alexandre-Moreira, Sandra Rodrigues-Mascarenas, L. H. A. Cavalcante-Silva
          </td>
          <td>2025-11-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Despite the success of immune checkpoint inhibitors in cancer, many patients do not respond or relapse following treatment. Therefore, new approaches to augment existing immunotherapies are needed. CRISPR screens have revealed the importance of TNF-α signal transduction mediators, such as TAK1, in facilitating tumor susceptibility to cytotoxic T cells. Here, we demonstrate that inhibition of TAK1 in tumor cells lowers the threshold for TNF-α-induced cytotoxicity. Upon TNF-α signaling, pharmacologic inhibition of TAK1 sensitized tumor cells to RIPK1-dependent apoptosis. However, RIPK1-independent apoptosis occurred upon genetic deletion of Tak1, suggesting a novel scaffolding function of TAK1 is required to induce RIPK1 kinase activity during cell death. Deleting Tak1 impaired in vivo tumor growth, enhanced α-PD-1 immunotherapy, and lead to durable anti-tumor memory, dependent on CD8 T cells and intact TNF-α signaling. Our results collectively demonstrate that compromising TAK1 function within tumor cells leverages the cytotoxic capacity of TNF to enhance anti-tumor immunity and generate deeper and more durable anti-tumor immune responses in preclinical models of cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57211ff5257cefccbaf3a51da4a814bb6d07d106" target='_blank'>
              Targeting tumor intrinsic TAK1 engages TNF-α-driven cell death through distinct mechanisms and enhances cancer immunotherapy
              </a>
            </td>
          <td>
            Jason D. Huska, Kelly J Doyle, Julie J. Purkal, Cara Hrusch, Ryan C Duggan, Erwin R. Boghaert, A. Souers, D. Phillips, Stephen K Tahir
          </td>
          <td>2025-10-16</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Background: Signal-induced proliferation-associated gene 1 (Sipa1), a RAP1 GTPase-activating protein, is expressed in both hematopoietic cells and stromal cells. It negatively regulates G-protein signaling pathways involving in cell adhesion and proliferation. We have demonstrated that Sipa1loss induces bone marrow (BM) mesenchymal stem and progenitor cells (MSPCs, CD45-TER119-CD31-CD44-CD51+SCA1+ and SCA1- subsets) alterations that drive the development of myeloproliferative neoplasm. Meanwhile, we have observed reduced Sipa1 expression in the BM MSPCs in mice with acute myeloid leukemia (AML) (Blood Adv. 2018, 2(5):534-548). However, the impact of the Sipa1 reduction on AML progression remains unclear.
 Methods: We have here explored the impact of Sipa1 expression in the host BM mesenchymal and immune cell niche by, 1) analyzing AML progression in Sipa1-/- and Sipa1+/+ recipient mice transplanted with MLL-AF9 AML cells with or without prior irradiation; 2) in vivo depletion of specific lymphoid subsets using neutralizing antibodies to determine their contributions; 3) immune and mesenchymal niche characterization using RNA sequencing and flow cytometry; 4) determining clinical correlation between Sipa1 expression in hematopoietic cells and treatment outcomes in patients with AML.
 Results: Remarkably, Sipa1 deficiency in host microenvironment led to delayed or no AML development, reflected in that 30% of the Sipa1-/- recipient mice did not develop AML while all Sipa1+/+ mice did after AML cell injection without prior irradiation. Notably, such a difference in AML development was not observed in lethally irradiated Sipa1-/- and Sipa1+/+ recipient mice where their immune cells were eliminated, indicating the critical involvement of Sipa1-/- immune cells in the AML inhibition. Further, in vivo depletion of NK cells by antibody neutralization could completely reverse the difference in AML development kinetics in the Sipa1-/- mice, suggesting that Sipa1 deficiency may boost NK cells anti-AML immune response. The enhanced anti-AML activity of Sipa1-/- NK cells was consistent with the increased maturation and activation of Sipa1-/- NK cells derived from spleen and blood. Furthermore, RNA sequencing suggested significant enrichment of the inflammatory genes associated with NK cell cytoxicity in Sipa1-/- BM MSCs (CD45-TER119-CD31-CD44-CD51+SCA1+) relative to that in Sipa1+/+ mice, providing another potential mechanism contributing to the increased anti-AML activity of Sipa1-/- NK cells, driven by the inflamed Sipa1-/- BM MSCs. Most importantly and notably, in line with these findings in mice, low SIPA1 expression in bone marrow mononuclear cells is associated with better survival and therapy responses to BET and mTOR inhibitors in AML patients (TCGA LAML dataset, and unpublished data from Prof. Caroline Heckman's lab in Helsinki University).
 Conclusions: Altogether, our study suggests that Sipa1 loss boosts anti-AML response of NK cells, possibly triggered by enhanced inflammatory host microenvironment. These findings along with the clinical correlation between low SIPA1 expression and better survival in AML patients point to the translational potential of these discoveries, meriting further investigation of therapeutic potential of Sipa1 deficient NK cells for AML and the underlying mechanisms.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f8871824fe2ad8aaef916abb388f27c2c0036c5" target='_blank'>
              Sipa1 loss in host niche boosts anti-AML immune response
              </a>
            </td>
          <td>
            Runqing Zhang, L. Sandhow, Huan Cai, Hong Qian
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="


 Activation and exhaustion marker expression have become critical for evaluating the efficacy of immune checkpoint inhibitors in cancer therapy. Exhaustion biomarkers, such as Programmed Death-Ligand 1 (PD-L1) and Lymphocyte-Activation Gene 3 (LAG-3), were analyzed in solid tumors alongside co-expression of T-cell activation markers, such as CD86 and Ki67, to gain insights into the immune cell status. Flow cytometry was used to characterize LAG-3 and PD-L1 expression on cytotoxic and memory T cells from patients with various solid tumors, including melanoma, non-small cell lung cancer (NSCLC), and breast cancer, using cryopreserved peripheral blood mononuclear cell (PBMC) samples. The expression of exhaustion markers, LAG-3 and PD-L1, was variable across patients with solid tumors, with elevated levels observed on CD8+ T cells. This suggests an up-regulation in response to persistent tumor antigenic stimulation. The co-expression of exhaustion markers on CD8+ T cells may indicate a role in T-cell dysfunction and immune evasion. These findings highlight the complexity of exhaustion marker expression in immune cells and their influence on immune responses in patients with solid tumors. By integrating LAG-3 and PD-L1 profiling with other markers of immune activation and exhaustion, this study underscores the potential of these markers as predictive biomarkers for immunotherapy response and provides insights into mechanisms of immune evasion in solid tumor cancers.



 Immune Mechanisms of Human Disease (HUM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5345c8124cfc479e7f2de77345d1f38e458a7f71" target='_blank'>
              Activation and exhaustion marker expression on immune cells from patients with solid tumors 9367
              </a>
            </td>
          <td>
            Angelina Bisconte, Rachel Owen, Jackie Benko, Jorge Pardo, Samantha Splitt, Deborah Phippard
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Upon activation, B cells integrate signals from antigen and T cell help to choose between a rapid extrafollicular (EF) response and entry into the germinal center (GC). EF differentiation produces short‐lived plasmablasts that provide immediate but relatively low‐affinity antibody, whereas GC entry commits B cells to iterative selection, somatic hypermutation, and affinity maturation, ultimately yielding high‐affinity plasma cells and memory B cells. At the B–T cell border, where both responses originate, B cells also undergo class switch recombination (CSR). In this review, we examine the molecular mechanisms of CSR, highlighting the interplay between the DNA deaminase AID, transcription, and noncanonical nucleic acid structures. We further discuss the differential requirement of glycolysis between the EF versus GC response and how the cytokine IL‐21 fine‐tunes B cell entry into the GC. Together, these perspectives integrate genomic alterations, metabolic demands, and cytokine‐mediated signaling at the critical decision point between EF and GC pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ecc034aac7cb165cdbc5d307ab3c3ccca1cecfd1" target='_blank'>
              Mechanisms Promoting Stability of B Cells
              </a>
            </td>
          <td>
            Vivian L S Kuan, Jayanta Chaudhuri
          </td>
          <td>2025-10-29</td>
          <td>Immunological Reviews</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="


 Immunotherapy combinations can improve patient outcomes, yet the interactions within the tumor microenvironment (TME) that drive therapeutic synergy are poorly understood. Tumor establishment drives monocyte recruitment and differentiation into tumor-associated macrophages (TAMs), which have essential roles in coordinating immune responses and are thus attractive targets for therapeutic modulation. In a murine model of combination anti-PD-1 and anti-PD-L1 checkpoint blockade, tumor control was associated with increased infiltration of CD8+ T cells and M1-like repolarization of TAMs. Live-cell imaging of the tumor microenvironment revealed stable contacts between tumor-infiltrating CD8+ T cells and TAMs, in which the extent of the contact interfaces increased with combination immunotherapy. Treatment with anti-PD-L1 was able to increase macrophage expression of pro-inflammatory factors and phagocytic activity, suggesting a role for TAMs to reactivate CD8+ T cells in the TME. However, co-treatment with anti-PD-1 was ultimately necessary for tumor control, indicating the need for combination targeting of the TME.



 Mayo Clinic David and Margaret Grohne Cancer Immunotherapy Pilot Award



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b4b5c68bd11e510478b663ba12c5b0fe316f16" target='_blank'>
              Macrophage repolarization by immune checkpoint blockade drives T-cell engagement in the tumor microenvironment 2076
              </a>
            </td>
          <td>
            Tina Kwok, Jessica N Lancaster, Haidong Dong, Ildefonso Silva
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Brain tumors such as glioblastoma remain among the most lethal and immunologically resistant cancers, in large part due to epigenetic programs that sculpt the tumor–immune microenvironment. DNA methylation, histone modifications, and chromatin remodeling do not merely drive tumor-intrinsic changes; they also profoundly reprogram immune responses, shaping antigen presentation, cytokine signaling, and immune cell recruitment. At the center of this regulation are T cells, whose effector functions are suppressed through promoter hypermethylation of antigen-processing genes, silencing of interferon pathways, and the establishment of exhaustion-specific chromatin states. Mutations such as IDH1/2 and H3K27M further reinforce these epigenetic barriers, fostering immune-cold microenvironments that disable cytotoxic T-cell activity. Emerging evidence highlights both CNS-specific adaptations, including microglial and astrocytic epigenetic programs that reinforce immune privilege, and conserved features of T cell exhaustion that mirror those in peripheral cancers. This duality underscores the need for therapeutic strategies that dismantle CNS-specific barriers while leveraging shared exhaustion programs across tumor types. Epigenetic drugs, ranging from DNA methyltransferase and EZH2 inhibitors to BET degraders and CRISPR-based epigenome editors, are beginning to restore antigenicity, reverse T cell dysfunction, and sensitize tumors to checkpoint blockade. Yet these approaches carry the paradoxical risk of disrupting CNS immune tolerance, potentially triggering harmful neuroinflammation or autoimmunity. To our knowledge, this is among the first comprehensive reviews to integrate CNS-specific immune privilege mechanisms with peripheral exhaustion pathways, providing a unified perspective on how epigenetic regulation orchestrates immune dysfunction across central and peripheral contexts. By mapping the continuum between immune evasion and global immunosuppression, we propose a conceptual framework for tailoring epigenetic-immunotherapy combinations to achieve durable antitumor immunity in the CNS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d7202ed1c4ffc9d0ee982c0f1ad42403d845276" target='_blank'>
              Beyond the genome: epigenetic regulation of immune responses and T cells in brain tumors
              </a>
            </td>
          <td>
            Shuo Sun, Yu Han, Haiying Li, Chengyan Wang, Shu Zhou, Xiaowei Zhang, Shuhong Dai, Yao Peng, Zhuoqun Wang
          </td>
          <td>2025-11-18</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Introduction Immunotherapy has shown clinical promise in multiple myeloma (MM), but relapse remains common, largely due to the immunosuppressive bone marrow (BM) microenvironment, characterized by T cell exhaustion and the accumulation of myeloid-derived suppressor cells (MDSCs). Recent advances highlight the therapeutic promise of 4-1BB (CD137) agonist antibodies in enhancing T cell–mediated anti-tumor responses, though their efficacy in MM remains poorly defined. Investigating 4-1BB expression dynamics in a preclinical MM model informed our rationale for targeting this pathway. Tasquinimod (TasQ), a small-molecule immunomodulatory agent, currently evaluated in a phase Ib/IIa clinical trial in MM patients (NCT04405167), offers a complementary strategy. By inhibiting the S100A9 signaling pathway, TasQ interferes with the recruitment and function of MDSCs, resulting in a less suppressive tumor microenvironment (TME) which reestablishes the anti -tumor immunity. In this study, we assessed the therapeutic potential of two distinct 4-1BB agonist antibody clones in an immunocompetent preclinical MM model. Building on these findings, we further explored the combination of the most effective 4-1BB agonist with TasQ, aiming to overcome the immunosuppressive tumor microenvironment, and strengthen anti-myeloma immune activity.
 Methods 4-1BB expression was analyzed during disease progression in 5T33MM mice using single-cell RNA sequencing of spleen and BM, 2 myeloma-infiltrating organs. These findings were validated by flow cytometry in both 5T33MM and 5TGM1 models. Therapeutic potential was assessed by treating 5TGM1 tumor-bearing mice with two 4-1BB agonist clones—LOB12.3 (IgG1κ; n=7/group) and 3H3 (IgG2a; n=5/group), using clone-specific isotype controls. Beginning on day 3 post-tumor inoculation, mice received 100µg of antibody intraperitoneally twice weekly until end stage. In a follow-up experiment, the lead 4-1BB agonist was combined with TasQ, administered at 30mg/kg in drinking water, to evaluate the impact of dual targeting the immunosuppressive TME (n=11/group). Tumor burden was assessed by determining the percentage of plasmacytosis in BM and spleen through cytospin stainings, together with M-protein measurement by serum electrophoresis. Immunomodulating effects were investigated using multi-parameter flow cytometry. Statistical significance was determined using the Mann–Whitney U test or one-way ANOVA, with p<0.05 considered significant.
 Results 4-1BB was predominantly detected on T cells and natural killer (NK) cells, with its expression further increasing as the disease progressed. Treatment of 5TGM1 mice with 4-1BB agonists significantly increased the percentage of CD4+ and CD8+ T cells in the BM and spleen. Interestingly, treatment with clone LOB12.3 resulted in a significant reduction in NK cell percentages in both the BM and spleen, while clone 3H3 selectively reduced splenic NK cells. Therapeutically, clone 3H3 significantly decreased M-protein levels and BM plasmacytosis (p<0.01), while no significant effects were observed for clone LOB12.3.
 Treatment with the IgG2a-formatted 4-1BB agonist combined with TasQ led to a significant reduction in M-protein levels and BM plasmacytosis (p<0001). Plasmacytosis was 62.50% in the isotype control group, decreased to 36.18% with 4-1BB agonist, 37.64% with TasQ, and further reduced to 14.09% in the combination therapy group, highlighting the enhanced efficacy of dual treatment. These effects were mediated by increased granzyme B–mediated T and NK-cell activation and enhanced differentiation of effector T cells (CD44⁺CD62L⁻). While this therapy did not alter the frequency of dendritic cells (DCs) in the BM, it enhanced their maturation, as evidenced by increased CD86 expression—particularly on type 1 and type 2 conventional DC subsets.
 Conclusion In conclusion, our findings demonstrate that 4-1BB activation can enhance anti-tumor immunity in MM; however, the therapeutic efficacy is dependent on the specific agonist used. Notably, the IgG2a-formatted 4-1BB agonist showed superior activity, underscoring the importance of isotype selection in achieving optimal immunotherapeutic outcomes. Moreover, co-administration with TasQ enhanced therapeutic efficacy, supporting the potential benefit of a combinatorial approach. Further investigation is warranted to elucidate the mechanisms driving these responses and to refine 4-1BB-targeted strategies for effective clinical translation.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/588054f9d7bef7f7dc4607713845e8f0a14c731a" target='_blank'>
              IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma
              </a>
            </td>
          <td>
            Hatice Satilmis, Adrien Denis, Emma Verheye, E. De Bruyne, E. Menu, M. Törngren, H. Eriksson, K. Vanderkerken, K. De Veirman
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="


 Long-lived plasma cells (LLPCs) sustain lifelong antibody secretion, forming the foundation of durable immune memory. However, the molecular mechanisms underpinning LLPC survival within the bone marrow (BM) remain incompletely understood. Using single-nucleus RNA-seq and ATAC-seq (10X Multiome) from matched blood and BM antibody-secreting cells (ASCs) of healthy adults, we profiled 8,059 nuclei, generating an integrated transcriptional and epigenetic map of ASCs across their developmental continuum with unparalleled resolution. In the BM LLPC cluster, Gene Set Enrichment Analysis (GSEA) validated the enrichment of the TNF/NF-κB signaling pathway and TLR cascades, emphasizing their anti-apoptotic roles. These clusters also demonstrate increased chromatin accessibility at key loci such as RELA, TLR1, TLR6, TLR10, NFKBIA, and TAB1, underscoring the central roles of TLR and TNF-α signaling pathways in activating the NF-κB pathway. Upregulated genes such as BCL2, NFKBIZ, TNFAIP3, and BIRC3 highlighted key survival mechanisms, while motif enrichment analysis revealed significant enrichment for REL and NF-κB binding motifs, supporting chromatin-level regulation of LLPC longevity. Together, these findings advance our understanding of LLPC survival and resilience and provide a framework for improving vaccine strategies and targeted immunotherapies.



 Computational and Systems Immunology (COMP)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e86cf15dec942c9c651d1f78f13be792e4e03baf" target='_blank'>
              Dissecting the transcriptional and epigenetic landscape of human antibody-secreting cells in blood and bone marrow long-lived plasma cells 4589
              </a>
            </td>
          <td>
            Hira Anis, Monica Cabrera-Mora, Christopher Scharer, Ignacio Sanz, Greg Gibson, F. Eun‐Hyung Lee
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Interferon-gamma (IFN-γ), as a pleiotropic cytokine, plays a pivotal role in antitumor immunity. Its remarkable immunostimulatory, antiproliferative, and pro-apoptotic effects make it a promising candidate for tumor immunotherapy. Here, we highlight the dual role of IFN-γ in the tumor microenvironment during tumor development and treatment. IFN-γ can enhance antigen presentation, boost cytotoxic T cell and natural killer cell activity, and inhibit angiogenesis, promoting tumor regression and correlating with favorable therapeutic outcomes. However, prolonged exposure may induce the upregulation of immune checkpoint molecules such as programmed death-ligand 1, trigger T cell exhaustion, and recruit regulatory T cells, phenomena associated with the development of treatment resistance in cancer therapy. This dual nature poses significant challenges for harnessing IFN-γ in tumor treatment, necessitating an in-depth understanding of its mechanisms within specific microenvironments. Although numerous studies have explored IFN-γ-based tumor therapies, their outcomes have been inconsistent. Thus, although IFN-γ-based therapeutic strategies hold considerable promise, their clinical translation requires precise modulation to fully exploit its antitumor effects while mitigating potential protumor risks. See also the graphical abstract(Fig. 1).">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e48bdd0772c494cb7597b77c69e2cc5a685517ff" target='_blank'>
              IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy
              </a>
            </td>
          <td>
            Jiahui Cui, Yi Zhang, Li Yang
          </td>
          <td>2025-10-14</td>
          <td>EXCLI Journal</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="The Interferon-Stimulated Gene 15 (ISG15) has a key role during viral infections, since it can modify and regulate the expression of proteins from the host and from viruses. Isg15−/− mice are more susceptible to infectious diseases. ISG15 is induced by type I Interferons (IFN-I) and apart from defense against pathogens, it can also play an important function in cancer or immune-mediated inflammatory diseases. Previous studies reported that ISG15 expression is increased in post-synaptic dendritic cells (DCs) upon interaction with CD4 + T cells. However, data regarding the role of ISG15 in DCs are scarce. The present study assesses the function of ISG15 in DCs activation, migration and ability to mediate T cell activation using bone marrow-derived DCs (BMDCs) and stimulation with lipopolysaccharide (LPS). Activation of DCs was not impaired but tended to be lower in Isg15-deficient mice, as observed by reduced CD40 induction in Isg15−/− BMDCs. Isg15−/− BMDCs induced less proliferation and Granzyme B expression in co-cultured CD8 + T cells. Interestingly, Isg15−/− BMDCs secreted reduced levels of the pro-inflammatory cytokines IL-1β and IL-12 upon LPS stimulation. Mechanistically, our data suggest that ISG15 regulates Caspase-1 activity in DCs leading to lower IL-1 β secretion. In conclusion, this study reveals an essential role for ISG15 modulating DCs inflammatory activity and raises new questions regarding the specific mechanisms of how this protein regulates innate immune responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05fa00535a2acdc99ae44733e69601b7e28b4dad" target='_blank'>
              ISG15 modulates inflammatory profiles and ability to activate CD8 + T cells in bone marrow-derived dendritic cells
              </a>
            </td>
          <td>
            P. Martínez-Fleta, Clara Pertusa, Irene Fernández-Delgado, R. Izquierdo-Serrano, M. Ramírez-Huesca, Nieves Fernández-Gallego, D. Calzada-Fraile, Elena Moya-Ruiz, Raquel Castillo-González, Susana Guerra, E. Martín-Gayo, F. Sánchez-Madrid
          </td>
          <td>2025-10-24</td>
          <td>Cellular and Molecular Life Sciences: CMLS</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Background: Cerebral malaria (CM) is a severe and often fatal complication of Plasmodium falciparum infection that causes devastating brain injury largely through immune-mediated mechanisms. Pathogenic brain-infiltrating CD8+ T cells are key drivers of CM pathology, yet the intracellular signals enabling their harmful autoimmune-like activity remain poorly defined. Here, we identify protein kinase C θ (PKCθ), a central antigen receptor-signalling mediator, as a critical contributor to experimental cerebral malaria (ECM). Methods/Results: Using a PKCθ null allele mouse strain on a C57BL/6N background, we demonstrate that PKCθ deficiency significantly improves survival in Plasmodium berghei ANKA (PbA)-infected mice without altering parasite burdens in the blood or brain. Mechanistically, loss of PKCθ skews T cell differentiation towards central memory (Tcm) rather than effector memory (Tem) phenotypes, thereby reducing effector differentiation and sequestration of CD8+ T cells in the cerebral microvasculature. This prevents extensive neurovascular damage, preserves neural tissue integrity, and alleviates neurological signs and symptoms. Our findings provide genetic evidence that PKCθ drives CD8+ T cell-mediated brain injury in ECM. Conclusions: These results underscore the potential for repurposing clinically PKCθ inhibitors as host-targeted interventions to protect against cerebral injury and improve outcomes in patients with CM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f72ad9681b0a4fb1435cab237ed155e8996cc887" target='_blank'>
              Inhibition of PKCθ Abrogates CD8+ T Cell-Mediated Neurotoxicity in Murine Cerebral Malaria
              </a>
            </td>
          <td>
            Karin Albrecht-Schgör, Victoria E. Stefan, Martina Steinlechner, Dominik Humer, K. Siegmund, Sebastian Peer, Thomas Gruber, Maja Überegger, Stephanie zur Nedden, Gabriele Baier-Bitterlich, Peter Lackner, Erich Schmutzhard, Nikolaus Thuille, V. Klepsch, G. Baier
          </td>
          <td>2025-10-22</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="


 Systemic lupus erythematosus (SLE) is an autoimmune disease involving immune and non-immune cells, with complex pathogenesis and limited therapies. Dysregulated B cells, particularly double-negative 2 (DN2) B cells (CD19?, CD27?, IgD?, CD21?, CD11c?), are central to SLE by driving autoimmune processes. However, the origins and development of DN2 B cells remain poorly understood. B lymphopoiesis occurs in the bone marrow and is strongly regulated by mesenchymal stromal cells (MSCs). MSCs are non-hematopoietic immunosuppressive cells, which regulate immunity, including promoting regulatory B cells over plasma cells. In SLE, MSCs fail to suppress B cell activation into plasma blasts, but their immunomodulatory properties remain underexplored. We hypothesize that pathogenic DN2 B cells partly originate from a dysregulated bone marrow niche due to impaired stromal cell function. Single-cell transcriptomics and proteomics of healthy bone marrow identified resident DN B cells (∼30% of total B cells), with a small percentage being DN2. SLE plasma-primed MSCs while maintaining their phenotype, showed reduced PGE2 and TGF-β production and promoted naïve B cell differentiation into DN2 B cells, unlike healthy plasma-primed MSCs. These findings suggest that SLE MSCs exhibit impaired immunomodulatory capacity, contributing to the expansion of pathogenic DN2 B cells. This study provides new insights into DN2 biology and MSC dysfunction, highlighting potential therapeutic targets for SLE.



 LRA and Boston Children’s Hospital Cell Discovery Network



 Hematopoiesis and Immune System Development (HEM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5523d5b604cb369018cf0d5d4d7bd4c741b26f91" target='_blank'>
              Functional genomics deciphers pathogenic B cell dynamics in lupus bone marrow 3662
              </a>
            </td>
          <td>
            Mariasilvia Colantuoni, Nada Abdel Aziz, Marcos Chiñas, Holly Wobma, P. Nigrovic, Lauren A. Henderson, Diana Gomez Martin, Maria Gutierrez-Arcelus
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Gliomas present as highly heterogeneous and aggressive central nervous system (CNS) tumors with challenging diagnosis and management. Traditional and current therapies are lacking efficacy in overcoming the complex and dynamic behavior of gliomas and the local tumor microenvironment. Emerging research highlights the significant role of innate immune receptors including Toll-like, NOD-like and RIG-like receptors, as well as cGAS-STING receptors, scavenger and C-type lectin receptors in glioma development and progression. These receptors can both impact immune modulation as well as facilitate tumor growth through interactions with tumor-associated macrophages, myeloid-derived suppressor cells and cytokine networks, contributing to immune evasion in the tumor microenvironment. Herein, we discuss the main signaling pathways induced through innate immune receptors in gliomas along with their functional properties in glioma pathology while exploring current applications to treatment. Utilizing innate immune receptors as therapeutic targets holds great promise, especially when used along with traditional chemotherapy and radiation schemes, strengthening immune responses. Future studies focusing on the deeper understanding of innate immune receptors signaling and complexity are highly required to enable novel immunoregulatory treatment schemes for gliomas.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b2b7b3e02786ee96fe5c12a17a3e23bd5c3a936a" target='_blank'>
              Innate Immune Signaling in Gliomas: Regulatory Mechanisms and Targeting Potential in Tumor Progression
              </a>
            </td>
          <td>
            Edmund Jung, Sara Al Jadidi, C. Piperi
          </td>
          <td>2025-10-01</td>
          <td>Life</td>
          <td>1</td>
          <td>17</td>
        </tr>

        <tr id="Natural killer (NK) cells serve as pivotal effector cells within the innate immune system, playing an indispensable role against infections and tumors. Individuals with diminished NK cell activity or NK cell deficiency are at a higher risk of developing cancers and experiencing severe viral infections. With global demographic shifts toward aging populations, elucidating the mechanisms of immunosenescence becomes increasingly critical for developing targeted therapeutic interventions against age-related disorders. This review provides a comprehensive summary of the phenotypic characteristics, functional changes, and mechanisms of NK cells in aging and diseases. By synthesizing current research, it highlights key pathways contributing to NK cell immunosenescence in the elderly and explores potential strategies to preserve or restore their cytotoxic and immunoregulatory functions. The review provides novel insights into NK cell immunosenescence and proposes innovative approaches to enhance NK cell activity in aging individuals, offering potential therapeutic avenues for mitigating age-related immune decline.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6176129feabcadd207bec7b9a7e512c4a503122e" target='_blank'>
              Phenotypes, mechanisms, and therapeutic strategies of natural killer cell immunosenescence
              </a>
            </td>
          <td>
            Zixuan Guo, Feng-tian Wu, Yao Chen, Jia Xu, Zhi Chen
          </td>
          <td>2025-10-21</td>
          <td>Immunity & Ageing : I & A</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Tumors attract both tumor-specific T cells and bystander T cells that do not directly fight the tumor. Understanding T-cell heterogeneity is essential for improving the efficacy of immunotherapies. Here, we demonstrate that most neoantigen-specific CD8+ T cells in the tumor are double-positive for PD-1 and IFN-γ, while those in the lymph nodes exhibit heterogeneous expression of PD-1 and IFN-γ. Using single-cell RNA sequencing (scRNA-seq), we show that the tissue microenvironment profoundly influences the transcriptional profiles of tumor-reactive T cells. In tumors, PD-1 marks highly clonally expanded tumor-reactive T cells. In contrast, neoantigen-specific CD8+ T cells in the lymph nodes include a TCF7+ stem-like subset and a transitional subset progressing toward terminal exhaustion. This study provides critical insights into the dynamic differentiation of tumor-specific T cells and highlights potential therapeutic targets for enhancing anti-tumor immunity.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77f6ce3694f3139188b09f3df0bdea17ec36389d" target='_blank'>
              Single-cell insights into CD8 T cell differentiation and exhaustion in the tumor microenvironment 3220
              </a>
            </td>
          <td>
            Kiddist Yihunie, Ying Luo, Tuoqi Wu, Chen Yao
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Melanoma patients treated with anti-PD1 or anti-PD1/anti-CTLA4 present intrinsic or acquired resistance to these immune checkpoint blockade (ICB) treatments. However, the interactions between tumor-stromal-immune cells in the microenvironment (TME) underlying these resistances remain unclear. In this study, we used a cohort of melanoma patients (n = 61) treated with ICB, pre-treatment (n = 33) and post-progression (n = 28), for whole-exome sequencing, single-nucleus RNA sequencing and high-resolution spatial imaging. We developed a framework to analyze response and resistance (intrinsic and acquired) via tumor-intrinsic programs, immune features, and tumor-stromal-immune interactions. Patients with low immune infiltration exhibited enrichment of macrophages associated with hypoxia and angiogenesis phenotypes. Samples with high immune infiltrates displayed an enrichment in lymphocytes, particularly TCF7+ CD8+ T cells. Pre-treatment samples from patients experiencing durable clinical benefit are encriched in memory B cells and plasmablast-like B cells.The presence of Bcells and of follicular dendritic cells in non-lymph node biopsies support the presence of tertiary lymphoid structures within the TME. Lastly, the presence of a TIMD4-expressing macrophage subset correlates with lymphocyte infiltration, indicating its potential role in promoting anti-tumor immunity. Our work defines TME immune profile interaction with tumor-stromal cells associated with clinical outcomes in melanoma.



 NCI HTAN



 Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2a8d3010e6c8bda33a8b18473b82b46e0a2ceaea" target='_blank'>
              Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma 4125
              </a>
            </td>
          <td>
            Giuseppe Tarantino, Yiwen He, Priyanka Solanky, Xinyu Cui, K. Pfaff, A.R. Thorner, Timothy R. Blosser, Elliot Boblitt, Allison Frangieh, Tyler J. Aprati, Boyang Zhang, Jiajia Chen, H. Faulkner, Aleigha Lawless, M. Manos, K. Helvie, T. Sharova, Dennie T. Frederick, Sachi Krishna, Chanell Mangum, Domenic Abbondanza, Cai McCann, Bruce Johnson, Alex K. Shalek, Eliezer M. Van Allen, Xiaowei Zhuang, Ryan J. Sullivan, Barbara Engelhardt, Sami Farhi, S. Rodig, F. S. Hodi, Genevieve M. Boland, David R. Liu
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) play critical roles in tumor immune evasion. These heterogeneous cells are broadly classified into granulocytic (G-MDSC), monocytic (M-MDSC), and their immature precursors, early-stage MDSCs (e-MDSCs). Elucidating their differentiation and expansion mechanisms is crucial for advancing cancer immunotherapy. This review examines the key signaling pathways (e.g., JAK/STAT, NF-κB, Notch), regulatory cytokines, metabolic factors, and epigenetic modifications central to MDSC biology. A comprehensive understanding of these intricate networks provides valuable insights into tumor immune evasion and facilitates the identification of novel therapeutic targets designed to overcome MDSC-mediated immunosuppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4682b63ca9757bb9c1ba2dada7a0f722d5dd5cac" target='_blank'>
              Molecular mechanisms governing the differentiation and expansion of myeloid-derived suppressor cells
              </a>
            </td>
          <td>
            Ke Wang, Xiao Wang, Nan Sun
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Introduction Glioblastoma (GBM) is a highly invasive brain tumor with limited treatment options and poor prognosis. Natural killer (NK) cells are key effectors of antitumor immunity, capable of eliminating cancer stem-like cells. However, GBM creates an immunosuppressive microenvironment that limits NK cell function. Here, we identify cystatin F as an immunosuppressive factor involved in regulating NK cell granule-mediated cytotoxicity. Methods We analyzed cystatin F expression in GBM and its correlation with immune exhaustion markers. NK cell activity was compared between GBM patients and healthy donors. In vitro co-cultures of cystatin F-expressing microglial cells and glioblastoma stem-like cells were used to assess NK cell function. To block cystatin F activation from dimeric to active monomeric form, a small-molecule inhibitor of cathepsin V, the activating protease, was applied. Results Cystatin F expression correlated with immune exhaustion and suppression markers in GBM. NK cells from patients showed reduced cytotoxicity compared to healthy donors. Co-cultures confirmed that cystatin F-expressing microglia impaired NK cell cytotoxicity, while inhibition of cathepsin V restored NK cell function in standard cytotoxicity assays, 3D spheroids, and microfluidic perfused models. Discussion These results indicate that cystatin F mediates NK cell suppression in GBM. Targeting its activation enhances NK cell cytotoxicity, offering a potential strategy to improve NK-based immunotherapy for glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3bb3c49f85522c7de4609841eca5e88d65fb2178" target='_blank'>
              Targeting cystatin F activation enhances NK cell cytotoxicity in glioblastoma models
              </a>
            </td>
          <td>
            E. Senjor, A. Habič, U. Švajger, Ana Mitrović, M. Proj, A. Porčnik, Borut Prestor, Miha Jerala, Matic Bošnjak, Stanislav Gobec, B. Breznik, Janko Kos, Milica Perišić Nanut
          </td>
          <td>2025-10-28</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Checkpoint inhibitors have revolutionized hepatocellular carcinoma (HCC) treatment, yet their efficacy remains limited in advanced stages, with suboptimal objective response rates. Growth differentiation factor 15 (GDF15), a dual-functional cytokine implicated in tumor progression and immunosuppression, represents a promising therapeutic target. This study aims to develop a novel GDF15-targeted strategy to improve HCC management and synergize with PD-1 blockade. GFRAL-Fc fusion proteins were generated by fusing the extracellular domain of GFRAL with IgG1 Fc. The anti-tumor efficacy and the anti-cachexia ability of GFRAL-Fc was evaluated in a spontaneous HCC model on GDF15 humanized mice. Additionally, the half-life and drug safety were evaluated in mice. To investigate the underlying mechanisms, a CyTOF analysis was utilized to analysis the immunoregulation effects of GFRAL-Fc within HCC. Finally, the anti-tumor effects of GFRAL-Fc in combination with Programmed Death-1 (PD-1) inhibitors were assessed. GFRAL-Fc targets GDF15 to simultaneously prevent GDF15-CD48 interaction-driven ERK activation and block GDF15-GFRAL binding. Treatment with GFRAL-Fc achieved dual antitumor effects: reducing tumor progression and attenuating cancer-associated cachexia. Combination with PD-1 blockade further enhanced antitumor efficacy, resulting in a substantial decrease in tumor nodules. Mechanistic studies revealed that GFRAL-Fc reprograms the immunosuppressive tumor microenvironment by suppressing Treg activation while enhancing CD8+ T cell cytotoxicity. Our findings validate GDF15 targeting as a viable strategy to overcome checkpoint inhibitor resistance in HCC. The GFRAL-Fc fusion protein demonstrates multimodal therapeutic benefits through metabolic regulation and immune remodeling, providing a clinically translatable approach to optimize PD-1-based regimens. This study addresses critical gaps in current HCC management and warrants further clinical validation. Schematic diagram of GFRAL-Fc functional: After binding with GDF15, GFRAL-Fc inhibits the GDF15-GFRAL pathway to suppress cancer-associated cachexia, while also inhibiting the GDF15-CD48 pathway to reprograming the tumor immune microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f424c4cc08908ec0d690fea5ad9e9738200e0f9" target='_blank'>
              GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Gege Shi, Wangqian Zhang, Fei Xie, Jiaxin Shi, Minghui Yan, Lei He, Zhaozhao Li, Yang Xiao, Duo Yu, Haiyan Cao, Haichen Du, Yueyuan Qiu, Kuo Zhang, Shuning Wang, Meng Li, Jieyu Zhang, Zhaowei Wang
          </td>
          <td>2025-10-15</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Emerging evidence suggests brain-resident myeloid cells, including perivascular macrophages and microglia, provide a reservoir for HIV infection in the central nervous system (CNS), and their inflammatory activation is a proposed pathogenic mechanism in HIV-associated neurocognitive disorders (HAND). We investigated whether cannabinoid receptor 2 (CB2), an immunomodulatory receptor expressed in myeloid cells, regulates viral replication and inflammation in HIV-infected macrophages and microglia. Using the synthetic CB2-specific agonist JWH-133, we found that CB2 activation reduced HIV replication in primary human monocyte-derived macrophages (MDMs) and human induced pluripotent stem cell-derived microglia (iMg) at differing doses, corresponding to the basal expression of CNR2, which encodes CB2, and related endocannabinoid transcripts in each cell type. JWH-133 broadly reduced release of cytokines from HIV-infected MDMs but not iMg. RNA-seq revealed that CB2 agonism primarily altered interferon and integrated stress response pathways in MDMs while altering homeostatic pathways, including synapse maintenance and phagocytosis, in iMg. Further analyses in iMg revealed that NLRP3 inflammasome activation, but not priming, was reduced by CB2 activation, which did not inhibit HIV-induced nuclear factor kB activation. This study identifies key differences in CB2 response between myeloid lineage cell types and implicates CB2-specific agonists as promising candidates for the regulation of HIV-associated neuroinflammation. Created in BioRender. Espinoza, C. (2025) https://BioRender.com/mxfla3i">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/71c568f55c0cf3f5f771b5d05ce139396b2d6389" target='_blank'>
              Differential Effects of Cannabinoid Receptor 2 Agonists on HIV Replication and Inflammatory Activation in Monocyte-Derived Macrophages and Induced Pluripotent Stem Cell-Derived Microglia
              </a>
            </td>
          <td>
            Alexander Starr, Sara Rathore, Marzieh Daniali, P. J. Gaskill, Ç. Akay-Espinoza, Kelly L Jordan-Sciutto
          </td>
          <td>2025-10-11</td>
          <td>Journal of Neuroimmune Pharmacology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a349f447081e148334ada4b0e5ec3e64399cf656" target='_blank'>
              Trophoblast stem cells and syncytiotrophoblasts lack inflammatory responses to LPS but retain robust interferon-mediated antiviral immunity
              </a>
            </td>
          <td>
            Cristine R. Camp, Joshua Baskaran, Matthew Brown, Carly Parker, Paige Drotos, Rachel C. West
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Recent advancements in the treatment of multiple myeloma (MM), including immunomodulatory agents, monoclonal antibodies, and T cell-redirecting therapies, have significantly improved patient outcomes. However, MM remains incurable. The interaction between MM cells and non-malignant cells within the immunosuppressive tumor immune microenvironment (TiME) plays a critical role in disease progression, but it has not been fully elucidated.
 Our previous study reported that myeloid-derived suppressor cells (MDSCs), dysfunctional dendritic cells (DCs), and tumor-promoting osteoclasts (OCs) are enriched in the bone marrow of myeloma patients and play critical roles in T cell dysfunction. However, the underlying mechanisms remain incompletely understood (Front Immunol. 2022). A myeloid inhibitory receptor, LILRB4, was identified as highly expressed in a super high-risk subgroup of MM cells by single-cell RNA sequencing of patient samples. LILRB4 expression facilitated the generation of monocytic MDSCs and was associated with poor outcomes in MM patients (Haematologica 2024 & 2025). These findings suggest a potential mechanism by which LILRB4 drives an immunosuppressive microenvironment through the induction of immunosuppressive myeloid cells.
 Here, we further observed a significant reduction in erythroid-lineage commitment in MM patients with high LILRB4 expression, and we explored its molecular and cellular impact on the interaction between myeloma cells and the tumor microenvironment (TME). We report that LILRB4 is highly expressed in MM and activates the SHP2/ERK/AP-1 signaling cascade, thereby enhancing the expression of AP-1-associated chemokines and promoting the transdifferentiation of erythroid cells into immunosuppressive erythroid-derived myeloid cells (EDMCs). Through in vivo and in vitro analyses, we demonstrate that CD45⁺ erythroid progenitor cells (EPCs) in the MM microenvironment lose their erythroid differentiation potential and instead transdifferentiate into EDMCs. This reprogramming is driven by elevated levels of CCL3 secreted by LILRB4⁺ MM cells. Compared with the control group, deletion of CCL3 significantly inhibited myeloma cell growth, increased peripheral blood hemoglobin levels, reduced EDMC proportions in the bone marrow, enhanced IFN-γ secretion by CD8⁺ T cells, decreased the frequency of regulatory T cells (Tregs), and reduced the proportion of macrophages. Additionally, the ratio of monocytic MDSCs (M-MDSCs), which preferentially differentiate into tumor-associated macrophages (TAMs), to granulocytic MDSCs (G-MDSCs) was also decreased. EDMCs emerged as another major source of tumor-associated myeloid cells, further contributing to the suppressive TiME.
 These results provide a novel model of hematopoietic diversion in which myeloma “hijacks” CD45⁺ erythroid progenitor cells, redirecting them toward a myeloid fate to evade immune surveillance. EDMCs, as potent immunosuppressive players, strongly inhibit CD8⁺ T cell function and accelerate disease progression. Additionally, our findings establish a mechanistic link between LILRB4 and MM-associated anemia, a well-known poor prognostic factor.Our study therefore suggests that LILRB4 overexpression induces key molecular changes that enable macrophage inflammatory protein-1 alpha (MIP-1α/CCL3)-mediated formation of an immunosuppressive myeloid tumor microenvironment, thereby promoting MM cell growth and survival.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1316f08649414674d11974365803ce69ba88ff10" target='_blank'>
              LILRB4 drives proinflammatory cytokine secretion in multiple myeloma to promote the immune-cell dysfunction via the generation of myeloid-derived suppressive cells
              </a>
            </td>
          <td>
            Lanting Liu, Hao Sun, Yijie Wang, Xiyue Sun, Gang An, Lugui Qiu, Mu Hao
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Objective Regulatory T cells (Tregs) play a pivotal role in tumor immune evasion, and strategies to overcome their immunosuppressive activity are urgently needed. This study investigates the immunomodulatory effects of microwave ablation (MWA) on TNFRSF4+ Tregs, focusing on the OX40L/TNFRSF4 signaling axis as a potential therapeutic target. Methods TNFRSF4+ Tregs were isolated from C57BL/6 mice and subjected to MWA-mimetic thermal stress. In vitro functional assays and in vivo LLC xenograft models were employed, with OX40 agonist intervention. Molecular mechanisms were analyzed via RT-qPCR, Western blot, and immunohistochemistry. The balance of tumor-infiltrating immune cells was quantified by multi-color flow cytometry. Results MWA induced three key effects: (1) Phenotypic shift: decreased CTLA-4+ (P<0.0001) Treg subsets, but increased OX40L+ (P<0.01) in LLC cells; (2) Functional impairment: reduced Treg-mediated support for LLC proliferation, migration, and invasion; (3) Enhanced CD8+ T cell cytotoxicity. In vivo, MWA reshaped the tumor microenvironment by significantly increasing the intratumoral CD8+/Treg ratio (P<0.001), indicating a shift toward an anti-tumor inflammatory state. Mechanistically, MWA suppressed NF-κB/IκBα/TRAF6 signaling, and these effects were amplified by an OX40 agonist, suggesting the pathway is potentially OX40L-dependent. Conclusion This study demonstrates that MWA disrupts Treg immunosuppression, likely by activating OX40L/TNFRSF4 signaling, and favorably alters the balance of effector to suppressor cells, providing a novel rationale for combining thermal ablation with OX40-targeted immunotherapies in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f38c9a306dd490d7b2909de55961bc75bf9d4ebe" target='_blank'>
              Microwave ablation triggers OX40L-mediated disruption of TNFRSF4+ Treg immunosuppressive activity
              </a>
            </td>
          <td>
            Runqi Guo, Yufeng Wang, Jie Sun, Yuanming Li, Zhixin Bie, Xiaoguang Li
          </td>
          <td>2025-10-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="


 Introduction: Chronic lymphocytic leukemia (CLL) is characterized by profound immune dysregulations. Venetoclax (Ven), a selective BCL-2 protein inhibitor, has shown robust clinical activity in both treatment-naïve and relapsed/refractory (R/R) CLL. In Ven-treated patients with CLL, a reduction in the number of non-malignant lymphocytes and a decline in tumor-supportive T-cell subsets were reported. However, the effects of Ven treatment on the patients' immunological profile remain incompletely characterized.
 Aims: This study aims to characterize the immunological effects of Ven-based therapies in CLL by tracking longitudinal changes in T-cell and NK-cell phenotypic and functional profiles.
 Methods:In this multicenter, observational study 68 patients with R/R CLL, eligible for therapy with Ven-based regimens, were enrolled. Forty-six patients received Ven + rituximab and 22 Ven monotherapy. Peripheral blood (PB) samples were collected at the time of treatment start (n=68), and after 1 (n=60), 6 (n=56) and 12 (n=57) months of therapy. The percentage and the phenotype of T and NK cells were assessed by multicolor flow cytometry.
 Results: Data of 58 enrolled patients have been analyzed to date. In parallel with the reduction of circulating leukemic cells, Ven treatment induced a significant decline in absolute CD3⁺, CD4⁺ and CD8⁺ T-cell counts, which was already evident after one month and persisted at the 6- and 12-month timepoints. During treatment, in the CD4⁺ T-cell compartment, the frequency of naïve (TN) and central memory (TCM) subsets remained stable over time, while within the cytotoxic subsets we observed a decrease in the effector memory (TEM) T cells and a parallel, significant increase of the terminally differentiated (TEMRA) T cells compared to the pre-treatment distribution. In the CD8+ T-cell compartment we observed a similar rise in the proportion of TEMRA, which was paralleled by a decrease in the proportion of TCM and TEM subsets. The evaluation of immune checkpoint expression on CD4⁺ T cells revealed a downmodulation of PD-1 that was already evident after one month of treatment and a reduction of BTLA, TIM-3 and LAG-3 levels that became evident at the later 6- and 12-month timings. Interestingly, a more detailed analysis performed in a subgroup of patients showed that the observed reduction in immune checkpoint expression was mostly restricted to the less differentiated (i.e. TN, TCM) CD4+ subpopulations. Concerning the CD8⁺ T-cell compartment, Ven treatment significantly lowered BTLA expression - particularly within the TN and TCM subsets - across all timepoints, whereas the levels of the other immune checkpoints remained largely unaltered. Of note, an expansion of the immunosenescent CD57⁺PD-1⁻ subset was persistently detected within the CD8⁺ TEMRA subset already after one month of treatment and within the CD4⁺ TEM and TEMRA subsets at the later 12-month timepoint. T-cell homing capacity was also evaluated, based on CXCR3 and CD62L expression. Interestingly, both CD4⁺ and CD8⁺ T cells showed increased CD62L expression after 12 months of treatment, indicating enhanced migration capacity to lymph nodes. In the context of innate immunity, Ven administration resulted in an overall decrease in the absolute number of NK cells, detectable as early as one month after treatment initiation. Notably, the frequency of the CD56dimCD16⁺ NK-cell subset, mostly responsible for cytotoxic activity and ADCC, increased significantly at the 6- and 12-month timepoints. By contrast, the proportion of the less represented CD56bright NK-cell subset remained stable in the PB of Ven-treated patients. We did not detect any relevant difference in the modulation of T-cell and NK-cell phenotype between patients treated with Ven plus rituximab and those receiving Ven monotherapy.
 Conclusion: This study provides a longitudinal evaluation of the immunomodulatory effects of Ven treatment in the largest cohort of patients with CLL analyzed to date. Our results indicate that Ven therapy reshapes both the T-cell and NK-cell compartments by alleviating features of exhaustion, enhancing lymph node homing potential and promoting the expansion of cytotoxic subsets. At the time of data presentation, conclusive results from additional phenotypic analyses and functional assays will be available. These immunological modulations may be harnessed to elucidate Ven off-tumor effects and to refine optimal therapeutic sequencing strategies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ba4e66f3d5a0eec4a163635c182e19c61aaa3c7e" target='_blank'>
              Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia
              </a>
            </td>
          <td>
            Giorgia Mancin, V. Griggio, Rebecca Jones, Giulia Bondielli, A. Visentin, R. Moia, A. Frustaci, A. Bosi, M. Varettoni, Francesca Perutelli, M. C. Montalbano, G. Catania, P. Sportoletti, L. Laurenti, F. Mauro, L. Orsucci, Luca Arcaini, Francesco Passamonti, M. Deodato, G. Gaidano, L. Trentin, B. Bruno, C. Vitale, M. Coscia
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>56</td>
        </tr>

        <tr id="


 Immunosenescence leads to impaired immunity against infections in the elderly. As a key component of adaptive immunity, T cells are crucial for immunity against infection and cancer and exhibit distinct phenotypic changes with age. Characterizing these age-related alterations in T cells is essential for developing strategies to address immune dysregulation in the elderly. In vitro activation model showed that aged mice have a higher frequency of PD1+ exhausted-like CD8 T cells at baseline and higher TCR-induced cell death upon activation. Inhibiting both apoptosis and necrosis rescues TCR activation-induced cell death. Using a murine hepatitis virus (MHV) intranasal infection model, we observed that aged mice had greater weight loss, higher mortality, and impaired CD8 T cell responses during MHV infection. Infected aged mice exhibited increased expression of inhibitory receptors on antiviral CD8 T cells and a decrease in the population of CD8 T cells producing IFN-γ. Single-cell RNA sequencing showed that aging altered the transcriptional profile of antiviral CD8 T cells and reduced T-Bet and ZEB2 expression, key factors for effector CD8 T cell differentiation. Aging also upregulated T cell exhaustion gene signature mediated by the transcription factor TOX. Overall, our findings demonstrate that aging reshapes the molecular program of antiviral CD8 T cells and compromised antiviral T cell immunity in the aged.



 Supported by NIH/ NIA AG-083398; NIAID AI-158294



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/80e47c0f1fb034ad0cc56d0aad4b1018f719c06e" target='_blank'>
              Aging compromises effector differentiation and induces exhaustion-like phenotype in CD8 T cells 2511
              </a>
            </td>
          <td>
            Ziang Zhu, Tuoqi Wu, Chen Yao
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Background/Objectives: Dendritic cell (DC)-based immunotherapies offer a promising strategy for cancer treatment but are limited by inefficient activation of cytotoxic T cells and, in turn, the host immune system. This report demonstrated that CD34+ hematopoietic stem cell (HSC)-derived allogeneic DCs engineered by an optimized lentiviral vector (LVV) expressing CD93, CD40-ligand (CD40L), and Chemokine (C-X-C motif) ligand-13 (CXCL13) significantly enhanced the host immune system, activated tumor-specific cytotoxic T cells, and led to complete regression of both primary and metastatic pancreatic tumors in humanized mouse models. This LVV shows comparable pre-clinical efficacy compared to the first-generation vector, in addition to being compliant for clinical use, which allows further pre-clinical development towards the human trials. Methods: This 2nd generation (Gen) LVV incorporates codon-optimized transgenes (CD40L, CD93, and CXCL13) with rearranged sequence to enhance expression, driven by a strong EF1α promoter. CD34+ HSCs were transduced with this modified 2nd Gen LVV and differentiated to Engineered DCs. Therapeutic efficacy of the DC therapy with the modified vector was tested on humanized mouse models of pancreatic tumors. This was accomplished by establishing an early-stage disease model (using MIA PaCa-2 (MP2)-tumors) and late-stage metastatic disease model of the pancreatic tumors to mimic the clinical setting using luciferase-expressing MP2-(Luc)-pancreatic tumor-bearing humanized mice. Results: The modified lentiviral construct had 6-fold greater expression of CD40L, 2% less toxicity, 4.5-fold greater CD40L, and 2.2-fold greater CXCL13 secretion than its predecessor. In vitro, Engineered DCs induced robust T cell proliferation in up to 20% of T cells, up to 4-fold greater interferon-gamma (IFN-γ) secretion than controls, and showcased antigen-specific cytotoxicity by CD8+ T cells. In vivo, two intradermal doses of the 2nd Gen DCs led to complete regression of primary pancreatic tumors and metastases. Treated mice exhibited prolonged survival, indicating the induction of durable anti-tumor immunity. Conclusions: Vector optimization retained the efficacy of DC-based therapy, achieving curative responses in pancreatic tumor models. These findings support the clinical development of this 2nd Gen DC immunotherapy for pancreatic and potentially other tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ff04e5a53312a33b8358477b343f0d0e27fa4577" target='_blank'>
              Modified Hematopoietic Stem Cell-Derived Dendritic Cell Therapy Retained Tumor-Inhibitory Function and Led to Regression of Primary and Metastatic Pancreatic Tumors in Humanized Mouse Models
              </a>
            </td>
          <td>
            Jose D. Gonzalez, S. Mahammad, S. Beraki, Ariel Rodriguez-Frandsen, N. Sheik, E. Kathirvel, F. Binette, D. Weinstein, A. Jewett, Lu Chen
          </td>
          <td>2025-11-01</td>
          <td>Vaccines</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Recently, we observed that pars planitis (PP) patients present alterations in peripheral blood (PB) Th17/Treg associated with dysregulation in the Th1 response. Yet, little is known about the systemic distribution of myeloid cells, which drive the recruitment and differentiation of the adaptive effectors toward pathogenic inflammatory Th1 and Th17 as well as regulatory lymphocytes in PP. Although myeloid populations in patients with uveitis have previously been addressed, the data did not provide an exact description of PP patients. Using flow cytometry, we evaluated monocyte and IDO-expressing monocyte-like myeloid-derived suppressor cell (MDSC) subpopulations in PB samples from 15 patients with different courses of PP (cystoid macular edema and non-macular edema subgroups; CME and nCME, respectively) and 17 healthy controls (HCs) in relation to the Th1, Th17, and immunoregulatory subsets. We observed that only PP patients from the CME subgroup presented a significantly higher fraction of CD16+ IDO-expressing MDSCs and intermediate CD14highCD16+ monocytes compared to the HCs; this corresponded with relative up-regulation of Th1 and Th17, and down-regulation of Treg. In addition, alongside the increased percentage of IDO-expressing CD16+ MDSCs, the MDSC compartment displayed an inappropriate level of IDO (more pronounced in the CD16− subset) only in CME patients. At the same time, the fraction of CD16− myeloid cells did not differ significantly among the patient cohorts and healthy participants. Our study is the first to evaluate subpopulations of circulating myeloid cells in PP patients and indicates that an increased fraction of CD16+ myeloid cells might reflect the immunological and clinical severity of PP.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cd1fd2d076c43e8bd265181bbac902c87dc1f38" target='_blank'>
              Circulating CD16-Positive Monocyte-like Myeloid-Derived Suppressor Cells and Intermediate Monocytes Associated with Clinical and Immunological Complications in Pars Planitis Patients
              </a>
            </td>
          <td>
            A. Kosmaczewska, Joanna Przeździecka-Dołyk, L. Ciszak, Zofia Rojek-Gajda, I. Frydecka, A. Turno-Kręcicka, Marta Misiuk-Hojło, Edyta Pawlak
          </td>
          <td>2025-10-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b6398ddc5edaa94a066851abec2558753a9728" target='_blank'>
              NLRP1 Shapes Immune and Inflammatory Signatures in Human Melanoma but Not in Mouse Models
              </a>
            </td>
          <td>
            V. P. Targhetta, Raquel de Souza Vieira, Hedden Ranfley, C. N. de Souza Breda, N. O. Câmara
          </td>
          <td>2025-11-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="ABSTRACT The immune system is tasked with mounting effective responses to pathogens while preventing inflammation triggered by innocuous antigens, including those derived from self, food, and commensal microbes. This balance is especially critical in the intestine, where dietary and microbial antigens are constantly encountered. Peripherally induced regulatory T cells (pTreg or iTreg) play a key role in suppressing inappropriate immune activation and maintaining gut homeostasis. Elucidating how pTreg cells are generated along the gastrointestinal tract is therefore critical to understanding peripheral tolerance. Recent studies have revealed that intestinal antigen‐specific pTreg cell differentiation is induced by a distinct lineage of antigen‐presenting cells (APCs) requiring expression of the transcription factors RORγt and PRDM16. Genetic perturbation of these APCs results not only in microbiota‐specific proinflammatory T cell responses but also in the breakdown of oral tolerance, which in turn predisposes to allergic inflammation. In this review, we summarize the discovery of these tolerance‐inducing APCs, highlight their role in instructing pTreg cell differentiation in response to microbiota and dietary antigens, and discuss the regulatory networks that support their function during intestinal immune tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3da30c377152a2f5e064e9a65d6e95246713e092" target='_blank'>
              Specialized Dendritic Cells Mediating Peripheral Tolerance to Intestinal Antigens
              </a>
            </td>
          <td>
            Liuhui Fu, Dan R. Littman
          </td>
          <td>2025-12-02</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Multiple myeloma (MM), the second most common hematologic malignancy, presents significant clinical challenges due to its relapsing/refractory nature and incurability, primarily attributed to the high complexity of the bone marrow (BM) microenvironment. Emerging evidence suggests that metabolic reprogramming within the tumor microenvironment (TME) plays a pivotal role in tumor progression and the anti-tumor function of CD8+ T cells. However, the limited understanding of the metabolic landscape of the MM BM microenvironment has hindered the identification of potential therapeutic targets. In this study, we demonstrate that although CD8+ T cells from MM patients exhibit elevated expression of immune checkpoint molecules, they do not enter a canonical exhausted state. Instead, their dysfunction is reversibly suppressed by microenvironmental alterations. Metabolomic profiling revealed a significant remodeling of the tryptophan metabolic pathway in the MM BM microenvironment, characterized by the accumulation of nitrogen-containing metabolites and indole derivatives, which directly impair CD8+ T cell-mediated anti-tumor activity. Further investigation identified indole-related metabolites as key metabolic regulators in the MM BM niche, promoting immune evasion by functionally suppressing CD8+ T cells. These findings not only uncover a novel mechanism of immune suppression in MM but also provide potential therapeutic targets for developing metabolism-focused immunomodulatory strategies.
 In multiple myeloma (MM) patients, bone marrow CD8+ T cells exhibit elevated PD-1 expression but comparable TIM-3 levels to non-myeloma controls. Notably, no significant differences were observed in cytokine secretion capacity or exhaustion-related transcription factor expression between PD-1+/TIM-3+ and PD-1-/TIM-3- T cell subsets. Thus, while a substantial population of CD8+ T cells persists in the MM microenvironment, they do not exhibit the canonical exhausted phenotype traditionally defined in chronic viral infections or other malignancies.
 Unexpectedly, fresh myeloma BM CD8+ T cells show blunted cytokine responses, reversible by overnight culture but inhibited by autologous BM supernatant. This suppression is BM-specific, as peripheral T cells remain unaffected by plasma.
 The <3 kDa hydrophilic fraction of bone marrow (BM) supernatant significantly impaired the cytotoxic capacity of BCMA CAR T cells. Untargeted metabolomic profiling revealed that the inhibitory BM supernatant exhibited distinct metabolic alterations, primarily enriched in the following pathways：Amino acid metabolism; Energy metabolism ; Nucleotide metabolism. Notably, multiple indole derivatives were upregulated in the tryptophan metabolic pathway.
 Metabolomic analysis revealed significant upregulation of indole-3-acetic acid (IAA), indole-3-propionic acid (IPA), and kynurenine in the inhibitory bone marrow supernatant. Functional validation demonstrated that indole, indoleacrylic acid, IPA, and IAA all exhibited dose-dependent suppression of CAR T cell-mediated tumor cytotoxicity. Notably, IAA displayed potent immunosuppressive activity even at low concentrations, suggesting enhanced immunomodulatory potential. Mechanistically, both IAA and IPA significantly upregulated aryl hydrocarbon receptor (AHR) expression， indicating that indole-related metabolites may impair antitumor T cell function through AHR-mediated signaling pathways.
 Overall, we have come to the following conclusions：flow cytometric and transcriptional analyses revealed that CD8+ T cells in the multiple myeloma (MM) bone marrow microenvironment exhibit an activated phenotype rather than classical exhaustion markers, despite their functional impairment. Ultrafiltration and functional assays demonstrated that the <3 kDa hydrophilic fraction of MM bone marrow supernatant significantly inhibits CD8+ T cell effector functions. Indole-3-acetic acid (IAA) and indole-3-propionic acid (IPA) are significantly elevated in the bone marrow of a subset of multiple myeloma (MM) patients, where they potently inhibit the anti-tumor function of CD8+ T cells, likely through activation of the aryl hydrocarbon receptor (AhR) signaling pathway on T cell surfaces.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d1c2fdacb0730e5456a357462f821514cc752968" target='_blank'>
              Indole-related metabolites suppress the anti-tumor function of CD8+ T cells in the bone marrow microenvironment of multiple myeloma
              </a>
            </td>
          <td>
            Yueyi An, Huixing Zhou, Xiaoyun Jin, Shengdian Wang, Wen Gao
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Regulatory T cells (Tregs) are a distinctive subset of CD4+ T cells critical in self-tolerance maintenance to prevent the development of autoimmunity. The mechanisms by which these cells provide immune regulation are numerous and, consequently, deeply involved in the pathogenesis of many autoimmune disorders. Treg-based adoptive cell transfer (ACT) therapy has generated interest as a novel, promising strategy to restore self-tolerance in autoimmunity. Polyclonal Treg-based ACT therapy was first implemented in clinical trials, presenting adequate safety profiles. Subsequent preclinical studies have shown antigen-specific Tregs to be safer and more effective than polyclonal approaches, so research has recently moved in this direction. Antigen-specificity can be conferred to Tregs by viral transduction of genes coding for engineered T cell receptors (eTCRs) or chimeric antigen receptors (CARs), with encouraging outcomes in different animal models of autoimmunity. This review focuses on the biology of Tregs, as well as on current preclinical and clinical data for Treg-based ACT in the field of autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/245990f7801c19be0c77d295d5bb4e3aed2c7143" target='_blank'>
              Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity
              </a>
            </td>
          <td>
            Eduardo Gozálvez, Adrián Lario, Guillermo Muñoz-Sánchez, Francisco Lozano
          </td>
          <td>2025-10-23</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Dendritic cells (DCs) are essential regulators of adaptive immunity, functioning as professional antigen‐presenting cells that bridge innate sensing with the induction of adaptive immunity and immune memory. The DC population is heterogeneous, encompassing numerous phenotypic subsets depending on the tissue, pathophysiological condition and species studied, which historically complicated their classification. Advances in bulk or single‐cell transcriptomics and ontogenetic studies have clarified DC heterogeneity and highlighted type 1 conventional DCs (cDC1s) for their unique ability to induce protective CD8+ T cell responses against cancer and intracellular pathogens. Beyond immunity, DCs also maintain tolerance to self and harmless antigens. Contrary to earlier assumptions that tolerogenic DCs are simply immature, recent evidence shows that both immunogenic and tolerogenic maturation involve an extensive and convergent reprogramming of cDC1s during the activation process licensing them for shaping T cell responses, a process referred to as DC maturation. This evolving understanding is reshaping how we study DCs, including the necessity to integrate the timing of DC maturation and their microanatomical redistribution during this process. The novel insights these studies are bringing carry significant implications for vaccines or immunotherapies against intracellular pathogens or cancers, and treatments against allergy or autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4f0236bce193fec556b42698afce4c36c4c5719f" target='_blank'>
              Identity, Functions, and the Spatiotemporal Maturation of Type 1 Conventional Dendritic Cells
              </a>
            </td>
          <td>
            Ramazan Akyol, Marc Dalod
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 Neutrophils foster a pro-tumorigenic microenvironment in multiple myeloma (MM) by releasing inflammatory cytokines, immunosuppressive factors, and reactive oxygen species (ROS), contributing to immune evasion and disease progression. Elevated neutrophil-to-lymphocyte ratio serves as a poor prognostic marker, yet neutrophil-targeted therapies remain underexplored. Our prior work identified three novel drug combinations that disrupt both epigenetic regulation and cell cycle control—particularly effective in transcriptionally active, treatment-resistant MM. These combinations also upregulate Smad signaling, indicating potential to reprogram the immune microenvironment and enhance anti-myeloma immunity.
 The CDKi/HDACi combination of dinaciclib and entinostat was identified as a potent combinatorial therapy, as it showed the greatest synergy in treatment-resistant myeloma subtypes and presented higher survival in a murine Vk*MYC; Nras LSL Q61R/+; IgG1-Cre (VQ) allograft mouse model. We investigated the CDKi/HDACi combination for further preclinical development. We explored the targets, mechanism of action, and efficacy of combined CDK/HDAC inhibition in vitro (cell lines) and in vivo (NSG xenografts and Bcl-xL transgenic spontaneous tumors) and confirmed that the combination leads to MYC suppression, upregulation of tumor suppressors like p16, anddelayed tumor progression. Freshly obtained smoldering myeloma patient bone marrow biopsy cells were utilized to evaluate the efficacy of the combination compared to single-agent treatment. The CDKi/HDACi combination was effective at selectively reducing the viability of human CD138+ MM cells ex vivo.Finally, a genetic signature of combined CDK/HDAC inhibition emerged for MM cells. RNA-seq and gene set enrichment analysis revealed downregulation of DNA replication, protein folding, and, importantly,immune pathways, including those related to leukocyte migration and pro-inflammatory chemokines (e.g., CXCL1, CXCL2, IL1A, IL23A). These changes align with the suppression of inflammatory and neutrophil-recruiting signals, suggesting that CDK/HDAC inhibition may indirectly suppress neutrophil activation and trafficking in the MM microenvironment.
 To overcome translational barriers associated with dinaciclib and entinostat, we evaluated next-generation agents: KB0742, a selective and orally bioavailable CDK9 inhibitor, in combination with quisinostat or zabadinostat, two potent HDAC inhibitors with more favorable pharmacokinetic and safety profiles. We validated their synergistic action in limiting proliferation and alteration of biomarker expression. Our next steps are to use co-culture conditions of MM cells with neutrophils, to observe the effects of CDKi/HDAi combination treatment by monitoring neutrophil activation markers, including CD11b and ROS production, compared to single agents. We will further investigate pro-inflammatory cytokines and chemokines involved in neutrophil recruitment and activation (e.g., CXCL1, CXCL2, CXCL8, IL1A, IL23A). These transcriptional changes, accompanied by increased re-expression of tumor suppressors (e.g.,p16) and TGFβ/SMAD signaling components, would predict reprogramming of an anti-inflammatory microenvironment by these combination treatments in myeloma.
 These findings point to a promising but underdeveloped therapeutic avenue whereby suppressing neutrophil-driven inflammation enhances anti-myeloma immunity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9784fe983e1a8413d51f126d5fbd75b2e2cf4b86" target='_blank'>
              HDAC and CDK inhibitor combinations suppress neutrophil activation in myeloma
              </a>
            </td>
          <td>
            Snehal M Gaikwad, Tyler J. Peat, Wendy Du Bois, Shuling Zhang, Nana Gyabaah-Kessie, Jing Zhang, Dickran Kazandijian, Aleksandra Michalowska, Beverly Mock
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ff39811b58af3141f8b13471490c1f390abe0d9" target='_blank'>
              Non-canonical inflammasome drives intrinsic anti-microbial responses in human Natural Killer cells
              </a>
            </td>
          <td>
            N. G. Leborgne, Jadie Acklam, Alexander J. Hogg, Zarema Albakova, Karen Hogg, K. Robinson, Grant Calder, Arnel Villamin, Callum Robson, Freya Pealing, Matthew A. Care, Monika Gonka, James M. Fox, James Iremonger, J. Hewitson, David G. Kent, Alison M. Layton, Frances E. Pearson, Max E. Noble, W. Grey, Jillian L. Barlow, Dave Boucher
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Cutaneous squamous cell carcinoma (cSCC) is a common cutaneous malignant tumor, with its development and progression closely linked to immune dysregulation within the tumor microenvironment (TME). This review highlights cSCC-specific TME features—such as UV-induced mutational burden and the immunosuppressive effects observed in transplant recipients—and systematically outlines the composition and functional roles of tumor cells, immune cells (Tregs, MDSCs, TAMs), and stromal cells (CAFs) within the TME. The immunosuppressive mechanisms mediated by these cellular components are clarified, particularly through pathways including PD-L1/PD-1 and TGF-β/Smad. Building on this foundation, the potential clinical value of immune checkpoint inhibitors (cemiplimab, pembrolizumab) in treating advanced cSCC is summarized based on data from relevant clinical trials. Additionally, the impact of gender differences on cSCC incidence and therapeutic outcomes is discussed. This review is distinguished from general tumor immunotherapy reviews by offering dedicated references for cSCC precision immunotherapy. In addition, priority is emphasized for future investigations into combination therapy regimens and the development of personalized tumor vaccines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b6e06f3a851d201413d7a123ccfc7ad5ab80bdc" target='_blank'>
              Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment
              </a>
            </td>
          <td>
            Qinyi Dong, Zijian Zhang, Siying Li, Lili Liang
          </td>
          <td>2025-11-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Background: Immunotherapy has transformed cancer care, inducing durable responses in both hematologic and solid tumors. Despite these advances, many patients derive limited benefit, potentially secondary to an immunosuppressive tumor microenvironment (TME), defined by defective antigen presentation, immunosuppressive cell infiltration, and stromal barriers that restrict T-cell trafficking.
 Our group has established the use of mesenchymal stem cells (MSCs) as modifiers of the tumor microenvironment (TME) (Studeny M…Andreeff, Cancer Res 2002; JNCI 2004). We demonstrated in solid tumors that intravenously injected MSCs have the innate capacity to migrate into the TME and contribute to the generation of tumor-associated fibroblasts at the invasive edge of the tumor and their metastases. While MSCs are believed to be immunosuppressive, we hypothesized that they could be modified into immunostimulatory cells and convert a “cold” TME into a pro-inflammatoryTME. In a clinical pilot trial, we demonstrated proof-of-concept that IFNβ-secreting MSCs homed to ovarian tumors and mediated intratumoral IFNβ delivery (NCT02530047)(Andreeff M et al. Cancer Res (2018)78:75).
 Results: We developed an immunotherapeutic strategy using induced pluripotent stem cell–derived mesenchymal stem cells (iMSCs) engineered to secrete IL-7 and IL-15, two potent cytokines selected for their robust immunostimulatory properties. iMSCs, clonally derived from iPSCs, offer superior expansion and scalable production compared to BM-MSCs. These iMSCs retained classical MSC morphology and proteogenomic profiles, supporting their identity and functionality. Telomere length and CyTOF-based cell cycle analysis revealed high proliferative capacity, far superior to BM-MSCs. Stable transgene expression was validated using GFP-tracked clones throughout differentiation and expansion. These iMSCs enhanced bone marrow regeneration following radiation therapy (Okeleji, O et al ASH2025).
 Proprietary gene editing ensured efficient and consistent integration of IL7 and IL15 transgenes, providing a robust platform for cytokine delivery. IL-7/IL-15-iMSCs produced supraphysiological cytokine levels (2,000–4,000 pg/mL), representing a nearly 20-fold increase over levels seen in previously engineered T cells. This enhanced cytokine output drove proliferation of resting and CD3/CD28-activated T cells, as confirmed via CFSE assays. CyTOF profiling revealed robust downstream STAT5 phosphorylation, pS6 activation, and BCL2 upregulation, indicative of efficient IL-7/IL-15 receptor downstream signaling. Hence, immunosuppressive iMSCs were modified to be potent immunostimulatory cells. We applied this concept to high-grade serous ovarian carcinomas (HGSOC). PBMCs conditioned with IL-7/IL-15-iMSCs significantly reduced the number of both platinum-sensitive and platinum-resistant ovarian cancer cells in vitro. To evaluate therapeutic efficacy in vivo, we administered IL-7/IL-15-iMSCs i.p. into the ID8 murine ovarian cancer model in immunocompetent mice. Multiplex immunofluorescence demonstrated that iMSCs home to tumors, secrete cytokines locally, and promote intratumoral T-cell, NK-cell, and macrophage infiltration, collectively leading to prolonged survival. This outcome was associated with a shift from an immune-excluded to an inflamed, immune-infiltrated TME. The ovarian TME was enriched in CD163⁺Arg1⁺PD-L1⁺M2-like macrophages, which exhibited a phenotypic shift toward an M1-like state, marked by Arginase-1 downregulation, in the IL-7/IL-15 treatment group. Experiments investigating activity of IL-7/IL-15-iMSCs in carboplatin-resistant ID8 models are ongoing and will be reported. Results in triple-negative breast cancer will be reported separately (Singh, S et al. ASH2025).
 Conclusion: We demonstrate that IL-7/IL-15-iMSCs display potent in vitro immunostimulatory activity, inducing robust T cell proliferation and activation. IL-7/IL-15-secreting iMSCs convert an immunosuppressive TME into a “hot” milieu, defined by massive T-cell and macrophage infiltration, M1 polarization, and restoration of T-cell functionality. Gene-modified iMSC-induced reprogramming of ovarian TME resulted in reduced tumor burden and improved survival in a murine ovarian cancer model. Results support the potential of IL-7/IL-15-iMSCs as a novel immunotherapeutic platform for overcoming immune resistance in cancer, including hematological malignancies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b9ab550875609985f12d7a0a7eb4312645f47adc" target='_blank'>
              Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct  Pro-inflammatory tmes
              </a>
            </td>
          <td>
            M. Muftuoglu, Sandeep Singh, Andrea D Bedoy, Li Li, Mahesh Basyal, Nath Dipmoy, Lauren B. Ostermann, Ivo Veletic, Christopher D. Pacheco, Poo Yee Mak, Edward Ayoub, Taeyun Kim, Kyle M. Garland, Robert Pierce, Mathew Angel, Sanjeev Luther, Christopher B. Rohde, M. Andreeff
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Cancer immunotherapy using dendritic cells (DC) pulsed ex vivo with tumour antigens is considered safe, but its clinical efficacy is generally modest. Here we engineer DC progenitors (DCP), which can replenish conventional type 1 DCs (cDC1) in mice, to constitutively express IL-12 together with a non-signalling chimeric receptor, termed extracellular vesicle-internalizing receptor (EVIR). By binding to a bait molecule (GD2 disialoganglioside) expressed on cancer cells and their EVs, the EVIR enforces EV internalization by cDC1 to promote their cross-dressing with preformed, tumour-derived MHCI-peptide complexes. Upon systemic deployment to mice, the engineered DCPs cause only mild and transient elevation of liver enzymes, acquire tumour-derived material, engage tumour-specific T cells, and enhance the efficacy of PD-1 blockade in an immunotherapy-resistant melanoma model comprising both GD2-positive and -negative cancer cells, without the need for ex vivo antigen pulsing. These results indicate that EVIR-engineered DCPs may avert the positive selection of antigen-negative cancer cells, potentially addressing a critical limitation of immunotherapies targeting defined tumour antigens. Tumour-antigen-pulsed mature dendritic cells (DC) have not been as efficient for cancer therapy as hoped to be, due to their sub-optimal antigen-presentation and migration capacities. Here the authors utilise DC progenitors, constitutively expressing IL-12 and an engineered extracellular vesicle-internalizing receptor (EVIR), which give rise to mature conventional type 1 DCs with improved antigen presenting capacities, resulting in improved anti-tumour immunity in a mouse model of melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a39e0ff151e628fa80cbe009a17a125f7c34be1c" target='_blank'>
              Dendritic cell progenitors engineered to express extracellular-vesicle–internalizing receptors enhance cancer immunotherapy in mouse models
              </a>
            </td>
          <td>
            Ali Ghasemi, A. Martinez-Usatorre, Yang Liu, Hadrien Demagny, Luqing Li, Yahya Mohammadzadeh, Andreas Hurtado, Mehdi Hicham, Linda Henneman, Colin E J Pritchard, Daniel E. Speiser, Denis Migliorini, Michele De Palma
          </td>
          <td>2025-10-15</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>56</td>
        </tr>

        <tr id="


 Introduction: The bone marrow (BM) microenvironment supports survival of the malignant multiple myeloma (MM) cells and is composed of cellular components that foster MM development and progression by suppression of immune responses. Despite major progresses in understanding the MM biology and pathophysiology, it is still incurable. Myeloid cells are well-described to suppress antitumor immunity (Barry et al., 2023; De Sanctis et al., 2023). However, the molecular mechanisms to achieve immunosuppressive myeloid cell states are unknown. Cytokine IL-4 is the primary driver of tumor infiltrating monocyte-derived macrophage (MO-MAC) phenotype as reported by LaMarche that deletion of IL-4Rα alone within early myeloid progenitors in BM reduced tumor burden; while deletion in downstream mature myeloid cells had no effect (LaMarche et al., 2024). Mechanistically, IL-4 derived from BM basophils and eosinophils acted on granulocyte-monocyte progenitors (GMPs) to transcriptionally program the development of immunosuppressive tumor-promoting myeloid cell.Hematopoietic Adaptor-Containing SH3 and SAM domains (HACS1) maps to a region on chromosome 21 that is frequently disrupted in hematopoietic malignancies, suggesting its involvement in these diseases (Claudio et al., 2001). Previously, we showed that Hacs1 is involved in MM development through changes of its microenvironment. It regulates IL4 signaling in B cell, T cell, macrophages and dendritic cells and affects their function (Wang et al., 2010). Hacs1-/- bone marrow derived macrophages (BMDMs) are hyper-responsive to IL-4 stimulation and display an alternative activation M2 phenotype. We found CD11b+/Gr-1+/ CD31+/Siglec F myeloid progenitors as well as immature myeloid progenitors and eosinophils were significantly increased in Hacs1-/- mouse bone marrow.
 Method: In the current study, we investigated the role of Hacs1 in MM immunosuppressive microenvironment utilizing Hacs1-/-mouse BM-myeloid derived suppressor cells (MDSCs) as well as MM tumor-bearing mice to study MM progression and therapeutic resistance.
 Results: Our results showed Hacs1-/-mouse bone marrow in MM tumor-bearing mice has upregulated PD-L1 expression in MDSCs, suppressing T cell function. Overexpression of Hacs1 or stimulation Hacs1 reduces MDSC accumulation, resulting in elevated T cell activity and reduced tumor load. Our data suggest that Hacs1 plays a key role in regulation of the immunosuppressive microenvironment in MM. Furthermore, myeloid cells from Hacs1-/-mouse BM have increased expression of MS4A3 gene, a key gene regulating cell differentiation to monocytic/granulocytic-myeloid-derived suppressor cells (M-MDSCs and G-MDSCs, respectively) (Liu et al., 2019). At the mechanistic level, MS4A3 enhances IL-3 and GM-CSF signaling in Hacs1-/-BM CD34+ cells, compared to Hacs1+/+cells.Conclusion: These data suggest that Hacs1 negatively regulate IL-4 signalling axis in bone marrow and drives pro-tumorigenic myelopoiesis and myeloid cell differentiation through MS4A3/IL3/GM-CSF signaling. Hacs1 is a key player in cellular signaling within the immune system with roles in immune regulation, cancer development, and potential serves as a MM therapeutic target.
 Keywords: Hacs1-/-, Multiple Myeloma, myeloid derived suppressor cells (MDSCs), bone marrow microenvironment, chemo resistance
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f2d0467e47b26436ae5260ef710bda44c102442" target='_blank'>
              Title: Hacs1 is a myeloma immunosuppressor driving pro-tumorigenic myelopoiesis and myeloid cell differentiation through MS4A3/IL3/GM-CSF signaling
              </a>
            </td>
          <td>
            DingYan Wang, , Jamie Li, Raymond Qu, Wiiliam JiaYi Wu, Xinmiao Andrew Yang, Derek Shiqi Xu, Jingdong Wu, Leqi Shen, Jeremy Dai, Yuan Gao, Jinyi Zhang, Anthony Gramolini Gramolini, Xiaoyuan Liu, K. Siminovitch, Keith Stewart
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="


 Despite long held beliefs that B cells and CD8 T cells act independently, our recent investigations demonstrate that B cells are responsible for shaping the phenotype and fate decisions of naïve and effector CD8 T cells. Following vaccination or infection, antigen-specific CD8 T cells are skewed toward terminal differentiation in B cell-deficient mice and in MD4 mice, which have a fixed BCR repertoire, as compared to WT controls. The result is significantly fewer CD127high memory-fated CD8 T cells and defective long-term memory. This phenotype is recapitulated upon B cell depletion using CD19-cre x iDTR mice or using anti-CD19 CAR T cells in WT mice, and in the context of multiple vaccine strategies and infections. Because these data indicated that the presence or absence of B cells leaves an imprint on naïve T cells, we looked for evidence of differential programming prior to activation. Flow cytometry analysis of naïve CD8 T cells isolated from the periphery of both MD4 mice and human populations depleted of B cells revealed an effector-skewing with decreases in FOXO1 and CD127, and corresponding increases in Granzyme A and other proteins associated with terminal differentiation. Overall, these data indicate B cells play an essential role in the establishment of not only the naïve CD8 T cell repertoire, but they also influence the CD8 T cell response following vaccination or infection.



 NIH grants AI066121, AI148919, and AI126899



 Vaccines and Immunotherapy (VAC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/27fcbb0061a3f3f5aa3ad9c90eb414e240a1edb8" target='_blank'>
              B cells shape näive and vaccine-elicited CD8 T cell phenotype and fate decisions 2073
              </a>
            </td>
          <td>
            Cameron Manes, Jennifer M Cimons, Marc D’Antonio, Michael G. Harbell, Ross P Kedl, Jared Klarquist
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Immunosuppression within the tumor microenvironment (TME) profoundly inhibits anti-tumor immunity, presenting a formidable challenge in cancer therapeutics. Despite this recognized obstacle, multi-targeted immunomodulatory strategies remain elusive. Here we developed a novel mRNA-lipid nanoparticle (LNP) vaccine designed to reprogram key cellular mediators of immune suppression within the TME, including C-C motif chemokine ligand 22 (CCL22), transforming growth factor-β (TGF-β), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Galectin-3, programmed cell death ligand 1 (PD-L1), indoleamine 2,3-dioxygenase 1 (IDO1), and arginase 1 (ARG1). This immunomodulatory vaccine was evaluated in a cohort of canines with spontaneous neoplasms, encompassing adrenal, hepatic, perianal, vulvar, and pulmonary malignancies. The vaccine demonstrated good tolerability, with only mild adverse events (Grade 1 anorexia, chills, and fatigue) observed in 25% of subjects (2/8). Remarkably, 75% of treated animals (6/8) achieved stable disease, with the median progression-free interval not yet reached a median follow-up of 168 days post-treatment initiation. Two dogs experienced disease progression. The overall disease control rate was 75%. In addition, vaccine administration reversed hematological and biochemical abnormalities and alleviated paraneoplastic syndromes associated with these malignancies. These findings demonstrate that our mRNA-LNP vaccine effectively exerts anti-tumor effects across various cancer types, offering a promising strategy for enhancing anti-tumor immunity in both veterinary and human oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8fef4f03c94eaba07eeff2c05c0e60c396891042" target='_blank'>
              Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types
              </a>
            </td>
          <td>
            Tiyun Han, Guilai Liu, Chenyi Bao, Jian Zong, Caiyi Fei, Jing Li, Shi Xu, Qingbo Ma, Yingjuan Qian
          </td>
          <td>2025-10-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 Some cancers trigger a response that resembles a viral infection, called viral mimicry, which can stimulate the immune system. This process has been linked to better responses to certain drugs in solid tumors, but its role in Acute Myeloid Leukemia (AML) is not well understood. In this study, we explore whether viral mimicry in AML is associated with immune activation and its response to BCL2 inhibition
 RNA-sequencing data from 707 AML samples from the BeatAML2 dataset was analyzed. Each patient was assigned a viral mimicry score based on the expression of interferon-stimulated genes. Immune infiltration was estimated using established gene signatures for T cells, monocytes, dendritic cells, and other immune populations. The expression of immune checkpoint genes such as PD-1, PD-L1, CTLA4, and TIM-3 were also measured. Drug sensitivity was assessed using ex-vivo area under the curve (AUC) values for azacytidine, venetoclax, and ABT-737. Spearman correlation (ρ) and FDR-adjusted p-values were used for statistical analysis.
 Expression of 1,442 genes were significantly linked to viral mimicry scores (p<0.05, |ρ|>0.3). The strongest association was with IFI44L, an interferon-stimulated gene (ρ=0.91, p<0.005). Other top genes included OAS3, MX1, and RSAD2, all tied to interferon signaling. Viral mimicry was moderate to strongly correlated with immune cell markers, including monocytes (ρ=0.47), dendritic cells (ρ=0.37), cytotoxic lymphocytes (ρ=0.36), CD8+ T cells (ρ=0.31), and NK cells (ρ=0.29), all with p<0.005. These findings suggest that higher mimicry is associated with broader immune activation. Immune checkpoint gene expression increased alongside viral mimicry scores. The highest correlation was with PD-L1 (CD274) (ρ=0.46), followed by TIGIT, CTLA4, and HAVCR2, each with ρ>0.30 and p<0.005. Viral mimicry scores were not associated with ABT-737 response, and most immune checkpoints lacked predictive value. Modest correlations with azacytidine (ρ=-0.31) and venetoclax (ρ=-0.24) suggest partial enrichment for HMA and BCL2 sensitivity (both p<0.005), but not enough for clinical prediction.
 This is the first study showing that viral mimicry in AML is linked to immune activation and higher expression of immune checkpoint genes, but it does not help predict response to BCL2 inhibitors. Although the clinical impact is not yet clear, these findings highlight a unique immune-related signature that could help guide future studies of immunotherapy or hypomethylating agents in AML. Further clinical validation is needed.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f628c14fb62d4b292b806619aec4afa5af2e330" target='_blank'>
              Viral mimicry in AML is linked to immune activation but not BCL2 inhibitor sensitivity
              </a>
            </td>
          <td>
            Mobina Shrestha
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Atherosclerosis remains the primary driver of cardiovascular and cerebrovascular morbidity and mortality. A pivotal event in its pathogenesis is the phenotypic conversion of vascular smooth muscle cells (VSMCs), particularly the transition from a contractile to a macrophage‐like state. Using a murine model of atherosclerosis, we demonstrate that this process is orchestrated by a progressively disrupted perivascular immune milieu characterized by an expansion of CD44⁺ memory CD4⁺ T cells at the expense of CD44− naive CD4⁺ T cells. Within this niche, CD44⁺ natural regulatory T cells (nTregs) actively promote VSMCs macrophage‐like reprogramming, whereas their CD44− counterparts exert an opposing, protective effect. Reciprocally, macrophage‐like VSMCs foster the trans‐differentiation of nTregs into pathogenic Th17 cells, amplifying vascular inflammation. In contrast, induced Treg cells (iTregs) display phenotypic stability and potently inhibit VSMCs macrophage‐like switching, restrict pathological VSMCs migration, and curtail VSMCs survival. Systemic infusion of iTregs selectively remodels the perivascular immune microenvironment toward an antiatherogenic profile. Adoptive transfer of iTregs at early disease stages decreased the abundance of macrophage‐like VSMCs, attenuated plaque burden, and these benefits were partially mediated by transforming growth factor β signaling. Collectively, iTreg‐based cellular therapy represents a promising strategy to intercept VSMCs macrophage‐like transformation and limit atherosclerotic progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f53dac592bfbe7181b6731e2e832bb43126fb9b5" target='_blank'>
              Infusion of Induced Regulatory T Cells Alleviates Atherosclerosis by Reducing Pathological Macrophage‐Like Vascular Smooth Muscle Cells
              </a>
            </td>
          <td>
            Ximei Zhang, Ye Chen, Yesheng Ling, Lin Wu, Ding-hui Liu, Linli Wang, Yong Liu, Guang-yao Shi, Bin Zhou, Bao-shun Hao, Zhenda Zheng, Shujie Yu, Min Wang, Jun Zhao, Donglan Zeng, Julie Wang, Yan Lu, Jun Tao, Wenhao Xia, Song Guo Zheng, Xiaoxian Qian
          </td>
          <td>2025-10-22</td>
          <td>MedComm</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/476c643da3b7bab359ba00f9ad0d1145a5743d99" target='_blank'>
              Mycobacterium tuberculosis-derived linoleic acid increases regulatory T cell function to promote bacterial survival within macrophages
              </a>
            </td>
          <td>
            Hongyu Cheng, Shenzhi Li, Hongjie Liu, Meiyi Yan, Jingxiang Wang, Jingping Huang, Shanshan Liu, Yifan Yang, Xinyu Cao, Pengfei Cui, Yuanna Cheng, Zhonghua Liu, Jie Wang, Xiaocheng Huang, Lin Wang, Lianhua Qin, Ruijuan Zheng, Carl G. Feng, Qiang Zou, Yicheng Sun, Zhe Ji, Hua Yang, Baoxue Ge
          </td>
          <td>2025-10-10</td>
          <td>Nature Microbiology</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="Respiratory viral infections establish tissue-resident memory T cells (TRM) in the lung, which provide optimal protection against subsequent infections, though the underlying mechanisms are incompletely understood. Here, we demonstrate in a mouse model of heterosubtypic influenza infection that lung TRM attenuate inflammation by macrophages during secondary versus primary responses, in part, through production of the immunoregulatory cytokine IL-10. During secondary infections, lung TRM were the predominant producers of early IL-10; inhibiting early IL-10 signaling resulted in increased macrophage-mediated inflammation, morbidity, and lung pathology. Moreover, lung TRM were shown to directly modulate lung macrophage responses and polarization in depletion experiments. Finally, IL-10 enhanced IFN-γ production by lung memory CD8+ T cells. Human influenza-specific TRM isolated from lungs recapitulated robust IL-10 expression associated with augmented effector responses of murine TRM. These data support a dual role of TRM in coordinating in situ secondary responses-augmenting effector responses for robust viral clearance while dampening inflammation to limit tissue damage.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc6c23ffc8d8e83d96806c3c1229b2a8d9fc04d1" target='_blank'>
              Lung tissue-resident memory T cells optimize protection by IL-10 regulation of innate immunity.
              </a>
            </td>
          <td>
            Alexander Y Yang, Julia Davis-Porada, Daniel H. Paik, Alex B George, Brea H Brown, Paige L Ruschke, Peter A. Sims, Ziv Frankenstein, Anjali Saqi, Donna L. Farber
          </td>
          <td>2025-10-13</td>
          <td>The Journal of experimental medicine</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Immunotherapy remains ineffective in many solid tumors due to poor T-cell infiltration and a metabolically suppressive tumor microenvironment. A dual strategy combining low-level light (LLL) therapy with a nanoscale stimulator of interferon genes (STING) agonist formulation (nanoSTING@Mn) is presented to enhance immune activation and metabolic fitness for durable tumor immunity against T-cell lymphoma (EL4) model. NanoSTING@Mn, composed of ADU-S100 complexed with Mn2⁺ and encapsulated in biomimetic liposomes, potently activates the cGAS-STING pathway, induces a type I interferon response, and promotes lymphocyte infiltration. These monocytes polarize into M1 macrophages, suppressing regulatory T cells. Simultaneously, LLL photo-biomodulation reprograms mitochondrial metabolism in tumor-infiltrating CD8⁺ T and natural killer cells, restoring their durability and leading to complete local tumor eradication. This combination expands a distinct CD8⁺ T-cell subset with Tcf-1⁺ progenitor-exhausted features and elevated memory/effector gene expression, enhancing proliferation and cytotoxicity, as shown by single-cell RNA sequencing. Intranasal nanoSTING@Mn delivery mobilizes these LLL-revived T cells to the lung, where they differentiate into resident memory T cells and establish systemic antitumor immunity. Upon intravenous rechallenge, disseminated tumor cells are eliminated, preventing metastasis and ensuring long-term protection. This synergistic approach offers a scalable platform to boost immunotherapy efficacy and redefines immune-based metastasis prevention strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2e9ba5699caa736e818a9807d89458c43c8a2b62" target='_blank'>
              Light Metabolically Reprograms CD8+ T Cells to Potentiate STING-Driven Tumor Eradication and Prevent Metastasis.
              </a>
            </td>
          <td>
            Asmita Banstola, Shilin Gao, ZhengKun Zhang, Yan Dong, Prabhat Upadhyay, Quanwei Zhang, Yongli Li, Zuan-Tao Lin, Zhilong Wang, Mei X. Wu
          </td>
          <td>2025-10-23</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is a highly treatment-resistant malignancy characterized by its poor prognosis and intrinsic resistance to therapy, driven largely by glioblastoma stem cells (GSCs) and an immunosuppressive tumor microenvironment (TME). This dual resistance plays a significant role in the failure of current treatment strategies. Consequently, there is an urgent need for novel therapeutic approaches that can effectively target GSCs while simultaneously reshaping the TME to promote anti-tumor immunity. In this study, we investigated the dual therapeutic potential of Xevinapant, a lead SMAC mimetic, through a combination of in vitro, in vivo, and single-cell transcriptomic analyses. We found that Xevinapant demonstrated potent anti-tumor activity through inducing dose-dependent apoptosis and significantly reduced cell viability in both human and mouse GSCs. In vivo administration of Xevinapant led to significant tumor suppression and extended overall survival in orthotopic models. Notably, our single-cell RNA sequencing result revealed that Xevinapant activated immune effector cell responses, contributing to the reprogramming of the immunosuppressive TME. Immune cell activation (both lymphoid and myeloid lineages) was further validated by flow cytometry using tumor-derived cells. To overcome potential therapeutic resistance, we derived Xevinapant-specific gene expression signatures and queried the LINCS database to identify small molecules with synergistic effects. Our analysis identified a promising compound ST-059620 that, when used in combination with Xevinapant, enhanced therapeutic efficacy and overcame resistance. Taken together, our findings highlight the dual mechanism of action of Xevinapant in targeting both tumor-intrinsic and microenvironmental resistance mechanisms. These results support the continued clinical development of Xevinapant and provide a strong rationale for combination strategies aimed at improving treatment efficacy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/14a501e3f81b4b4d8beaca0ed97f02367fa8f4c1" target='_blank'>
              TMIC-25. SMAC Mimetic Targets Glioblastoma Stem Cells and Reprograms the Associated Tumor Microenvironment
              </a>
            </td>
          <td>
            Qiong Wu, Jianan Chen, Anders E. Berglund, Dongliang Du, Robert Macaulay, Arnold B Etame
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="BACKGROUND
Brucellosis poses a significant threat to animal and human health globally. However, how Brucella subverts the immune response to establish persistent infections remains unclear.


METHODS
We utilized single-cell RNA sequencing (scRNA-seq) to decipher the immune landscape of mice infected by Brucella abortus. Flow cytometry, transgenic cell line and mouse, and antibody blockage were utilized to explore the relevant mechanisms.


RESULTS
Brucella infection induced significant changes in the composition and signaling pathways of immune cells, and flow cytometry analysis further confirmed the scRNA-seq data. An in-depth analysis with macrophages, the main target cell for Brucella, demonstrated activation of type I IFN and type II IFN signaling, TNF production, diverse cell deaths, etc. Specifically, Vir-2308 Brucella infection induced IFN-β expression, primarily originating from macrophages. In vitro, a significantly lower level of intracellular Brucella survival was observed in ifnar1-/- macrophages. In vivo, ifnar1 genetic deficiency rendered the mice less susceptible to Brucella challenge with a lower bacterial load and higher levels of macrophages and neutrophils. Interestingly, Brucella infection induced a dramatic reduction of NK cells along with the upregulation of CD94:NKG2A, one typical immune checkpoint module of NK cells. Further blockage of the NKG2A receptor in mice significantly reduced the bacterial load in the tissues, concurrent with a higher ratio of mature dendritic cells and a lower proportion of B cells.


CONCLUSIONS
scRNA-seq revealed that Brucella infection significantly alters the immune microenvironment in mice, providing insight into a better understanding of brucellosis pathogenesis and the immune evasion strategies of this sophisticated pathogen.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/30ce606edc594568f304e17b3f30c914a97c8658" target='_blank'>
              Single-cell transcriptome profiling reveals the immune dysregulation characteristics of mice infected by Brucella abortus.
              </a>
            </td>
          <td>
            Guangzhi Zhang, Qingchun Shen, Jianxin Ye, Yu Feng, Pascal Boireau, Xuezheng Fan, Lang Lv, Yan Li, Xiaofeng Xu, Heleer Cha, Chenguang Shen, Yinghui Zhang, Xiao-wei Peng, Hui Jiang, Jiabo Ding
          </td>
          <td>2025-10-11</td>
          <td>The Journal of infectious diseases</td>
          <td>1</td>
          <td>11</td>
        </tr>

        <tr id="


 Background:
 Natural killer (NK) cells play a profound role in the immune system, contributing to antitumor and antiviral defenses. Recent advances in immunology have discovered adaptive NK cells with cytomegalovirus (CMV) infection.In this study, we identified a novel peripheral blood NK cell subset, CD19dimNKG2C+ NK cells (referred to as B-like NK cells) related to Epstein-Barr virus (EBV) infection and with stronger killing activity.
 Methods:
 We conducted a single-center retrospective analysis to investigate patients with CD19dimCD56+ cells at Sun Yat-sen University Cancer Center from March 1, 2013 to December 30, 2023.
 Flow cytometry: Cells were stained with a panel of antibodies to identify T cells, NK cells, and B cells. NK cell activation and inhibitory receptors panel, and intracellular cytokine and killing markers panel were also assessed.
 Imaging full-spectrum flow cytometry: We used the FACSDiscover™ S8 from BD Company to verify whether the formation of CD19dimCD56+ cells was related to trogocytosis.
 Sequencing: Using fresh PBMC samples to construct scRNAseq and Epi Multiome ATAC + Gene Expression.
 EBV infection-related indicators detection: Serum and plasma samples were collected from 100 positive and negative cases, respectively.
 Results:A retrospective analysis of 85,540 lymphocyte subset raw data wasincluded in this analysis, with CD19dimCD56+ cells detection rate ranging from 0.12% to 27.61% among 64 lymphoma patients. Furthermore, we found that patients who had CD19dimCD56+ cells in their peripheral blood before treatment had a better prognosis.Traditional flow cytometry, imaging full-spectrum flow cytometry,and morphological staining confirmed that this group of novel CD19dimCD56+ cells were mature NK cells, only expressing CD19 and being negative for all other B-cell markers. Its formation was not caused by trogocytosis, and the morphology of this group of cells was similar to that of traditional NK cells.Compared with traditional NK cells, CD19dimCD56+NK cells exhibited stronger killing activity, manifested by the expression of more cytotoxic indicators such as granzyme B and perforin, the production of more intracellular cytokines IFN-r and TNF-a after stimulation, and a significant increase in the expression of the activating receptor CD159c (also known as NKG2C), while the expression of the inhibitory receptor CD159a (also known as NKG2A) significantly decreased.The CD19dimCD56+ NK cells had higher expression of CD57 and CD159c (NKG2C) compared to traditional NK cells, presenting a memory adaptive phenotype related to viral infection, suggesting that this group of novel NK cells had been infected by a virus before. The results of EBV infection-related indicators also showed that the Rta-IgG level of positive cases was significantly lower than that of the negative group, suggesting that the positive cases had been infected with EBV but did not replicate in large quantities. Based on the above results, we refer to this group of novel CD19dimNKG2C+ NK cells as B-like NK cells.scRNAseq analysis also confirmed CD19dimNKG2C+ cells were NK cells,not B cells (In the dimensionality reduction diagram, this group of cells and NK cells are clustered together). Similarly, at the genetic level, it also indicated that this group of cells wasan adaptive epigenetic memory NK cell subset, characterized by high transcript levels of KLRC2 and CD3E together with marked downregulation of CD7, KLRC1, and FCER1G.Differential gene pathway analysis linked this subset to EBV infection, and EBV-associated lncRNA LINC02446 was correlated with this subset.Trajectory analysis suggested its potential origin from CD56dim NK cells. Gene regulatory network analysis highlighted the role of the transcription factor IKZF2 in its development and function. Cell communication analysis revealed expression of antigen-presenting molecules (HLA-DRB5, HLA-DQA2), suggesting stronger antigen-presenting capacity. Bulk ATAC-seq and Multiome ATAC + Gene Expression showed increased transcriptional accessibility of CD19, KLRC2, and BCL11B, implicating that the corresponding chromatin has undergone opening.
 Conclusion: This study untangles the identity of the CD19dimNKG2C+ cells NK cell subset as a cytotoxic adaptive NK population linked to EBV infection. Its presence correlates with favorable prognosis, highlighting its potential role in EBV-related immune memory and offering a novel target for immunotherapy.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2376432186ece72b99bdcb12ee01c4127a7d281f" target='_blank'>
              B-like natural killer cells related to the epstein-barr virus infection present an adaptive immune phenotype and stronger killing activity in lymphomas
              </a>
            </td>
          <td>
            Yuanbin Song, Yang Liang, Chenfei Liu, Jingxia Xu, Lu Lu, Pei-Dong Chi, Yiling Song, Hailin Zheng, Lezong Chen, Chunlei Dai, Tao Chen, Langqi Wang, Yongshuai Jiang, Xianyuan Li, Honghong Yan, Xumiao Zhang, Xiao Zhang, Yinglin Su, Zhenzhen Chou, Junqi Huang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Waldenström Macroglobulinemia (WM) is an incurable lymphoid malignancy characterized by a spectrum of differentiation states from clonal B lymphocytes (Ly) to IgM-expressing plasma cells (Pc). Activation of mitochondrial apoptosis by Bcl-2 antagonists is already under clinical investigation for treatment-naïve (TN) and relapsed/refractory (R/R) patients. However, the biological mechanisms whereby WM cells evade mitochondrial apoptosis remain undefined. In this work, we leveraged functional and single-cell transcriptomic approaches to unravel fundamental principles of apoptosis evasion in WM.
 We collected viable WM cells from the bone marrow of 27 WM patients (25 MYD88L265P and 2 MYD88WT; 25 patients were TN, 2 were R/R). Samples were subjected to intracellular BH3 profiling (iBH3), a functional assay that derives the apoptotic priming and the anti-apoptotic dependencies based on the pattern of cytochrome c release in response to pro-apoptotic stimuli. Surface staining with anti-CD19 and anti-CD138 antibodies was included to discriminate Ly and Pc in each sample. We found that the apoptotic profile differed considerably between malignant Ly (CD19+CD138-) and Pc (CD19+CD138+). WM Pc displayed lower apoptotic priming (P=0.002) and lower Bcl-2 dependency (P=0.03) than WM Ly. In contrast, non-Bcl-2 anti-apoptotic dependencies, particularly Mcl-1 dependency, were higher in Pc than Ly (Mcl-1 dependency: 93.0 and 42.8%, respectively, P<0.001).
 Despite being predominantly Bcl-2 dependent, Ly showed remarkable heterogeneity across samples. Integrating Ly apoptotic profiles with patient clinical data, we found a positive correlation between the amount of serum monoclonal component (MC) and co-dependency upon Mcl-1 specifically detected in Ly (Pearson r=0.68, P<0.001). We also observed an increasing gradient of Mcl-1 dependency (P<0.001) when comparing Ly from patients affected by chronic lymphocytic leukemia (a prototypical Bcl-2 dependent malignancy, N=17), hyposecretive (MC<30 g/L, N=20), and hypersecretive WM (MC<30 g/L, N=7).
 To assess whether Ly and Pc express different sets of pro- and anti-apoptotic genes, we performed single-cell RNA sequencing coupled with BCR sequencing on 8 WM bone marrow samples, 3 of which were hypersecretive. As expected, BCL2 was upregulated in WM Ly compared to residual normal memory B-cells. With respect to normal Pc, WM Pc expressed a higher level of the MCL1/PMAIP1 couple and a lower level of the pro-apoptotic BCL2L11 (encoding Bim). Focusing on tumor cells only, we identified 9 clusters with different transcriptional profiles. Five of them (Clusters 1-5) covered the Ly population, two harbored features of intermediate lymphoplasmacytic states, one corresponded to canonical JCHAINhighPRDM1high Pc, and an additional minor cluster was composed of atypical JCHAINhighPRDM1neg Pc. Consistent with iBH3 results, there was a clear-cut progressive increase of MCL1 expression during the differentiation of WM Ly towards canonical WM Pc. In contrast, BCL2, as well as BIRC3 and BIRC6, remained high up until the intermediate clusters and then dropped down at the Pc end of the differentiation trajectory. Interestingly, PMAIP1 followed a wave-like pattern with very high expression in intermediate states and low levels on the two ends of the differentiation process. BCL2A1, an anti-apoptotic gene often involved in therapy resistance, was highly expressed in a fraction of WM Ly belonging to Cluster 5. More importantly, within the WM Ly population, the highest expression of MCL1, at levels comparable to those observed in intermediate states,was detected in Cluster 4. This Ly cluster was particularly enriched in hypersecretive patients and may underpin the functional Mcl-1 dependency associated with this clinical phenotype.
 Lastly, we searched for targetable signaling pathways transcriptionally upregulated in clusters with high MCL1expression. While B-cell receptor signaling and NF-kB activity were comparable across clusters, IRE1/XBP1 pathway and, to a lesser extent, STAT3 activity were increased in JCHAINhighPRDM1high Pc and may represent actionable targets to suppress Mcl-1 addicted cells.
 In sum, cell differentiation stage coordinates the expression of Bcl-2 family genes and modulates anti-apoptotic dependencies in WM. Such transcriptional and functional intratumor heterogeneity may underlie the relatively low rate of deep responses to Bcl-2 antagonism in WM and suggest novel combination strategies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a9fe24492d9101d3917015b59b6d5449cccef431" target='_blank'>
              Cell differentiation stage drives mechanisms of apoptosis evasion in Waldenström macroglobulinemia
              </a>
            </td>
          <td>
            Cristina Frusteri, A. Real, F. Nadeu, Laura Fumagalli, Valentina Manconi, Ali Jafari Kia, Eleonora Terrabuio, A. Montresor, Maria Pia Manto, Eleonora Gugole, Angela Mercuri, L. Bonaldi, Gabriela Constantin, M. Krampera, C. Visco, M. Scupoli, Carlo Laudanna, Isacco Ferrarini
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Although chimeric antigen receptor (CAR)-T cells have demonstrated remarkable efficacy against hematologic malignancies, their effectiveness in solid tumors is limited by poor tumor infiltration and severe cytokine release syndrome (CRS). CAR-macrophage (CAR-M) therapy has emerged as a promising alternative, leveraging the innate tumor-homing capacity of macrophages while enabling antigen-specific phagocytosis and immune activation without triggering CRS. Prostate-specific membrane antigen (PSMA) represents an ideal therapeutic target due to its high expression in prostate cancer cells. In this study, we engineered PSMA-specific CAR-M with potent anti-tumor activity against prostate cancer cells both in vitro and in vivo. PSMA-specific CAR-M exhibited strong antigen-dependent phagocytic capability and underwent polarization toward a pro-inflammatory, tumoricidal phenotype upon PSMA recognition. Mechanistically, interaction with PSMA-expressing prostate cancer cells induced metabolic reprogramming, characterized by enhanced glycolytic activity and suppressed oxidative phosphorylation, which reinforced the anti-tumor function of CAR-M. Our findings highlight PSMA-targeted CAR-M therapy as a promising immunotherapeutic approach for prostate cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b18be8ba7a38c7fcc049e00187fed5999372458" target='_blank'>
              PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy
              </a>
            </td>
          <td>
            Yangli Xu, Duoli Xie, Chunhao Cao, Zhuqian Wang, Yue Ju, Lili Guan, Xuelong Li, Shanshan Wu, Luo Zhang, Chao Liang, Xiushan Yin
          </td>
          <td>2025-10-29</td>
          <td>Journal of Hematology & Oncology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Age-related accumulation of somatic mutations in hematopoietic stem and progenitor cells (HSPCs), causing clonal hematopoiesis (CH), often precedes the development of hematologic malignancies. Chronic inflammation and aberrant cytokine expression that are common in aging, contribute to clonal expansion and genomic instability. Acute myeloid leukemia (AML) is an (epi)genetically and physiologically diverse malignancy, characterized by clonal proliferation and incomplete differentiation of HSPCs. The innate immune system, with pattern recognition receptors (PRRs), plays a pivotal role in maintaining hematopoietic homeostasis. Dysregulated signaling through PRRs disrupts hematopoiesis, fostering malignant cell proliferation. In addition, cytokines and interferons exert multifaceted effects on HSPCs, impacting their proliferation, differentiation, and survival. Therapeutic approaches targeting innate immune pathways, offer promising avenues for treating hematologic malignancies. Understanding the intricate crosstalk between innate immunity and hematopoiesis would provide insights into novel therapeutic strategies for combating hematologic malignancies, offering hope for improved patient outcomes and survival. In this review, we discuss about the malfunctioning innate immune-inflammatory axes in the context of abnormal hematopoiesis and the therapeutic approaches that are utilizing/targeting these pathways with efficacy. This review delves into the derangements of innate immune and inflammatory pathways implicated in the development of AML and myelodysplastic syndromes (MDS), shedding light on the therapeutic strategies targeting these pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dde18cfb4c76b3db17292e304b00038b9b81709c" target='_blank'>
              Innate immune-inflammatory signaling milieu in myeloid leukemia and aging-associated clonal hematopoiesis pathologies
              </a>
            </td>
          <td>
            Satyaki Bhowmik, A. Bose, A. Sengupta
          </td>
          <td>2025-10-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Mucosal-associated invariant T (MAIT) cells are unique unconventional T cells with diverse roles in immunity, yet how their context informs their function is not well known. This contextual regulation is particularly relevant in cancer, where MAIT cells have an enigmatic role. We performed a systematic review and meta-analysis to identify MAIT cell transcriptomic signatures under different environmental conditions. We identified four bulk-RNA-sequencing studies that compared multiple activation stimuli. We found a stimulus-specific transcriptional signature for immune checkpoint genes, that we confirmed in a single-cell RNA-sequencing dataset. We used flow cytometry to examine in vitro human MAIT cells across four activation stimuli and confirmed that stimulus drives unique checkpoint signatures upon MAIT activation for Lag3, PD-L1, PD-1, NKG2A and Tigit. Strikingly, PD-L1 was more highly induced in vitro than PD-1 in MAIT cells up to 72 hours. Our data suggest that human MAIT cell regulation is context-dependent. These findings have the potential to critically inform efforts targeting MAIT cells for cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9ecf762a805ede9d94ba29010a5a748ff3406109" target='_blank'>
              Immune Checkpoint Expression in Mucosal-Associated Invariant T (MAIT) Cells is Stimulus-Dependent.
              </a>
            </td>
          <td>
            C. Clutter, Audrey Re, Kenadee Jacobson, Kendell Clement, Jeffrey Aubé, Ryan M O'Connell, D. Leung
          </td>
          <td>2025-12-06</td>
          <td>Journal of leukocyte biology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="
 The tumor microenvironment of glioblastoma is dominated by immunosuppressive microglia/macrophages that dampen anti-tumor immunity, comprising a major barrier to effective immunotherapy. Developing strategies to reprogram these macrophages is essential to overcome treatment resistance. Bacterial extracellular vesicles (bEVs) are secreted nano-sized (~25–100 nm) particles that modulate myeloid cell activity in a species-dependent manner. We developed a scalable strategy to purify bEVs from the human commensal Escherichia coli Nissle strain consisting of: tangential-flow filtration, Benzonase depletion of free nucleic acids, and size-exclusion chromatography, yielding ~3.5 mg of bEV-associated protein per liter of culture. E. coli Nissle bEVs activated NF-κB and IRF pathways in THP-1 dual-reporter monocyte-derived cells in a dose-dependent manner, with an ED50 approximately seven-fold lower than that of purified LPS or heat-killed bacteria, indicating a distinctly higher potency. We further depleted free LPS that may co-isolate with bEVs, and noted a ~3000-fold reduction in LPS content, with less than 10% protein loss. LPS-depleted bEV bioactivity surpassed LPS amount-matched crude bEVs, supporting that bEV, not residual copurifying LPS, drove the observed in vitro bioactivity. bEVs activated peripheral-blood mononuclear cell-derived CD11b⁺CD68⁺ macrophage-like cells at concentrations as low as 1 ng/mL, while lymphocyte populations experienced minimal effects, in line with bEVs acting primarily on myeloid cells. We next treated M-CSF, IFNγ, and IL-4 polarized human monocyte-derived macrophages with bEVs. In IL-4 polarized (M2-like) macrophages, bEVs induced a more pronounced M1-like reprogramming compared to IFN-γ treatment, increasing CD38, CD80, and CD86 while decreasing CD47 and CD206. This reprogramming persisted even at sub-ED50 concentrations, as low as 0.6 ng/mL. Collectively, this workflow consistently yielded bioactive bEVs that robustly reprogram macrophages. Future work will test the ability of bEVs to reprogram GBM-associated microglia/macrophages, with the ultimate goal of combination with immunotherapies to overcome treatment resistance in the immunosuppressive GBM microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/314efedf3ab7696248eb4216de5020641b87b2b2" target='_blank'>
              IMMU-16. Development of high-purity bacterial extracellular vesicles for suppressive myeloid cell reprogramming in glioblastoma immunotherapy
              </a>
            </td>
          <td>
            Irem Karaman, Justin Ruiz, O. T. Pumar, Asmita Pathak, Jonathan Mitchell, B. León, Selma Maacha, Wael El-Rifai, Defne Bayik, Dionysios C. Watson
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="


 Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet resistance and immune-related adverse events (irAEs) remain significant challenges. γδ T cells and B cells are recognized as critical players in the tumor microenvironment (TME), but their roles in shaping T cell phenotypes and contributing to ICI resistance are not fully understood. Using syngeneic tumor models in autoimmune-prone NOD mice, which enable simultaneous profiling of tumor immunity and autoimmunity, we investigated mechanisms underlying ICI sensitivity and resistance. In the resistant tumor model, CD8+ T cells exhibit a naïve phenotype, with elevated TCF-1 expression and reduced activation markers such as PD-1 and CTLA-4. In contrast, activated CD8+ T cells dominate the sensitive tumor model, highlighting T cell phenotypes as key drivers of ICI responses. Further analyses implicated γδ T cells and B cells in these divergent responses. Depleting γδ T cells in the resistant model significantly improved tumor control, underscoring their role in mediating resistance. Conversely, CD8+ T cell activation was enhanced in B cell-deficient mice, suggesting B cells may restrict antitumor immunity. Together, these findings provide critical insights into the interplay between T cells, γδ T cells, and B cells within the TME and highlight potential therapeutic strategies to overcome ICI resistance without inducing irAEs.



 National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number: T32AI138945



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a88c64fd65f389029580f6961ad4a61916ee0e46" target='_blank'>
              The Interplay Between γδ T cells and B cells Contributes to Immune Checkpoint Inhibitor Resistance 3426
              </a>
            </td>
          <td>
            Camille Hansen, Arabella Young
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Persistent antigen exposure, a hallmark of chronic infections and tumors, drives the formation of a distinct population of CD8+ T cells, known as exhausted CD8+ T (TEX) cells, with increased expression of immune checkpoint molecules and reduced effector function. Immune checkpoint inhibition (ICI) therapy has emerged as a powerful tool to reinvigorate the function of TEX cells. However, despite the immunostimulatory effects of radiotherapy (RT), combining RT with ICI has yielded modest clinical benefits in cancer patients. While the success of ICI therapy largely depends on the presence of progenitor TEX cells, the impact of high-dose ionizing radiation (IR) on the TEX population, particularly enriched within the treatment field, remains understudied. Here, we show that chronically infected mice with LCMV-Clone 13 subjected to sublethal whole-body irradiation (WBI) exhibited a lasting numerical decline and impaired antigen-specific function in their TEX cells. Using single-cell RNA sequencing and multiparameter flow cytometry, we observed that WBI gradually altered the subset composition of surviving TEX cells, highlighted by the loss of progenitor and effector-like TEX cells while terminally-exhausted TEX cells were enriched. Lastly, WBI rendered ICI therapy less effective in rescuing TEX cells and decreasing viral burden. These findings provide important insights into how high-dose IR alters the fate of TEX cells, potentially impairing their responsiveness to ICI therapy.



 Supported by NIH Grants GM134880, AI114543



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ef55b305a83cb203c9064f70e6ab8c59e03b2320" target='_blank'>
              Ionizing radiation impairs the efficacy of immune checkpoint inhibition by driving terminal exhaustion of progenitor exhausted CD8+ T cells 4054
              </a>
            </td>
          <td>
            Mohammad Heidarian, S. Kannan, Xin Zhao, M. Mix, Hai-Hui (Howard) Xue, John T. Harty, V. Badovinac
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>53</td>
        </tr>

        <tr id="Decades of experimental work have helped define the heterogeneity of the various cell types that compose the immune system. The different cell types arise from distinct hematopoietic stem and progenitor cells in a coordinated fashion during ontogeny, providing a set of diverse cells that contribute to host defense. Cells can also differentiate into different subsets in response to the cytokine and tissue environment, creating a level of cellular heterogeneity that helps direct the nature and magnitude of the immune response. Here we are discussing a variation whereby cellular heterogeneity arises due to the expression of X‐linked immune genes that escape X chromosome inactivation, giving an advantage to a subset of cells more prone to respond to stimulation by external (pathogens) but also internal signals (i.e., mechanosensing). Interestingly, these inflammatory subsets are much more likely to be differentially enriched in patients with autoimmunity or inflammatory diseases which are well known to be predominant in females. We are using plasmacytoid dendritic cells (pDCs) as a model cell type, as these cells are a rare but critical subset of innate immune cells, with a rapid and massive capacity to produce type I IFNs (IFN‐I) upon sensing of nucleic acids from pathogens, but also from the self, and these cells have been linked to the pathogenesis of many autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/98b5143104584df960a1c460b9d9fe7799416cad" target='_blank'>
              Escape From X Chromosome Inactivation as a Driver of Plasmacytoid DC Heterogeneity in Health and Disease
              </a>
            </td>
          <td>
            Franck J. Barrat, J. Guéry
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="


 Pediatric high-grade gliomas (pHGG) are characterized by an immunologically cold and highly immunosuppressive tumor microenvironment (TME). It is dominated by M2-like tumor-associated macrophages (TAMs), which impair CAR T-cell function and persistence. However, broad myeloid targeting can be detrimental, as recent evidence shows that inflammatory macrophages are essential to support CAR T-cell activity. We therefore identified CD123 as selectively expressed on immunosuppressive TAMs, making it a promising target to remodel the TME. Meanwhile, B7-H3 is a tumor-associated antigen that is broadly expressed in pHGGs, making it an ideal target for CAR T-cell therapy. We now hypothesize that dual targeting of CD123+ TAMs and B7-H3+ tumor cells would synergistically deplete suppressive myeloid populations, restore T-cell function, and enhance anti-tumor efficacy.



 To evaluate the therapeutic potential of CD123 and B7-H3 dual CAR T-cell therapy in modulating the TME, preserving supportive myeloid subsets, and enhancing anti-tumor efficacy in pHGG.



 Using immunocompetent pHGG models, we tested CD123 and B7-H3 CAR T-cells through in vitro cytotoxicity, antigen stimulation, and co-cultures with bone marrow–derived M1 or M2 macrophages. In vivo, CD123 CAR T-cells were administered intratumorally as monotherapy or in combination with B7-H3 CAR T-cells. Endpoints included TAM depletion, phenotypic and transcriptomic TME remodeling, tumor progression, and survival.



 CD123 CAR T-cells exhibited minimal cytotoxicity against B7-H3+ glioma cells but selectively depleted M2-like TAMs in vitro and in vivo. M2 macrophages suppressed B7-H3 CAR T-cell persistence in vitro; this suppression was reversed by co-treatment with CD123 CAR T-cells. Dual CAR T-cell therapy significantly enhanced anti-tumor activity, reduced myeloid and microglial infiltration, and extended survival in vivo.



 Targeted depletion of CD123+ TAMs enhances B7-H3 CAR T-cell efficacy by mitigating immunosuppressive signaling while preserving beneficial myeloid support. This dual-targeting strategy offers a mechanistically guided approach to overcoming TME-driven resistance in DIPG and other pHGG.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/43e9945f878d4e3f16528ee181777513363175aa" target='_blank'>
              EXTH-114. Dual CD123 and B7-H3 CAR T Cells Potentiate Immune Responses and Remodel the Tumor Microenvironment in Pediatric Gliomas
              </a>
            </td>
          <td>
            Khatereh Khorsandi, Kaleem L Coleman, Paulina Velsquez, Dalia Haydar
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Introduction: Relapsed and refractory hematologic malignancies remain a significant clinical challenge despite integration of newer therapeutic strategies engaging the immune system as standard of care. As such, identifying and characterizing specific defects in the anti-tumor immune response will be key to the development of newer therapies that improve survival. We have previously reported that the immune checkpoint Siglec-15, a member of the sialic acid binding immunoglobulin-like lectin family of proteins, is overexpressed in hematologic malignancies and circulates at high levels in the plasma of children in leukemia. Importantly, inhibition of Siglec-15 restored local anti-tumor immune responses and abrogated tumor progression highlighting a crucial role for Siglec-15 in immune evasion in murine models of leukemia and lymphoma. However, the mechanism(s) by which Siglec-15 promotes immune escape and leukemogenesis has not yet been defined. Here we investigate how Siglec-15 creates an immunosuppressive immune microenvironment through aberrant hematopoiesis in a murine model of leukemia.
 Methods: Using a well-established model of murine B-cell acute lymphoblastic leukemia (B-ALL), control (Cas9) or CRISPR knockout Siglec-15 BCR-ABL1+cells wereinjected into un-irradiated, immune competent (wild type, WT) or immune deficient (Rag1-/-) C57BL/6 mice and single cell RNA sequencing (scRNA seq) performed on paired bone marrow (N=4/group) and spleen (N=4/group) samples. To validate scRNA findings, multiparameter flow cytometry was performed to determine impact of knockout of Siglec-15 on hematopoiesis and innate immune subsets.
 Results: scRNA seq suggests that knockout of Siglec-15 in B-ALL restores circulation of mature neutrophils that are associated with an anti-tumoral, pro-inflammatory phenotype as compared to control where there are predominantly more immature neutrophils that have a pro-tumoral and immunosuppressive gene signature. With Siglec-15 KO, there is increased expression of genes such as Egr1, Ccl6, Klf6 that are known to promote neutrophil differentiation, pro-inflammatory cytokine production and recruitment to tumor sites. By flow cytometry, there is an increase in pluripotent stem cells in the bone marrow of Siglec-15 knockout mice (p<0.01, one-way ANOVA, n=10 mice/group) compared to control. Further, there is increased skewing to myeloid primed multipotent progenitors, MPP2/3 and FCyR+ MPP3, with Siglec-15 knockout (p<0.01, one-way ANOVA, n=10 mice/group). Interestingly, there is no expansion of the immediate myeloid precursors, common myeloid precursors and granulocyte -monocyte precursors, in control mice, there is a significant decrease with knockout of Siglec-15 (p<0.001). However, we observe an increase in innate and adaptive effector immune cells, including neutrophils, B and T cells, in the bone marrow and spleen of knockout mice.
 Conclusions: We have found that there are significant Siglec-15 dependent changes in the bone marrow and spleen in B-ALL by scRNA sequencing. Preliminary data suggests that Siglec-15 may promote aberrant myelopoiesis in murine model of B-ALL at early time points. Ongoing experiments aim to examine the extent to which B-ALL promotes aberrant myelopoiesis in children. Together, these data implicate Sig-15 as an immune checkpoint that may be inhibited therapeutically to promote an immune response to leukemia cells.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/da7888656dfb2e3a70892bf153bf689cc4183854" target='_blank'>
              Siglec-15 dependent alteration of the leukemia immune microenvironment
              </a>
            </td>
          <td>
            Dailia B. Francis, Marina E. Michaud, Jodi Dougan, Miyoung Lee, Manoj K. Bhasin, Christopher Porter
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="

 Intravenous immunoglobulin (IVIG) has been established as the first-line treatment for Kawasaki disease (KD). However, 10%–20% of patients are unresponsive, increasing their risk of coronary artery complications.



 To elucidate the pathogenesis of IVIG non-responsiveness, we performed single-cell transcriptomic profiling on 24 peripheral blood mononuclear cell (PBMC) samples from responsive and non-responsive KD patients before and after IVIG treatment. Finally, the expression of key cytokines was validated using public bulk RNA-seq data and enzyme-linked immunosorbent assay (ELISA).



 Non-responders exhibited elevated inflammatory cells, lymphocyte dysfunction, and a stronger inflammatory cytokine response driven by the S100A12–TLR4–MYD88 axis, initiated by Mono_CD14_CD16 cells, which was closely associated with interferon activation. Despite T/NK-cell exhaustion, cytotoxic activity was preserved. All processes appeared to be closely associated with interferon activation. Disrupted Tfh–B-cell coordination was observed alongside plasmablast enrichment. Furthermore, monocytic myeloid-derived suppressor cells (MDSCs) suppressed T-cell function and promoted inflammation. The expression levels of S100A8/A9, S100A12, TNF, TNFSF8/10, and interferon-α were consistent with the transcriptomic data.



 Our findings reveal the immune landscape in IVIG non-responsive KD and suggest potential targets for alternative therapies.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9446ea4d954c19ee97fd926cdd0f31fbcec94bf2" target='_blank'>
              Single-cell transcriptomic analysis reveals a systemic immune dysregulation in intravenous immunoglobulin non-responsive Kawasaki disease
              </a>
            </td>
          <td>
            Chenhui Feng, Qirui Li, Minna Yang, Yeshi Chen, Mingming Zhang, Hongmao Wang, Xiaohui Li
          </td>
          <td>2025-11-27</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 During a recall immune response, memory B cells differentiate into plasma cells (PCs), which are indispensable for antibody production and humoral immunity. Furthermore, memory B cells proliferate sooner and require less stimulation to differentiate into PCs relative to naïve B cells and can thus be considered ‘poised’. The exact mechanisms explaining this discrepancy remain incompletely understood. Our lab has previously observed that mouse Marginal Zone (MZ) B cells are analogously ‘poised’ to become PCs relative to Follicular (FO) B cells. Transcriptomic analyses have shown that MZ B cells are enriched for hallmark mTORC1 signaling, unfolded protein response (UPR) pathway, and Myc target gene signatures compared to FO B cells, which are all required for PC differentiation. We hypothesized that these same gene signatures would be enriched in human memory B cells. From a cohort of healthy human donors, RNA-sequencing was performed on splenocytes. Indeed, we observe these same hallmark gene signatures enriched in memory B cells along with others involved in the synthesis of ribosomal proteins and translation. These results suggest that human memory B cells are better equipped to produce massive amounts of proteins that involve mTORC1 and Myc activity along with the UPR pathway, all of which are needed for antibody production by PCs. The better we understand PC differentiation mechanisms, the higher potential they can be manipulated for clinically relevant purposes.



 5RO1AI175185-02 - Biochemical Mechanisms for Sustained Humoral Immunity



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dd3d5c1fdc51b8e4993b6ad53828921baab12d6d" target='_blank'>
              Are human memory B cells ‘poised’ to become plasma cells? 4156
              </a>
            </td>
          <td>
            Isaiah Rozich, Brian T. Gaudette, Jennifer Londregan, David Allman
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Activation of the stimulator of interferon genes (STING) modulates cellular responses in a cell-context-dependent manner. Intrinsic IFN-stimulated gene (ISG) expression enhances cellular responses to STING activation. We previously demonstrated that chronic myelomonocytic leukemia (CMML) is characterized by cell-intrinsic ISG upregulation. While STING-activation can mediate hematopoietic stem-cell (HSC) self-renewal or exhaustion and CD14+-monocyte depletion, the distinct effects of acute, short-term and long-term STING activation in distinct clonal hematopoietic populations remains unclear.
 Therefore, we sought to evaluate the effects of STING activation dynamics in normal and CMML HSC and monocyte populations. To do so we first treated BM mononuclear cells (MNCs) from patients (pts) with CMML (n=11) or healthy donors (HDs, n=6) in co-culture with mesenchymal stromal cells with a STING agonist (dazostinag). Given that monocytic lineage is characterized by high expression of cysteine-cysteine chemokine receptor 2 (CCR2), MNCs were also treated with TAK-500, an IgG1 anti-CCR2 antibody linked to a STING agonist payload, to evaluate the specific effects of STING activation in monocyte populations. Dazostinag or TAK-500 depleted total and CCR2+ MNCs from CMML pts but not from HDs Accordingly, STING activation with dazostinag or TAK-500 induced a dose-dependent depletion of monocytic cell lines (MOLM13, THP1) through IRF3 phosphorylation and caspase 3 cleavage. To evaluate if acute STING activation impairs CMML's HSPCs repopulation potential we performed colony-formation studies in BM CD34+ cells from CMML pts (n=8) and observed that TAK-500 and dazostinag impaired myeloid, but not erythroid, colony-formation.
 We previously reported that Vav-KDM6B/Tet2f/f/Vav-Cre (KDM6B/Tet2)mice recapitulate features of CMML. Single-cell RNA-sequencing (scRNA-seq) of MNCs from these mice and control (Vav-cre) mice confirmed myeloid bias and expansion of CCR2+ monocytes that upregulate IFN response genes and inflammatory signals in KDM6B/Tet2 mice. BM CCR2+ monocyte expansion in KDM6B/Tet2 mice was confirmed by flow cytometry. Therefore, to evaluate the effects of acute STING activation in vivo, we treated KDM6B/Tet2 mice with a single dose of TAK-500. TAK-500 enhanced CCR2+ BM cell apoptosis and reduced LSK colony formation capacity. In vivo depletion of MOLM-13 and human CD45+ cells was also observed after acute TAK-500 treatment in xenograft models and in a CMML patient-derived xenograft model, respectively.
 To dissect the effects of short-term STING activation, we then treated KDM6B/Tet2 mice with vehicle or TAK-500 weekly for 3 consecutive weeks. Therapy was associated with peripheral blood monocyte depletion, BM CCR2+ cell depletion, and apoptosis. TAK-500 also induced LSK expansion and depletion of granulomonocytic, common-myeloid, and megakaryocytic/erythroid progenitors. LSK expansion with reduced colony-forming capacity and CD14+ monocyte differentiation was sustained in colony-formation assays. Bulk RNA-sequencing of sorted LSKs demonstrated downregulation of genes involved in RNA metabolism and translation, G1/S transition and neutrophil degranulation, suggesting reduced cell activity and differentiation. scRNA-seq of BM MNCs after 3 weeks of therapy confirmed depletion of CCR2+ cells, myelomonocytic precursors and monocyte populations with TAK-500 but not with vehicle. STING activation induced type I IFN gene expression (e.g Irf7) in monocytes and splenic extramedullary hematopoiesis. Analysis of cell-cell communication networks revealed increased number of interactions involved in cell migration, inflammation and immune interactions between monocyte and other cell types.
 To compare the effects of short vs long-term STING activation, we treated control and KDM6B/Tet2 mice with TAK-500 over a period of 14 weeks. In contrast to short-term STING activation, long-term TAK-500 exposure was not associated with CCR2+ cell depletion, changes in LSK or progenitor populations or transformation in KDM6B/Tet2 mice. scRNA-seq of MNCs revealed decreased expression of inflammatory genes on monocyte and progenitor populations compared to short-term exposure which suggests cell-adaptive responses to overcome inflammatory and cell death programs associated with acute STING activation.Together, these data highlight the complex effects of STING activation dynamics in distinct hematopoietic populations and their role in CMML pathophysiology.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/14d404567ac411e598fe7813e54939096a5ebec9" target='_blank'>
              Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia
              </a>
            </td>
          <td>
            Yue Wei, Xiaoping Su, Ziyi Li, S. Loghavi, Hui Yang, Hong Zheng, Kirbie Linthicum, Vicky A. Appleman, Tiquella Hatten, Harry Huang, Jeffrey Raizer, Alexander Parent, N. Lineberry, Siddha Kasar, G. Garcia-Manero, G. Montalban-Bravo
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>140</td>
        </tr>

        <tr id="The tumor microenvironment (TME) plays a critical role at all stages of tumor progression. Cancer-associated fibroblasts (CAFs), as the main components of this environment, display diversities in origin, phenotype, and function, which contribute to cancer progression by regulating the tumor cell biology via cell–cell contact, releasing numerous regulatory elements such as growth factors (GFs), cytokines, and chemokines, and even remodeling the extracellular matrix (ECM). In this Review, we discuss the current understanding of CAFs’ pro- or anti-tumor functions in various hematological malignancies, including acute and chronic leukemia, lymphoma, and multiple myeloma (MM). The accumulating evidence highlighted that CAFs not only are implicated in these neoplasms’ initiation, development, and metastasis but also are involved in chemoresistance to various chemotherapy drugs such as daunorubicin and bortezomib. Intriguingly, cell culture-based methods’ results outlined that targeting signaling pathways that are used by CAFs to exert their pro-tumorigenic effects could be exploited in favor of tumor inhibition, which requires more investigation. Therefore, this therapeutic approach should be considered in future studies to develop a novel targeted therapy in hematological malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9c626fb73b1c7437edf3b7ee6bad0590c30c6a7c" target='_blank'>
              The emerging role of cancer-associated fibroblasts in hematological malignancies: from their influence on tumor progression and drug resistance to novel therapeutic opportunities
              </a>
            </td>
          <td>
            Sahar Jalilivand, Somayeh Yazdanparast, Mehdi Bakhtiyaridovvombaygi, Mehrdad Izadirad, Fatemeh Mikanik, Ahmad Gharehbaghian
          </td>
          <td>2025-11-11</td>
          <td>Clinical and Experimental Medicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 CD8 T cells are a critical component of the immune response to infections as well as in prevention and restriction of cancer growth. Across multiple solid cancer types, tumor infiltration of CD8 T cells is associated with improved patient survival. CD8 T cell cytotoxicity and cytokine production have been characterized as the primary mechanisms by which these cells execute their immune function. However, basal cell motility, defined as random walk and exploratory spread, is an essential and underappreciated aspect of the CD8 T cell-mediated antitumor response. Cell motility enables effector CD8 T cells to search for and reach their cell targets within a solid tumor microenvironment. Here, we investigate the impact of IL-21 on effector CD8 T cell motility. We show that compared to effector CD8 T cells expanded in the presence of IL-2 alone, those expanded in IL-2 and IL-21 exhibit increased cell motility in vitro and in vivo. We also show that IL-21 enhances mitochondrial respiration and mitochondrial calcium in effector CD8 T cells. Our data suggests that increased mitochondrial calcium and mitochondrial ATP promote CD8 T cell motility through IL-21-mediated STAT3 activity. Therefore, IL-21 plays an important role in effector CD8 T cell mitochondrial fitness, cytoskeleton stiffness, and cell motility, which can be leveraged in the design of adoptive T cell therapies for the treatment of solid tumors.



 Supported by NIH R01 CA260909; T32AI007405.



 Cytokines and Chemokines and Their Receptors (CCR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c85e17d7c962d1daada79818491cc536bfb732e9" target='_blank'>
              Enhancement of effector CD8 T cell motility by IL-21 through STAT3 4131
              </a>
            </td>
          <td>
            Maureen Hoen Rauhut, Fahiima Abdullahi, Felipe Valença-Pereira, Mercedes Rincon
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 The treatment landscape of diffuse large B-cell lymphoma (DLBCL) has progressed with the emergence of immune-cell therapies (ICTs), such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies. However, many patients still remain incurable despite these innovative options. Treatment resistance in DLBCL is associated with the immunosuppressive tumor microenvironment (TME), and myeloid-derived suppressor cells (MDSCs) play a crucial role in contributing to it. Furthermore, an increase in MDSCs has been linked to disease progression, poor prognosis, and reduced effectiveness of ICTs. Therefore, understanding how DLBCL cells promote MDSC development is essential for overcoming treatment resistance to ICTs. To address this issue, in this study, we investigated how DLBCL cells induce monocytic (M)-MDSCs from normal peripheral blood mononuclear cells (PBMCs) using an indirect co-culture system and traced the molecular changes involved. Four human DLBCL-derived cell lines (HDBCLs), including two double-expressor HDBCLs (KPUM-UH1 and KPUM-MS3) (Sasaki N, Exp Hematol 2011) and two activated B-cell-like HDBCLs (HBL1 and DLBCL2), were used. PBMCs from healthy donors were indirectly co-cultured with HDBCLs for 96 hours, and flow cytometry was used to analyze PBMCs for the induction of M-MDSCs displaying the CD14+/HLA-DR-/low phenotype. Total RNA was extracted from the CD33+ myeloid fraction of PBMCs after co-culture, and gene expression profiles (GEP) were analyzed using microarray analysis. Consequently, we first demonstrated that all four HDBCLs tested were effective in inducing CD14+/HLA-DR-/low myeloid cells from normal PBMCs within 96 hours of co-culture. The induced CD14+/HLA-DR-/low myeloid cells were also shown to be potent in inhibiting T cell proliferation, confirming these cells as M-MDSCs both phenotypically and functionally. The ability to induce M-MDSCs was highest in DLBCL2, followed by HBL1, while KPUM-UH1 and KPUM-MS3 showed modest M-MDSC-inducing capabilities. Based on the finding that M-MDSCs were induced through indirect co-culture with HDBCLs, we screened soluble factors in the conditioned medium (CM) of HDBCLs secreted by these cells using cytokine arrays, and found that all four HDBCLs secreted MIF. Additionally, the results showed that DLBCL2 cells produced high levels of interleukin-10 (IL-10), while HBL1 cells secreted IL-10 at low levels, and KPUM-UH1 and KPUM-MS3 cells did not produce detectable IL-10. We then examined the functional roles of MIF and IL-10 in the induction of M-MDSCs by HDBCLs. Interestingly, the MIF inhibitor 4-IPP greatly reduced M-MDSC induction by all four HDBCLs, and exposure to recombinant (r) MIF alone had minimal ability to induce M-MDSCs from normal PBMCs, indicating that MIF plays an essential but preparatory role in M-MDSC induction. Conversely, blocking IL-10 with a neutralizing antibody significantly decreased M-MDSC induction from PBMCs by IL-10-secreting HDBCLs, and adding rIL-10 increased the M-MDSC-inducing effect of IL-10-non-secreting HDBCLs, indicating that IL-10 plays a more facilitative role in inducing M-MDSCs. To understand the molecular regulation in PBMCs during the induction of M-MDSC by the co-existence with HDBCLs, we examined gene expression changes in CD33+ myeloid cells at 24, 48, and 96 hours after co-culturing with HDBCLs. We also examined the molecular dynamics in co-culture with non-IL-10-secreting cell lines that occurred after 96 hours of rIL-10 treatment. Results from gene set enrichment analysis revealed that gene sets associated with inflammatory response and tumor necrosis factor-alpha (TNF-α) signaling, as well as inflammatory molecules such as IL-1α, were upregulated 24 hours after co-culture. However, these upregulated gene sets became less expressed after 48 hours and eventually were downregulated after 96 hours. Additionally, the downregulation of inflammatory response and TNF-α signaling was further amplified by rIL-10. In conclusion, our study demonstrated that the multistep process of M-MDSC induction from PBMCs, triggered by HDBCLs, begins with an initial transient hyper-inflammatory phase induced by MIF and transitions into a post-inflammatory immunosuppressive phase accelerated by IL-10. Our findings suggest that targeting phase-specific cytokines and related molecules could reduce the induction, maturation, and proliferation of M-MDSCs, ultimately enhancing therapeutic outcomes, especially in ICTs.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ebe1659b4ff0741b0dd9144d5311758dfae1768" target='_blank'>
              Multistep molecular trajectory during monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells
              </a>
            </td>
          <td>
            Yu Inoue, Y. Shimura, Yui Niiyama-Uchibori, Shotaro Chinen, Takahisa Nakamura, Haruya Okamoto, Takahiro Fujino, T. Tsukamoto, S. Mizutani, Junya Kuroda
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 We are witnessing a significant increase in complex T cell-mediated immune disorders, such as food allergies and autoimmune disease. This trend suggests that the activation threshold for T cells may be altered, and understanding how to modulate this threshold has profound implications for disease treatment. In this study, we demonstrate that the effector program of CD8? T cells (including naïve, circulating memory, and tissue-resident cells) induced by TCR and cytokine stimulation is regulated by the class II histone deacetylase, HDAC5. HDAC5 exhibits little to no deacetylase activity against histone tails, but can function in the cytoplasm as a scaffolding protein or to directly deacetylate protein targets. Using small interfering RNA (siRNA) in cell lines of primary human CD8+ cytotoxic intraepithelial lymphocytes (IE-CTLs), we show that the loss of HDAC5 decreases their activation. Furthermore, inhibiting HDAC5 activity with the HDAC4/5 inhibitor LMK235 reduces the activation potential of ex vivo isolated human intestinal IE-CTLs following stimulation, suggesting that HDAC5 enzymatic activity is required for this effect. Finally, our data indicate that HDAC5 inhibition broadly impacts CD8? T cell activation, including in circulating memory and naïve subsets. This work identifies HDAC5 as a critical enzyme regulating the activation of CD8? T cells and highlights the potential of targeting HDAC5 to modulate CD8? T cell activation thresholds in inflammatory disorders.



 Supported by NIH BIBIB 2 T32 EB 9412; NSF Graduate Research Fellowship Program; University of Chicago Celiac Disease Research Center.



 Immune Response Regulation: Molecular Mechanisms (IRM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3f63a425ec70d967412fb047c150bfd3ab601d0" target='_blank'>
              HDAC5 regulates the activation of cytotoxic CD8+ T cells 4190
              </a>
            </td>
          <td>
            Megan Borregard, C. Ciszewski, Yandong Zhang, Hening Lin, B. Jabri
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>70</td>
        </tr>

        <tr id="


 T cell-engaging bispecific antibodies (TCBs) depleting B cell subsets are promising therapeutics for cancer and autoimmune diseases, with several approved or in development. However, an unavoidable consequence is immunosuppression in already vulnerable patients. Depleting B cells compromises the ability to fight infections and vaccine efficacy. These risks vary with underlying disease, effects on off-target cell populations and the TCB target. Differentiating drug candidates’ secondary TCB effects is key in drug development, but preclinical models may not fully capture complex B cell biology. We employed a multimodal systems immunology approach of two human in-vitro systems: immune organoids capturing productive germinal center responses, and an immunocompetent bone marrow model with B precursor- and differentiated plasma cells. We integrated data from high-dimensional flow cytometry, single cell RNA- and CITE-sequencing, to assess the consequences of TCB-mediated immune responses across different tissues. This allowed us to capture a differential off-tumor B cell subset toxicity of TCBs directed against two therapeutically validated TCB targets, in line with the reported clinical infection risk and B cell depletion that diverge between both. Overall, this translational work shows the value of human in-vitro approaches as a preclinical evaluation for immunosuppression, by accurately capturing complex human immune biology and therapeutic activity of candidate molecules.



 Translational and Interventional Immunology (TI)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ab71e60522c5a275a95f316de0a2c67184842200" target='_blank'>
              Translating immunosuppressive risks of T-cell bispecifics using human in vitro models and systems immunology 9247
              </a>
            </td>
          <td>
            Lea Schroer, Jenna M. Kastenschmidt, Michael Bscheider, Nick Corr, Susanne Fischer
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="


 Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the accumulation of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB). Several alterations in the BM microenvironment have been linked to AML onset and progression, some of which affect the immune system and promote tumor evasion. Genetic alterations also contribute to these processes, including overexpression of the MN1 gene, which is addressed in this study. MN1 overexpression is associated with a more aggressive leukemic phenotype and therapeutic resistance. Among the pathological findings in the leukemic BM microenvironment, the relative increase in AML-associated macrophages (AAMs) appears to support AML progression. AAMs display a phenotype similar to that of healthy M2-like macrophages and are thus linked to anti-inflammatory and immunosuppressive activity. In this context, therapeutic approaches aimed at reprogramming AAMs toward a more inflammatory and antitumoral profile, resembling M1-like macrophages, have been investigated. This study aimed to evaluate the immunomodulatory effects of BPI-2358, a tubulin polymerization inhibitor and JNK pathway activator, on AAMs in AML models driven by MN1 overexpression. Human PB-derived M2 macrophages were treated with BPI-2358 (0.125–0.5 µM) for 48 hours. Immunophenotyping (CD80, CD86, CD206, CD163) and cytokine analysis (TNF-α, IL-1β, TGF-β) revealed a shift toward a pro-inflammatory profile. Our findings showed that BPI-2358 treatment had a significant impact on marker expression, leading to an upregulation of CD86 and a downregulation of CD163 in human samples. Additionally, we detected elevated levels of pro-inflammatory cytokines, including IL-1β and TNF-α, along with a reduction in TGF-β secretion. Similarly, murine BM-derived M2 macrophages treated under the same conditions showed increased expression of M1-related genes (Cd80, Tnf-α, Nos2) and downregulation of Arg1, a classical M2 marker, by qRT-PCR. A phagocytosis assay was performed using M2-polarized murine macrophages treated with BPI-2358 (0.5 μM) and MN1-GFP⁺ murine AML cells. Treated macrophages exhibited an increased phagocytic capacity compared to untreated controls. A cell proliferation assay was performed by co-culturing BM-derived M2 murine macrophages, pre-treated with BPI-2358 (0.5 μM), with MN1-GFP⁺ murine AML cells at a 1:1 ratio. Cell growth was monitored over a 10-day period by performing regular cell counts. Notably, a significant decrease in MN1 cell proliferation was observed on days 3 and 4 in co-cultures with BPI-2358-treated macrophages, indicating that the treatment impaired leukemic cell expansion. Moreover, exposure to an AML-conditioned microenvironment induced a tolerogenic macrophage profile in vitro, which was partially reversed by treatment, highlighting the functional plasticity of these cells. Transcriptomic analysis by RNA-seq revealed differential gene expression and pathway enrichment consistent with macrophage reprogramming. Transcriptomic analysis showed that BPI-2358 upregulated 4,829 genes, including those involved in tissue damage response, tissue remodelling, and the pro-inflammatory cytokine Il1b. The treatment also significantly suppressed the IL-6/JAK/STAT3 pathway, a key driver of the immunosuppressive M2 phenotype and tumor immune evasion. Ex vivo cytotoxicity was assessed in a panel of primary AML samples (n=25) treated with BPI-2358 (0.125–0.5 µM) for 72 hours. Flow cytometry was used to evaluate viability of leukemic blasts (CD34⁺ or CD117⁺ for CD34⁻ AMLs) and macrophages (CD34⁻ or CD117⁻ HLA-DR⁺ CD14⁺) using Annexin V/DAPI staining and TMRE for mitochondrial membrane potential. Finally, the in vivo efficacy of BPI-2358 was assessed in an MN1-driven AML mouse model (MN1-GFP⁺). Mice received BPI-2358 (7.5 mg/kg IP, daily), and flow cytometry analysis of the BM showed a reduction in leukemic engraftment. The treatment did not impact the animals' body weight, suggesting minimal systemic toxicity. A significant decrease in the frequency of circulating MN1⁺ cells was observed, along with a marked reduction in MN1⁺ cell infiltration in the spleen. This was further supported by a significant decrease in spleen weight in the BPI-2358-treated group. These findings reinforce the potential of macrophage reprogramming as a complementary strategy in AML treatment, especially in molecularly high-risk subtypes such as those associated with MN1 overexpression.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7341436505bbad9e3856fea1f022bb194207dcdb" target='_blank'>
              BPI-2358 reprograms immunosuppressive macrophages and impairs leukemic progression in MN1-overexpressing AML In Vivo
              </a>
            </td>
          <td>
            L. Pinheiro, I. Weinhäuser, D. Pereira-Martins, Katherine Hampton, Annalisa Altera, D. Fowler-Shorten, Matthew Markham, A. Polski-Delve, Tabitha Bartlett, C. Hellmich, Luíse A A Simões, Cleide Lúcia Araujo, Rita De Cássia Cavaglieri Medeiros, L. Quek, G. Huls, J. Schuringa, S. Rushworth, E. Rego
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>48</td>
        </tr>

        <tr id="
 Brain metastases (BM) from lung adenocarcinoma represent a formidable clinical challenge due to limited therapeutic efficacy. To gain insight into complex tumor microenvironment (TME) of BM, we analyzed single-cell RNA-sequencing data comprising 66,769 cells from primary tumors (PTs; 44,355 cells) and matched BM lesions (22,414 cells). Our analysis revealed a profound shift in cellular composition during metastasis: while T cells predominated PT (44.12%), tumor cells became the most abundant population in BM (55.17%), with corresponding reductions in T cells (27.57%) and macrophages (19.3%). Cell–cell communication analysis identified fibroblasts as central mediators in both PT and BM, with a transition from collagen signaling in PT to thrombospondin signaling in BM, facilitating interactions with tumor cells, B cells, and oligodendrocytes. Ingenuity Pathway Analysis revealed enrichment of collagen-related genes in fibroblasts (MFAP4, COL15A1, FBLN1, FBLN2) and Th1/Th2 pathway genes in T cells (IKZF1, SH2D1A, RASGRP1, SKAP1). Subclustering uncovered seven distinct fibroblasts subpopulations and a notable shift from PT-enriched C0 to BM-enriched C1, suggesting dynamic phenotypic adaptation. Pseudotime trajectory analysis further clarified fibroblasts differentiation states. T-cell subclustering revealed a significant increase in immunosuppressive regulatory T cells (84.1%) and proliferating CD4+ T cells (10.5%) in BM, highlighting mechanisms of immune evasion. COL15A1 expression correlated with poor patient survival and emerged as a promising therapeutic candidate, showing increased sensitivity to Dabrafenib, Trametinib, Piperlongumine, Cabozantinib, Staurosporine, and Vemurafenib. Additional gene drug associations were observed, with FBLN1, RASGRP1, MFAP4, SH2D1A, and IKZF1 linked to potential sensitivity to Erlotinib, Afatinib, Fluorouracil, and Brefeldin A. These findings provide a high-resolution map of the BM TME and highlight COL15A1 and related pathways as potential targets for precision therapy in patients with BM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc3a5b204d80d9cd5d66d31480f9cf9dd3274795" target='_blank'>
              TMIC-44. Fibroblast reprogramming and immune evasion define the tumor niche in brain metastases
              </a>
            </td>
          <td>
            Sanskriti Dey, J. Chuang, Chih-Yang Wang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immune evasion is a hallmark of cancer development and poses an important impediment to the effectiveness of immune checkpoint inhibitors (ICIs). Cancer cells take advantage of heterogeneous intrinsic and extrinsic pathways to circumvent immune detection, such as metabolic remodeling (e.g., increased glycolysis, activation of IDO1), genomic mutation (e.g., JAK/STAT, β-catenin), and epigenetic suppression of immune-regulatory genes. Concurrently, TME promotes immune suppression through Tregs, MDSCs, TAMs, and fibroblast-mediated extracellular matrix remodeling. Hypoxia and cytokine dysregulation also undermine antigen presentation and T-cell functionality. These immunoevasion strategies form the foundation of both native (innate) and adaptive resistance to ICIs, while recent evidence places emphasis on microbiota composition being able to modify therapeutic response. The PD-1/PD-L1 pathway remains the focus of ICI therapy, but PD-L1 expression is limited by spatial, temporal, and technical heterogeneity. Beyond PD-L1, integrated biomarker approaches including tumor mutational burden (TMB), microsatellite instability (MSI), IFN-γ gene signatures, and circulating tumor DNA (ctDNA) have arisen to further inform patient stratification. Emerging therapeutic technologies—e.g., dual checkpoint blockade, engineered cytokines, personalized neoantigen vaccines, and adoptive T cell therapy (CAR-T, TCR-T)—are designed to overcome resistance and maximize clinical efficacy. Integration of multi-omics and AI-based models provides additional precision in the tailoring of immunotherapy. This review integrates existing knowledge of immune escape and resistance, highlighting dynamic biomarker development and combinatorial approaches for next-generation personalized cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ea6fa22f99aea24aa51b0cd66f7e9b27adb85e90" target='_blank'>
              Immune Evasion and Resistance in Cancer Progression: Overcoming Checkpoint Inhibition Challenges with Personalized Immunotherapy Guided by PD-L1 Expression
              </a>
            </td>
          <td>
            Archana Venkatesan, Karthick Sivanatham
          </td>
          <td>2025-10-21</td>
          <td>Journal of Analytical Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) remains one of the most lethal primary brain tumors, characterized by profound immunosuppression and resistance to conventional immunotherapy. A hallmark of the GBM microenvironment is the prevalence of functionally exhausted T cells, marked by sustained expression of inhibitory receptors such as PD-1 and impaired effector function. These exhausted T cells represent a major barrier to durable anti-tumor immunity and effective immunotherapeutic intervention. To address this, we explored PD1-IL2v, an engineered immunocytokine designed to selectively stimulate PD-1⁺ cells with IL-2 signaling while minimizing activation of regulatory T cells. Using both the immunogenic GL261 and the immune checkpoint-resistant SB28 murine models of GBM, we administered PD1-IL2v either systemically or directly into the tumor. Flow cytometry was employed to assess changes in tumor-infiltrating lymphocytes, with particular focus on exhaustion and effector phenotypes. Notably, local administration of PD1-IL2v, but not systemic delivery, effectively reactivated CD8⁺ T cells within the tumor microenvironment. PD1-IL2v treated mice exhibited enhanced cytokine production, increased proliferation, and restoration of cytotoxic activity in T cells. Phenotypic profiling of tumor infiltrating lymphocytes (TILs) revealed an expansion of a stem-like subset of exhausted T cells (PD-1⁺TCF1⁺), alongside the emergence of a novel, differentiated population with superior effector functions, termed “better-effector” T cells. Therapeutic intervention with PD1-IL2v led to complete tumor rejection in a subset of animals, and increased infiltration of functional T cells into the tumor core. Our findings underscore T cell exhaustion as an untapped reservoir of tumor-reactive T cells that can be therapeutically reinvigorated using PD1-IL2v. This approach not only restores anti-tumor immunity but also induces superior effector populations capable of driving tumor regression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1d2a360e4ecb23a3988292b555a7155b5788a697" target='_blank'>
              IMMU-26. Reinvigorating exhausted T cells in glioblastoma via PD1-IL2v immunocytokine therapy
              </a>
            </td>
          <td>
            U. Salazar, B. Taskoparan, Sereina Deplazes, V. Nicolini, Laura Codarri-Deak, H. Okada, C. Klein, Johannes vom Berg
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="


 Clonal hematopoiesis (CH), defined as an expanded hematopoietic stem cell (HSC) clone with somatic mutations in the absence of blood malignancy, is common in aging and associated with increased severity of inflammatory non-hematologic disorders. The co-occurrence of CH in patients with solid tumors correlates with poor prognosis and a more aggressive phenotype of the malignancy. This leads to the notion that CH mutations alter anti-cancer immunity, and that CH-derived monocytes and macrophages may contribute to a proinflammatory tissue microenvironment. Being innate immune cells, monocytes and macrophages can mount a heightened inflammatory and defense responses to secondary challenges (“trained immunity”) that are known to accentuate tumor control. On the other hand, excessive or prolonged stress stimulus may lead to its suppression (“immune tolerance”). The effect of DNMT3A mutations found in CH on innate immune responses has not been explored.
 Using colitis-associated colon cancer (CAC) as a model, we previously reported that CH driven by heterozygous loss of Dnmt3a, mimicking the most common genetic alteration in human CH, promoted initiation and progression of solid tumors in the context of severe chronic inflammation. We hypothesized that Dnmt3a-CH tilts myeloid responses toward immune tolerance rather than trained immunity, compromising tumor control.
 To assess the impact of Dnmt3a-CH to tumor immune microenvironment (TME), we created a mouse model with 10% test BM cells (Dnmt3a+/– or WT control) marked with CD45.2 mixed with 90% CD45.1+CD45.2+ WT competitor and engrafted into pre-conditioned CD45.1+ recipients prior to CAC induction by the azoxymethane (AOM)/dextran sulfate sodium (DSS) method. Mice with Dnmt3a+/– BM developed more numerous, larger CAC tumors, solidifying the prooncogenic role of Dnmt3a-CH. Flow cytometry revealed preferential infiltration of Dnmt3a+/– BM-derived cells in the TME, particularly immune-suppressive M2-like macrophages. Increased abundance of Dnmt3a+/– anti-inflammatory M2-like macrophages was confirmed by scRNA-seq on FACS-sorted tumor-infiltrating donor-derived CD45.2 cells from mice non-competitively transplanted with Dnmt3a+/– compared to WT control BM. Cytokine profiling in whole tumor lysates revealed reduced pro-inflammatory IL-1β and TNF-α indicating a switch to a tolerogenic immune state in Dnmt3a+/– BM chimerae.
 Repeated inflammatory insults can cause a switch to immune tolerance. To test this, mice transplanted with Dnmt3a+/– and WT control BM were subjected to 3 bouts of DSS-induced bacterial colitis or kept untreated. Despite developing more pronounced colitis as evidenced by greater shortening of the colon and increased weight loss, Dnmt3a+/–-engrafted recipients showed decreased pro-inflammatory cytokine levels in serum and elevated levels of immunosuppressive IL-10. Strikingly, although in vitro differentiated BM-derived macrophages (BMDMs) from untreated Dnmt3a+/– mice showed higher phagocytic activity compared to WT controls, this function was dramatically impaired after DSS challenge in alignment with an immune tolerance phenotype. Similar results were observed in human THP-1 cells CRISPR-edited to disrupt one DNMT3A allele. After stimulation with high-dose lipopolysaccharide (LPS) to mimic an inflammatory challenge associated with endotoxemia secondary to colitis, DNMT3A-disrupted THP-1 macrophages exhibited significantly dampened phagocytosis compared to WT controls. RNA-seq analysis revealed the DNMT3A+/- THP-1 showed reduced expression of gene sets and pathways related to inflammation and innate immune defense.
 These observations demonstrate that tolerogenic reprogramming of Dnmt3a-CH macrophages after an inflammatory insult establishes a tumor-permissive immune microenvironment in CAC. Indeed, myeloid-specific heterozygous Dnmt3a loss (by LysM-Cre) was sufficient to promote tumor initiation, while depletion of phagocytes in vivo using clodronate liposomes during CAC induction reversed Dnmt3a-CH-induced increase in colon tumor burden.
 In conclusion, DNMT3A-driven CH enables colitis-associated tumorigenesis by priming myelopoiesis towards innate immune tolerance under excessive inflammation, creating an immunosuppressive TME and corrupting tumor control. Targeting innate immune tolerance in individuals with DNMT3A-CH may represent a strategy to mitigate the risk of inflammation-associated cancers.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e59f93632128a080292d7ca72e60726d86ccb977" target='_blank'>
              DNMT3A-driven clonal hematopoiesis permits colitis-associated tumorigenesis by promoting innate immune tolerance
              </a>
            </td>
          <td>
            Qingchen Yuan, Yang Feng, Christopher Thai, Andrey Smirnov, Eric Helm, Bowen Yan, Prabhjot Kaur, Annalisse R. Mckee, Cassandra Berntsen, Daniil E. Shabashvili, Jixiu Shan, Jason Brant, Dorina Avram, Hossein Khiabanian, Jonathan Licht, Olga A. Guryanova
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="


 Background Cellular immunotherapy has revolutionized cancer treatment. Yet its efficacy in acute myeloid leukemia (AML) remains limited due to an immunosuppressive tumor microenvironment (TME) often characterized by deficient immune-stimulatory cytokines and elevated immunosuppressive metabolites. Adenosine (Ado), a key inhibitor is degraded by the non-redundant enzyme adenosine deaminase (ADA), which converts Ado into the immune-stimulatory inosine (Ino). IL-12 is a potent cytokine that strongly boosts immune cells, but its systemic toxicity limits clinical use. To address this, we engineered tumor-homing, non-pathogenic Escherichia coli (E. coli) to co-display surface-tethered IL-12 and ADA, enabling localized cytokine delivery and metabolic reprogramming. We hypothesized that this dual strategy efficiently reprograms the immunosuppressive niche in AML, thereby unlocking robust local NK (and T cell) anti-leukemic immunity.
 Method Non-pathogenic E. coli K12 DH5α were engineered to surface-display murine and human IL-12, ADA, or IL-12+ADA fusion using optimized outer membrane scaffolds with FLAG tags using an approach in our recently published paper (Yang et al, Nature Biotechnology 2024). Expression was induced with rhamnose and confirmed by flow cytometry. IL-12 bioactivity was validated via HEK-Blue reporter assay. ADA kinetics and activity were assessed via LC-MS and colorimetric assays. NK cells were co-cultured for 24h with E. coli displaying ADA, IL-12, ADA+IL-12, or scaffold control followed by multicolor flow cytometry to assess Ado-signaling (A2AR, CD73, CD39, CD26), surface markers (i.e., CD25, NKG2D, NKp30), and AML-directed cytotoxicity (Zombie-NIR, IFNg, TNFα) against the AML targets NOMO1 and OCI-AML3. To model TME metabolism, cells were treated with 1mM Ado, Ino or PBS. In-vivo efficacy was tested in a immunocompetent B16-F10 melanoma model and BALB/c mice bearing GFP⁺/NanoLuc⁺ WEHI-3 AML cells. Leukemic burden (bioluminescence imaging, blood), weight, and survival were monitored. Bacterial distribution was assessed by CFU assays in relevant organs.
 Results Engineered E. coli co-displaying IL-12 and ADA showed robust FLAG-tagged surface expression (>80%) with significant IL-12 bioactivity (OD650, 0.9 vs. 0.2, p<.001). Murine ADA displayed by YiaT181 showed highest enzymatic activity (Km=0.05, Vmax=53µmol/min), fully converting Ado to Ino within 4h. NK cells cocultured with IL-12 displaying E. coli showed strong upregulation of key activation markers compared to scaffold control (CD25, 56 vs. 25% and NKp30, 68 vs. 35%, p<.001), leading to a ≥3.4-fold greater AML-directed cytotoxicity and IFNγ production. Importantly, rhIL-12 (50ng/ml) increased expression of the Ado-generating metabolic checkpoint CD73 (2 to 9%, p=.003) and Ado receptor A2AR on NK cells (31 to 51%, p=.001), indicating increased Ado susceptibility. Ado exposure reduced AML-directed killing by ~50% (p<.001) and NK cell activation (NKp30 expression was 33 vs. 18%, p=.003). ADA-expressing E. coli restored NK cell immunity and AML lysis in-vitro (55 vs. 15%, p<.001). Co-display of IL-12 and murine ADA maintained full NK effector function under Ado-rich conditions and enhanced AML-targeted lysis (15 vs. 56%, p<0.01). In-vivo, i.v. delivery of E. coli expressing ADA, IL-12, or ADA+IL12 fusion was well-tolerated and demonstrated potent antileukemic activity in immunocompetent WEHI-3 AML models. Substantial tumor control led to prolonged survival in the IL-12+ADA group (2 of 3 alive at d29, median survival not reached) vs a median of 10 days in control mice. Robust tumor control was reached in the IL-12 (26d) and ADA (17d) group. Post-mortem analysis of mice revealed unprecedented tumor-guided bacterial migration to the bone marrow, a phenomenon not previously reported. ADA-engineered bacteria accumulated up to 4x105 CFU and IL-12 displaying bacteria up to 3x104 CFU in the bone marrow. Intratumoral delivery of IL12+ADA-engineered E. coli induced complete tumor regression and 100% survival in a B16-F10 melanoma model, with tumor rechallenge confirming durable antitumor immunity, suggesting immune memory and long-term immune protection.
 Conclusion Engineered nonpathogenic E. coli co-displaying IL-12 and ADA effectively reprogram the AML TME, enhance NK cell activation, and drive sustained anti-tumor responses. This live microbial platform offers a safe, localized, and versatile immunotherapy strategy applicable to both hematologic and solid tumors.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/04c11cfcf5a3539fa2c39d0839134cb7fc2116bd" target='_blank'>
              Dual-function engineered bacteria remodel AML tumor microenvironment via IL-12 delivery and adenosine depletion to sustain NK cell immunity
              </a>
            </td>
          <td>
            Stephanie Sendker, Shaobo Yang, Anna Clara Bader, Alice Chen, Eden Bobilev, Ashley Hu, Xingyu Deng, Fuguo Liu, Veronica Hui, Maily Nguyen, Andreia Maia, Sara Piccinelli, Kerim Berkay Aslan, Fabian Göllner, A. Ali, Rémy Duléry, Hetal Nath, Daniel Chen, Mounica Vallurupalli, Andrew Lu, Stephanie Chamberlain, Tereza Kochs, Nathalie Javidi-Sharifi, Michal Sheffer, Roman Shapiro, Andrew Lane, Robert J. Soiffer, Mubin Tarannum, Jerome Ritz, R. Romee
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Extracellular vesicles (EVs) express features of parental cells and are fundamental in modulating the crosstalk between cancer cells and their environment. Increasing evidence suggests that EVs have a pivotal role in tumorigenesis, cancer development, and drug resistance. EVs are also involved in controlling the communication between hematopoietic stem cells and the surrounding microenvironment in the bone marrow (BM), during several processes such as self-renewal, mobilization, and lineage differentiation. Proteins expressed in cancer cell-derived EVs can be useful to further understand the regulation of hematopoietic stem cell fate, a fundamental mechanism in acute myeloid leukemia (AML). Furthermore, EVs are implicated in transmitting drug-resistance mechanisms in solid and not-solid cancer types. Here, using a proteomic approach, we analyze and validate the protein profile of EVs from three AML cell lines with different genotypes, namely OCI-AML-2, OCI-AML-3, and HL-60. The majority of the identified proteins were significantly enriched in the Gene Ontology category ‘Extracellular Exosome’. Network model analysis of EV proteins revealed several significantly modulated pathways, including inflammation activation and metastatic processes in AML cell-derived EVs. The EVs proteomic profiling allows us to identify the EVs-associated molecules and pathways that could impact cancer progression and drug resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/849ae2dd1616d0c72e1ed7ba719a71d6a8bb6984" target='_blank'>
              Extracellular Vesicles Profiling in Acute Myeloid Leukemia Cell Lines: A Proteomic Characterization
              </a>
            </td>
          <td>
            B. Dufrusine, M. Cufaro, Alice Di Sebastiano, Erika Pizzinato, Pina Nardinocchi, I. Cicalini, S. Pilato, Antonella Fontana, D. Pieragostino, Enrico Dainese, Luca Federici
          </td>
          <td>2025-10-22</td>
          <td>Cells</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="


 Despite significant advancements in targeted therapies and immunotherapies, a substantial proportion of non-small cell lung cancer (NSCLC) patients remain unresponsive to treatment. One contributing factor is tumor-induced immunosuppression, which impairs effective T cell responses. Natural killer (NK) cells, while playing a pivotal role in antitumor immunity, have been shown to negatively regulate adaptive immune responses in various contexts. In this study, we characterized the phenotype of NK cells within the NSCLC microenvironment and investigated their potential contribution to immune suppression. CD3- CD56+ NK cells were isolated from tumor resection specimens and profiled using single-cell RNA sequencing and CITE-seq. Identified NK cell clusters were subsequently quantified in tumor-infiltrating lymphocyte (TIL) cultures exhibiting different expansion rates. Our analyses identified a tumor-specific NK cell subset associated with reduced recurrence-free survival (RFS). This subset was preferentially enriched in TIL cultures with low expansion rates compared to those with high expansion rates, suggesting a potential role in limiting T cell proliferation. Future investigations will focus on confirming the regulatory role of this NK cell subset and elucidating the mechanisms underlying its suppressive function.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/96876b361473daba1aa036fd63568ae3002f5c55" target='_blank'>
              Immunoregulatory NK cells in non small cell lung cancer (NSCLC) 3221
              </a>
            </td>
          <td>
            Jules Sotty, D. Chung, Nicolas Jacquelot, Jehan Vakharia, Azin Sayad, Ben X Wang, P. Ohashi
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 Acute graft-versus-host disease (aGVHD) is one of the most severe complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT), primarily caused by donor-derived alloreactive T cells that attack recipient tissues, leading to systemic inflammation and multi-organ damage. While the effector role of donor T cells is well recognized, their developmental origin, activation dynamics, and persistence remain poorly understood. The thymus is the central organ for T-cell development and immune tolerance, yet its role in aGVHD pathogenesis remains underexplored.
 In preliminary experiments using a murine aGVHD model, we observed marked thymic atrophy, along with a significant reduction in total thymocyte numbers. Flow cytometric analysis revealed a near-complete absence of CD4⁺CD8⁺ double-positive (DP) thymocytes, with only a small population of single-positive (SP) CD4⁺ and CD8⁺ cells remaining. These findings suggest that thymic architecture and function are severely compromised during aGVHD, potentially interfering with both positive and negative selection processes. This impairment may lead to the premature release of incompletely developed T cells into the peripheral circulation.
 Unexpectedly, we identified a substantial accumulation of DP T cells in peripheral target organs, including the colon, liver, and skin, in aGVHD mice. These cells were virtually absent in bone marrow–transplanted, T cell–depleted (BM-TCD) controls. Given that DP cells are typically restricted to the thymus and are rarely found in the periphery under normal conditions, their presence in peripheral tissues suggests a pathological process of premature egress from the thymus due to structural and functional failure. This observation raised the hypothesis that these peripheral DP cells may be developmentally abnormal and functionally involved in mediating tissue injury.
 To investigate the biological properties of these DP cells, we performed both single-cell RNA sequencing (scRNA-seq) and spatial transcriptomic profiling of three representative tissues in aGVHD mice: the colon (a representative target organ), the thymus (the central lymphoid organ), and the spleen (a peripheral lymphoid organ). The aGVHD model was established using GFP-labeled C57BL/6 donor cells transplanted into lethally irradiated BALB/c recipients. The BM-TCD group served as the negative control.
 scRNA-seq analysis revealed that peripheral DP cells in the aGVHD colon expressed high levels of cell cycle–related genes such as Birc5, Cdca8, Pclaf, and Mki67, indicating strong proliferative potential. In contrast, expression of lineage-defining transcription factors and effector molecules typically associated with SP T cells, including Cd83, Tnfsf8, and Gata3, was minimal. These data suggest that the peripheral DP cells are in a non-canonical, undifferentiated state distinct from conventional effector T cells. Spatial transcriptomic data confirmed that these DP cells were enriched in subepithelial regions of the colon, which colocalized with areas of epithelial disruption and immune infiltration, implicating them in direct tissue damage.
 We further compared DP cells from the thymus of BM-TCD mice with splenic DP cells from aGVHD mice. Thymic DP cells exhibited high expression of normal developmental markers including Rag1, Rag2, Rorc, Ccr9, and Sox4, consistent with ongoing T-cell maturation within a healthy thymic environment. In contrast, splenic DP cells from aGVHD mice expressed elevated levels of activation and cytotoxicity-associated genes such as Gzmb, Il2rb, and Cd38, suggesting that they had transitioned into an activated and potentially pathogenic state. This phenotypic shift supports the concept that the inflammatory milieu of aGVHD promotes extrathymic activation and reprogramming of aberrantly exported DP cells.
 Our findings reveal that thymic dysfunction in aGVHD permits the release of immature DP T cells into the periphery, where they acquire pathogenic features and accumulate in target tissues. This thymus–periphery axis may be a key driver of ongoing inflammation and damage in aGVHD. Therapeutic strategies that restore thymic function or eliminate pathogenic DP cells may provide novel avenues to alleviate disease severity.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4d45448d48e53c36fcb43dee5871db163da2fc50" target='_blank'>
              Thymic dysfunction promotes the emergence of pathogenic peripheral CD4⁺CD8⁺ T cells and induces tissue injury in acute gvhd
              </a>
            </td>
          <td>
            Meng Zhang, Hengwei Wu, Xinyi Lai, Xiangjun Zeng, Mengmeng Huang, Yingru Jiang, Yanjuan Liu, Yanmin Zhao, Fang Ye, He Huang
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="


 Immune checkpoint inhibition (ICI) has dramatically advanced cancer treatment but is associated with adverse outcomes including ICI-induced myocarditis. Recent work demonstrated that T cells restricted to cardiac antigens are indispensable, yet how these cells provoke fatal cardiac damage remains poorly defined. To interrogate the mechanisms underlying myocarditis, we derived a transgenic mouse line with cardiomyocyte-restricted ovalbumin expression. Transfer of naïve OTI T cells into transgenic recipients did not induce pathology, but the addition of ICI led to myocarditis. Critically, PD-1 blockade alone proved sufficient. Our findings suggest that PD-1 blockade facilitates de novo CD8 T cell priming, independent of conventional microbial stimuli. Current work aims to determine if ICI obviates the need for classical 2nd and 3rd priming signals. Additionally, we characterized diseased hearts following CD8 T cell priming and subsequent cardiac infiltration. T cells constitute half of the infiltrating immune cells, while inflammatory monocytes/macrophages and DCs dominate the non-lymphocyte population. Elevations in innate cytokines IL-1β and IL-6 were also identified. We then targeted T cell-mediated innate inflammation to ameliorate disease. Thus, these studies use a novel mouse model to 1) underscore the role for CD8 T cells, 2) reveal a noncanonical activation pathway of CD8 T cells during PD-1 blockade, and 3) posit a role for innate inflammation as a driver of pathology.



 Supported by AHA predoctoral fellowship (24PRE1198808); NIH/NIAID AI123176; NIH/NHLBI HL156852



 Basic Autoimmunity (BA)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3a81d81333df1541d1c40b6e6fdc183b42d1e5e" target='_blank'>
              Immune checkpoint blockade induces de novo CD8 T cell priming and innate inflammation leading to myocarditis 3714
              </a>
            </td>
          <td>
            Kathrynne A. Warrick, Jeffery D. Molkentin, C. Pasare
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Tumor-immune infiltration is an important predictor of immunotherapy response in undifferentiated pleomorphic sarcoma (UPS). However, most patients respond poorly to immunotherapy due to a lack of tumor infiltrating T cells and an enrichment of tumor-promoting macrophages. Increasing tumor-immune infiltration is therefore critical to improve survival and treatment response in UPS patients. Our goal is to determine why some tumors recruit more immune cells than others. We are investigating how Vgll3, a frequently overexpressed gene in UPS, regulates tumor immune infiltration. In a mouse model of UPS, recent work showed increased immune infiltration into Vgll3-overexpressing tumors (Vgll3+) and a robust response to chemotherapy compared to immune-excluded sarcomas. We are now defining the cellular and molecular mechanisms by which Vgll3 drives immune infiltration to identify pathways that could potentially be targeted therapeutically in genetically distinct, immune-excluded tumors. We observed stronger type I IFN production by Vgll3+ sarcoma cells than sarcoma cells with normal levels of Vgll3, and that Vgll3+ tumors are enriched in a subset of immunostimulatory IFN-responsive classical monocytes. Our studies will reveal new insights into the mechanisms of sarcoma-immune cell infiltration, highlight differential responses of immune subsets to tumor-derived factors, and uncover therapeutic targets to enhance treatment response and survival outcome in UPS patients.



 Supported by funds from the Board of Governors Regenerative Medicine Institute at Cedars-Sinai (to HSG).



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20e44e54d02e13d3da3880c3c66228daf1821c74" target='_blank'>
              Role of Vgll3-driven Type I IFN in Shaping the Sarcoma Immune Landscape 9365
              </a>
            </td>
          <td>
            Basia Gala, E. Ko, Karina Nance, Helen S. Goodridge, Jlenia Guarnerio
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Background/Objectives: In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often through unknown mechanisms. Methods and Results: Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis, but, in the absence of PD-1, tumor cells express NK cell inhibitory receptors, highlighting the necessity for leukemic cells to evade the host’s NK immune response in order to exit the bone marrow. PD-1 expression reduces natural antitumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefits by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL. Conclusions: These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b41b3b2aebacf7f7340a2020174ac633c1537ec" target='_blank'>
              PD-1 Expression Promotes Immune Evasion in B-ALL
              </a>
            </td>
          <td>
            Ana Casado-García, Gonzalo García-Aguilera, Julio Pozo, Ninad Oak, S. Barrena, Belén Ruiz-Corzo, Jaanam Lalchandani, Ana Chamorro-Vera, Ana Castillo-Robleda, Beatriz Soriano, Silvia Alemán-Arteaga, Elena G. Sánchez, Jorge Martínez-Cano, Andrea López-Álvarez de Neyra, Paula Somoza-Cotillas, Oscar Blanco, Susana Riesco, Pablo Prieto-Matos, Francisco Javier García Criado, M. B. García Cenador, C. Cobaleda, Carolina Vicente-Dueñas, Kim E. Nichols, Alberto Orfao, Manuel Ramírez-Orellana, I. Sánchez-García
          </td>
          <td>2025-11-12</td>
          <td>Hematology Reports</td>
          <td>0</td>
          <td>47</td>
        </tr>

        <tr id="


 Cancer immunotherapies have shown significant promise in multiple myeloma (MM). However, their long-term efficacy is limited by immune evasion, and MM remains incurable. A key evasion strategy involves upregulating inhibitory phagocytosis checkpoints (IPCs), which prevent antigen-presenting cells (APCs) from phagocytosing cancer cells. This pathway is critical for the immune effects of standard anti-MM agents, including bortezomib (BTZ), an inducer of immunogenic cell death (ICD), and the monoclonal antibody daratumumab (DARA). Yet, the mechanisms regulating IPCs in MM remain poorly understood.
 To address this gap, we screened IPC axes in MM cells and APCs using bone marrow (BM) aspirates from MM patients (n=39) and healthy donors (n=5) via multiparametric flow cytometry. Immunophenotyping included 9 parameters for MM cells and 16 for APCs, covering IPC and lineage markers. We identified the B2 microglobulin (B2M) / leukocyte immunoglobulin-like receptor B1 (LILRB1) axis as the dominantly expressed IPC in MM. B2M, expressed on MM cells, binds LILRB1 on APCs. Notably, B2M is a known adverse prognostic factor in MM.
 Computational analysis of flow-cytometry data using a semi-automated pipeline allowed us to define 8 distinct myeloid cell clusters, with consistently high LILRB1 abundance, especially in conventional type 1 dendritic cells (DCs). Single-cell RNA-seq data from 90 MM BM samples confirmed LILRB1 expression in DCs, monocytes (Mo) and macrophages (MΦ). qRT-PCR of BM Mo-derived DCs found that LILRB1 mRNA levels increased from healthy donor to smoldering MM to overt MM, suggesting a link to disease progression.
 To functionally assess the B2M/LILRB1 axis, we knocked out B2M in MM cell lines (n=3) and re-expressed a chimeric B2M mutant (B2MMUT) lacking functional LILRB1-binding site by introducing 16 missense mutations. B2M functions as an MHC-I subunit, so this mutant allowed us to isolate its checkpoint role without the confounding effects from complete B2M loss. Yeast 2-hybrid assays confirmed a direct interaction between B2M and LILRB1, but not for B2MMUT. Phagocytosis assays found that B2MKO and B2MMUT cells were more susceptible (more than 2-fold) than WT to phagocytosis by DCs and MΦ after BTZ or DARA treatment (p<0.01). LILRB1 knockdown (KD) in APCs, using an antisense oligonucleotide, similarly enhanced the phagocytic potential after BTZ treatment (p<0.05).
 Since MM cells actively secrete B2M (s-B2M), we analyzed the media from MM cell lines with different B2M statuses: B2M WT, B2MKO, and B2MMUT. We found s-B2M in the media from B2M WT cells, but no B2M in the KO cells and s-B2MMUT in the B2MMUT. Exposure of DCs to the conditioned media of WT s-B2M, but not s-B2MMUT, reduced phagocytosis after BTZ or DARA (p<0.05) of B2MKO cells, suggesting that s-B2M impairs APC function in a LILRB1-dependent manner. Treatment of APCs with His-tagged recombinant B2M (rB2M) confirmed activation of downstream LILRB1 signaling, assessed by modulation of p-SHP1.
 Interestingly, APCs internalized rB2M in a LILRB1-dependent manner, as both LILRB1 KD and treatment with rB2MMUT resulted in reduced internalization. Correlative light and electron microscopy (CLEM) and TEM revealed that internalized rB2M localized to perinuclear vesicles near the microtubule-organizing center (MTOC). Confocal imaging found that rB2M uptake increased microtubule stability, as assessed by a higher acetylated-to-tyrosinated tubulin ratio. Functionally, this correlated with impaired APC maturation following lipopolysaccharide stimulation (assessed by phalloidin staining) and a reduced ability to activate T cells after ICD, as measured shown by reduced T cell-mediated MM cell lysis.
 To evaluate the in vivo relevance, we generated a murine MM cell line (5TGM1) expressing a chimeric B2M (B2Mmut), which cannot bind the murine LILRB1 ortholog. Mice injected with B2Mmut cells exhibited reduced tumor engraftment and growth compared to those injected with WT cells, accompanied by increased infiltration of CD3⁺ and CD8⁺ T cells.Ongoing studies are assessing the effect of the B2M/LILRB1 axis on BTZ or DARA efficacy in vivo and will be presented at the meeting.
 This work provides fundamental insight into the immune role of B2M in MM, revealing the B2M/LILRB1 axis as a novel immune checkpoint in MM driven by impaired APC function. Targeting this axis represents a new therapeutic vulnerability to restore immune competence and improve MM outcomes.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/92134e520cb60136119f8590dc507a1192c1b610" target='_blank'>
              The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma
              </a>
            </td>
          <td>
            M. Turi, Pietro Folino, Francesca Barello, Tallya Maciel, Selma Cifric, Paola Rampa, Mehmet K Samur, Giovanni de Nola, Rita Starace, Vanessa Favasuli, Alessandro Salatino, Sofia Pasparaki, Carlo Campa, Delaney Vinaixa, Cole Clericuzio, Priya Thurman, Megan E Johnstone, F. Bonello, Abigail Lytton-Jean, Cirino Botta, Eugenio Morelli, Nikhil C Munshi, Kenneth Anderson, Annamaria Gullà
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Effector T cells are central to immune defense against Mycobacterium tuberculosis (Mtb), exerting complex and multifaceted roles that contribute to both protection and immunopathology. CD4+ T cells activate macrophages, maintain granulomas, and coordinate broad immune functions through diverse subsets, including cytokine-producing, cytotoxic, and regulatory cells. CD8+ T cells target infected cells through cytolytic activity and cytokine secretion, while unconventional T cells provide rapid, innate-like responses, particularly at mucosal sites. Recent advances in single-cell and spatial transcriptomics have revealed heterogeneity, functional plasticity, and spatial compartmentalization among T-cell subsets. Tissue-resident memory T cells in the lung parenchyma have emerged as key predictors of protective immunity. These insights are reshaping our understanding of T-cell-mediated control of Mtb and highlight the limitations of interferon (IFN)-γ-centric vaccine strategies. Future strategies must aim to elicit a broader range of T-cell responses, promote effective tissue localization, enhance polyfunctionality, and overcome regulatory or exhaustion-associated dysfunctions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bc0156b9542ecfa4c556d034e4b45afc8d02e45d" target='_blank'>
              Effector Functions of Conventional and Unconventional Mycobacterium tuberculosis (Mtb)-Specific T Cells.
              </a>
            </td>
          <td>
            S. Panda, Kendall Kearns, C. L. Lindestam Arlehamn
          </td>
          <td>2025-11-03</td>
          <td>Cold Spring Harbor perspectives in medicine</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="


 Introduction While autologous CD19-directed CAR-T cell therapy has been highly efficacious in certain B cell malignancies, its efficacy in chronic lymphocytic leukemia (CLL) has been limited by toxicity and T cell dysfunction characteristic of CLL pathophysiology. CAR natural killer (CAR-NK) therapy holds promise as a possible alternative due to a favorable toxicity profile and off-the-shelf allogeneic sourcing potential. A potential challenge for CAR-NK therapy in CLL is the emergence of compensatory pro-survival signaling in tumor cells which may inhibit tumor cell apoptosis. Receptor tyrosine kinase-like orphan receptor (ROR1) is ubiquitously expressed on CLL cells, and signaling via its ligand Wnt5a has been associated with both ibrutinib and venetoclax resistance; however, its connection to cell therapy resistance remains underexplored. Here, we studied Wnt5a-induced ROR1 signaling as an underlying CAR-NK resistance mechanism in CLL and leveraged our findings to develop a novel dual CAR-NK construct designed to overcome apoptotic resistance in CLL.
 Methods ROR1 expression on peripheral blood-derived primary CLL cells was measured via flow cytometry. CLL cells were incubated with 200ng/mL of recombinant Wnt5a and were assessed for their apoptotic priming via BH3 profiling, a functional assay that measures the proximity of tumor cells to the apoptotic threshold and cellular dependence on specific anti-apoptotic proteins. Resistance to NK-mediated killing was evaluated by treating CLL cells with 1ug/mL Wnt5a and exposing them to either CD19-CAR-NK or untransduced primary NK cells, with Annexin V and propidium iodide (PI) staining used to assess CLL cell apoptosis. The ROR1 inhibiting monoclonal antibody (mAb) zilovertamab was used to investigate attenuation of Wnt5a/ROR1-associated survival. Tandem, 2nd generation anti-CD19/ROR1 (dual) CAR constructs were designed by joining an anti-CD19 scFv with an anti-ROR1 scFv via a (G4S)4 linker, followed by a 4-1BB costimulatory domain and a CD3Z signaling domain. CAR constructs were transduced into Jurkat and peripheral blood-derived primary NK cells via an optimized baboon lentivirus protocol. Effector cell activation and cytotoxicity against primary CLL cells, a CD19+ CLL-derived cell line MEC-1, and the ROR1+ NCCIT cell line were evaluated via flow cytometry-based readouts of NK activation marker expression and Annexin/PI staining.
 Results ROR1 expression was confirmed as present in primary CLL cells in all samples (n=33, ΔMFI [ROR1-Isotype] range: 346–2199). Stimulation of the cells with Wnt5a led to reduced apoptotic priming by 11–18% at 4h and 14–42% at 24h (BIM 0.1 µM), with greater reductions observed in high-ROR1 samples. Correspondingly, high-ROR1+ CLL samples incubated with Wnt5a exhibited up to 20% reduction in cell death compared to untreated conditions when co-cultured with either CD19 CAR-NK or untransduced primary NK cells. In venetoclax-treated CLL cells, zilovertamab reversed Wnt5a-induced resistance to NK-mediated killing, restoring cell death levels from 7.6% to 13.9% and restored apoptotic priming by increasing BIM-induced cytochrome C release from 5% to 18%.
 Dual CAR-Jurkat cells showed increased expression of CD69 in the presence of either CD19+ MEC1 or ROR1+ NCCIT cell lines, while single-directed CARs exhibited no increase in activation against nonspecific targets. Dual CAR-NK cells similarly demonstrated higher CD69 expression in primary CLL patient cells (n=6) compared to single-targeting and untransduced NK cells at 16h. Cytotoxicity assays also showed that the dual CAR-NK kills at least as well as CD19-CAR-NK, and outperformed ROR1-CAR-NK and untransduced NK cells across high- and low-ROR1 patients.
 Conclusion We demonstrated that Wnt5a-induced ROR1 signaling is a key pathway that reduces CLL cell priming for apoptosis and enhances CLL cell survival against NK cells, a process reversible ex vivo by zilovertamab. We subsequently developed a novel tandem CD19/ROR1 CAR-NK product with enhanced activation against CLL cells compared to single-directed CARs. This dual CAR-NK also has the potential to subvert single antigen escape. In vivo studies are underway using NSG mice engrafted with HG3 CLL cells engineered to express both ROR1 and constitutive Wnt5a to assess whether a novel dual CAR-NK product expressing the D10-derived anti-ROR1 scFv (derived from zilovertamab) more effectively reduces tumor burden compared to non-ROR1-inhibiting CAR constructs.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e744636b917a48416c5a21d06b1eaab753958a65" target='_blank'>
              A tandem CD19/ROR1 CAR-NK to overcome Wnt5a-mediated apoptotic resistance in chronic lymphocytic leukemia
              </a>
            </td>
          <td>
            Salem Elias, Andrew Lu, Fuguo Liu, Xingyu Deng, Olivia Stringham, Jeremy Zhang, Nathalie Javidi-Sharifi, Lara Bencsics, Stephanie Chamberlain, R. Romee, M. Davids
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>57</td>
        </tr>

        <tr id="


 Suppressive immune cells and their associated cytokines and chemokines promote vascular endothelial proliferation and malformation, hindering immune cell penetration into the tumor core. In a phase II trial combining bevacizumab with atezolizumab in metastatic NSCLC patients (with a disease control rate of 87.5%) whose disease progressed after atezolizumab monotherapy, we analyzed blood biomarker changes collected at baseline, one week post-therapy, and at disease progression. Myeloid cells, including neutrophils, PMN-MDSCs, and M-MDSCs, were significantly correlated with responses to therapy. Durable responders exhibited high CXCL5 levels (p = 0.005) in blood. Additionally, lower neutrophil-to-lymphocyte ratios (p = 0.022), PMN-MDSCs (p = 0.036), and PD1+CD8+ T cells (p > 0.001) were associated with improved overall survival. Lower levels of suppressive proteins, including TCTP (p = 0.013), IL-6 (p < 0.001), IL-18 (p = 0.03), VEGF-A (p < 0.001), TIE-2 (p = 0.06), PD-L2 (p = 0.041), and CD147 (p = 0.008), were associated with better survival outcomes, highlighting their roles in therapy resistance. In vivo, vascular malformation and immune cell exclusion were prominent, with differential immune cell distribution between the tumor core and edge depending on hypoxia and vascular abnormalities. Combination therapy reduced suppressive and exhausted immune cells. These findings underscore the role of myeloid cells and factors such as IL-6, TCTP, and VEGF-A in resistance to therapy.



 This research was supported by NRF (National Research Foundation of Korea) funded by the Korean Government (RS-2022-NR075028)



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b83f651a43406b89a53faee6059bef8047e5b3f" target='_blank'>
              Immune exclusion driven by myeloid cells contributes to resistance to checkpoint inhibitor and anti-angiogenic therapy in NSCLC 4771
              </a>
            </td>
          <td>
            J. Koh, Young Kyoung Lee, Mi Soon Kim, B. Ku, Sehhoon Park, Myung-Ju Ahn
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) remains a paradigm of immunotherapy resistance, characterized by minimal effector T cell infiltration and failure to respond to immune checkpoint blockade (ICB) therapies such as anti-PD-1. In contrast, autoimmune states such as experimental autoimmune encephalomyelitis (EAE)—a murine model of multiple sclerosis—elicit robust, antigen-specific T cell responses within the central nervous system. We hypothesized that proinflammatory mechanisms sustaining autoimmunity in EAE could be co-opted to overcome immune tolerance in GBM. Single-cell RNA sequencing was used to profile T cell phenotypes from EAE and syngeneic GBM (CT-2A) models. EAE was induced in tumor-bearing mice, and tumor-specific EAE variants were generated using tumor cell lysate immunization. Cytokine expression was profiled via Luminex and white matter changes were visualized with diffusion tensor imaging and T2 mapping. Functional studies included adoptive transfer of CD3+ T cells or regulatory T cells, and hydrogel-based delivery of IL-6, IL-23, and anti-TGF-β to tumor-draining lymph nodes (TDLNs). T cell bioenergetics were assessed via Seahorse metabolic profiling and flow cytometry. EAE induction in GBM-bearing mice significantly improved survival and increased intratumoral Th1 and Th17 T cell infiltration. Tumor lysate immunization reproduced these effects and sensitized tumors to anti-PD-1 therapy. IL-6, IL-23, and IL-1β were identified as shared inflammatory mediators in both EAE and tumor-immunized states. Targeted lymphoid conditioning via hydrogels loaded with recombinant IL-6, IL-23, and anti-TGF-β reprogrammed TDLNs, enhanced T cell activation and oxidative phosphorylation, and extended survival (P<0.0001). Therefore, autoimmune inflammatory circuits can be repurposed to recondition the immunosuppressive GBM TME. Lymphoid niche modulation using a combination of IL-6, IL-23, and TGF-β blockade offers a novel strategy to sensitize GBM to currently available immunotherapeutic strategies such as anti-PD-1.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec557fff3154e9f6980a04bed886b991ce663c85" target='_blank'>
              IMMU-13. Leveraging the immune milieu of experimental autoimmune encephalomyelitis to perpetuate an anti-tumor T cell response in glioblastoma
              </a>
            </td>
          <td>
            John Choi, Lily H Kim, John Klich, Andrew Tran, Peggy Ho, Rohit Verma, Kwang Bog Cho, Si Yeon Lee, Gordon Li, Lawrence Steinman, Michael Lim
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Glioblastoma (GBM), the most common and malignant primary brain tumor, exhibits profound immune suppression, hindering immunotherapy efficacy. GBM-derived extracellular vesicles (EVs) play a major role through the immunosuppressive polarization of myeloid cells. Inhibition of EV-myeloid cell interactions thus represents a novel target to mitigate GBM-mediated immune suppression. However, there are multiple mechanisms of EV-target interaction, and downstream pathways of GBM-EV signaling are poorly understood. We explored two pharmacological agents targeting different mechanisms of EV uptake: Methyl-B-cyclodextrin (MBCD), which disrupts lipid rafts, and cytochalasin D, which inhibits actin polymerization. Our results showed immunosuppressive myeloid cell (CD11b+/ CD15-/ HLA-DRlow/ CD14high) populations increased upon GBM-EV treatment. Following cytochalasin D treatment, fewer immunosuppressive myeloid cells were observed (7.40%±1.01 vs. untreated 9.66%±2.86), with rescuing T cell proliferation. Conversely, MBCD treatment increased immunosuppressive myeloid cell levels (10.42%±2.38 vs. untreated 8.87%±3.97) without impacting T cell proliferation. This study demonstrates the feasibility of pharmacologically targeting EV-myeloid cell interactions to rescue tumor mediated immune suppression by inhibiting actin-dependent endocytosis with cytochalasin D. The converse results using MBCD treatment indicate differential importance of different EV uptake pathways in monocyte regulation.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c83aad2ce4bc7312164a625b88f12016523ef26e" target='_blank'>
              Selective Targeting of EV Uptake Pathways in Glioblastoma to Combat Tumor-Induced Immune Suppression 4324
              </a>
            </td>
          <td>
            Minori Aoki, Mohammad Asad, Julio Inocencio, Stefan Mitrasinovic, C. Crisman, Ian Parney, Patrick Lasala, Vijay Agarwal, Emad Eskandar, B. Himes
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is the deadliest primary brain tumor, characterized by immunosuppression, low infiltration of lymphocytes, and lack of response to immune checkpoint blockade (ICB) therapies. In other solid tumors, the presence of functional B cells is predictive of response to ICB. However, in GBM, although B cells are antigen-experienced, they do not differentiate to functional plasma cells. B cell activation is opposed by inhibitory signaling, especially mediated through the key inhibitory receptor CD22, which must be halted for differentiation to proceed. We hypothesized that GBM-infiltrating B cells are functionally arrested via CD22 and the immunosuppressive GBM microenvironment, which is characterized by high numbers of tumor-associated myeloid cells (TAMs). Using patient GBM samples and GBM single-cell RNA sequencing data, we showed that TAMs such as microglia strongly express the CD22 ligand α2,6 sialic acid and the α2,6 sialic acid-synthesizing enzyme ST6GAL1. We created an in vitro model of TAMs by treating murine bone-marrow-derived myeloid cells (BMDMs) with supernatant from the murine glioma cell line CT2A. Tumor cell supernatant doubled the expression of α2,6 sialic acid on the TAMs compared to BMDMs, driven by increased expression of St6gal1, showing that secreted factors from tumor cells may remodel TAMs toward a more immunosuppressive state. To elucidate the direct impact of myeloid cells on B cells, we cocultured B cells with TAMs or the microglial cell line BV2. B cells cocultured with TAMs and BV2 cells showed increased phosphorylation of repressive signaling molecules downstream of CD22, including p-SHP-2 and p-SHIP1. This study suggests that myeloid cells are reprogrammed in the context of the tumor microenvironment to become more suppressive to B cells. In future work, we aim to develop a therapeutic targeting α2,6 sialic acid on TAMs in vivo to restore B cell function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c16dc7ca0407ae61b2e9c308129f9a72d793423" target='_blank'>
              TMIC-72. Glioma-associated myeloid cells promote B cell inhibition
              </a>
            </td>
          <td>
            Alina R Murphy, Si Wang, G. Vázquez-Cervantes, Hanxiao Wan, Joshua Katz, Rebecca Du, Jiawei Huo, Tzu-yi Chia, Leah K. Billingham, Suzi Delay, M. Lesniak, Peng Zhang, J. Miska, Catalina Lee-Chang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="


 Respiratory syncytial virus (RSV) infection causes significant morbidity in elderly adults. To determine how advanced age impacts myeloid cell (MC) antiviral responses, we developed a 3D human lung model (HLM) to recapitulate the small airway. The HLM is composed of layered primary differentiated small airway epithelial cells at air-liquid interface, fibroblasts embedded in collagen, and endothelial cells. Introduced blood MC (monocytes and dendritic cells) from 36-40yo (Adult) or 69-88yo (Elderly) donors migrated throughout the HLM. Recovered MC were assessed using flow cytometry, microscopy, and transcriptional profiling. MC acquired phenotypes and morphology of tissue-resident cells, indicating adaptation to the airway environment and differentiation into tissue-resident macrophages. However, prior to infection, sorted Elderly MCs showed reduced expression of genes promoting macrophage differentiation and function, e.g. PPARG, MARCO, INHBA, yet showed higher basal expression of pro-inflammatory genes, e.g. IL18, CDKN1A, TLR9, compared to sorted Adult MCs. After RSV challenge, HLM built with Elderly MC harbored significantly more RSV RNA, consistent with poor induction of genes in IFN signaling, viral sensing, and macrophage activation pathways. Thus, diminished expression of canonical macrophage genes, increased baseline inflammation, and reduced ability to build up antiviral IFN responses contribute to the impaired viral clearance in HLM bearing Elderly MC.



 Funded by NIH R01 EB025596



 Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/23985d18f4cdd665e0b30abb7a4851c7e3a9795d" target='_blank'>
              Age shapes the myeloid cell antiviral response to RSV infection in a human airway tissue model 4051
              </a>
            </td>
          <td>
            S. Kovats, Mandi M. Roe, Taylor Do, Magdalena Chlebicz, Sean Turner, Laura Mejia, Antonius Oomens, H. Gappa-Fahlenkamp
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="ABSTRACT Introduction Interleukin-17 (IL-17), a proinflammatory cytokine primarily produced by Th17 cells, plays a complex role in transplant immunology. Its involvement in graft-versus-host disease (GvHD) and immune regulation following hematopoietic cell transplantation (HCT) has garnered significant clinical interest, though findings remain inconsistent. Areas covered This narrative review summarizes clinical studies in human HCT recipients investigating IL-17 cytokine levels, Th17 cell activity, and IL-17 gene polymorphisms associated with transplant outcomes. While several studies report associations between elevated IL-17 or Th17 levels and increased GvHD risk, results vary widely due to differences in study design, patient populations, and measurement methods. Expert opinion IL-17 is a promising, though context-dependent, biomarker and therapeutic target in HCT. Its dual roles in promoting inflammation and supporting antimicrobial defense complicate therapeutic modulation. Future studies should focus on standardized assays, multi-omics approaches, and longitudinal designs to clarify its clinical utility. Tailored strategies that modulate IL-17 without impairing immune reconstitution or graft-versus-leukemia effects are likely to guide future interventions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0db235e925e864b912118d57d47d04857d8ff4d5" target='_blank'>
              Interleukin-17 and transplant immunology: clinical evidence from hematopoietic cell transplantation
              </a>
            </td>
          <td>
            J. L. Espinoza, Tung Dac, N. Hoang, Thao Giang, Akiyoshi Takami
          </td>
          <td>2025-10-14</td>
          <td>Expert Review of Clinical Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="


 Chimeric antigen receptor T (CART) cell therapy has shown unprecedented success in the treatment of hematological malignancies. However, the immunosuppressive tumor microenvironment of both solid and liquid tumors is a major barrier for CART efficacy. Immunosuppressive myeloid cells inhibit CART efficacy. Colony-stimulating factor 1 receptor (CSF1R) promotes macrophage proliferation, survival, and anti-inflammatory response and is upregulated on myeloid cells in many cancers, making CSF1R an appealing therapeutic target. We aimed to test the interactions between CSF1R, myeloid cells, and CART response, and to study CSF1R targeting in the context of CART cell therapy. We utilized CD19-targeted CART cell therapy (CART19) in lymphoma preclinical models and thyroid-stimulating hormone receptor (TSHR)-targeting CART cell therapy (TSHR-CART) in thyroid cancer models.
 We first measured CSF1R expression on myeloid cells in vitro. Suppressive myeloid cells, polarized from healthy donor monocytes using an anaplastic thyroid cancer (ATC) cell line, 8505c, or mantle cell lymphoma cell line, JeKo-1, significantly upregulate CSF1R (p=0.0002) compared to media control. After polarization, myeloid cells significantly inhibit TSHR-CART and CART19 antigen-specific proliferation compared to freshly isolated monocytes (p=0.012, p<0.01, respectively) indicating that suppressive myeloid cells contribute to CART failure in multiple tumor types.
 We then performed single cell RNA sequencing on peripheral blood taken at baseline from patients with mantle cell lymphoma treated with CART19. We found a significant increase of CSF1R on monocyte subsets in CART19 non-responders vs responders (padj=0.0037).
 Next, we determined the impact of CSF1R blockade on CART cell therapy in vivo. Using lymphoma models, B6 mice were engrafted with the luciferase+ CD19+ murine lymphoma cell line TBL-12 (1x106 cells i.v. 1 day after 250 mg/kg cyclophosphamide). Tumor burden was significantly reduced after 7 days of treatment with low dose CART19 (0.5x106 i.v.) + anti-mouse CSF1R antibody (16mg/kg i.p. twice weekly) vs CART19 + IgG control (p=0.0146). We then tested the impact of CSF1R blockade in mice experiencing tumor relapse. After TBL-12 engraftment, mice were treated with anti-mouse CSF1R or IgG control antibody followed two days later with high dose CART19 (1x106 i.v.) to induce remission. Mice were re-challenged with TBL-12 14 days later. Mice treated with anti-mouse CSF1R antibody showed increased tumor control and significantly higher survival (p=0.0416).
 Using thyroid cancer models, first we identified high macrophage infiltration in biopsy specimens of patients with ATC compared to normal thyroid tissue and benign thyroid tumors through immunohistochemistry (IHC) of patient samples (p<0.01, p<0.0001, respectively). To test if macrophages are associated with CART failure in ATC, NSG mice were subcutaneously engrafted with 1x106 TSHR+ THJ529 tumors, an ATC cell line derived from patient biopsy samples from the Mayo Clinic thyroid cancer biobank, followed by i.v. treatment with 1x107 TSHR-CART or untransduced T cell control (UTD). IHC staining of tumor tissue collected at experimental endpoints revealed a dose-dependent, significant infiltration of human CD3+ T cells into the tumors which inversely correlated with murine F4/80+ myeloid cell and murine YM-1+ M2 macrophage infiltration.
 This led us to hypothesize that myeloid cell targeting with CSF1R blockade can improve TSHR-CART efficacy. We utilized the same ATC model described above to test CSF1R targeting. When TSHR+ THJ529 tumors reached approximately 100 mm3, mice were randomized by tumor volume and treated with CSF1R inhibitor PLX5622 (600mg/kg) or vehicle control, followed by either UTD or TSHR-CART cells 5x106 i.v. Mice treated with TSHR-CART + PLX5622 showed significantly improved tumor control vs TSHR-CART + vehicle control (p<0.0001) or UTD + PLX5622 (p<0.0001).
 Together, our results highlight immunosuppressive myeloid cells which express CSF1R as a major cell type limiting CART efficacy in both solid and liquid tumors. We also identified a strategy to overcome myeloid-mediated suppression of CART cells by targeting CSF1R with antibody or small molecule inhibitors.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2e70c6725806d92da3358391536cc8d0798874cb" target='_blank'>
              Targeting CSF1R to overcome myeloid cell suppression in CART therapy
              </a>
            </td>
          <td>
            Grace DeFranco, Kun Yun, Claudia Manriquez Roman, Jennifer M Feigin, Samuel Olivier, M. Hefazi Torghabeh, C. Stewart, Brooke L. Kimball, E. Siegler, T. Huynh, J. Gleba, M. Pawlush, Andrew Zakko, Michael Redig, Skyeler Klinge, Long K Mai, Aylin Alasonyalilar Demirer, James L Miller, Erin Miller, R. Sakemura, Ismail Can, O. Sirpilla, Omar L Gutierrez Ruiz, Dominic A. Skeele, Sophia Y. Goldberg, Sara Foote, Ateka Saleh, Hong Xia, E. Ogbodo, Yushi Qiu, R. Smallridge, Abba Zubair, H. Tun, John A. Copland, S. Kenderian
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="


 Background: Autologous stem cell transplantation (ASCT) remains the standard of care consolidation in eligible patients with multiple myeloma. Typically, this is followed by lenalidomide maintenance therapy until progression or intolerance. This combinatorial approach results in improved progression-free survival compared to drug-based consolidation. However, the majority of patients ultimately relapse, consistent with myeloma progression and immune escape. Increasing evidence suggests that myeloma may invoke a suppressive tumor microenvironment (TME), principally in the bone marrow (BM), which may impair endogenous T cells and/or therapeutic T cell engagers or chimeric antigen receptor T cells targeting tumor antigen. Immunosuppressive myeloid cells are known to be abundant in the TME, and we and others have previously implicated macrophages in this process.
 To examine potential cellular sources of immunosuppression in the TME, we used flow cytometry to analyze myeloid cells in the BM from patients undergoing ASCT for myeloma. BM mononuclear cells were isolated from aspirates drawn at approximately 2-6 weeks prior to ASCT (n=13), 90 days post-transplant, and at relapse or 1-year post transplant. Post-transplant samples were categorized as relapsed (n=12) or controlled for >1 year (n=8). BM from patients with progressive myeloma was characterized by a population of CD64+CD172+ macrophages that express CD169, putatively marking BM residency, and exhibiting a highly immunosuppressive phenotype evidenced by expression of CD163, CD155, PD-L1, and CSF-1R. Notably, the frequency of CD169+CD163+ macrophages (within CD64+ cells) but not the CD64+CD172+ macrophage population as a whole were expanded in patients at the time of relapse (mean frequency pre-ASCT: 3.46%, D+90: 2.96%, controlled: 4.02%, relapse: 13.83%; P<0.05 relapse vs. controlled; P<0.01 relapse vs. pre-ASCT or D+90), and correlated with multiple myeloma burden in the BM (r2 = 0.477, P=0.0103).
 Using a preclinical system of ASCT in mice bearing VK*MYC myeloma, we identified a similar macrophage subset in the BM, characterized as CD11b+Ly6GnegCD11c+CD64+ with high expression of CSF-1R, PD-L1, and F4/80. We sought to target these putatively immunosuppressive macrophages, using antibody-based CSF-1R inhibition, to determine whether we could augment lenalidomide maintenance after ASCT. We used a suboptimal T cell dose wherein endogenous anti-myeloma immunity is limited and assessed each therapy alone and in combination. We used cereblon (CRBN)-transgenic mice that are genetically modified to allow engagement of thalidomide and its derivatives (including lenalidomide), resulting in degradation of the IMiD targets, Aiolos and Ikaros. As expected, CSF-1R inhibition efficiently ablated the CX3RC1+Ly6Clo monocyte population in the blood and BM (mean frequency in lineage negative in blood: 2.9% vs. 18.1% in isotype-treated; in BM: 0.4% vs. 5.8% in isotype-treated; p<0.001 for both sites). While single agent CSF-1R inhibition or lenalidomide had no significant effect on disease progression, the combination of the two agents had a synergistic effect in attenuating myeloma relapse after ASCT. At 108 days follow-up, median overall survival for mice receiving CSF-1R inhibition and lenalidomide was not reached, while median survival was 65 days for either isotype- or lenalidomide-treated mice, and 77 days for mice receiving only CSF-1R inhibition (P<0.05). Myeloma M band progression was also significantly reduced with combination therapy (p<0.001).
 Conclusion: The ability of CSF-1R inhibition to deplete CSF-1R+ macrophages and prevent tissue fibrosis has previously been demonstrated in preclinical models of chronic graft-versus-host disease (GVHD). Subsequent clinical trials have proven axatilimab, a human anti-CSF-1R antibody, to be well tolerated and effective for the treatment of chronic GVHD, leading to FDA approval. Given lenalidomide is already a standard maintenance therapy, combination therapy with axatilimab represents a readily testable clinical strategy for augmenting progression-free survival in patients with multiple myeloma after ASCT.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/93ee7098bb14373b537fde66a2a31ad8ddc75d5f" target='_blank'>
              CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation
              </a>
            </td>
          <td>
            Simone A. Minnie, Rachael Adams, Kathleen S. Ensbey, Christine R. Schmidt, Melissa Comstock, Justina Lyons, Samuel R. W. Legg, Tomoko Sekiguchi, Nicole S. Nemychenkov, Julie R. Boiko, M. Koyama, Andrew Spencer, Damian Green, Geoff Hill
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="


 This work aims to understand how myeloid cell development and function are dysregulated in Down syndrome (DS). Introduction: Individuals with DS experience severe immune dysregulation, including altered myeloid cell function and hyperactive interferon (IFN) signaling. However, it’s unclear which phenotypes are cell-intrinsic effects of trisomy 21 (T21) or how IFN signaling impacts myeloid cell function in DS.



 Induced pluripotent stem cells (iPSCs) generated from individuals with and without DS were used to create hematopoietic stem and progenitor cells (HSPCs). These HSPCs underwent myelopoiesis, and cell subsets were characterized by flow cytometry. Myeloid functions, such as phagocytosis and NET formation, were measured after stimulation in the presence or absence of IFNs.



 T21 samples showed lower ratio of mature to progenitor immune cells during myelopoiesis and impaired production of total myeloid cells and monocytes. IPSC-derived and primary T21 monocytes showed impaired phagocytosis of S. Aureus at baseline and after IFN treatment. Meanwhile, unstimulated and PMA-stimulated T21 neutrophils showed elevated and earlier NET formation.



 T21 results in cell-intrinsic alterations in monocyte production and defects in phagocytosis of bacteria, both in the presence and absence of interferons. Elevated and earlier NET production suggest that T21 neutrophils are primed for NET formation.



 NIH grant R01AI150305, NIH grant R24OD035579, Linda Crnic Institute for Down Syndrome, Global Down Syndrome Foundation, and the Anna and John J Sie Foundation.



 Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/66da24ad513bbfe58177e311cbeb37debf473082" target='_blank'>
              Multimodal analysis of dysregulated myeloid cell function in Down syndrome 9171
              </a>
            </td>
          <td>
            Brian F. Niemeyer, Eleanor C. Britton, Madeline Hipp, Pamela Navarrete, A. Rachubinski, Joaquin M. Espinosa
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="


 Background: Despite recent advancements in the treatment of chronic lymphocytic leukemia (CLL), Richter's transformation (RT) into diffuse large B-cell lymphoma (DLBCL) remains a therapeutic challenge with poor outcomes (Coombs et al., 2023). While CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) has shown efficacy in de novo DLBCL, its effectiveness in RT is less well defined (Kittai et al., 2024). Factors such as prior treatment, T cell exhaustion, and distinct immune microenvironments may contribute to limited efficacy in DLBCL (Fraietta et al., 2018; Jain et al., 2023). We evaluated clinical outcomes and immune correlates of CD19 CAR-T in patients with RT at our institution.
 Methods: We retrospectively analyzed 15 patients with RT-DLBCL treated with CD19 CAR-T between 2017 and 2024. A comparator cohort of 19 patients with de novo DLBCL treated with CD19 CAR-T was also analyzed. Pre-infusion peripheral blood mononuclear cells (PBMCs) were analyzed using multiparametric flow cytometric profiling. RNA expression from tumor biopsies was analyzed using NanoString transcriptomic profiling with the IO360 panel, which includes 770 genes found in the tumor microenvironment.
 Results: Fifteen patients with RT-DLBCL were included, 47% male with a median age at infusion of 69 years (range 47-77). The median interval from CLL to RT diagnosis was 41 months (range: 7-210), and from RT diagnosis to CAR-T was 20 months (range: 2-50). CAR-T products used were tisagenlecleucel (tisa-cel, 53%), lisocabtagene maraleucel (liso-cel, 27%), and axicabtagene ciloleucel (Axi-cel, 20%). One patient had received an allogeneic CAR-T product 7 months prior to Tisa-cel. Three patients received hematopoietic stem cell transplant before CAR-T (2 autologous, 1 allogeneic). Leading up to CAR-T, 93% had received RT-directed therapy (median 4 lines) and 66% had received prior CLL therapy. Cytokine release syndrome (CRS) occurred in 67% (7% grade ≥3) and immune effector cell-associated neurotoxicity syndrome (ICANS) in 40% (13% grade ≥3). Overall response rates (ORR) were 80% at day 30 and 47% at 3 months. The median follow-up was 9 months.
 In the comparator de novo DLBCL cohort, median age at CAR-T was 68 (25–76), with 68% male. Most (74%) had received 1–2 prior lines of therapy before CAR-T. The majority (18/19) received axi-cel, and one patient received tisa-cel. Three patients received an autologous stem cell transplant before CAR-T. CRS of any grade occurred in 79% (11% grade ≥3), and ICANS in 74% (42% grade ≥3). The ORR was 88% at day 30 and 82% at 3 months. The median follow-up period was 26 months (range: 1-67).
 Flow cytometry revealed significantly higher frequencies of exhausted T cells in RT patients compared to de novo DLBCL (p=0.0329). RT patients had significantly higher frequencies of TCF1⁺ PD1⁺ (p=0.0217) and TCF1⁺ TIGIT⁺ (p=0.0158) CD8+ T cells, indicating a predominance of dysfunctional precursor-exhausted populations in circulation prior to CAR-T infusion. Moreover, there was an increase in central memory (CM, CD45RO⁺ CCR7⁺) CD8+ T cells in RT samples compared to de novo DLBCL (p=0.0436). Notably, these CM cells exhibited a significantly more exhausted phenotype in RT patients than in de novo cases (PD-1+ p=0.0266, TIGIT+ p=0.0490). Supporting the exhaustion phenotype found by flow cytometry, Nanostring analysis confirmed a significant increase in ENTPD1 expression, a gene that encodes the ectonucleotidase CD39, in tumors from RT patients compared to de novo DLBCL (p=0.02), as well as an increase in DUSP2 expression (p<0.0001), a phosphatase associated with exhaustion on tumor-infiltrating T cells and poor outcomes (Lu 2020; Dong 2018).
 Conclusions: CD19 CAR-T therapy shows promising initial responses in RT, though durability remains limited. Compared to de novo DLBCL, RT patients exhibit higher pre-treatment T cell exhaustion and more immunosuppressive tumor gene expression profiles, which may underlie poorer CAR-T durability. Ongoing transcriptomic analyses will further elucidate tumor-intrinsic and microenvironmental mechanisms of CAR-T resistance in RT.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8898e13acca4c0791f3ab6eeb2b41de76671fe10" target='_blank'>
              Immune exhaustion limits CD19 CAR-T efficacy in Richter's transformation
              </a>
            </td>
          <td>
            M. B. Hammami, C. Savid-Frontera, Sean Haney, Douglas Marachion, Sean Yoder, Mohammad Hussaini, Michael D. Jain, Frederick L Locke
          </td>
          <td>2025-11-03</td>
          <td>Blood</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immune responses to pathogens and effective vaccines elicit germinal center (GC) responses wherein B cells undergo affinity maturation and develop into plasma cells (PCs) and memory B cells (MBCs). The GC reaction is initially seeded by a limited group of founder B cells, and subsequently further diversified by continual entry of naïve B cells that compete with GC founder cells for antigen and T cell help. Whether these later-arriving invaders contribute to the development of PCs or MBCs is not known. To investigate the fate of GC invaders we developed a dual-recombinase reporter approach that enables pre- and post-GC B cell lineage tracing and used it to examine immune responses to vaccination and influenza infection. Notably, fate-mapped invaders preferentially give rise to MBCs as opposed to PCs. Moreover, antibodies expressed by invader-derived MBCs harbor fewer somatic mutations, exhibit lower affinity, and their antibodies bind to subdominant antigenic epitopes relative to founder MBCs. Our findings indicate that invader GC B cells are an important source of humoral immune memory diversification after infection or vaccination.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/229139309f06d11f28f5b8cfb8ca81b0820c29dc" target='_blank'>
              B lymphocytes that enter the germinal center late preferentially differentiate into memory cells that recognize subdominant epitopes
              </a>
            </td>
          <td>
            Pengcheng Zhou, H. Hartweger, Andrew J. MacLean, Victor Ramos, Kai-Hui Yao, Brianna Hernandez, Zijun Wang, A. Gazumyan, M. Nussenzweig
          </td>
          <td>2025-11-01</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>59</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-T cell therapy, despite revolutionizing hematologic malignancies, remains limited in solid tumors due to immunosuppressive microenvironments and systemic toxicities from combination immunotherapies. Recent engineering innovations demonstrate that physically linking anti-PD-L1 antibodies to interleukin-12 within CAR-T cells creates tumor-localized immunomodulation, concentrating therapeutic activity at PD-L1-positive sites while minimizing systemic exposure. In preclinical models, PD-L1-binding IL-12 fusion proteins achieved superior antitumor responses (100% vs. 50% complete responses) compared to non-binding controls, with significantly reduced inflammatory toxicity. Spatial proteomic analysis revealed comprehensive tumor microenvironment remodeling including enhanced CD8 + T cell infiltration and reduced immunosuppressive myeloid populations. Validation in human CAR-T cells targeting TAG72-positive ovarian cancer confirmed appropriate PD-L1 binding and enhanced cytotoxicity. This rational engineering strategy addresses multiple barriers simultaneously through molecular sequestration, offering a promising platform applicable to alternative checkpoint-cytokine combinations and other cellular therapeutics. Clinical translation represents a critical next step for extending CAR-T efficacy to solid malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f7a6546fc7d661b815d3d60a952bbd89932e2713" target='_blank'>
              Tumor-localized immunomodulation: a critical advance in engineering CAR-t cells for solid malignancies
              </a>
            </td>
          <td>
            Maryam Abid, Ursula Abu Nahla, Muhammad Nabeel Saddique
          </td>
          <td>2025-11-04</td>
          <td>Annals of Medicine &amp; Surgery</td>
          <td>0</td>
          <td>3</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2024', '2025'],
    y: [2, 12],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>